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“Para ser grande, sê inteiro: nada 
Teu exagera ou exclui. 
 
Sê todo em cada em cada coisa. Põe quanto és 
No mínimo que fazes. 
 
Assim em cada lago a lua toda 
Brilha, porque alta vive.” 
 
Ricardo Reis/ Fernando Pessoa, 1888 – 1935 
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Hence on every lake the whole moon shines as it lives high”) 
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ABSTRACT 
 
Systemic lupus erythematosus (SLE) is a multisystem, autoimmune disease characterised 
by the presence of autoantibodies. Active inflammation in patients with SLE can cause 
clinical effects in various organs and serum biomarkers can be helpful in monitoring the 
disease. Over time, patients with SLE have an increased risk of developing atherosclerosis. 
This risk is partially due to standard risk factors such as smoking and hypertension, but also 
due to SLE-specific immunological factors. In this thesis I have studied three linked 
questions; 
1) Systemic inflammation can lead to endothelial activation and increased release of nitric 
oxide. This leads to nitration of serum proteins. Using capture ELISA, I studied levels of 
nitrated nuclesosomes and nitrated albumin in patients with SLE. Nitrated nucleosome levels 
were higher in patients with SLE than controls, and were related to some forms of disease 
activity notably in the central nervous system, but not atherosclerosis. 
2) High-density lipoprotein (HDL) and its main structural component, apolipoprotein A1 
(ApoA1), have an atheroprotective role. Using direct ELISA, I measured serum levels of anti-
ApoA1 and anti-HDL antibodies in patients with SLE. IgG anti-apoA1 levels were associated 
with increased disease activity and with drug treatment, but not with atherosclerosis.  
3) Previous authors used vascular ultrasound to demonstrate asymptomatic carotid plaque 
in between 30% and 40% of patients with SLE. I used new, more sensitive measures of 
carotid and femoral atherosclerosis in 100 patients with no previous history of CVD to 
investigate the factors associated with presence, area, volume and echogenicity of plaque. 
Thirty-six patients had plaque. Intima–media thickness (IMT) was associated with age and 
disease duration but not activity. Total plaque area (TPA), however, was increased in 
patients with persistently active disease and also with anti-HDL levels. Lipid profile was 
associated with both IMT and TPA. Plaque echogenicity was associated with disease activity 
and renal function.  Comparison of these 100 SLE patients with an age/sex matched control 
group showed significant differences in morphology and echogenicity of plaque.  
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 1: INTRODUCTION 
1.1: Systemic Lupus Erythematosus 
1.1.1: Pathogenesis 
Systemic lupus erythematosus (SLE) is a chronic, autoimmune, multisystem disease whose 
hallmark is the heterogeneity of its clinical presentations and the unpredictability of disease 
flares and remissions (Merrill and Buyon 2005, Rahman and Isenberg 2008, Ruperto, 
Hanrahan et al. 2011). The various clinical phenotypes result from a complex interplay 
between immunological (C3, anti-dsDNA), genetic and environmental factors which 
culminates with an irreversible break in immunological tolerance (Isenberg 1997). 
Environmental triggers include viral infections, drugs and ultraviolet (UV) light. The virus 
most commonly associated with the onset of lupus or flares is EBV. EBV-antibodies and 
EBV DNA have been reported in 99% and 100% of children and young adults with SLE 
(James, Kaufman et al. 1997). SLE-like features may be induced by several drugs, namely 
hydralazine, procainamide and quinidine and are usually limited to the skin and joints. The 
environmental factor whose link to SLE is best established is UV radiation and the 
occurrence of a photosensitive rash is included in the American College of Rheumatology 
revised (ACR) classification criteria for SLE (Tan, Cohen et al. 1982, Hochberg 1997). 
The relevance of the hormone environment, namely sexual hormones, in the pathogenesis 
of lupus is well illustrated by the marked female predominance (10:1) but the exact 
mechanisms remain unknown.  
Genetics also appear to be pivotal in the pathogenesis of SLE: concordance rates for lupus 
are 25% for monozygotic twins compared with 2% for dizygotic twins. Other genetic factors 
have been identified, namely certain HLA subtypes (A1, B8 and DR3) and null alleles 
associated with complement (C1q, C2 or C4) (Rahman and Isenberg 2008). These genes 
encode components of the immune system. HLA is part of the major histocompatibility 
complex (MHC) which mediates the interaction between antigen and antigen-presenting cell 
which in turn triggers the activation of T-cells. Complement activation is a key element in 
immune-complexes-mediated response found in SLE which is thought to be responsible to a 
great extent for target-organ damage, namely in pathogenesis of lupus nephritis. Epigenetic 
changes namely DNA methylation and post-translational modification of histones either 
inherited or induced by environmental factors are also thought to play a role (Wallace and 
Hahn 2007). 
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The pivotal trigger in the development of SLE is the presence of an immune response 
against endogenous nuclear antigens. Auto-antigens are likely to derive from apoptotic 
debris whose clearance is thought to be impaired. The presence of large amounts of 
circulating endogenous nucleic acids leads to interferon alpha (IFN) production, which in 
turn stimulates antigen-presenting cells to present them. Consequently, T cells and B cells 
are activated, ultimately leading to the mounting of a full-blown immunological response 
against self-antigens. The consequent antibody and inflammatory cytokine production 
provide the necessary stimulus for the perpetuation of this process, namely through an 
immune-complex mediated response (Wallace and Hahn 2007).  
Immune complexes and complement activation are thought to be the main mediators of 
target-organ damage. Failure to clear immune complexes allows them to deposit in tissues 
leading to the recruitment and activation of inflammatory cells such as neutrophils and 
macrophages. The production of inflammatory cytokines such as tumour necrosis factor 
alpha (TNF) and reactive oxygen species (ROS) ultimately leads to tissue injury and target-
organ dysfunction (Wallace and Hahn 2007). Complement depletion/ consumption as a 
result of this process are other characteristic serological features of SLE. 
More than 100 autoantibodies have been identified in relation with SLE, the majority of which 
are not relevant in clinical practice (Sherer, Gorstein et al. 2004) and I shall therefore focus 
on those that are.  
Anti-nuclear antibodies (ANA) are the most commonly identified antibodies in lupus and 
although the specificity of this test is low (10-35% of healthy individuals >65 years are ANA 
positive), its sensitivity is high: ANA negative patients have a less than a 3% chance of 
having SLE. The titres of ANA vary, but they do not appear to correlate with disease activity 
or organ-specific involvement. Contrary to ANA, anti-double stranded DNA antibodies (anti-
dsDNA) (Rahman and Isenberg 2008) are highly specific for SLE: they are present in 70% of 
patients with lupus and less than 0.5% of healthy controls and their relevance in the 
pathogenesis of SLE is well established (Isenberg, Manson et al. 2007). In addition, serum 
levels of anti-dsDNA appear to reflect disease activity in the majority of patients (ter Borg, 
Horst et al. 1990). A small number of patients have high anti-ds-DNA and/ or low C3 levels 
with no clinical evidence of disease activity i.e., although they appear to be serologically 
active they remain clinically quiescent (Ng, Manson et al. 2006). However, 80% of these 
patients suffer a disease flare within a 5-year period (Ng, Manson et al. 2006, Rahman and 
Isenberg 2008). 
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Another group of autoantibodies found in SLE are the anti-extractable nuclear antigens 
antibodies (ENA) which are a heterogeneous group of antibodies whose targets are non-
DNA antigens. ENA levels tend not to vary over time (Agarwal, Harper et al. 2009). 
Moreover, they don’t appear to be affected by the use of B cell depletion and it is thought 
they are produced by long-lived plasma cells (Ng, Leandro et al. 2006). There are four main 
ENA subtypes: anti-Ro, anti-La, anti-Sm and anti-RNP. Anti-Ro and anti-La antibodies are 
associated with an increased risk for foetal congenital heart block (Costedoat-Chalumeau, 
Amoura et al. 2005, Brucato 2008). Anti-Ro and anti-La also appear to be associated with 
sicca syndrome, skin involvement and photosensitivity (Cervera, Khamashta et al. 1993). 
Anti-Sm has a relatively low prevalence (10-30%), but it is the most specific antibody for SLE 
and its presence is considered pathognomonic (Mannik, Merrill et al. 2003, Ng, Leandro et 
al. 2006, Wallace and Hahn 2007). Anti-RNP antibodies are associated with ‘overlap 
features’ including Raynaud’s phenomenon and myositis.  
Finally, anti-nucleosome antibodies (anti-NCS) have been found in the sera of 70-90% 
patients with lupus and their levels were found to correlate with disease activity, namely with 
renal flares (Amoura, Koutouzov et al. 2000, Ng, Manson et al. 2006, Muller, Dieker et al. 
2008).  In addition, it appears that patients with high anti-NCS levels tend to flare more 
frequently. Despite this, anti-NCS levels are not used routinely in clinical practice and this is 
probably due to the need for a laborious technique and insufficient added benefit to other 
serological markers such as C3 and anti-dsDNA. 
 
1.1.2: Epidemiology and clinical Features 
The overall prevalence of SLE ranges between 40 to 200 per 100,000 persons depending 
on the predominant ethnic origin considered (Rahman and Isenberg 2008). Epidemiologic 
studies reflecting different ethnic backgrounds suggest that SLE is more frequent in non-
Caucasian individuals (Danchenko, Satia et al. 2006, Lau, Yin et al. 2006, Jakes, Bae et al. 
2012). Ethnicity also appears to influence the type of SLE presentation. In particular, AC-
origin patients frequently present with severe renal disease and hypertension (Ward and 
Studenski 1990), while Hispanic-origin patients have a greater incidence of arthritis (Vila, 
Alarcon et al. 2004). Although these differences suggest that the genetic background could 
play an important role, the impact of environmental factors, namely socio-economic, must 
also be taken into consideration (Murphy and Isenberg 2013). 
 A clear female predominance is observed in SLE with over 90% of patients being women 
(Rahman and Isenberg 2008), which suggests a central role for sex hormones in the 
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pathogenesis of the disease. This is supported by several studies which showed an 
association between the use of exogenous hormones (contraceptive pill and hormone 
replacement therapy – HRT) with lupus onset and flares (Costenbader, Feskanich et al. 
2007). Furthermore, a correlation between age and incidence of SLE mirrors peak years of 
female sex hormone production, with a peak during childbearing years (Manzi, Wallace et al. 
2001). The onset of SLE occurs usually after puberty, typically between the 20s and 30s, 
with the highest prevalence of SLE being amongst women aged between 14-64 years 
(Manzi, Wallace et al. 2001). Finally, the female to male ratio tends to decrease with age, 
with a fall in prevalence among women which remains stable throughout in men (Boddaert, 
Huong et al. 2004). There are various target organs potentially involved in SLE, most 
commonly joints, skin and blood (>80% patients) but also the kidneys, central nervous 
system (CNS) and cardiopulmonary systems (30-50%) (Dean, Tyrrell-Price et al. 2000). In 
addition to organ specific symptoms, systemic manifestations such as fatigue, malaise, fever 
and anorexia can also occur. The first criteria for SLE classification were established in 1971 
and later revised in 1982 (Tan, Cohen et al. 1982) and 1997 (Hochberg 1997) by the 
American College of Rheumatology. The latest version is showed in Table 1.  An alternative 
classification was proposed by the Systemic Lupus International Collaborating Clinics 
(SLICC) in 2012 (Petri, Orbai et al. 2012). Seventeen classification criteria derived from wide 
a set of expert-rated patient scenarios were considered, depicting a wide range of multi-
organ clinical features and immunological findings. The SLICC criteria for SLE classification 
requires: 1) Fulfilment of at least four criteria, with at least one clinical criterion AND one 
immunologic criterion OR 2) Lupus nephritis as the sole clinical criterion in the presence of 
ANA or anti-dsDNA antibodies. In the derivation set, the SLICC classification criteria resulted 
in fewer misclassifications than the current ACR classification criteria (49 versus 70, 
p=0.0082), had greater sensitivity (94% versus 86%, p<0.0001) and equal specificity (92% 
versus 93%, p=0.39). In the validation set, the SLICC Classification criteria resulted in fewer 
misclassifications (62 versus 74, p=0.24), had greater sensitivity (97% versus 83%, 
p<0.0001) but less specificity (84% versus 96%, p<0.0001). Amezcua-Guerra et al 
compared the 1997 ACR and the 2012 SLICC criteria and concluded that both systems were 
similar to classify SLE in an uncontrolled real-life scenario with the caveat that several new 
items contained in the 2012 SLICC criteria could represent a step forward for research 
purposes in selected clinical settings (Amezcua-Guerra, Higuera-Ortiz et al. 2015). 
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Criteria Definition 
Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to 
spare the nasolabial folds. 
Discoid rash Erythematosus raised patches with adherent keratotic scaling and 
follicular plugging. Atrophic scarring may occur in older lesions. 
Photosensitivity Skin rash as a result of an unusual reaction to sun light by patient 
history or physician observation. 
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by 
physician. 
Non-erosive 
Arthritis 
Involving 2 or more peripheral joints, characterized by tenderness, 
swelling or effusion. 
Serositis Pleuritis: convincing history of pleuritic chest pain or rubbing heard by 
a physician or evidence of pleural effusion. 
OR 
Pericarditis: documented by electrocardiogram, rub or evidence of 
pericardial effusion. 
Renal disorder Persistent proteinuria (>0.5g/day or >3+ if quantitation not performed) 
OR 
Cellular casts (red cells, haemoglobin, granular, tubular or mixed) 
Neurologic 
disorder 
Seizures (in the absence of other precipitating factors) 
OR 
Psychosis (in the absence of other precipitating factors) 
Hematologic 
disorder 
Haemolytic anaemia with reticulocytosis 
OR 
Leukopenia (<4,000/mm3 on ≥2 occasions)  
OR 
Lymphopenia (<1,500/ mm3 on ≥2 occasions) 
OR 
Thrombocytopenia (<100,000/ mm3 in the absence of other 
precipitating factors) 
Immunologic 
Disorder 
Anti-dsDNA     OR     Anti-Sm     OR     Anti-Phospholipid antibodies 
(IgG/ IgM anticardiolipin antibodies or positive lupus anticoagulant 
using a standard method or false-positive test result for at least 6 
months confirmed by Treponema pallidum immobilization or 
fluorescent treponemal antibody absortion test). 
Positive ANA Abnormal titre of ANA by immunofluorescence or and equivalent 
assay at any time point in time and in the absence of precipitating 
factors (drugs) 
 
 
 
 
Table 1: Update of the 1982 ACR Revised Criteria for the Classification of SLE (adapted from 
Hochberg et al). 
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A patient may be classified as having SLE when at least 4 criteria are present, although they 
do not necessarily have to be present simultaneously. These classification criteria show 
excellent sensitivity and specificity (>85% and >95% respectively) in established disease 
and were developed mainly to be used in clinical studies as a way to ensure that the 
literature is uniform when referring to SLE.  
In addition to the signs and symptoms included in the classification criteria, there is a much 
broader range of clinical features which can be found more or less frequently in patients with 
SLE which correlate with the involvement of specific target organs, such as the skin, 
musculoskeletal system, kidney and nervous system.  
There is a growing awareness of the importance of co-morbidities related directly with SLE 
or associated with treatment, namely the high incidence of cardiovascular disease which 
remains one of the main causes of mortality and morbidity for patients with SLE (CVD-
related morbidity will be discussed at length on section 1.2.5: Cardiovascular disease and 
SLE). Other co-morbidities such as vitamin D deficiency and osteoporosis have a high 
incidence among patients with SLE due to the chronic use of steroid-based treatment 
regimens, renal disease and avoidance of sun exposure. The prevalence of osteopenia can 
reach as high as 75%, while osteoporosis is reported in over half the patients (Bichile and 
Petri 2014). The potential increased occurrence of malignancy was also a concern due 
particularly to the use of immunosuppressants such as cyclophosphamide. An increased risk 
of haematological malignancies such as non-Hodgkin’s lymphoma has been a concern and 
most recently, the standardized incidence ratio was raised 3-fold in patients with SLE 
(Bernatsky, Ramsey-Goldman et al. 2013) but this did not reach statistical significance. 
Other malignancies such as lung cancer, hepatocellular carcinoma and genital cancers may 
also be more prevalent in SLE (Ramsey-Goldman, Mattai et al. 1998). The use of 
immunosuppressive drugs may impair viral clearance and eradication which could explain 
the excess of human papilloma virus-associated cancers among women in SLE (Bernatsky, 
Joseph et al. 2008). 
 
1.1.3: Treatment and Prognosis 
SLE is characterized by the presence of chronic inflammation with periods of exacerbation 
alternating with sustained low grade activity which can be clinically non-apparent and even 
quiescent disease. Regardless of the degree of systemic inflammation and clinical 
manifestations, the presence of a largely chronic inflammatory state may result in permanent 
organ damage. Controlling inflammation is therefore of paramount importance when treating 
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patients with SLE. The first step on the treatment ladder came in the early 50’s, following 
Philip Hench’s use of compound E (hydrocortisone) in patients with inflammatory arthritis 
(Luijten, Fritsch-Stork et al. 2013). Since then, the cornerstone of lupus-therapy has been 
the use of glucocorticoids with a major improvement on survival: from a 4-year survival rate 
of only 50% in the 50’s, to 80% of patients being alive 15 years after being diagnosed with 
SLE nowadays (Isenberg and Rahman 2006). 
However, the efficacy of steroid-based regimens comes with a considerable array of side 
effects, including hypertension, osteoporosis, glucose and lipid metabolism impairment. In 
order to achieve optimal disease activity control while minimizing steroid dose requires the 
use of steroid sparing agents. The most commonly used steroid sparing drugs are 
immunosuppressive agents like methotrexate (MTX), azathioprine (AZA), mycophenolate 
mofetil (MMF) and cyclophosphamide (CYC). CYC is a powerful cytostatic alkylating agent 
usually reserved for severe manifestations and until recently was considered the standard 
care for proliferative lupus nephritis, usually in combination with pulsed corticosteroids on a 
monthly basis until disease control is achieved (Illei, Austin et al. 2001). Despite being a 
highly effective drug, CYC is associated with significant toxicity and side effects ranging from 
an increased risk of infections, infertility and increased risk of malignancies (Radis, Kahl et 
al. 1995, Wang, Wang et al. 1995). Several alternative immunosuppressive agents have 
therefore been considered and used to limit the need to prescribe CYC. MTX is a folic acid 
analogue which inhibits purine synthesis and adenosine deaminase activity used mainly to 
treat joint and skin manifestations of SLE but its efficacy is modest when major organ system 
involvement is concerned (Fortin, Abrahamowicz et al. 2008). MMF and AZA are 
immunosuppressants which act as DNA-synthesis inhibitors which are usually reserved for 
major organ involvement such as nephritis (Contreras, Pardo et al. 2004). MMF appears to 
be more effective than AZA as an induction treatment for lupus nephritis and some studies 
even suggest superiority compared with CYC in induction therapy (Ginzler, Dooley et al. 
2005). Moreover, subgroup analysis appears to favour the use of MMF among patients of 
African American and Hispanic descent (Isenberg, Appel et al. 2010). In addition, MMF is a 
direct active agent whereas AZA must be metabolized into its active metabolite 6-
mercaptopurine which is predominantly cleared by thiopurine methyltransferase. 
Polymorphisms affecting this enzyme activity are notoriously common and can lead to 
increased toxicity, including myelosuppression and hepatotoxicity (Sahasranaman, Howard 
et al. 2008). Nonetheless, the use of AZA as a steroid-sparing agent in maintenance 
regimens is both effective and safe (Contreras, Pardo et al. 2004, Mok, Ying et al. 2009). 
Another drug class which is both effective and safe in the lupus treatment armoury are the 
anti-malarial agents like hydroxychloroquine. Their mechanism of action is not yet fully 
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understood but it is thought that they affect leukocyte phagocytosis and migration through 
inhibition of lysosome acidification (Kuznik, Bencina et al. 2011). They also affect binding to 
Toll like Receptors [TLR 7 and 9]. Antimalarial agents have a good safety profile with 
retinopathy being a rare complication. It has been shown that its use limits disease flares 
and decreases accrual damage particularly when started early in the disease course (Group 
1991, James, Kim-Howard et al. 2007). Further beneficial effects on lipid profile and anti-
thrombotic properties have also been recognized as discussed on section 1.2.5: 
Cardiovascular Disease and SLE. 
Further improvement can be achieved through the better management of complications such 
as infections (antibiotics) and renal disease (angiotensin converting enzyme (ACE)-
inhibitors).  
Due to treatment optimization and, perhaps no less importantly, earlier diagnosis, survival 
has improved dramatically. However, the bimodal pattern of mortality in SLE first described 
by Urowitz et al. (Urowitz, Bookman et al. 1976) is still observed. Early mortality occurring in 
the first 5 years after diagnosis is mainly due to infection and severe renal disease, whereas 
late deaths occurring in patients with relatively inactive disease were mainly attributable to 
cardiovascular disease (CVD). This pattern has been repeatedly observed by other groups 
and although mortality and morbidity improvement has been achieved, the rate of CVD-
related complications remains high (Rubin, Urowitz et al. 1985, Frostegard 2008, Croca, 
Rodrigues et al. 2011).  
In fact, despite all the advances made, prolonged, complete remission remains elusive for 
the majority of patients. One way to improve prognosis may be through earlier diagnosis of 
complications usually associated with late mortality. The development of better ways to 
identify CVD, ideally before symptomatic disease manifests, could potentially have a positive 
impact in reducing mortality and morbidity in patients with SLE.  
Over recent years, the use of targeted therapies focused mainly on B cells but also on 
specific inflammatory cytokines and pathways has been explored. Blocking IL 6 and IFNα 
have generated increasing interest, as have therapies targeting  costimulatory interactions 
and small molecule inhibitors that interfere with cell signalling pathways (Lo and Tsokos 
2012, Sthoeger, Sharabi et al. 2014). Nonetheless, despite all the new agents targeting 
different aspects of the inflammatory response, the anti-B-cell biologics have been shown to 
yield the most consistent benefits in terms of achieving optimal disease control while 
minimizing steroid and immunosuppression use. Either through B cell depletion agents such 
as rituximab and ocrelizumab or by antagonizing the effects of B lymphocyte stimulator 
factors (belimumab), the use of targeted biological therapy is gradually becoming more 
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appealing as it promises to be effective and safe, with less toxicity and lower risk of 
infections compared with the classic treatment regimens. This shift in the treatment 
paradigm is best illustrated by the approval of belimumab as the first novel therapy for SLE 
in over 50 years. Multicentre, randomized controlled trials with long term follow up are 
required to prove not only the efficacy but also the safety and cost-effectiveness of these 
new drugs compared with the current standard of care (Cobo-Ibanez, Loza-Santamaria et al. 
2014, Kamal 2014).  
 
1.1.4: Disease Activity Definition –BILAG Scoring System 
When assessing patients with SLE, generally three patterns of disease activity can be 
identified: disease flare, chronically active disease and quiescence (Nuttall and Isenberg 
2013). Disease activity may be defined based on clinical features and/ or serological 
markers such as anti-dsDNA and C3. Importantly, clinical aspects attributable to active SLE 
must be distinguished from chronic damage or non-related causes namely infections and 
drug toxicity(Feld and Isenberg 2014). Defining disease activity in SLE is of paramount 
importance as it is the basis for majority of treatment decisions. Moreover, it is also crucial 
for the design of clinical trials, an improvement in disease activity must be one of the most 
relevant end-points considered. Serologically, raised anti-dsDNA levels in combination with 
low C3 levels are usually an indication of underlying active disease. However, serology 
alone is insufficient to assess the severity and extent of a disease flare and therefore, 
several clinical activity indices have been developed over the years (Bombardier, Gladman 
et al. 1992, Urowitz and Gladman 1998, Isenberg and Ramsey-Goldman 1999, Strand, 
Gladman et al. 1999). The most commonly used are the British Isles Lupus Assessment 
Group Scale (BILAG), the SLE Disease Activity Index (SLEDAI), the European Consensus 
Lupus Activity Measure (ECLAM) and the Systemic Lupus Activity Measure (SLAM). These 
indices were based on long term observational studies and have been shown to reflect 
changes in disease activity as well as predict damage and mortality. The BILAG differs from 
the other lupus activity indices because rather than providing a global score for disease 
activity, it reports disease activity in different organs/ systems separately (Symmons, 
Coppock et al. 1988, Hay, Bacon et al. 1993, Gordon, Sutcliffe et al. 2003). Nonetheless, 
there is a positive correlation between all these indices and presently there is no indication of 
the superiority of one over the others. The scoring system routinely used at the Lupus Clinic 
at University College London Hospital (UCLH) is the BILAG and therefore, for the purpose of 
my thesis I will only focus on this index.  
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The BILAG was developed with the aim of providing accurate and reliable activity 
assessment across a range of organs and systems. It is based on the principle of the 
physician’s ‘intention to treat’. (Gordon, Sutcliffe et al. 2003). To score on the index, the 
symptom/ sign must have been present within the previous 4 weeks and it has to be 
unequivocally ascribable to SLE rather than to a non-specific intercurrent condition such as 
an infection.  
In the original BILAG there are eight organ or systems considered: general, mucocutaneous, 
neurological, musculoskeletal, cardiorespiratory, vasculitis, renal and haematological. A 
score is given to each system based on the clinical features present over the last 4 weeks 
depending upon whether they are new, worse, the same or improving compared to 
previously (Gordon, Sutcliffe et al. 2003). Although the score can be calculated manually, a 
purpose designed software has been developed (British Lupus Integrated Prospective 
System – BLIPS (Isenberg and Gordon 2000). Immunological data do not contribute to the 
BILAG score, although basic haematology and renal function assessment help to determine 
the scores of the respective systems. 
Each organ system receives a score between A and E. An “A” score denotes severely active 
disease requiring disease-modifying treatment i.e. high dose steroids (prednisolone 
>20mg/day) and/or immunosuppressants. A score of “B” signifies that although the disease 
is active, the physician would only consider treating it with NSAIDs, hydroxychloroquine or 
less than 20mg prednisolone daily. “C” describes stable mild disease and “D” refers to a 
system which is currently inactive but which had previously been affected. Finally, a score of 
“E” means that that particular system was never involved. A severe flare of lupus can be 
defined as a new score of A in any system and a moderate flare has been defined as a 
score of B in any system which previously scored D or E (Gordon, Sutcliffe et al. 2003). 
A numerical score can also be derived from the BILAG providing a global disease activity 
score which correlates well with the global scores from the SLEDAI, SLAM and ECLAM. A 
global BILAG score was initially designed to be calculated from the formula A=9; B=3; C=1; 
D=0 and E=0 (Stoll, Stucki et al. 1997). More recently, a revised optimal scoring system for 
classic BILAG has been published in which A= 12; B= 5; C= 1; D and E=0 (Yee, Cresswell et 
al. 2010). Unless stated otherwise, whenever I mention the global BILAG score I will be 
referring to this later numerical version.  
During the last few years new version of the BILAG (BILAG 2004) was produced. However, 
most of the serum samples that I used in my longitudinal studies were taken before BILAG 
2004 was available, so that in thesis I refer to the classic BILAG score unless otherwise 
stated.  
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1.2: Cardiovascular Disease 
1.2.1: Atherosclerosis – Pathophysiology 
Currently, it is thought that atherosclerosis is essentially a chronic inflammatory process 
(Ross 1999) leading to the transition from an incipient fatty streak to a mature atheromatous 
plaque.  The fatty streak, which is common in children and young infants, is the earliest type 
of lesion and is purely inflammatory, consisting only of monocyte-derived macrophages and 
T lymphocytes. It is hypothesized that the premise for atherosclerosis is a response-to-injury 
mechanism, where endothelial dysfunction plays the initial event which triggers the 
subsequent events. Potential causes for endothelial dysfunction include raised and modified 
lipids (oxidized LDL), free radicals caused by smoking, hypertension, diabetes, elevation of 
plasma homocysteine levels and infections (Chlamydia pneumonia). All of these and other 
factors combined with a predisposing genetic background lead to endothelial damage and 
ultimately to endothelial dysfunction and atherosclerosis (Ross 1999). Following endothelial 
dysfunction, several compensatory responses arise which in turn change the normal 
homeostatic properties of the endothelium. There is an increased endothelial permeability 
mediated mainly by nitric oxide (NO), prostacyclin, platelet-derived growth factor (PDGF) 
and angiotensin II as well as an increased adhesiveness, mainly mediated by L-selectin, E-
selectin, P-selectin and intercellular adhesion molecule 1 (ICAM1). Furthermore, there is a 
loss of the normal anticoagulant nature of the endothelium which develops procoagulant 
properties though the production of vasoactive molecules, cytokines and growth factors. If 
this process continues uninterrupted, smooth muscle cells proliferate and migrate through 
the action of various cytokines such as PDGF, fibroblast growth factor 2 (FGF2) and 
transforming growth factor beta (TGF), forming an intermediate lesion. This process called 
remodelling eventually leads to arterial wall thickening and to a compensatory arterial 
dilatation aimed at preserving the arterial lumen. At this stage, inflammatory cells (mainly 
monocyte-derived macrophages and T lymphocytes) adhere to the endothelial surface and 
enter the arterial wall (diapedesis), multiplying within the lesion. Their activation leads to the 
release of proteolytic enzymes, cytokines, chemokines and growth factors ultimately 
producing focal necrosis. In later stages, neutrophils are also recruited. Their main effects 
can be divided into two groups: proteolytic (leading to gradual thinning of the fibrous cap) 
and oxidising, through the production of ROS which contribute to the modification of lipids 
present in the plaque. 
Moreover, circulating lipids, mainly low density lipoproteins (LDL), start to seep into the 
arterial wall where they undergo progressive oxidation, ultimately stimulating scavenger 
receptors in the surface of macrophages and leading to the phagocytosis of oxidized-LDL. 
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However, the internalization of LDL by macrophages leads to the formation of lipid peroxides 
and facilitates the accumulation of cholesterol esters, resulting in the formation of foam cells. 
The formation of foam cells leads to the removal and sequestration of modified LDL, 
minimizing their effects on the endothelial and smooth muscle cells. However, the ability of 
macrophages to sequester LDL is limited and once their capacity is surpassed, the 
accumulation of modified LDL within the arterial wall is inevitable. In addition to the effects 
previously described, oxidised LDL also has a chemotactic effect, amplifying the recruitment 
of inflammatory cells. Additionally, oxidised LDL induces the production of inflammatory 
cytokines such as TNF and interleukin 1 (IL1) which in turn enhance the binding of LDL to 
the endothelium and smooth muscle cells. Platelets also play a pivotal role through signalling 
pathways bridging inflammation and thrombosis(Croce and Libby 2007). In response to 
injury, the endothelium releases von Willebrand factor which leads to platelet recruitment to 
the plaque site. The recruited platelets then bind to the endothelial cells via an interaction 
between glycoprotein I and von Willebrand factor. Furthermore, this interaction leads to 
platelet activation and production of vasoactive molecules such as thromboxane A2, 
adenosine and thrombin as well as other proinflammatory mediators like PDGF which in turn 
are involved in the recruitment and activation of inflammatory cells. 
Finally, another contributor for atherothrombosis is the formation of new blood vessels. It is 
thought that the main trigger for angiogenesis is the hypoxic environment within the arterial 
wall which leads to the production of vascular endothelium growth factor (VEGF) and 
hypoxia inducible factors (HIF). The new vessels formed possess leaky endothelial junctions 
and contribute to an increased risk of haemorrhage within the plaque. The end result of 
repeated cycles of inflammatory cells recruitment and activation, LDL accumulation and 
oxidation, migration and proliferation of smooth muscle cells and fibrosis is the gradual 
growth and restructuring of the lesion which becomes a core of lipid and necrotic tissue 
overlaid by a fibrous cap – an advanced atherosclerotic plaque (Ross 1999). 
 
1.2.2: Atherosclerosis – Histology 
The term “atherosclerosis” derives from the Greek “athero” meaning wax and “sclerotic” 
meaning hard which is a very accurate description of an atherosclerotic plaque with its 
typically necrotic, lipid-rich core encased in a fibrous cap over the plaque’s luminal edge. It 
wasn’t until the mid-1990s that the terminology used to defined atheromatous plaques was 
defined by the American Heart Association (AHA) consensus group as shown in Table 2 
(Stary, Chandler et al. 1995).  
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AHA type Histological description 
Early lesions 
Type I Isolated groups of lipid-filled macrophages (foam cells). Normal 
macroscopical appearance. 
Type II Increased number of foam cells stratified into layers together with 
foamy smooth muscle cells. Fatty streaks are visible on gross 
examination. 
Pre-atheroma/ Intermediate lesions 
Type III Histological appearance intermediate between early fatty streaks 
and atheroma. Increased lipid content. Organized layers are 
observed. Erosion can occur. 
Advanced atherosclerotic plaques 
Type IV- Atheroma  Early necrosis: focal macrophage infiltration into lipid-rich areas. 
Overlying fibrous cap. 
Late necrosis: loss of matrix and extensive cellular debris. 
Overlying fibrous cap. 
Type Va- 
Fibroatheroma 
Thin, fibrous cap (<65m). Extensive macrophage and 
lymphocyte infiltrate with rare SMCs. Large underlying necrotic 
core. Intra-plaque haemorrhage/ fibrin may be present. 
Type Vb: Calcified Abundant mineralization. Decreased inflammatory infiltrate. 
Type Vc- Fibrotic Abundant collagen fibres. Minimal lipid accumulation. 
Complicated atherosclerotic plaques 
Type VI Presence of defects on the luminal surface (erosions, fissures, 
ruptures) leading to the formation of haematomas or thrombi. 
 
 
Table 2: AHA Consensus of Atherosclerotic Lesions Based on Morphologic Descriptions (adapted 
from Stary et al.). 
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The two non-progressive lesions (Type I and II) usually appear during the first decades of life 
and have little impact on the arterial lumen diameter. The lipids found in these early lesions 
are mainly LDL which is thought to derive from circulation after being entrapped in the 
subendothelial space (Napoli, D'Armiento et al. 1997, Khalil, Wagner et al. 2004). 
This first attempt at a formal, systematic description of the various clinically relevant 
atherosclerotic lesions has been repeatedly reviewed and adapted to accommodate specific 
types of plaques thought to be particularly relevant in certain types of CVD. One of the most 
relevant adaptations was proposed by Virmani et al. (Virmani, Kolodgie et al. 2000) who 
found to be lacking, in the original AHA classification, alternative entities which are mainly 
relevant for the occurrence of coronary thrombosis, namely the erosion and the calcified 
nodule. The recognition of particular types of plaques predominantly associated with the 
occurrence of acute coronary syndromes (ACS) led to the development of the concept of 
“stable vs. unstable plaque”. Atherosclerotic plaques which remain clinically quiescent are 
deemed “stable” as opposed to vulnerable or unstable plaques which are prone to erosion 
and have therefore a greater likelihood of leading to acute thrombus formation (Davies and 
Thomas 1985). It is now believed that the majority of ACS arise from the transformation of a 
stable plaque into an unstable one (Davies and Thomas 1985, Farb, Burke et al. 1996, 
Burke, Farb et al. 1997). Finn et al. (Finn, Nakano et al. 2010)recently published a review on 
the concept of vulnerable/ unstable plaque. The exposure of highly thrombogenic intra-
plaque elements, such as tissue factor, to the blood flow leads to activation of the clotting 
cascade and ultimately to thrombus formation. To date, three histological phenotypes have 
been associated with luminal thrombosis: plaque rupture, plaque erosion and calcified 
nodule. Therefore, a plaque should be considered vulnerable when its morphology makes it 
prone to any of these events. The histological plaque phenotype thought to be associated 
with greater instability is the Thin-Cap Fibroatheroma (TCFA) or Type Va according to the 
AHA classification. These plaques typically have large necrotic cores with a rich-
inflammatory infiltrate which is surrounded by a frail fibrous cap which usually <65 m thick. 
Similar findings were obtained when assessing carotid plaques as demonstrated by Carr et 
al.  who showed that there was a greater prevalence of plaque rupture, fibrous cap thinning 
and fibrous cap foam-cell infiltrates in symptomatic carotid stenosis compared to patients 
with asymptomatic stenosis (Carr, Farb et al. 1996).  
The thinning of the fibrous cap is thought to arise from a decrease in smooth muscle cells 
and type I and II collagen fibres induced by the action of proteolytic enzymes produced by 
activated macrophages within the necrotic core (Moreno, Falk et al. 1994, Libby 1995, Shah, 
Falk et al. 1995). Bassiony et al. showed in a series of 99 endarterectomy plaques the 
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number of macrophages infiltrating the fibrous cap was three-times greater in symptomatic 
common carotid plaques compared to asymptomatic and this was not influenced by the size 
of the necrotic core area (Bassiouny, Sakaguchi et al. 1997).  
Other factors related to plaque morphology can also play a role. It was found that a closer 
proximity of the necrotic core to the lumen was two-times higher in symptomatic carotid 
plaques compared to asymptomatic plaques (Bassiouny, Sakaguchi et al. 1997). Moreover, 
the presence of neovessels within the plaque itself or its fibrous cap was significantly 
associated with symptomatic carotid plaques. Furthermore, the presence of neo-
vascularization was found to be associated with increased plaque necrosis and rupture 
(McCarthy, Loftus et al. 1999). Anatomical location of plaque or the shear-stress forces 
produced by blood flow may also contribute for the development of vulnerable plaques 
(Gijsen, Wentzel et al. 2008, Finn, Nakano et al. 2010).  
Unstable plaques are more frequently found in the proximal coronary arteries and are more 
common in patients with high total cholesterol (t-cholesterol)/ high density lipoproteins (HDL) 
ratio, in women >50 years and in patients with higher levels of high-sensitivity C-reactive 
protein (CRP) (Virmani, Burke et al. 2006).  
Ultimately, CVD is clinical expression of the presence of atherosclerotic plaques, ranging 
from an asymptomatic state to chronic disease (stable angina and chronic peripheral 
ischaemia) to potentially life-changing acute events (myocardial infarction - MI, stroke).  It is 
the underlying histology of plaques, along with their preferential location, which is 
responsible for their broad clinical presentations. Thus, these depend mainly on the 
progression of atherosclerosis in the vessel wall itself i.e., a progressive reduction of arterial 
flow due to a slowly growing plaque leads to chronic symptoms, which tend to gradually 
worsening symptoms such as intermittent claudication  whereas plaque rupture and 
thrombus formation can quickly lead to major events like ACS (Virmani, Burke et al. 2006, 
Finn, Nakano et al. 2010). 
 
1.2.3: Traditional risk factors and novel biomarkers 
One of the greatest challenges for both researchers and clinicians with a combined interest 
in CVD and SLE is to identify at-risk patients before the onset of clinically evident 
atherosclerosis. In order to achieve this, it is important to establish a risk profile, which in 
turn frequently means identifying risk factors. A risk factor can be defined as a measurable 
biological characteristic of an individual that precedes a well-defined outcome, predicts that 
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outcome and is in the direct biological causal path (Balagopal, de Ferranti et al. 2011). The 
term risk factor is frequently mis-used to describe a biomarker which is in fact a biological 
indicator for processes that are involved in developing the disease that may or may not be 
causal (Balagopal, de Ferranti et al. 2011). In other words a biomarker can only be 
considered a risk factor when there is evidence to support the idea that an intervention 
results in a change of risk (Stampfer, Ridker et al. 2004). The major risk factors associated 
with the development of CVD have all been described many years ago and their relevance 
and impact remain unparalleled (Dawber, Kannel et al. 1959, Kannel, Dawber et al. 1961) . 
Variables such as older age, male gender, hypertension, diabetes and hypercholesterolemia 
have thus long been viewed as the cornerstone of any CVD-risk assessment algorithm. 
However, as previously stated the traditional risk factors grossly underestimate the CVD risk 
in the context of auto-immune diseases, in particular SLE. Although this is a well-established 
fact, the traditional risk factors are beginning to be viewed in a different light. For example, 
the concept of vascular age as opposed to chronological age is starting to emerge. Based on 
the observation about the large variability in the incidence of CVD among individuals of the 
same age, several population studies based either on coronary artery calcium score (CACS) 
(Schisterman and Whitcomb 2004, Nasir, Vasamreddy et al. 2006) or carotid-intima-media 
thickness (CIMT)(Stein, Fraizer et al. 2004, McClelland, Nasir et al. 2009) have supported 
the notion that vascular age may be a better risk predictor than chronological age (Budoff, 
Nasir et al. 2009). Similarly, the way hypercholesterolemia is viewed is also changing, in 
particular elevated circulating LDL. In simple terms, the way to assess LDL-related risk is 
based on the Friedwald method which assesses total cholesterol and TG enzymatically and 
HDL after precipitation of apolipoprotein B-containing lipoproteins. LDL cholesterol is then 
calculated as the cholesterol fraction remaining after HDL and VLDL-cholesterol are 
subtracted from the total cholesterol. Besides its well-known limitations, namely the 
presence of very high TG levels (>4.5mmol/L), the measurement of LDL-cholesterol 
concentration represents a limited surrogate marker of LDL-related atherogenicity. LDL 
particles and not the cholesterol contained in their hydrophobic core interact with the vessel 
wall during plaque formation and progression (Barter, Ballantyne et al. 2006). For any given 
LDL-cholesterol level, the LDL particle number may vary depending on the quantity of 
cholesterol carried by each particle. Cromwell et al showed in a study of the Framingham 
cohort that discordance between LDL-cholesterol and LDL-particle number is found in about 
a fifth of individuals and that when this happens, LDL-particle was strongly associated with 
outcomes while LDL-cholesterol had no relation (Cromwell, Otvos et al. 2007). These two 
examples of new ways to look at the traditional risk factors may improve their predictive 
value when assessing patients with SLE. 
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Over the last decade, the search for alternative, more sensitive and specific CVD risk factors 
has been a major focus of interest. Several biomarkers from serological variables such as 
CRP, plasma fibrinolysis activation markers and vitamin D to genetic profiling and pulse 
wave velocity indices (brachial-ankle and/or carotid femoral) have cyclically been proposed 
as candidate risk factors. However, none of these new biomarkers has been able to pass the 
high hurdle of causality and have therefore had limited success in expanding the 
epidemiological profile (Fruchart, Nierman et al. 2004, deGoma, Knowles et al. 2012). 
Ultimately, the real atherosclerotic burden can best be established by using imaging 
methods which allow for a comprehensive vascular assessment through plaque 
measurement and characterization. 
 
1.2.4: Cardiovascular disease risk stratification 
Regardless of the vascular territory predominantly affected by atherosclerosis, identifying 
asymptomatic patients with already significant subclinical disease is the key for primary 
prevention. It was based on this premise that risk stratification algorithms have repeatedly 
been developed and improved in a bid to calculate the future risk of cardiovascular events 
with the highest predictive value possible. The main risk stratification tools are based on 
levels of well-established CVD risk factors such as age, sex, serum cholesterol, smoking and 
blood pressure. The Framingham risk score (Anderson, Odell et al. 1991, Wilson, D'Agostino 
et al. 1998) is the most widely used, but others have also been developed, namely the 
Reynolds score (Ridker, Paynter et al. 2008) which includes high-sensitivity CRP, the 
Prospective Cardiovascular Munster (PROCAM)(Assmann, Cullen et al. 2002) and the 
Sheffield table system (Haq, Jackson et al. 1995). These different methods are similar in 
their overall low sensitivity and specificity as they exclude various emerging, genetic and 
otherwise unknown risk factors. Moreover, the vast majority of these indexes fail to take into 
account factors which have been shown to influence CVD risk such as SLE or RA. An 
exception for this statement is the QRISK algorithm which takes into account the diagnosis 
of RA as one of its risk factors for life-long cardiovascular disease (Hippisley-Cox, Coupland 
et al. 2008). To my knowledge there are no other risk assessment tools which account either 
for RA or other types of systemic inflammatory conditions, specifically SLE. When applied to 
patients with chronic inflammatory conditions such as SLE, these risk stratification tools can 
be useful in identifying high risk individuals (risk of CVD-related events >20% over 10 years). 
However, they fail to detect the majority of those patients with SLE who eventually develop 
CVD because they are labelled as low risk by the same set of criteria. This discrepancy is 
due to a combination of flaws in the different scoring systems. In the context of SLE, the best 
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example is the Framingham risk score: as it is heavily weighted for age and gender, the risk 
of coronary artery disease in young women with SLE is greatly underestimated. 
Optimizing early medical treatment and controlling modifiable risk factors has been shown to 
reduce cardiovascular events in both symptomatic and asymptomatic patients (Wright and 
Flapan 1994, Downs, Clearfield et al. 1998). Patients with subclinical atherosclerotic disease 
would ideally be identified before any events occur, thus enabling primary prevention 
strategies and minimizing mortality and morbidity.   
As will be discussed in detail in section 1.5, carotid US has been shown to be a sensitive, 
non-invasive, reproducible imaging study to detect atherosclerosis, predict its clinical 
complications and monitor its progression and regression in response to treatment. IMT has 
been shown to correlate with several traditional and emerging CVD risk factors(Ebrahim, 
Papacosta et al. 1999, O'Leary and Polak 2002) and although its risk prediction value is 
debatable, its use in assessing asymptomatic patients for CVD has been suggested by the 
American Heart Association and the European Society of Hypertension- European Society of 
Cardiology(Greenland, Abrams et al. 2000, European Society of Hypertension-European 
Society of Cardiology Guidelines 2003). In addition to IMT measurement, another, an 
arguably even more useful indicator of CVD risk is the presence of plaque as will be 
discussed later (Chapter 1.5.2: Importance of Vascular US in CVD Assessment). 
 
1.2.5: Cardiovascular Disease and SLE 
Besides the potentially multisystem involvement directly related with its autoimmune nature, 
SLE is also one of the strongest known risk factors for CVD (D'Cruz, Khamashta et al. 2007, 
Pennell and Keenan 2011). The range of cardiovascular involvement in SLE is broad 
including atherosclerosis, vascular inflammation/vasculitis, Raynaud’s phenomenon, 
endothelial dysfunction and a procoagulant tendency associated with the presence of 
antiphospholipid antibodies. Focusing on atherosclerosis-related cardiovascular disease, 
Magder et  al reported a 2.66-fold increased risk of CVD in the Hopkins Lupus Cohort 
compared with the Framingham controls (Magder and Petri 2012).  The impact of CVD-
related events on both mortality and morbidity is tremendous: the incidence of coronary 
artery disease both in its acute (MI) and chronic (angina, chronic heart failure) forms is over 
7 times greater in patients with SLE than in healthy controls, even after accounting for 
traditional CVD risk factors, including sex, age and lipid profile (Manzi, Meilahn et al. 1997, 
Esdaile, Abrahamowicz et al. 2001). Impressively, younger female patients with SLE (age 
35-44 years) have an over 50 times greater risk of having a MI compared with the 
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Framingham dataset (Manzi, Meilahn et al. 1997). When looking at the typical bimodal 
mortality pattern found in SLE, the real importance of CVD becomes apparent: a decade 
after the diagnosis of SLE, one of the leading causes of death is MI (Urowitz, Bookman et al. 
1976, Abu-Shakra, Urowitz et al. 1995, Urowitz, Gladman et al. 1997, Bernatsky, Boivin et 
al. 2006). Patients with SLE also have a greater risk for stroke, with an overall prevalence 
that can reach 20%, as well as high recurrence rate and greater mortality than matched 
controls (Kitagawa, Gotoh et al. 1990). 
The reason why SLE is such a dramatic risk factor for CVD is yet to be fully explained. It 
appears that in patients with SLE, there is an accelerated atherosclerotic process (Asanuma, 
Oeser et al. 2003, Roman, Shanker et al. 2003) which seems to arise from a complex 
interplay of traditional and lupus-specific risk factors (Esdaile, Abrahamowicz et al. 2001, 
Bessant, Hingorani et al. 2004, Selzer, Sutton-Tyrrell et al. 2004, Bessant, Duncan et al. 
2006). On the one hand, the presence of longstanding systemic inflammation associated 
with persistently active SLE could contribute to plaque formation and disruption. On the other 
hand, it has been found that patients with lupus have a high prevalence of traditional CVD 
risk factors such as hypertension, altered lipid profile and impaired glucose tolerance 
(MacGregor, Dhillon et al. 1992, Esdaile, Abrahamowicz et al. 2001, Bessant, Duncan et al. 
2006), which to some extent may be the result of chronic treatment with corticosteroids 
(Petri, Perez-Gutthann et al. 1992, Karp, Abrahamowicz et al. 2008). However, to date no 
undisputed correlation has been found between corticosteroid use and atherosclerosis in 
SLE. Magder et al reported that the risk of cardiovascular events is increased by two to 5-
fold for prednisolone doses above 10mg and 20mg respectively (Magder and Petri 2012). 
This could be due to the effects of corticosteroids on BP and lipid profile, as reported for the 
Hopkins Lupus Cohort where a daily dose of 10mg of prednisolone was associated with an 
average total cholesterol rise of 0.19mmol/L, a weight gain of 5.5lbs and an increased BP by 
1.1mmHg (Petri 2000). However, there are also conflicting data suggesting that there is an 
increased CVD risk among patients who are under treated with steroids, which could imply 
that poorer disease control is more relevant in determining a higher CVD risk than steroid 
treatment per se (Asanuma, Oeser et al. 2003). In summary, the raised CVD risk is likely to 
be due to interplay between direct vascular damage arising from inflammatory phenomena 
associated with SLE, such as vasculitis and immune-complex mediated endothelial cell 
damage; treatment-related factors such as steroid-induced hyperlipidaemia, hypertension 
and obesity and other SLE-independent factors, such as homocysteine levels, smoking and 
family history. Contributing factors indirectly related with SLE, namely nephrotic syndrome 
secondary to lupus nephritis and the presence of anti-phospholipid antibodies should also be 
considered (Petri, Perez-Gutthann et al. 1992, Petri, Roubenoff et al. 1996). Although the 
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majority of SLE-study groups report an association between CVD-related morbidity and 
mortality and anti-phospholipid antibody positivity (Toloza, Uribe et al. 2004, Gustafsson, 
Simard et al. 2012, Magder and Petri 2012), there are fewer studies where this association 
was not found to be significant (Roman, Shanker et al. 2003). 
Treatment can also affect CVD-risk in a positive way: the use of hydroxychloroquine (HQ) for 
example, may play a potentially protective role as it has been shown to be associated with 
lower cholesterol levels, independently of other variables (Petri, Lakatta et al. 1994, Cairoli, 
Rebella et al. 2012) and may potentially counteract the negative effects of prednisolone on 
lipid profile (Petri, Lakatta et al. 1994). Furthermore, HQ appears to inhibit platelet 
aggregation and decrease the binding of anti-β2GP1 to phospholipid layers thus decreasing 
the risk of thrombosis (Espinola, Pierangeli et al. 2002, Rand, Wu et al. 2008, Rand, Wu et 
al. 2010). 
One of the main issues when addressing CVD in the context of SLE is the poor performance 
of standard stratification tools based on the Framingham risk equation (Bessant, Hingorani 
et al. 2004, O'Neill, Pego-Reigosa et al. 2009) as previously discussed. The inability to 
assess accurately the actual CVD risk for each individual patient has led to an inability to 
shift CVD-associated mortality and morbidity in SLE, opposing the trend observed for other 
causes of mortality such as lupus nephritis(Bjornadal, Yin et al. 2004, Bernatsky, Boivin et al. 
2006). There is a need for alternative ways to assess and identify patients with SLE with 
potentially higher risk for developing CVD, with particular emphasis in non-invasive 
screening tools aimed at detecting subclinical atherosclerosis. Ahmad et al. published a 
study focusing on assessing the strength of the association between traditional 
cardiovascular risk factors and presence of carotid plaque assessed by B-mode ultrasound 
(Ahmad, Shelmerdine et al. 2007). The US findings of 200 women with SLE were compared 
with those of 100 healthy controls. An increased prevalence of plaque was observed among 
the SLE cohort, particularly on the internal carotid artery (11% vs 4%; P<0.05). Traditional 
risk factor models performed less well in SLE compared with controls but when using a 
multivariable model which exclusively included SLE factors (incluiding azathioprine use and 
APL), a significant performance improvement was noted. The authors thus conclude that it is 
the Lupus phenotype that more sensitively identify patients with greater risk for 
atherosclerosis suggesting that SLE-specific factors are likely to have an additive effect over 
traditional cardiovascular risk factors rather than sensitizing patients. 
The use of SLE-specific stratification algorithms has been proposed, with particular 
emphasis on composite risk-assessment scores based on traditional risk factors and novel 
biomarkers. A good example is the PREDICTS score proposed by McMahon et al who argue 
that this is a useful tool to improve the identification of patients with SLE who have a greater 
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risk for CVD (McMahon, Skaggs et al. 2014). This study included 210 patients with SLE and 
100 age-matched healthy control subjects who underwent 2D carotid US to assess the 
presence of atherosclerotic plaque and the IMT at two time points (0 and 2 years). For all the 
participants, complete data on traditional CVD risk factors (age, sex, diabetes hypertension, 
lipid profile) and treatment where applicable was collected (including cumulative steroid use). 
Moreover, all the participants were tested for a panel of serological variables that included 
pro-inflammatory HDL (piHDL), leptin, serum TNF-like weak inducer of apoptosis (sTWEAK), 
serum homocysteine, high-sensitivity CRP (hsCRP), adiponectin and apolipoprotein A1. 
Although some variables were shown to correlate significantly with the presence of plaque, 
namely the presence of diabetes, age equal or greater than 48 years, high piHDL, high leptin 
and high sTWEAK levels, no single variable demonstrated an ideal combination of sensitivity 
and specificity. Consequently, a high risk PREDICTS profile was proposed based on the 
presence of at least 3 positive biomarkers or a combination of diabetes plus at least one of 
the biomarkers considered. Based on this definition, patients who had the high risk profile 
had a 28 fold increased odds for the presence of plaque and increased IMT progression, 
with a 79% specificity and a 89% sensitivity (negative predictive value 89% and positive 
predictive value 64%)(McMahon, Skaggs et al. 2014). In summary, the widely accepted 
notion is that in SLE the combination of disease-specific and traditional CVD risk factors lead 
to an accelerated atherosclerotic process, which in turn contributes to plaque destabilization 
ultimately leading to plaque disruption and the occurrence of potentially fatal acute events. 
 
1.3: Lipoprotein metabolism 
1.3.1: Overview of lipoprotein metabolism 
Lipoproteins (Lp) are large macromolecular complexes that transport hydrophobic lipids 
through bodily fluids and tissues, playing an essential role in the absorption of dietary 
cholesterol and long chain fatty acids, as well as in the transport of triglycerides (TG) and 
cholesterol to and from the liver and peripheral tissues (Longo DL (editor) 2011). Lp contain 
a core of hydrophobic lipids (TG and cholesteryl esters) surrounded by hydrophilic lipids 
(phospholipids and unesterified cholesterol) and proteins.  
There are 5 major groups of Lp which differ mainly in their protein density i.e. the protein to 
cholesterol ratio. Chylomicrons are the lowest density lipoproteins followed by very low 
density lipoproteins (VLDL), intermediate density lipoproteins (IDL), low density lipoproteins 
(LDL) and high density lipoproteins (HDL). HDL is the smallest and most dense Lp whereas 
chylomicrons and VLDL are the largest and least dense. Most plasma TG are transported in 
chylomicrons or VLDL while cholesterol is transported as cholesteryl esters in LDL or HDL. 
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The proteins associated with Lp are apolipoproteins (Apo) which are required for the 
assembly, structure and function of Lp. ApoA1 is synthesized in the liver and intestine and it 
is found on virtually all HDL particles while ApoB is the major structural component of 
chylomicrons, VLDL, IDL and LDL. ApoE is present in chylomicrons, IDL and LDL and plays 
a critical role on the metabolism and clearance of TG-rich particles. There are two main Lp 
methabolic pathways: the endogenous and the exogenous pathway.  
The exogenous pathway is responsible for the efficient transport of dietary lipids through 
which dietary cholesterol and fatty acids (FA) are esterified in the small intestine by the 
enterocytes to form cholesteryl esters, while longer chain FA are incorporated firstly in TG 
and secondly into chylomicrons. Chylomicrons are extensively processed in the peripheral 
tissues through the action of lipoprotein lipase (LpL) releasing free FA which are in turn 
either oxidized to generate energy or re-esterified and stored as TG (Longo DL (editor) 
2011). As the hydrophobic core is hydrolysed and the hydrophilic lipids (cholesterol and 
phospholipids) and surface Apo are transferred to HDL, chylomicrons gradually shrink in size 
(chylomicron remnants) and are finally removed from the circulation at the liver through an 
ApoE mediated process.  
The endogenous pathway describes the hepatic secretion of ApoB-containing Lp and their 
metabolism. As with chylomicrons, the TG contained in VLDL are hydrolysed by LpL on 
peripheral tissues (muscle and adipocytes) gradually becoming IDL. The cholesterol content 
of IDL is almost all removed by the hepatocytes by LDL-receptor (LDL-R)-mediated 
endocytosis via binding to ApoE and the remainder of IDL is remodelled to form LDL. During 
this process, most of the TG are hydrolysed and all Apo (expect ApoB-100) are transferred 
to other Lp. Finally, the clearance of LDL is done mainly on the liver through LDL-R 
mediated endocytosis. 
Figure 1 illustrates the overall Lp metabolism, depicting both the exogenous and 
endogenous pathway. 
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Figure 1: The exogenous and endogenous lipoprotein metabolic pathway: the exogenous pathway 
transports dietary lipids to the periphery and the liver. The endogenous pathway transports hepatic lipids 
to the periphery (LPL: lipoprotein lipase; LDL: low density lipoprotein; IDL: intermediate density 
lipoprotein; VLDL: very low density lipoprotein; LDL-R: LDL-receptor). 
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1.3.2:  Structure and physiological role of HDL 
Although all nucleated cells synthesise cholesterol, only hepatocytes and enterocytes can 
effectively excrete cholesterol from the body into bile or the intestinal lumen. In peripheral 
cells, cholesterol is transported from the plasma membranes to the liver by a process termed 
“reverse cholesterol transport”. This multi-step process results in the net movement of 
cholesterol from peripheral tissues back to the liver via the plasma compartment and relies 
to a great extent on HDL function. 
Nascent HDL are synthesized in the liver or intestine as complex of protein and 
phospholipids and their most abundant component is a 243 amino acid chain called 
apolipoprotein A1 (ApoA1). Initially, HDL is a flattened, cholesterol free lipoprotein particle 
which gradually incorporates cholesterol into its structure via trans-membrane efflux 
mediated by ATP-binding cassette protein A1 (ABCA1). The ability to achieve cholesterol 
uptake depends on the action of a plasma enzyme, lecithin-cholesterol acetyltransferase 
(LCAT) which converts free cholesterol into hydrophobic cholesteryl esters which are then 
sequestered into the lipoprotein core finally composing the spherical HDL (Devlin 2011) as 
represented in Figure 2. 
Circulating HDL gradually increases its size and ultimately delivers its cholesterol content to 
the liver and steroid-producing organs (adrenals, ovaries and testis). The removal of 
cholesterol from within the HDL structure is mediated by the cholesteryl ester transfer protein 
(CETP) which exchanges the cholesteryl esters carried by HDL for the triglycerides carried 
by ApoB-containing Lp that are further processed into LDL finally reaching the LDL-R 
pathway. Alternatively, HDL cholesterol can also be directly up taken by the hepatocytes via 
the scavenger receptor class BI (SR-BI). The remodelling of HDL also occurs in the plasma 
compartment as phospholipids are transferred from other circulating Lp to HDL. Following 
CETP-mediated lipid exchange, HDL is maximally enriched with TG thus becoming an 
optimum substrate for either hepatic or endothelial lipase which hydrolyse TG and 
phospholipids yielding smaller, flattened HDL particles which are then released back into 
circulation to resume this cycle (Devlin 2011).  
Figures 3 depicts the overall HDL metabolism and reverse cholesterol transport. 
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Figure 2: Schematic representation of the structure of HDL: the main structure is formed by 
apolipoprotein A1 and to a lesser extent by phospholipids. Cholesterol is transported mainly as 
cholesteryl esters located inside the HDL particle core. 
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Figure 3: HDL metabolism and reverse cholesterol transport: the liver and the intestine produce nascent 
HDL particles. Free cholesterol is acquired from macrophages and other peripheral tissues and esterified 
by LCAT thus forming mature HDL particles. HDL cholesterol can then be taken up by the liver via the SR-
BI or alternatively, cholesteryl esters can be transferred from HDL to VLDL and chylomicrons by CETP 
which in turn are taken up by the liver (HDL: high density lipoprotein; LDL: low density lipoprotein; IDL: 
intermediate density lipoprotein; VLDL: very low density lipoprotein; CETP: cholesteryl ester transfer 
protein; LCAT: lecithin-cholesterol acyltransferase, LDL-R: LDL-receptor). 
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HDL has long been viewed as having a protective role in atherosclerosis, mostly due to its 
central role in reverse cholesterol transport, thus contributing to the mobilisation of 
cholesterol from foam cells present in atherosclerotic plaque, leading  to its stabilization and 
even regression. However, HDL has other beneficial actions which have gradually been 
recognized, namely anti-thrombotic, anti-oxidant and anti-inflammatory properties (Ames, 
Batuca et al. 2010, Di Bartolo, Nicholls et al. 2011). In vitro models show that HDL inhibits 
endothelial expression of proinflammatory adhesion molecules such as VCAM and 
chemokines, reducing monocyte recruitment. HDL anti-oxidant role is mainly mediated by 
paraoxonase 1 (PON1) which prevents the oxidation of LDL present in the subendothelial 
space (Batuca, Ames et al. 2007, Hahn 2010). The paraoxonase family comprises 3 
isoenzymes: PON1, PON 2 and PON 3. PON 1 is synthesized in the liver and transported 
along with circulating HDL, although it is also present in the arterial wall. Its main function is 
to prevent LDL oxidation and PON1 deficient mice are highly susceptible to developing 
atherosclerosis. PON-1 is stabilized by apoA1 and its levels decrease with age and are 
increased with treatment with lipid-lowering agent such as statins (Senti, Tomas et al. 2001, 
Batuca, Ames et al. 2007). PON2 is a constitutively expressed intracellular protein which 
protects the cells against oxidative stress. PON3 function and activity are less well known, 
but it appears to mirror PON1, as it circulates attached to HDL once it is synthesized in the 
liver. Moreover, its substrate isn’t strictly LDL and, as opposed to PON1, its levels are not 
regulated by the presence of oxidized lipids. 
Considering that the presence of oxidized LDL is one of the main stimuli for endothelial cell 
activation and monocyte recruitment, this action confers to PON1 an exceptional role in 
protecting the integrity of the arterial endothelium. However, for this PON1-mediated HDL 
effect to occur, apoA1 structure must be intact as it is responsible for transporting PON1 in 
its functional conformation (Mackness, Hunt et al. 1997). 
As its main structural component, apoA1 is pivotal to HDL function and therefore its integrity 
is essential to normal lipid homeostasis (Hahn 2010, O'Neill, Giles et al. 2010, Vuilleumier, 
Bratt et al. 2010). 
The protective role of apoA1 has been underlined by recent studies. In animal models, the 
infusion of high-dose ApoA1, or its over-expression, leads to reduction of inflammation (i.e. 
macrophage content) in experimental atheroma. Moreover, it also appears to improve 
endothelial dysfunction, decrease oxidized LDL and reduce monocyte recruitment, 
regardless of the effect on HDL levels. Recent studies suggest that the use of apoA1 
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mimetic peptides may offer the same benefits and could potentially be considered as a 
treatment option in the future (Di Bartolo, Nicholls et al. 2011).  
1.3.3: Anti-HDL antibodies, anti-ApoA1 antibodies and dysfunctional HDL 
As discussed before, although it is clear that there is an increased CVD risk in SLE, no 
straightforward culprit has been identified.  As previously discussed, the impact of SLE-
associated factors has to be considered in conjunction with traditional risk factors as no 
unequivocal link between various novel biomarkers and the atherosclerotic burden has been 
established (Lerner and Kannel 1986, Roman, Shanker et al. 2003).  
In the general population, high levels of t-cholesterol, LDL and TG as well as low levels of 
HDL are independently associated with increased cardiovascular risk, particularly among 
women (Pearson, Blair et al. 2002). Several studies have shown that patients with SLE have 
a more atherogenic lipid profile, namely with reduced HDL and raised TG levels compared 
with control subjects (Ettinger, Goldberg et al. 1987, Borba, Carvalho et al. 2006). 
Furthermore, oxidative modifications of LDL including β2-glycoprotein 1 oxidized LDL 
complexes which have been identified in patients with SLE are associated with arterial 
thrombosis (Kobayashi, Kishi et al. 2003). Moreover, altered lipid profile has also been 
shown to influence non-CVD related outcomes, particularly regarding adverse renal 
outcomes (Tisseverasinghe, Lim et al. 2006).  
The pathogenesis of the altered lipid profile observed in SLE is not yet fully established, but 
it is thought to be multifactorial. The presence of sustained inflammation most likely plays a 
central role, namely through the increase in inflammatory cytokines such as TNFα and IL-6 
which have been shown to influence lipid levels, shifting them towards an atherogenic profile 
(Svenungsson, Gunnarsson et al. 2003, Chung, Avalos et al. 2007).  
One of the proposed mechanisms, which may contribute to the presence of accelerated 
atherosclerosis in SLE, is the presence of certain auto-antibodies which target components 
of the lipid metabolism cycle. For the purposes of my thesis, I will focus on two main groups: 
anti-ApoA1 and anti-HDL antibodies. 
ApoA1 is the main component of HDL whose protective role relies greatly on its presence 
and structural integrity. Furthermore, apoA1 is essential to stabilize PON-1 allowing it to play 
its role in preventing lipid peroxidation and oxidised LDL formation (Vuilleumier, Charbonney 
et al. 2008). The presence of anti-apoA1 could have a deleterious impact at several levels: 
1) impairment of normal HDL function contributing to the presence of dysfunctional or 
inflammatory HDL; 2) impaired anti-oxidant capacity by compromising PON1 activity; 3) 
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formation and deposition of immunocomplexes leading to tissue damage. However, 
alternative mechanisms through which anti-ApoA1 may contribute to enhanced 
atherogenesis have also been proposed. 
Delgado Alves et al reported on the effects of anti-apoA1 and anti-HDL on PON-1 function in 
patients with SLE and primary APS. They found that on the SLE subgroup PON-1 activity 
was reduced; an inverse correlation between PON-1 activity and anti-HDL levels also 
emerged. Furthermore, PON-1 levels paralleled serum total antioxidant capacity, while anti-
HDL was negatively correlated with the latter (Delgado Alves, Ames et al. 2002). These 
findings were supported by further work which confirmed the inverse correlation between the 
presence of anti-HDL and reduced PON-1 activity. A similar correlation was noted between 
anti-apoA1 and reduced PON-1 activity (Batuca, Ames et al. 2007, Batuca, Ames et al. 
2009). 
The atheroprotective role of ApoA1 is well established and there is evidence to support the 
idea that presence of anti-ApoA1 may contribute to the development of atherosclerosis in 
non-SLE patients, namely in patients with ACS and diabetes (Vuilleumier, Charbonney et al. 
2008, Pagano, Satta et al. 2012, Teixeira, Cutler et al. 2012). Furthermore, Montecucco et al 
have shown that the presence of anti-ApoA1 IgG is associated with increased intra-plaque 
macrophage neutrophil and metalloproteinase content and inversely with collagen in vivo. 
This profile is has been shown to be associated with increased plaque vulnerability and 
increased risk of plaque rupture, suggesting that the presence of anti-ApoA1 IgG may be 
associated with high-risk plaques (Montecucco, Vuilleumier et al. 2011).  
Pagano et al showed that, in patients with MI, the presence of anti-apoA1 was associated 
with higher levels of IL 6, TNFα and metalloproteinase 9 (Pagano, Satta et al. 2012). In vitro 
studies suggested that this effect was mediated by stimulation of the TLR2/ CD14 pathway 
and hypothesised that this could be due to molecular mimicry, as there is a strong structural 
homology between apoA1 and TLR2 (Pagano, Satta et al. 2012). 
The presence of anti-ApoA1 and anti-HDL in the sera of patients with SLE has been 
reported by different research groups (Dinu, Merrill et al. 1998, Delgado Alves, Ames et al. 
2002, Alves and Ames 2003, Delgado Alves, Kumar et al. 2003, Batuca, Ames et al. 2007, 
Batuca, Ames et al. 2009, O'Neill, Giles et al. 2010).  
Lahita et al noted that the levels of apoA1 were reduced in a cohort of patients with SLE 
compared with HC (Lahita, Rivkin et al. 1993). Follow-up work by Dinu et al showed that in 
520 samples from 175 patients with either SLE or primary APS, antibodies directed against 
purified apoA1 could be found in 32.5% and 22.9% of samples respectively and the high 
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affinity of these antibodies for mature HDL molecules was confirmed. An association 
between anti-apoA1 and antiphospholipid antibodies (aPL), namely anti-β2 GP1 was noted 
(Dinu, Merrill et al. 1998).  
A strong correlation between titres of anti-apoA1 and anti-HDL antibodies has been noted 
(Delgado Alves, Kumar et al. 2003, Batuca, Ames et al. 2009, O'Neill, Giles et al. 2010), 
suggesting that apoA1 may be one of the key antigens for anti-HDL. However, this does not 
exclude the possibility of other potential targets within the HDL complex. In fact, the 
presence of anti-apoA1 is not necessarily accompanied by anti-HDL and vice versa. O’Neill 
et al reported that although there was a statistically significant correlation between anti-HDL 
and anti-apoA1 antibodies (r= 0.387), only 67% of samples positive for anti-apoA1 were also 
positive for anti-HDL (O'Neill, Giles et al. 2010). 
Batuca et al showed that the presence of anti-apoA1 and anti-HDL correlated with impaired 
PON-1 activity, increased nitric oxide metabolites (modified Griesse reaction) and reduced 
total anti-oxidant capacity. Furthermore, a positive correlation between these auto-antibodies 
and VCAM-1 and ICAM-1 was also noted. Finally, anti-ApoA1, anti-HDL and reduced PON-1 
activity were associated with increased BILAG score and SLICC damage index (Batuca, 
Ames et al. 2009). 
A link between disease activity and anti-HDL and anti-apoA1 antibodies was identified. 
O’Neill et al reported that anti-apoA1 and anti-HDL levels varied over time and that patients 
with persistently high disease activity had significantly higher levels than those with 
quiescent disease (O'Neill, Giles et al. 2010). The association between increased anti-apoA1 
and anti-HDL IgG and reduced PON-1 activity with both clinically defined active disease and 
damage scores was supported by further studies (Batuca, Ames et al. 2009). No 
associations with treatment were reported by either group. 
Another proposed mechanism which could explain the increased CVD risk in SLE is the 
presence of dysfunctional HDL (d-HDL). As previously discussed, HDL levels correlate 
inversely with the risk of atherosclerosis-related events (Navab, Anantharamaiah et al. 
2006). However, when reviewing the data from the Framingham cohort, over 40% of events 
occurred in subjects with normal HDL levels (Gordon, Castelli et al. 1977) and subsequent 
studies have shown that a “normal” lipid profile does not necessarily exclude the risk of CVD 
as a significant number of events occur in subjects with normal HDL and LDL (Ansell, Navab 
et al. 2003, Navab, Ananthramaiah et al. 2005). Stemming from this observation, the 
hypothesis that there could be a dysfunctional form of HDL with compromised anti-
inflammatory action and potentially a proatherogenic role emerged. The measurement of the 
qualitative function of HDL is based on its ability to prevent LDL oxidation and therefore, the 
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basis to define d-HDL experimentally lies on its inability or decreased ability to prevent 
oxidation of LDL. This can be assessed through the use of fluorescence methods by 
comparison to a “normal” HDL control as, in the absence of preserved HDL function, LDL 
are oxidized and in turn oxidize a fluorochrome-releasing substrate giving off a fluorescent 
signal (Navab, Hama et al. 2001, McMahon, Grossman et al. 2006). The inflammatory 
potential of HDL may also be estimated by assessing monocyte migration in coculture with 
either aortic or smooth muscle cells in the presence of LDL (Van Lenten, Wagner et al. 
2001), although the cell-free assay described originally is more frequently used. Based on 
this broad methodology, several studies on the role of d-HDL emerged. Van Lenten et al 
described a series of experiments through which the function of HDL was hindered in the 
presence of an acute phase-like environment and hypothesized that this could be due to the 
displacement and/ or exchange of proteins associated with HDL, namely paraoxonase and 
apoA1 (Van Lenten, Hama et al. 1995). Based on the data obtained from in vivo models, 
which demonstrated that MPO binds to HDL by selectively targeting and oxidizing apoA1, 
thus leading to an impaired cholesterol efflux and reduced LCAT activation, Undurti et al 
further explored the full impact of MPO-induced modifications on HDL function (Undurti, 
Huang et al. 2009). In a series of experiments, they showed that through MPO-catalysed 
oxidation, not only was there a loss of non-cholesterol efflux actions of HDL, namely of its 
anti-apoptotic and anti-inflammatory effects, but also that the modified HDL particles actually 
had a pro-inflammatory action, namely enhanced NF-kB activation and increased expression 
of vascular surface adhesion molecules (Undurti, Huang et al. 2009). 
Ansell et al reported that d-HDL levels correlated better with the presence of CVD than those 
of HDL and that treatment with simvastatin led to a decrease in d-HDL (Ansell, Navab et al. 
2003). Skaggs et al explored the impact of d-HDL in monocyte function and found that d-
HDL caused a small, but functionally significant, alteration of monocyte atherosclerosis-
related transcripts, namely by driving a pro-atherogenic phenotype through platelet-derived 
growth factor receptor β (PDGFRβ)-mediated pathways. They showed that in the presence 
of d-HDL there was an upregulation of PDGFRβ, increased PDGFR-dependent chemotaxis 
and enhanced TNFα secretion which could partially explain the  deleterious cardiovascular 
role of d-HDL (Skaggs, Hahn et al. 2010). 
The fact that inflammation appears to be a key factor in determining the shift from “normal” 
HDL to d-HDL led to exploration of its potential role in chronic inflammatory conditions such 
as SLE and RA. McMahon et al assessed d-HDL levels in 154 women with SLE and 
compared them with healthy controls (HC) and patients with RA. They reported that patients 
with SLE had significantly higher levels of d-HDL than HC and patients with RA and that the 
proportion of patients with SLE who had d-HDL was also higher. Moreover, patients with 
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SLE with CAD had significantly higher levels of d-HDL compared with those without CAD. A 
strong correlation between d-HDL and oxidized LDL levels was also noted (McMahon, 
Grossman et al. 2006). In a different study, the same group reported on the associations 
found between d-HDL and IMT thickness and carotid plaque presence. D-HDL was detected 
in a greater proportion of patients with plaque compared with those without plaque (86.7% vs 
40.7% respectively, p<0.001) and the presence of d-HDL was also associated with thicker 
IMT.  After multivariate analysis, the odds ratio for plaque presence and increased IMT in the 
upper quartile in patients with d-HDL were 16.1 and 2.5 respectively. Although the positive 
predictive value for a single positive d-HDL and presence of plaque was lower than 30%, the 
negative predictive value was over 95%. Thus, it was concluded that d-HDL appeared to 
correlate with increased subclinical atherosclerosis and that it could potentially be used to 
identify patients with increased atherosclerotic risk (McMahon, Grossman et al. 2009). 
Ultimately although there is a pathophysiological rationale implicating the likely involvement 
of, anti-HDL, anti-apoA1, reduced PON-1 activity and d-HDL in the increased/ accelerated 
risk of atherosclerosis in SLE, definite evidence remains elusive. At best, they can be 
considered biomarkers of CVD and their presence is indicative of a greater likelihood of 
heightened atherosclerotic risk.  
One of the goals of my thesis is to investigate whether the presence of anti-HDL and anti-
apoA1 has any associations with the actual atherosclerotic burden assessed by vascular US 
in patients with SLE. I will consider not only IMT and presence/ absence of plaque, but also 
more detailed analysis of plaque, namely by considering total plaque thickness (TpT), total 
plaque area (TpA), plaque volume and texture.  
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1.4: Nitration  
1.4.1: Nitric oxide metabolism 
Nitric oxide (NO) is a diffusible messenger involved in several physiological processes 
ranging from vasodilatation, clotting modulation (inhibits platelet aggregation), macrophage-
dependent elimination of intracellular parasites, bronchodilation and neurotransmission. NO 
is synthesized from L-arginine by a family of enzymes called nitric oxide synthases (NOS). 
There are three identified NOS isoforms: neuronal NOS (nNOS, NOS1) found in neuronal 
tissue and skeletal muscle; inducible NOS (iNOS, NOS2) which has an ubiquitous 
distribution; and endothelial NOS (eNOS, NOS3) present in vascular endothelial cells, 
cardiac myocytes, and in platelets (Oess, Icking et al. 2006). All three NOS isoforms are 
dependent on calmodulin (CaM) a multifunctional protein which acts as an intermediate 
messenger transducing calcium signalling by binding calcium ions and modifying its 
interactions with various target proteins (Chin and Means 2000). When the intracellular 
calcium levels are high, CaM binds to nNOS and eNOS but it has a tight association with 
iNOS which is independent of calcium levels. Thus, while the enzymatic activity of nNOS 
and eNOS is modulated by changes in intracellular calcium levels, leading to transient NO 
production, iNOS is continuously activated, releasing NO regardless of fluctuations in 
intracellular calcium levels. iNOS activity is therefore mainly regulated at the gene 
expression level (Janeway 2005). NOS enzymatic activity is modulated by the presence of 
its substrates and cofactors within the cell and under certain conditions, NOS may generate 
superoxide (O2
.-) instead of NO, a process referred to as uncoupling (uncoupling of NADPH 
oxidation and NO synthesis) (Janeway 2005).  
Nitric oxide is a highly reactive compound (half-life of a few seconds) which cannot be stored 
inside the cells producing it. Therefore, it diffuses freely across cell membranes, which in 
turn make it a unique transient paracrine and autocrine signalling molecule. Its signalling 
function is dependent on the levels of biosynthesis and local availability. Moreover, NO 
production by NOS is tightly regulated at transcriptional and translational levels, through co- 
and posttranslational modifications, and by subcellular localization (Janeway 2005). 
Besides the functions described above, NO also plays a pivotal role in oxidation (Khan and 
Ali 2006). Under physiological circumstances, it can be produced in response to a variety of 
stimuli and it is essential to the preservation of homeostasis (Radi, Peluffo et al. 2001). 
However, depending on its concentration and the microenvironment where it occurs, NO 
production can be potentially harmful. High concentrations of NO can interfere with 
mitochondrial function, produce DNA damage and induce changes into circulating proteins 
(Khan and Ali 2006). These changes aren’t necessarily mediated directly by NO itself but 
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through reactive nitrogen species (RNS). As mentioned before, NO is a highly unstable 
compound which quickly diffuses to the extracellular compartment after being produced, 
reacting swiftly with other circulating reactive molecules such as oxygen and ROS, chlorine 
and fluorine. One of the key reactants is superoxide (O2
.-) leading to the formation of 
peroxynitrite (Radi, Peluffo et al. 2001). Peroxynitrite is a short-lived RNS which leads to the 
reduction of NO bioavailability, meaning that the beneficial physiological effects it would 
normally produce are impaired. Moreover, peroxynitrite also contributes to the generation of 
other pro-oxidant species which can produce tissue damage, proimmunogenic DNA 
modifications and protein dysfunction (Khan and Ali 2006) 
Changes in the normal NO metabolism, namely the production of RNS have been identified 
as key elements in the pathogenesis of a series of diseases such as acute and chronic 
inflammatory conditions (asthma, ARDS, SLE), ischaemia-reperfusion injury and 
neurodegenerative diseases such as Alzheimer’s disease (Radi, Peluffo et al. 2001, Khan 
and Ali 2006). The measurement of NO and RNS is notoriously complex due to their high 
instability in biological systems. A chemiluminescent reaction using ozone (NO + O3 → NO2 
+ O2 + light) is the most commonly used but other methods are also available (Janeway 
2005). An indirect way to assess NO production is to measure the elements to which it can 
induce changes. NO and RNS-mediated protein modifications are stable, frequently 
irreversible, and can therefore be used a surrogate marker for NO and RNS activity, 
particularly since they occur during periods of significantly increased NO production.  
For the purposes of this thesis, I will focus on NO-induced protein modifications and their 
biological significance. 
 
1.4.2: Biological significance of protein nitration 
Free-radical damage to proteins mediated either by ROS or RNS results mainly in the 
modification of amino acid residues, side chain cross linking and fragmentation (Khan and 
Ali 2006). Cysteine (Cys) and the aromatic amino acids such as tyrosine (Ty), phenylalanine 
and histidine are particularly susceptible to modifications to the protein structure that result in 
changes in its basic properties, namely charge and conformation. Cys residues have a thiol 
group (carbon-bonded sulfhydryl: C-SH) which is susceptible to suffer S-nitrosation which is 
a reversible modification responsible for dynamic, post-translational regulation of most  
major classes of proteins (Faassen and Vanin 2007). Another protein modification induced 
by NO is nitrosylation which occurs when NO binds to a transition metal ion like iron or 
copper contained in proteins such as heme proteins. The nitrosylation of heme proteins like 
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cytochromes leads to the impairment of their normal enzymatic activity. When this involves 
ferrous iron, nitrosylation is particularly stable rendering it irreversible. In this thesis I will 
focus on protein nitration which involves the reaction between peroxynitrite and other RNS 
and both free and protein bound L-Ty leading to the formation of 3-nitrotyrosine (3-NTy). 
This post-translational modification is achieved by the substitution of a hydrogen by a nitro 
(NO2
-) group in to one of the two equivalent carbon atoms in the ortho position in respect to 
the OH- group of the phenolic ring of the Ty residue (Souza, Peluffo et al. 2008). The 
formation of 3-NTy is quite stable and was previously thought to be irreversible. However, 
recent studies suggest that it can potentially be reversible through the action of the enzyme 
denitrase which could mean that protein nitration could play a regulatory role (Irie, Saeki et 
al. 2003). However, it is unlikely that this would be the case when the NO production is 
greatly amplified such as found in inflammatory conditions. Therefore, the nitration of 
proteins is viewed generally as harmful as it usually leads to a loss of protein function. 
In SLE, there is increasing evidence suggesting that NO can play a role in its pathogenesis 
(Khan and Ali 2006). The presence of chronic, sustained inflammation may lead to 
persistently increased production of NO and consequently of RNS, which can in turn 
produce the effects previously discussed. Murine models of SLE have greater NO levels 
than control mice and the systemic blockade of NO production leads to an improvement of 
disease activity (Khan and Ali 2006). In patients with SLE, the serum nitrite/ nitrate ratio 
which can be used as a surrogate marker for NO production was found to be associated with 
disease activity and anti-dsDNA levels (Khan and Ali 2006). The source for the increase in 
NO levels in SLE could potentially be attributed to enhanced NOS activity in the endothelial 
cells (due to vasculitis) and keratinocytes (due to skin involvement). 
As previously stated, protein-bound nitrotyrosine is a post translational modification induced 
by NO-derived oxidants which can be found abundantly not only in mouse, but also in 
human atheroma (Leeuwenburgh, Hardy et al. 1997, Parastatidis, Thomson et al. 2007). In 
patients with CVD, 10-100mol of 3-NTy per mol of Ty were identified in the serum, however 
tissue concentrations of 3-NTy were found to be even higher. When looking at the 3-NTy 
content of LDL found in atherosclerotic plaques, it was found to be almost 90 times greater 
than peripheral concentrations (Leeuwenburgh, Hardy et al. 1997). Therefore, there is 
increasing evidence that raised 3-NTy levels may correlate with CVD and could potentially 
be considered as a risk factor for CVD (Shishehbor, Aviles et al. 2003). 
Moreover, several studies suggest that high systemic levels of nitrotyrosine may be 
associated with increased CVD risk and may even be modulated by lipid-lowering agents 
like statins (Shishehbor, Aviles et al. 2003, Shishehbor, Brennan et al. 2003, Shishehbor, 
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Patel et al. 2006), further strengthening the hypothesis that protein nitration could be a 
biomarker for increased atherosclerotic burden. 
In addition to the potential role of generalized protein nitration associated with sustained 
chronic inflammation, the nitration of specific targets could have a particular relevance. 
ApoA1, the major component of HDL is a potential target for nitration which could in turn be 
associated with changes on apoA1 or HDL function. 
It has been shown that apoA1, modified by tyrosine nitration and chlorination, in both plasma 
and artery walls was greatly increased in patients with CAD compared with healthy controls 
(Marsche, Hammer et al. 2002, Parastatidis, Thomson et al. 2007). 
It has been shown that apoA1 can be nitrated and that MPO may be the main driver inducing 
this modification (Zheng, Nukuna et al. 2004, Zheng, Settle et al. 2005). Zheng et al 
proposed that apoA1 could be a selective target for MPO-catalysed oxidative modification in 
human atheroma nitration. Furthermore, they suggested that MPO-induced nitration of 
apoA1 could be a potential mechanism for generation of a proatherogenic dysfunctional form 
of HDL (Zheng, Nukuna et al. 2004). The same group later reported on their findings 
regarding the mapping of the different tyrosine residues in the apoA1 molecule that can 
potentially be nitrated. They reported that in human atheroma, the MPO-induced nitration of 
apoA1 occurs preferentially on Tyr-192 and Tyr-166 and that these changes were 
associated with impaired ABCA1-dependent cholesterol efflux from macrophages (Zheng, 
Settle et al. 2005). Vasquez et al also reported on the impact of apoA1 nitration on impaired 
ABCA1-mediated cholesterol efflux in obese women and suggested that increased apoA1 
nitration could be a biomarker of increased oxidative stress even in the absence of diabetes 
or dyslipidemia (Vazquez, Sethi et al. 2012). Finally, Gugliucci et al reported on a case 
control study of 15 patients with type 2 diabetes and 15 age and sex-matched controls 
comparing the levels of PON-1 activity and nitrated apoA1 and found that nitrated apoA1 
predicted 64% of PON-1 activity. Moreover, diabetic patients had significantly lower PON-1 
activity and increased nitrated apoA1 compared with healthy controls in the absence of 
statistically significant differences in the lipid profile (Gugliucci, Hermo et al. 2006). This 
finding raises the possibility that the presence of enhanced nitrosative stress could lead to 
apoA1 modifications and consequently impairment of HDL function due to reduced PON-1 
activity. 
In summary, there is evidence to support the presence of a sustained inflammatory state in 
SLE which can lead to systemic endothelial activation leading to the production of large 
amounts of NO. Nitration of proteins is a stable NO-induced change which can act as a 
surrogate marker for production of NO and consequently the extent of endothelial activation 
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which could lead to endothelial dysfunction over time. Considering that endothelial 
dysfunction is the first event in the atherosclerotic process, assessing nitration levels in 
patients with SLE could be useful as it will allow for an estimation of the severity of 
endothelial insult. Moreover, since it has been shown that patients with SLE have increased 
CVD and may have an accelerated atherosclerotic process, the presence of raised nitration 
levels could potentially correlate with the presence of subclinical CVD thus becoming useful 
as CVD-risk biomarker. 
In my research, I selected three targets for nitration: nucleosomes, albumin and apoA1. I 
chose nucleosomes because both nucleosomes and anti-NCS levels have been found to be 
elevated in patients with SLE and, as previously discussed, considering their potential role in 
the pathogenesis of SLE, measuring the levels of nitrated nucleosomes (NN) could prove to 
be useful. The second nitration target I selected was albumin because it is a ubiquitous 
protein in the serum and nitrated albumin (NA) could therefore be used as an overall marker 
of nitrative stress. Finally, the choice of apolipoprotein A1 stemmed from the notion that if 
apoA 1 has a potentially CVD protective role, as it is the main structural component of HDL, 
the presence of modifications could hinder its function thus predisposing to increased 
atherosclerotic burden. In order to investigate this hypothesis, I measured total and nitrated 
ApoA1 levels in a cohort of patients who also underwent vascular US scanning, thus 
enabling me to assess the correlation between nitrated ApoA1 levels and the presence of 
atherosclerotic plaques.  
Moreover, measuring both NN and nitrated apoA1 may provide a means to assess nitration 
and allow an assessment of whether the nitration of nucleosomes and apoA1 correlates with 
anti-NCS and anti-ApoA1 levels which could be a potential mechanism for rendering them 
more antigenic. 
My hypothesis is that levels of nitration (measured through NN, NA and nitrated ApoA1) in 
patients with SLE may be elevated, particularly during flares of disease activity. Furthermore, 
I hypothesize that the immunological profile of the patients, such as the ENA status, as well 
as their treatment could influence the levels of nitration. To test these hypotheses, I 
measured NN and NA levels in 397 samples taken at different time-points of varying disease 
activity in a population of 49 patients with SLE.  
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1.5: Vascular Ultrasound 
1.5.1: Basic Principles in Vascular Ultrasound 
The term “ultrasound” (US) describes longitudinal pressure waves within a propagating 
medium, which oscillate at frequencies above the approximate threshold of human hearing, 
customarily set at 20,000 Hertz (Hz) or 20 kHz (K = 103).   Sound waves are longitudinal 
mechanical vibrations or pressure mechanical waves caused by the oscillations of particles 
in a medium leading in part to the transference or propagation of some of the energy through 
the medium and can be classified as a form of non-ionising radiation. The medium is 
essential for the sound wave to be able to propagate contrary to self-propagating 
electromagnetic radiation which can move without a supporting medium. In fact, the sound 
wave is the medium in a state of oscillation and transferring energy (Venables 2011).  
Sound waves have certain physical characteristics that can be used to describe them. These 
include frequency, period, wavelength, propagation speed, amplitude, and intensity. 
Frequency, period, amplitude, and intensity are determined by the sound source. 
Propagation speed is determined by the medium (acoustic impedance) and both the source 
and the medium determine wavelength (Venables 2011). 
The types of interactions between ultrasound and tissue are similar to those of light, and 
include the following reflection, refraction, scattering, diffraction, divergence, interference, 
and absorption. With the exception of interference which can either increase or decrease 
intensity, all these interactions reduce the intensity of the beam (attenuation)(Hutchison 
2011, Venables 2011). 
In Medicine, the most common application of US is in imaging known as ultrasonography. It 
has become possible, in vascular ultrasonography, to assess not only the arterial wall 
structure, but also the changes it undergoes as a result of atherosclerosis. It can also 
provide information on blood flow patterns. Therefore ultrasound is a key player in the 
evaluation of vascular disease.  
Images produced for diagnostic ultrasound result from the reflected portion of a sound beam. 
If a sound beam is directed at right angles, called normal incidence, to a large interface 
(greater than the sound beam width), the beam will be partially reflected back towards the 
sound source. The angle of reflection of the sound beam is equal to its angle of incidence. 
To obtain maximum detection of the reflected sound, the transducer (which sends and 
receives sound) must be positioned so that the sound beam strikes the interface 
perpendicularly. The percentage of beam reflected at tissue interfaces depends on the 
tissue’s acoustic impedance and the beam’s angle of incidence. The acoustic impedance is 
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a measure of the resistance to sound passing through a medium (expressed in kg / m2-sec). 
The higher the density of the medium, the higher the acoustic impedance. It is primarily the 
change in the acoustic impedance at a biological interface that makes it possible to visualise 
soft tissue structures with an ultrasonic beam. The amount of reflection is determined by the 
angle of incidence between the sound beam and the reflecting surface. The higher the angle 
of incidence, that is the closer it is to a 90 angle, the less the amount of reflected sound. 
The ideal angle of incidence is perpendicular to the structure that is being assessed 
(Hutchison 2011).  
1.5.1.1: US transducers 
A transducer is a device that can convert one form of energy into another. Ultrasonic 
transducers are used to convert an electrical signal into ultrasonic energy that can be 
transmitted into tissues, and to convert ultrasonic energy reflected back from the tissues into 
an electric signal. Ceramic material is used for the construction of piezoelectric crystals, 
which have the ability to change shape when a voltage is applied across it, thus the vibration 
of these crystals is used as a source of ultrasound energy.  
Transducers consist of an array of closely spaced piezoelectric elements that can be excited 
individually or in groups to produce ultrasound beams, since each element has its own 
electrical connection to the ultrasound instrument. In addition, echo signals detected by 
individual elements are amplified separately before being combined into one signal for each 
reflector (Venables 2011). 
The imaging of the carotid and femoral arterial bifurcations, and the lower limb arterial tree 
for this thesis was performed with a broad bandwidth linear array transducer. A 3D probe 
was used to image carotid arteries when plaque was found. 
In diagnostic ultrasound, reflection of the sound beam is of primary interest. Therefore 
transducers are used in pulsed mode. A short pulse of ultrasound is produced in a known 
direction and allowed to propagate into a medium. Any reflections that occur along the path 
of the pulse cause echoes to propagate back to the transducer. In pulsed mode the 
transducer is now capable of receiving these echoes as signals because it is no longer 
transmitting. The signals from distinct, separate boundaries are themselves distinct, and 
separate, since reflection only occurs while the pulse propagates across any particular 
boundary. Displaying any sequence of echo signals in time as they return means that the 
time gap between the initial transmission pulse and the reception of any particular echo 
signal may be measured. If the velocity of sound in the medium is known, then a measured 
time gap for any echo signal may be used to calculate the distance away from the probe of 
the reflecting boundary that caused the echo signal. This results in spatial information, 
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known as echo ranging or the pulse-echo principle, the basis for imaging. This concept 
forms the basis for most ultrasonic scanning modes (Lutz, Buscarini et al. 2011). 
The majority of US devices have a large array of technical options and features which fall 
beyond the scope of this thesis. Briefly, those most commonly used in vascular US are the 
“Freeze”, the “Zoom”, the “Callipers” and the “Gain” function. The “Freeze” function allows 
for the image to be held (frozen) on the screen thus enabling measurements to be made and 
images recorded. The “Zoom” will magnify certain areas of interest in the US image 
increasing the detail of a certain view.  The “Callipers” can be used to make length 
measurements by selecting the start and finish point of a certain region and it is usually used 
in conjunction with other functions such as “Freeze” and/ or “Zoom”. Finally, the “Gain” 
function allows for brightness control as it amplifies the electronic signal received by the 
transducer thus regulating the strength of the echoes being received (the greater the gain 
defined, the greater will be the brightness of the image obtained). 
1.5.1.2: Brief overview of Ultrasonic Scanning Modes 
B-mode ultrasound 
B-mode refers to brightness mode. The object of B-mode is to produce a two-dimensional 
sectional image through the body. The amplitude of the signals, received from the internal 
structures (acoustic boundaries) which form the image, are represented as a series of dots 
of varying brightness. The B-mode image is built up from these dots line by line. On average 
100 or more B-mode lines are needed per one image. Since signals are obtained from many 
directions, a special arm is required to determine the location of pulse-echo information 
(Lutz, Buscarini et al. 2011). 
M-mode ultrasound 
Referred to as motion-mode, this is in essence a strip chart recording of the changing 
position of the B-mode dots. This mode displays changes in the position of reflecting 
structures with respect to time, that is reflector depth on one axis and time on an orthogonal 
axis. M-mode is commonly used in the evaluation of rapid motion, including heart valves, 
cardiac chambers and vessel wall motion (Lutz, Buscarini et al. 2011). 
Real-time B-mode ultrasound 
Dynamic or real time imaging provides continuous data acquisition at a rate sufficient to give 
the impression of instantaneous motion of moving structures. It is the rapid sequential 
display of static ultrasound images taken in a short period of time and viewed as they are 
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acquired resulting in an impression of motion. Depending on the real time scanning 
equipment, 15 up to 120 images per second can be produced. This is currently what is used 
in ultrasound imaging.  
Doppler Ultrasound 
The Doppler Effect is a change in the perceived frequency of sound emitted by a moving 
source. The resultant shift in the Doppler frequency is related to the velocity of the reflectors 
(Polak, Bajakian et al. 1992) and is named after the physicist Christian Doppler (1803-1853), 
who discovered it in 1843.  
There are two Doppler techniques to measure blood flow frequency shifts, differing in the 
way of presenting and interpreting the results: the spectral Doppler technique and colour 
Doppler flow imaging. In the case of spectral Doppler, a single sound beam cuts the vessel, 
and flow velocity is detected only along this sound beam direction and displayed as a 
spectral distribution. In the continuous wave (CW) Doppler mode this measurement is 
carried out over the whole depth of the sound beam, while in pulsed wave (PW) Doppler 
mode only echo signals from a sample volume in a pre-selected depth are analysed 
(Rubens and Grant 2011).  
The relationship between peak systolic frequency shift and lumen narrowing of an artery is 
the basic principle that permits the use of Doppler ultrasound to detect and grade significant 
stenosis of the carotid and peripheral arteries.  
In this study, I used only colour and power Doppler and therefore I will only describe these 
two methods. 
Colour Doppler 
Doppler colour flow imaging was first introduced for echocardiography instrumentation in 
1984, for peripheral vascular imaging in 1986, and for general radiology use in 1987. 
Doppler shifts from moving particles are shown in colour, providing flow information 
throughout the grey scale field. These colour flow systems detect and process the amplitude, 
phase, and frequency of the returning echoes (Rubin and Adler 1993). With the use of the 
pulse echo imaging principle, colour Doppler denotes both velocity and flow direction in 
colour codes. Multiple sample volumes along each line of the image determine direction and 
average flow rate in each part of the real time image. Flow is displayed by encoding in colour 
an estimate of the mean Doppler frequency shift at a particular position.  
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A different colour is assigned to represent flow direction. Colour intensity indicates the 
degree of the frequency shift and the magnitude of the velocity of blood flow.  In vascular 
ultrasound the colour scale most frequently used is red to mark flow direction towards the 
probe and blue to mark direction away from the probe. However, the operator can select 
other colour scales as provided by many ultrasound scanners (Hutchison 2011). 
Colour Doppler has some limitations such as aliasing. With pulsed ultrasound, there is an 
upper limit of the Doppler shift which can be displayed, the Nyquist limit, defined as the pulse 
repetition frequency/2. When high velocity blood flow is present, Doppler shifts above the 
Nyquist limit are generated, leading to the appearance of bright, turbulent-appearing flow in 
colour Doppler, i.e. aliasing. Aliasing can be a problem as it distorts the direction and velocity 
information in Doppler imaging. If the PRF is set too low, this will limit the maximum 
frequency that can be displayed correctly, causing a “wrap around” of colour almost as if the 
flow was in the opposite direction. One must also be aware that setting too high a PRF could 
prevent the detection of low velocities. Colour Doppler is also angle dependent and the 
homogeneous representation of colour velocities is extremely dependent on the proper 
angle being used.  Colour flow imaging can pinpoint specific areas of abnormal flow for 
further interrogation, but interpretation from the colour image alone in terms of velocities, 
turbulence and flow patterns should be treated with caution until one can understand and 
allow for all possible artefacts inherent in the colour image (Hutchison 2011). 
 
Power Doppler 
As previously stated, colour Doppler imaging shows flow by encoding in colour an estimate 
of the mean Doppler frequency shift. In contrast, power Doppler encodes the power in the 
Doppler signal in colour by using the amplitude information from the colour Doppler signal. 
This feature allows the visualisation of flow in small vessels that would otherwise be difficult 
to detect (Martinoli, Pretolesi et al. 1998, Hudson-Dixon, Long et al. 1999). Power Doppler 
provides a perfusion-type display of blood flow and is three to five times more sensitive than 
colour Doppler (Rubin and Adler 1993). 
The primary advantage of power Doppler is its increased sensitivity for the detection of low 
perfusion echoes. The amplitude information acquired by this mode is independent of red 
cell velocity and the direction of blood flow. Power Doppler does not rely on frequency shift 
information, is not dependent on beam angle, and is free from aliasing. This is ideal for 
imaging tortuous vessels. This technique also provides edge definition for plaques. 
The main disadvantages of this technique include its failure to provide directional or velocity 
information and therefore all vessels in the path of the beam are represented in the same 
65 
 
colour mode. Excessive motion can seriously affect the image and therefore it is not suited 
to rapid scanning along vessels (Rubens and Grant 2011).  
 
1.5.1.3: Brief anatomical overview of the carotid and femoral territories 
In human anatomy, the principal arteries supplying to the head and neck region are the 2 
common carotids (CCA). The right CCA begins at the bifurcation of the innominate artery 
whilst the left CCA springs directly from the aortic arch. Although there is a great degree of 
anatomical variation, around the jaw level, both CCAs balloon out forming the carotid bulb 
and then divide into their main branches, the external carotid artery (ECA) and internal 
carotid artery (ICA) (Figure 2). The first supplies the exterior of the head and neck as well 
the face and eye region, whereas the latter supplies the brain and intra-orbital cavity by 
joining its contra-lateral in a circle of arteries located on the base of the skull (Circle of Willis) 
thus regulating the intra-cranial circulation. Similarly, the common femoral artery (CFA) 
divides into two main arteries at groin level, the superficial and the deep femoral artery.  The 
first runs along the inside of the thigh and divides into the calf arteries in the popliteal region 
whereas the latter divides proximally, eliciting the smaller arteries that supply the muscles of 
the thigh and buttock  (Gray, Standring et al. 2005).  
Generally, the CCA is a relatively long and straight segment and therefore the blood flow is 
usually laminar, minimizing shear-stress forces on the arterial wall. Conversely, the bulb 
region is characterized by turbulent blow flow due to the presence of an anatomical divide. 
As will be discussed later, the change in blood flow increases the likelihood of endothelial 
damage and consequently of enhanced cholesterol deposit and plaque formation. The CFA 
bifurcation differs from that of the CCA as it does not dilate before dividing. Nonetheless, 
there the blood flow also becomes more turbulent in the region, increasing the likelihood of 
plaque formation. 
A simple schematic of the anatomical aspect of the CCA and CFA bifurcations is showed in 
Figure 4. 
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1.5.2: Importance of Vascular US in Cardiovascular Disease Assessment 
 
Figure 4: Overview of the carotid and femoral territories:  A) Common carotid artery (CCA) and 
its two main branches, the internal and external carotid arteries. The carotid bulb is showed in 
detail. B) Common femoral artery (CFA) division into deep and superficial femoral arteries. 
 
67 
 
Atherosclerosis may be assessed in various ways and quantifying it is extremely useful for 
determining the extent of its burden and evolution over time as it allows for risk stratification 
and determining response to treatment. Risk stratification is particularly important in CVD as 
it impacts on patient management, namely the type and intensity of medical treatment, 
ideally allowing for primary prevention. A number of well-known risk factors such as age, 
sex, serum cholesterol, smoking and blood pressure can be used in a series of risk-
stratification algorithms such as the Framingham risk score (D'Agostino, Vasan et al. 2008). 
Unfortunately, although these systems may be useful, they are imperfect and, particularly in 
the context of SLE, they can grossly underestimate the real CVD risk as previously 
discussed. Other imaging methods have been developed to increase the sensitivity of risk 
prediction such as coronary calcium scoring (Alexopoulos and Raggi 2009) but the radiation 
load necessary to such tests is substantial and cannot be neglected. Another limitation of 
some of these methods is their low predictive value, i.e. they fail to increase the area under 
the curve of receiver-operator curves for prediction of events based on traditional risk 
factors. US is a completely non-invasive, radiation-free imaging method which allows for 
accurate assessment of superficial vessels such as the carotids and femorals, rendering it a 
particularly appealing technique for assessing asymptomatic patients. US techniques aiming 
to quantify the atherosclerosis-related burden have also been developed for the purpose of 
risk stratification. They include one-dimensional (B-mode) measurement of IMT and plaque 
thickness (Ebrahim, Papacosta et al. 1999, Lorenz, von Kegler et al. 2006, Simon, Megnien 
et al. 2010), 2D plaque area and 3D measurement of plaque and vessel wall volume. The 
measurement of both plaque area and volume has greatly increased the predictive value of 
vascular ultrasound scanning for cardiovascular events among patients free of CVD at 
baseline. A correlation was found between carotid plaque and IMT thickening with the 
occurrence of both stroke and myocardial infarction (Bots, Hoes et al. 1997, O'Leary, Polak 
et al. 1999, Lorenz, Markus et al. 2007) thus highlighting the utility and consistency of using 
non-invasive measurements to assess risk factors based on vessel wall biology. The 
combination of US data including both IMT and plaque assessment allows for a more 
accurate evaluation of the actual “vascular health”. Therefore, data from carotid US can 
potentially change the risk stratification obtained through traditional risk stratification 
algorithms which is of particular importance in patients for which those are notoriously flawed 
such as in SLE.  
1.5.1.4: Normalization of US vascular images 
With the generalization of vascular US use since the 1980’s, the need to characterize US 
findings, specifically plaque images, emerged and with it the realization of its subjectivity and 
difficulty of comparing results between different operators and different US equipment. A 
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more objective assessment of plaque echodensity was achieved with the use of computer-
assisted measurements of digitalized B-mode images (el-Barghouty, Nicolaides et al. 1996). 
The software initially used was the commercially available Adobe Photoshop TM (Adobe 
Systems, San Jose CA) but later other, dedicated software like the programme I used in the 
course of my research were developed.  
The underlying concept  for this type of image processing is the fact that the black and white 
images obtained in B-mode are composed of a spectrum of pixels with different values on a 
computer gray scale which usually ranges from 0 (absolute black) to 255 (absolute white). 
Furthermore, different colour pixels appeared with varying frequencies enabling the 
construction of a histogram which revealed a skewed distribution. For that reason, the 
median value of the gray scale was used as the measurement of the overall echodensity for 
any given image, thus defined as the grey scale median (GSM). The notion that every US 
image can be translated into a grey scale whose extremes can be set to specific values, is 
the basis for image normalization (Biasi, Sampaolo et al. 1999). 
In order to allow for comparability, each individual image can be normalized by means of 
digital image processing using blood and adventitia as the two reference extremes of the 
spectrum: blood (black) defined as the zero value (absolute echolucence) and adventitia 
(white) as the maximum value (absolute echogenicity). Thus, the brightness of all pixels in 
the image, namely those present in the plaque, could be represented on a linear scale 
defined by these two reference values (Elatrozy, Nicolaides et al. 1998). The choice of these 
two references was made based on the repeated analysis of high quality images by two 
experienced independent observers and subsequently measuring the GSM value of blood 
(0-5) and adventitia (180-190). The distinction between adventitia and other highly 
echogenic media such as bone/ calcification was ensured as the latter usually present higher 
values (>250) (Griffin, Nicolaides et al. 2007). 
Moreover, the definition of the image (number of pixels per mm) can also be adjusted to a 
set value, further limiting the differences attributable to method/ equipment use. Thus, the 
process of normalization allows for the differences between images obtained in different 
conditions such as equipment or patient characteristics (body fat, muscle mass) to be 
attenuated by establishing a similar colour range and definition. 
It can be argued that the US images thus processed do not correspond to the actual image 
obtained when scanning a patient. However, the results obtained from several large scale 
reproducibility studies have shown that normalization does not change the characteristics of 
US images obtained, namely those of atherosclerotic plaque and actually improves 
variability, by attenuating differences related with the US equipment used and type of image 
69 
 
gain considered (Biasi, Sampaolo et al. 1999, Sabetai, Tegos et al. 2000, Tegos, Sabetai et 
al. 2000) .  
Tegos et al performed a thorough assessment of the comparability of the US characteristics 
of carotid plaques, i.e. the reproducibility of before and after plaque image normalization. 
Initially, a 3-step experimental phase was done by assessing 26 carotid plaques from 16 
patients: firstly,   all plaques were scanned by three independent operators using the same 
protocol and equipment and individual pre and post-normalization GSM measurements; 
secondly, all plaques were assessed in a similar manner by the same operator using two 
different US devices and finally, all plaques were assessed by the same operator, using the 
same equipment but with four different types of image settings on the US i.e. varying levels 
of image gain (described in the 1.5.1.1 section: “US transducers”). When comparing the 
distributions of GSM in non-normalized and normalized images, no statistically significant 
differences were found. After this experimental phase, an evaluation of the clinical 
application of the examination was done by assessing 315 patients with a total of 419 carotid 
bifurcation plaques producing greater than 50% stenosis on duplex examination which were 
treated as an independent case (Tegos, Sabetai et al. 2000). Plaques were further divided 
into asymptomatic (n= 273) and symptomatic (n= 146) and comparison of the GSM between 
these 2 groups showed a statistically significant difference. Although this difference was 
apparent for the pre-normalized images (GSM symptomatic vs. asymptomatic: 10.5 vs. 20), 
it became even more pronounced after normalization (GSM symptomatic vs asymptomatic: 8 
vs. 28). These findings suggest that plaque image normalization is a reproducible method 
which reduces the variability of the US tissue characteristics of carotid plaque attributable to 
different degrees of US gain and different US equipment. Moreover, it demonstrated its 
clinical usefulness by emphasising the differences between two clinically distinct groups 
(symptomatic vs. asymptomatic) in terms of plaque echostructure (Tegos, Sabetai et al. 
2000). 
El-Barghouty et al. assessed 190 patients with 329 carotid plaques producing an over 50% 
stenosis determining their echogenicity on vascular US using computerised measurements 
of the GSM. Plaque heterogeneity was determined by comparing the GSM between the 
most echogenic and most echolucent areas within each plaque (heterogeneity index). The 
presence of ipsilateral cerebral infarction was assessed by CT brain scan. It was found that 
cerebral infarction was more common in patients with echolucent plaques, i.e. plaques with 
lower GSM, than echogenic plaques (GSM 29.7 vs. 37.8, p< 0.01). Furthermore, plaques 
with GSM≤ 32 were significantly associated with a higher incidence of cerebral infarction 
compared to those above this level, regardless of the presence or absence of symptoms. 
Thus, the authors showed that the identification of high risk carotid plaques could be done by 
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using GSM in both symptomatic and asymptomatic patients, as echolucent plaques (i.e. 
GSM< 32) were five times more likely to have silent ischaemic stroke documented by CT 
scan than those whose GSM was greater (Elatrozy, Nicolaides et al. 1998).  
The paper of Biasi et al. (1999) echoed these findings (Biasi, Sampaolo et al. 1999). They 
selected 186 patients with 232 asymptomatic carotid plaques causing ≥60% stenosis. 
Patients with conditions predisposing to cardioembolic cerebrovascular disease (atrial 
fibrillation, congestive heart failure) were excluded to limit potential confounding factors. 
Upon recruitment, CT brain scans were performed and the presence of ischaemic lesions in 
the middle and anterior cerebral artery territory was noted. In the first part of the study, the 
pre and post-image normalization variability of 26 carotid bifurcation plaques (19 patients) 
using different storage media, different US probes and different degrees of magnification 
was assessed. Significant differences in plaque echogenicity were found depending on the 
type of image storage method used, but these were eliminated after image normalization. 
Similarly, although significant differences were found in plaque images taken with different 
linear array probes and when different magnifications were used, these were eliminated after 
image normalization. The second part of the study focused on the clinical usefulness of 
normalization which was illustrated by the fact that a significant difference between 
asymptomatic plaque echogenicity and the presence of non-lacunar CT-demonstrated brain 
infarcts only became apparent after image normalization (Biasi, Sampaolo et al. 1999). 
In conclusion, the use of image normalization enables the quantification of carotid plaque 
echogenicity and to overcome the subjectivity of pre-existing classifications by using a 
simple, computer-assisted method. Furthermore, it decreases variability associated with 
different types of US equipment and may improve inter-observer variability. Finally, the 
normalization of plaque images may improve the strength of the correlation between the 
presence of plaque and the risk of ischaemic infarcts, not only in symptomatic but more 
importantly in asymptomatic patients. 
 
1.5.2: Importance of Vascular US in Cardiovascular Disease Assessment 
1.5.2.1: IMT Measurement 
As shown in Figure 5, histologically, the wall of elastic arteries such as the aorta and the 
common carotid is formed of three main layers: the intima, the media and the adventitia. The 
intima is the innermost, composed of a single layer of flattened endothelial cells together 
with a supporting layer of elastin rich collagen. Also in the intima, fibroblasts and myointimal 
cells can be found. It is these cells which can accumulate lipids, ultimately leading to the 
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thickening of the intima layer which is one of the first signs of atherosclerosis. The media is a 
broader, elastic layer formed by concentric fenestrated sheets of elastin and collagen and a 
small amount of smooth muscle fibres. Finally, the adventitia is relatively thin connective 
tissue layer predominantly formed by fibroblasts and collagen and elastin fibres. This 
particular morphology allows enough elasticity to accommodate high pressure blood flow as 
well as preventing extensive stretching during systole. Blood vessels supplying the adventitia 
and outer media are also present within the adventitia (vasa vasorum). A transverse view of 
a transverse histological cut of a common carotid artery is shown on Figure 5-A. 
Other types of arteries such as the muscular (common femoral) and the smaller arterioles 
have slightly different morphology, rendering it impossible to accurately identify and measure 
the IMT. Therefore, whenever referring to the IMT, I will be doing so in relation to the 
common carotid arteries. 
B-mode US has allowed direct visualization of both the lumen and the vessel wall of 
superficial arteries (Pignoli, Tremoli et al. 1986). By the use of this technique it is possible to 
identify on the common carotid artery wall, two echogenic bands separated by a relatively 
anechoic space as shown on Figure 5-B. 
These lines were shown to be generated by the blood-intima and media-adventitia 
interfaces, respectively (Baldassarre, Werba et al. 1994). The distance between these two 
lines was defined as the intima-media thickness (IMT) and importantly it has been shown to 
directly correlate with histology (Gamble, Beaumont et al. 1993, Wong, Edelstein et al. 
1993). 
The appearance of the intima-media junction on US can be described using a qualitative 
scale, the AUS score which ranges from 0 to 10 as shown on Figure 6. 
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Figure 5: IMT views - Cross section of a common carotid artery in a transverse histological 
cut (A) and on a B-mode longitudinal view (B). The red rectangle highlights the intima-media 
complex on both images (arterial lumen-L; intima-I; media-M and adventitia-A). 
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Figure 6: Arterial ultrasound score (AUS): The AUS describes increasing changes to the IMT as 
visualized in US, ranging from 0 (completely normal IMT) to 10 (symptomatic plaque). 
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A score of 0 represents normal IMT which appears as a straight, uniform thin line on US as 
the echoes are reflected back at a 90 angle from a completely normal endothelium (Figure 
6A). In score 2, small gaps in the IMT correspond histologically to the presence of lipid 
streaks. Lipid deposits are echolucent, i.e. they permit the passage of ultrasonic waves 
without echoes and therefore the representative areas appear black on US (“acoustic 
holes”). Thus, the presence of lipid streaks in the endothelium leads to a scattering of the 
echoes and consequently the wavy appearance of the IMT (Figure 6B). Score 4 describes 
the stage when IMT thickening can be observed (>0.1cm) whereas score 6 corresponds to 
the presence of a plaque occupying less than 50% of the total arterial lumen (Figures 6C 
and 6D respectively). Finally, scores 8 and 10 describe the presence of plaques that either 
occupy >50% of the arterial lumen (Figure 6E) or are symptomatic (Figure 6F) (Belcaro, 
Barsotti et al. 1991, Belcaro, Laurora et al. 1993). The increase in IMT is the result of intimal 
thickening, smooth muscle hyperplasia and intimal fibrocellular hypertrophy. These features 
are traditionally seen in arteriosclerosis which is mainly associated with age-related sclerosis 
and systemic hypertension (Roman, Saba et al. 1992). 
The most relevant clinical correlate between the intima-media junction and CVD risk is the 
IMT. The first studies of IMT measurement were developed by Bond et al. (Bond, Wilmoth et 
al. 1985) through US studies performed in monkey models. Subsequently the technique was 
adapted and evolved to be used in human studies (Bond, Wilmoth et al. 1989, Baldassarre, 
Amato et al. 2007). 
Earlier clinical studies suggested that an increase in the IMT of extra-cranial carotid arteries 
correlated with both carotid and coronary atherosclerosis and paralleled the significance of 
traditional risk factors (Baldassarre, Veglia et al. 2000, Amato, Montorsi et al. 2007, 
Baldassarre, Amato et al. 2007, Touboul, Hernandez-Hernandez et al. 2007). It was 
therefore, hypothesised  that the measurement of carotid IMT could be used as a surrogate 
marker of atherosclerosis (Espeland, O'Leary D et al. 2005) as well as a predictor of 
cardiovascular events (i.e., the thicker the IMT the higher the rate of myocardial infarction or 
stroke (O'Leary, Polak et al. 1999). Interestingly, IMT studies in children and young adults 
have shown an association between increased carotid IMT and exposure to traditional risk 
factors such as high LDL and t-cholesterol (Li, Chen et al. 2003, Stein, Fraizer et al. 2004, 
Wiegman, de Groot et al. 2004). Notwithstanding this association between IMT and 
traditional CVD risk factors, it appears that the individual genetic background may also play 
an important role (Lanktree, Hegele et al. 2009). In fact, many of the factors that influence 
IMT can be considered, at least partially, to be genetically determined, namely the presence 
of familial hypercholesterolemia, systolic blood pressure and type 1 diabetes. These factors 
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are also closely related with the development of arteriosclerosis which is defined as arterial 
sclerosis (smooth muscle hyperplasia and intimal fibrocellular hypertrophy) which is mainly 
due to chronic pressure overload against the arterial wall due to increased blood pressure. 
Thus, the presence of arteriosclerosis could be the underlying cause for IMT thickening 
(Roman, Saba et al. 1992).  
This notion that there is a strong genetic determination for IMT thickness is supported by 
studies done in children, showing that those with hypercholesterolemia and diabetes had 
increased IMT compared to healthy controls (Jarvisalo, Jartti et al. 2001).  
Despite the widespread use of IMT measurement in clinical trials (Hurst, Ng et al. 2007) 
recent data appear to suggest that its predictive role is not that strong. Lorenz et al. (Lorenz, 
Markus et al. 2007) reviewed and summarized the data from more than 37,000 patients and 
reported that the age and sex-adjusted overall estimates of the relative risk of myocardial 
infarction were 1.26 (95% CI, 1.21-1.30) per standard deviation of the common carotid IMT 
difference and 1.15 (95% CI, 1.12-1.17) per 0.10mm of the common carotid artery IMT 
difference. The age and sex-adjusted relative risks of stroke were 1.32 (95% CI, 1.27-1.38) 
per standard deviation of common carotid IMT difference and 1.18 (95% CI 1.16-1.21) per 
0.1mm common carotid artery IMT difference. The conclusions were that the IMT appeared 
to be a stronger predictor of stroke than of MI. The main sources of heterogeneity were 
related to age distribution, definition of the carotid segment and the type of IMT 
measurement protocol used. This report, although not denying the concept that IMT may be 
a surrogate marker for atherosclerosis, exposes its limitations, arguing that this was probably 
due, at least partly, to the relatively poor data about IMT progression (Adams, Nakagomi et 
al. 1995, Bots, Baldassarre et al. 2007). More recently, Den Ruijter et al. (Den Ruijter, Peters 
et al. 2012) have published a meta-analysis including 14 population-based cohorts (45 828 
patients) for a median follow-up of 11-years. Classical Framingham risk scoring was 
performed together with the extended model, which included common carotid IMT 
measurements to estimate the absolute 10-year risk for developing first-time MI or stroke. 
The net reclassification improvement with the addition of IMT was small (0.8%; 95% CI, 0.1-
1.6%). In those at intermediate risk the net reclassification improvement was 3.6% in all 
individuals (95% CI, 2.7-4.6%). The conclusion was that the addition of IMT to the traditional 
Framingham risk score offered little improvement to the 10-year prediction of first-time MI or 
stroke, with unlikely clinical benefits. However, all these studies were done in the general 
population for which the Framingham score was devised. It could be argued that in SLE, the 
impact of re-stratification using the IMT could potentially be greater as the CVD risk in these 
patients is notoriously difficult to estimate through standard methods. 
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Notwithstanding this, further studies (Rundek, Arif et al. 2008) appear to suggest that the use 
of plaque area and texture may offer a stronger correlation with CVD-related events as will 
be discussed below. 
1.5.2.2: 2D Plaque analysis 
 B-mode US of the carotid artery permits direct visualization of the systemic arterial 
vasculature. Furthermore, it allows the measurement of the thickness of the arterial wall as 
well as the detection of plaque, its location, size and nature each of which has a strong 
positive correlation with the occurrence of CVD-related events.  
The definition of plaque is not homogeneous in the literature. According to the Mannheim 
Carotid IMT Consensus, plaque is defined as “a focal structure that encroaches into the 
arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or demonstrates a 
thickness >1.5 mm as measured from the media-adventitia interface to the intima-lumen 
interface” (Touboul, Hennerici et al. 2004, Touboul, Hennerici et al. 2007). In my own 
vascular US assessment, I have used a slightly different definition of plaque according to the 
standard practice of Professor Andrew Nicolaides and Dr Maura Griffin at the unit where the 
scans were carried out, as cited in their previous publications and epidemiological studies. 
Thus, for the purposes of this thesis, plaque was defined as “a focal structure that 
encroaches into the arterial lumen of at least 0.5 mm or 50% of the surrounding IMT value or 
demonstrates a thickness >1.2 mm as measured from the media-adventitia interface to the 
intima-lumen interface” (Ebrahim, Papacosta et al. 1999, Griffin, Nicolaides et al. 2002). 
The risk factors for IMT thickening and presence of plaque appear to differ slightly: carotid 
plaques appear to be more influenced by conventional risk factors such as age, gender, type 
2 diabetes and smoking (Moskau, Golla et al. 2005).  
Carotid plaque is more frequently observed in the bulb region compared to the common 
carotid artery. Two explanations can be offered to justify this difference: on the one hand, the 
blood flow in the bulb area is turbulent, as opposed to the laminar blood flow typically 
observed in the common carotid, and this increases shear force stress on the arterial wall, 
facilitating endothelial injury in the bulb. On the other hand, even in the presence of plaque, 
the medial layer in the bulb area is much thinner than that of the common carotid where it is 
more common to find IMT thickening and plaque concomitantly. This suggests that a purely 
atherosclerotic process is involved in carotid plaque formation in the bulb region, while a 
combination of atherosclerosis and arteriosclerosis could be present in common carotid 
plaque formation (Li, Duncan et al. 1994). 
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The presence of carotid plaques has been shown to be an independent risk factor for 
cardiovascular events, with a much higher positive predictive value than IMT thickness 
(Griffin, Nicolaides et al. 2002). There is a difference between CCA IMT versus bulb IMT and 
plaque: the first correlates better with cerebrovascular disease while the latter are more 
directly associated with coronary artery disease-related events (Allan, Mowbray et al. 1997). 
Although the presence of thickened IMT in the CCA may be a precursor for plaque formation 
it is not a necessary condition, as epidemiological studies show that there can be plaque in 
the carotid bulb in the absence of increased CCA IMT thickening (Bonithon-Kopp, Touboul et 
al. 1996, Prati, Vanuzzo et al. 2006). 
The relevance of the positive predictive value of carotid plaque (in either CCA or bulb) for 
coronary artery disease-related events (MI and death) was firmly established through a 
series of large-scale population studies. The most relevant are summarized in Table 3.  
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Study n 
(% 
women) 
Age 
(years) 
Follow-
up 
(years) 
Carotid US 
parameters 
Endpoint HR for this 
endpoint in 
patients with 
plaque  
(95% CI)α 
Tromsᴓ 
study 
(Johnsen
, 
Mathiese
n et al. 
2007) 
6,226 
(52) 
25-84 6 Plaque area at 
CCA, bulb and 
ICA 
MI 3.95 (women) 
1.56 (men) 
APSIS 
(Held, 
Hjemdahl 
et al. 
2001) 
558 (33) 60 (SD 
7) 
3 Plaque at CCA, 
bulb, ICA, ECA 
and CFA 
MI/ CAD 
death 
1.83-2.00 
 
KIHD 
(Salonen 
and 
Salonen 
1991) 
1,228 (0) 42-60 2.5 n plaque vs. 
non-stenotic 
plaque vs. 
stenotic plaque 
MI Non-stenotic: 
4.15 vs. 
Stenotic: 6.71 
ARIC 
(Hunt, 
Evans et 
al. 2001) 
12,375 
(54) 
45-64 5.2 Plaque at CCA, 
bulb and ICA 
MI/ CAD 
death 
1.04-1.78 
Rotterda
m study 
(van der 
Meer, 
Bots et 
al. 2004) 
6,389 
(62) 
≥55 7-10 Plaque at CCA, 
bulb and ICA 
MI 1.83 
 
 
 
 
 
Table 3: Carotid plaque as a prognostic indicator for acute coronary events (adapted with 
permission from (Nicolaides 2011)(n: number subjects; HR hazard ratio; CI confidence interval; APSIS: 
angina prognosis study in Stockholm; ARIC: atherosclerosis risk in communities study; KIHD: Kuopio 
ischaemic heart disease study.  adjusted for age, gender and conventional risk factors). 
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Overall, all these studies suggest that, regardless of the location, the presence of carotid 
plaque is associated with an increased risk for ACS. Furthermore, it is suggested that 
greater plaque area and the presence of >50% stenosis can be associated with further 
increase in the risk for ACS. Recently, Johri et al showed that in patients with carotid plaque 
(IMT ≥0.14cm) there was significant increase in moderate (luminal narrowing greater than 
50% of at least one segment or severe coronary artery disease) or severe (luminal 
narrowing of at least 70% within any segment of the main artery branches) coronary artery 
disease compared with those with no carotid plaque (IMT< 0.14cm) (46 vs 3 p< 0.001) 
(Johri, Chitty et al. 2013). 
Besides quantitative plaque characterization, i.e. thickness and area, the plaque composition 
has also been shown to correlate with the risk of CVD-related events. As described above, 
an atherosclerotic plaque is made of varying proportions of lipids, smooth muscle cells, 
fibrotic tissue, platelets and inflammatory cells such as macrophages and neutrophils. Due to 
the different way each of these components interacts with the sound waves used in US, the 
aspect of a plaque in US is greatly influenced by its composition. Whilst lipid deposits are 
echolucent (black), calcium deposits and connective tissue are echogenic (white) and 
therefore, depending on the relative amount of these components, the US image of the 
plaque can offer an idea of the plaque composition. Calcified and non-calcified material can 
be distinguished easily as sound waves cannot travel through calcified deposits. This means 
that when an echogenic area is made of calcified material, there is a posterior shadow. In 
contrast, non-calcified echogenic areas allow for US to penetrate and be reflected back thus 
not eliciting the same shadowing effect. Initially it was thought that these non-calcified 
echogenic areas were composed of fibrotic tissue. However, studies using contrast US using 
micro bubbles have shown that they are actually rich in small blood vessels which 
correspond histologically to neo-vascularization within the plaque. These hyperperfused 
areas are thought to correlate with the presence of macrophages (Shah, Balan et al. 2007, 
Griffin, Kyriacou et al. 2010). 
Based on these principles, a scale ranging from 1-5 has been devised to characterize 
different types of plaque according to their visual aspect (Figure 7). A type 1 plaque is almost 
exclusively echolucent i.e. >80% of the plaque appears to be black in US (Figure 7-A and 7-
Aa). A type 2 plaque is predominantly echolucent (>50% black) but some non-echolucent 
components start to appear (Figure 7-B). A type 3 plaque is constituted by echolucent and 
echogenic material in similar proportions (Figure 7-C) while a type 4 plaque is almost 
exclusively echogenic but has no posterior shadowing as its echogenicity is given by the 
presence of collagenous or fibrotic tissue (Figure 7-D and 7-Dd). Finally, a type 5 plaque is 
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composed predominantly calcified material, hence a posterior shadowing effect in observed 
obscuring the image (Figure 7-E and 7-Ee).   
81 
 
 
Figure 7: Qualitative score for plaque echostructure based on its US appearance (relative 
predominance of echolucent and echogenic components). Type 1 (A and Aa): >80% echolucent structure; 
Type 2 (B): >50% echolucent but echogenic components start  to become apparent; Type 3 (C): similar 
proportion of echogenic and echolucent  elements; Type 4 (D and Dd): predominantly echogenic but no 
posterior shadowing is observed; Type 5 (E and Ee): calcified plaque with posterior shadowing obscuring 
the lumen and far wall). 
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The type of plaque has been shown to correlate with the risk of stroke in a large scale 
observational study, the “Asymptomatic Carotid Stenosis and Risk of Stroke (ACSRS) study” 
(Nicolaides 1995, Nicolaides, Sabetai et al. 2003). This study followed up 1115 subjects with 
asymptomatic carotid plaque during a mean 84 month period and found that 94% of strokes 
had happened in patients who had type 1, 2 or 3 plaques. Furthermore, when comparing the 
relative risk of stroke, plaques 1-3 had a 5 fold increased risk of being associated with stroke 
compared to type 4 and 5 plaques. Moreover, even when comparing type 1 or 2 plaques 
with type 3 or 4, the first were associated with twice the risk of stroke. This finding suggests 
that the type of plaque may be as important as its size in terms of risk of stroke. 
The main limitation to this classification method is that is observer-dependent and therefore 
there is a degree of variability which can be particularly relevant in plaques with borderline 
appearance.  As previously discussed, the use of normalization can minimize variability by 
standardizing resolution, equipment-related variables and image acquisition differences. The 
use of automated software which is able to determine objectively the texture features of 
plaques further minimizes variability.  US images are coded in a grey-scale ranging from 
black to white which enables the software to recognize different patterns or textures. The 
underlying basis for texture analysis software is the Grey-scale median (GSM). The basis for 
this colour coding system is Haralick’s texture features (Textural Features for Image 
Classification, 1973) which relies on the principle of grey-level co-occurrence matrix. This 
value is obtained through a series of complex equations which compare the number of grey 
pixels in an image with the blood (black) and adventitia (white) as reference points (Tesar, 
Shimizu et al. 2008). 
Therefore, with plaque texture analysis software, the GSM is calculated as a numerical 
value, with lower values corresponding to more echolucent i.e. lipid-rich plaques thus 
eliminating the subjective component of the previously described classification method. 
However, qualitative plaque texture classification is still useful when texture analysis 
software is not available, provided that it is done by an experienced observer and that inter-
observer variability is low. 
The use of texture analysis software also allow for further plaque composition 
characterization. It identifies the presence of black areas near the lumen and determines 
their area. This corresponds to the necrotic core previously described, which is associated 
with a greater risk of plaque rupture, particularly if a thin fibrous cap is present. The software 
also identifies discrete white areas within the plaque which correspond to the presence of 
neo-vessels. 
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In my thesis I will use both the qualitative visual scale plaque classification and the GSM 
calculated by image analysis software as specified in the Material and Methods section. 
1.5.2.3: 3D Plaque analysis 
3D imaging relies on the principle of image reconstruction using serial 2D pictures and can 
be applied to a range of methods like CT, US or MRI. The use of 3D US was first developed 
by Fenster et al. in the context of prostate cancer (Tong, Downey et al. 1996, Fenster, 
Downey et al. 2001). Its potential use in vascular imaging particular in carotid arteries was 
explored  with a view to assess carotid atherosclerotic burden (Landry, Spence et al. 2004). 
The 3D US technique relies mainly on the type of probe used as well in specialized software 
that can then reconstruct the final 3D image from a series of consecutive 2D “slices”. The 
precise methods through which this is done are extremely complex and outside the scope of 
this thesis and therefore I will not explore them. Grossly, the US probe used in 3D US has a 
particular arrangement of the piezoelectric crystals that generate and receive the echoes 
which compose the US image (Figure 8).  
The use of 3D US acquisition methods has evolved from a free-hand technique that required 
the translation of a transducer over the artery while 2D images were acquired to form a 
volumetric dataset to the use of automated single sweep 3D imaging methods, allowing for 
the acquisition from a stable probe position (Johri, Chitty et al. 2013, Kalashyan, Saqqur et 
al. 2013). 
These measures allows the transducer to code the visual information obtained as a matrix of 
points (“voxels”) representative of the volume scanned which are then processed by 
specialized software ultimately producing a 3D image (Chiu, Egger et al. 2006, Egger, 
Spence et al. 2007). After image processing by the software, the end result is an initial 
image which corresponds to a conventional one obtained by 2D US (acquired phase) and 3 
further images which would correspond to the constructed images produced by the software 
in different perspectives (i.e., if the acquired phase was obtained in a transverse cut, the 
constructed images would be longitudinal and coronal views) as well as a final 3 D 
reconstruction. 
An example of this is shown in Figure 9 where a grape is depicted. Further explanation of 
the method and software will be offered in the methods section. 
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Figure 9: 3D US of a grape: 1 represents the acquired phase (transverse view). 2 and 3 are constructed 
views (coronal and longitudinal respectively). 4 is the 3D reconstructed image based on the acquired and 
constructed views. 
 
Figure 8: Vascular US probes: Conventional linear vascular US probe (A) and 3D 
US probe (B). 
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One of the great advances made by 3D US was in vulnerable plaque identification and 
assessment. It is much more sensitive than conventional 2D US techniques in detecting 
small plaque ulcerations and it has a higher resolution which allows it to detect fibrous cap 
thinner than 200m which is below the detection limit of most conventional US probes. 
Moreover, 3D imaging allows for accurate measurement of the volume of juxtaluminal black 
areas which are known to represent a major risk factor for plaque rupture. The accuracy of 
3D US parallels that of intra-vascular US with virtual histology which has shown to have 
overall predictive accuracies greater than 93% in discriminating plaque components, i.e. 
fibrotic tissue, fibrofatty tissue, necrotic core and calcium (Diethrich, Pauliina Margolis et al. 
2007, Nair, Margolis et al. 2007).  
Similar to what has been previously described for the GSM in 2D plaque imaging, a mean 
grey value (MGV) can be obtained in 3D US. Heliopoulos et al. performed 3D US in 110 
symptomatic (stroke) and 104 asymptomatic atherosclerotic plaques. The plaques’ MGV 
was determined and it was found that symptomatic patients had significantly lower MGV 
than asymptomatic patients when considering plaques producing  less than 70% stenosis 
(Heliopoulos, Vadikolias et al. 2008). 
In addition to texture features, 3D US can also determine the volume of both vessel wall and 
plaque. The relation between these two variables is much more accurate in assessing the 
evolution of plaque size over time than conventional 2D US. In the clinical setting, 3D US 
can be a sensitive way to assess the response to treatment with lipid lowering agents at 
plaque level. Ainsworth et al. reported on the effect of atorvastatin on plaque volume and 
were able to detect significant changes after only three months of treatment (Ainsworth, 
Blake et al. 2005). Thus, 3D US could provide alternative intermediate end points to assess 
the efficacy of treatment approaches in CVD. 
Johri et al compared the predictive value of 2D and 3D carotid ultrasound for the presence of 
coronary artery disease (CAD) and found that the presence of plaque identified by either of 
these two methods had a high positive predictive value for the presence of CAD. Using an 
IMT-thickness cut-off of 0.14cm, the 2D carotid US yielded 93.9% sensitivity while a 
threshold of 0.09mL of plaque volume showed 98% sensitivity for the presence of CAD. 
However, the negative predictive value of 3D US was significantly higher than that of the 2D 
assessment, with a specificity of 93.3% vs 75% respectively (Johri, Chitty et al. 2013). 
Makris et al recently reviewed the clinical evidence regarding the reproducibility and 
effectiveness of 3D ultrasound in carotid plaque characterization and concluded that  
besides good reproducibility in the assessment of various plaque features, it appears to yield 
86 
 
a an increased sensitivity to identify plaque changes post-treatment (Makris, Lavida et al. 
2011). Nonetheless, there are still no solid data to confirm the superiority of 3D US 
compared with the traditional 2D approach. Further research to establish the cost-
effectiveness and increased sensitivity in identifying vulnerable plaques and/or re-stratify 
patients with asymptomatic carotid stenosis is required.  
On balance, automated 3D carotid US is a reproducible, non-invasive method which can 
assess the presence and characterize atherosclerotic plaques in a way which appears to be 
as reliable as the traditional 2D ultrasound (Kalashyan, Shuaib et al. 2014) with at least 
similar sensitivity and specificity for CVD-risk prediction. 
 
1.5.3: Vascular US use for assessing cardiovascular disease in the context of SLE 
In a recently published review, the current options for imaging assessment of CVD in SLE 
were explored (Croca and Rahman 2012). The roles for MRI and CT based imaging 
techniques for evaluating SLE-associated myocardial dysfunction and both coronary and 
peripheral (carotid) artery atherosclerosis have now been largely explored. In some 
instances, such as cardiac magnetic resonance for assessing subclinical myocardial 
dysfunction, the sensitivity is undisputed but its cost and real-life clinical benefits prevent its 
more generalized use (Been, Thomson et al. 1988, Mavrogeni, Spargias et al. 2009, O'Neill, 
Woldman et al. 2009). Other methods are considered unsuited for assessing asymptomatic 
patients due to either radiation exposure or procedure risk deriving from their invasive 
nature.  
Carotid US is an accurate, non-invasive method for assessing atherosclerotic disease 
through the measurement of the IMT and plaque quantitative and qualitative 
characterization. The prevalence of carotid plaque in the context of SLE ranges from 17% to 
40% (Manzi, Selzer et al. 1999, Svenungsson, Jensen-Urstad et al. 2001, Doria, Shoenfeld 
et al. 2003, Roman, Shanker et al. 2003, Selzer, Sutton-Tyrrell et al. 2004, Wolak, Todosoui 
et al. 2004) whereas in control groups of healthy women its mean prevalence is 18% 
(Svenungsson, Jensen-Urstad et al. 2001, Roman, Shanker et al. 2003, Thompson, Sutton-
Tyrrell et al. 2008). The Aging Vascular Study (EVA) which assessed the presence of carotid 
plaque in a cohort of asymptomatic women between the ages of 59 and 71 years show a 
prevalence of plaque of 19% which is still lower than the average 30% reported for much 
younger SLE-cohorts (Zureik, Ducimetiere et al. 2000). 
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Manzi et al. (Manzi, Selzer et al. 1999) reported on the use of B-mode carotid US in a cohort 
of 175 patients with SLE, 15% of whom had a previous CVD-related event. IMT and number 
of plaques and plaque thickness were considered. It was reported that 40% had at least one 
focal plaque and over 20% had at least one plaque occupying >50% arterial lumen. A higher 
prevalence of plaque was found in patients with higher cumulative damage measured by the 
modified SLICC damage score and with higher cumulative steroid dose and duration of 
treatment. The same group reported on the longitudinal progression of plaque size and IMT 
thickness comparing a cohort of 217 patients with SLE and 104 matched healthy controls 
(mean follow-up period of 5 years) (Thompson, Sutton-Tyrrell et al. 2008). They reported 
progression of plaque in 27% of patients (defined as an increase in plaque thickness and/or 
number of plaques) and a mean rate of IMT increase of 0.011mm/year. Plaque progression 
was significantly higher in the lupus cohort compared to healthy controls (27% vs. 10%) but 
no differences were found in IMT progression, though this may have been different if a 
longer follow-up period had been observed. The same group revisited the assessment of B-
mode imaging of carotid arterys in a cohort of 392 women with SLE and no previous CV 
events (Kao, Lertratanakul et al. 2013).  In this prospective, observational study including 
392 adult women with SLE (mean age was 43.5 years) under follow-up for at least 8 years, 
38 patients had a cardiovascular event and 17 had suffered what was defined as “hard 
event” including myocardial infarction, fatal cardiac arrest and cerebrovascular accident. 
Increased baseline IMT and presence of plaque was predicitive of all types of cardiovascular 
events (HR 1.35 and 4.26 respectively), independently of traditional CV risk factors and 
medication use. It was thus concluded that women with SLE without previous CV events, 
carotid IMT and plaque were predictive of future CV events. 
 
The factors more strongly associated with increased IMT were increased serum creatinine 
and lower diastolic blood pressure. The presence of impaired kidney function closely 
correlates with the presence of vascular damage (O'Rourke and Safar 2005). Therefore it 
can be hypothesized that systemic inflammation associated with SLE is involved in vascular 
damage which is relevant for the pathophysiologic processes underlying both CVD and 
kidney dysfunction (Doria, Shoenfeld et al. 2003, Manger, Kusus et al. 2003). Low diastolic 
blood pressure on the other hand, is a well-known marker of arterial stiffening which in turn 
is considered to be the precursor of atherosclerosis as it marks the presence of endothelial 
dysfunction (O'Rourke, Staessen et al. 2002). With regards to plaque progression, it was 
found that the most influential factors were higher triglycerides and C3 levels as well as the 
use of immunosuppressants at baseline. Although the link between higher triglycerides and 
plaque progression is not surprising, the same cannot be said for the relation with higher C3 
levels and immunosuppressant use. Higher C3 levels have been previously described in 
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association with coronary calcifications (Manger, Kusus et al. 2003) but the links between 
complement levels and vascular disease are yet to be clarified. 
To my knowledge, no studies have been done using plaque area or texture feature analysis 
in SLE nor have there been any reports on the use of 3D US in this specific population. 
In summary, the use of carotid US in the assessment of atherosclerosis in the context of 
SLE has already been explored but its full potential, particularly in asymptomatic patients, is 
yet to be achieved. Ideally, a link between disease-related markers, either traditional (C3, 
anti-dsDNA) or novel (nitration measures, anti-apoA1) would be established. Thus, when a 
patient was diagnosed with SLE and presented a serological profile pointing towards a 
higher CVD-risk, carotid US imaging could be used to assess her  baseline atherosclerotic 
profile and follow-up its evolution over time. The combination of clinical assessment, 
serological profiling and imaging studies could prove to be the key for early diagnosis and 
primary prevention of CVD related events, and thus allow for mortality and morbidity 
reduction among patients with SLE. 
My aim in this part of my thesis is to assess the presence of plaque in patients with SLE who 
are completely asymptomatic for CVD, i.e. they have not had strokes/ transient ischaemic 
accidents (TIA), MI/ angina and peripheral vascular disease/ intermittent claudication. 
Furthermore, I aim to establish the prevalence of plaque and characterize it in terms of its 
composition/ texture, area/ volume and correlate these data with the patients’ characteristics. 
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2: AIMS 
Stemming from the concept of increased atherosclerotic burden among patients with SLE 
and bearing in mind the theoretical background established in the Introduction, one of my 
key goals in this thesis is to assess the presence of plaque in a cohort of 100 patients with 
SLE with no prior history of cardiovascular disease –related events or symptoms suggesting 
that underlying, clinically significant atherosclerosis is present by performing high-sensitivity 
vascular ultrasound scans of the carotid and femoral territories.  
Besides obtaining IMT measurements and establishing plaque prevalence, I aim to fully 
characterize each individual plaque in terms of its composition/ texture as well as its area/ 
volume. Additionally, I will compare the data from the SLE cohort with a group of age and 
sex matched non-SLE controls that underwent similar ultrasound assessment and establish 
whether there are differences in IMT thickness, plaque prevalence, size and texture.  
The vascular ultrasound cohort will be extensively characterized including demographics, 
SLE-associated features (organ involvement, disease activity indexes and classic auto-
antibody profile), general metabolic profile (including lipid profile, renal function and blood 
pressure measurements), treatment and specific, not standardly used serological tests. In 
this cross-sectionally cohort of patients I have chosen to assess antibodies directed against 
both HDL and anti-apoA1 (IgG and IgM subclasses) as well as to determine levels of nitrated 
nucleosomes and nitrated apoA1 as they could be a surrogate marker for endothelial 
activation.   
Aiming to comprehensively characterize protein nitration (nucleosomes and albumin) and 
anti-apoA1 IgG antibodies levels over time, I have assessed these two targets in a separate, 
longitudinal cohort of patients, using multiple samples collected over time and spanning a 
representative period of each individual patient’s disease course (periods of flare and 
remission) . This will allow me to establish if these two variables vary over time and whether 
they correlated with treatment, auto-antibody profile and disease activity.  
Additionally, I aim to determine the prevalence of anti-apoA1 antibodies early in the course 
of SLE and whether this influences patient outcome, namely in terms of mortality and 
morbidity, particularly in what concerns cardiovascular events.  
After carrying out these tasks I will be able to establish the prevalence of asymptomatic 
atherosclerosis in a cohort of patients with SLE with no clinically evidence of cardiovascular 
disease and determine IMT, plaque distribution, size and echogenicity/ texture. Moreover, I 
will be able to report on the impact of non-SLE related variables (lipid profile and blood 
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pressure) and SLE-related factors (disease activity and auto-antibody profile) on IMT and 
plaque characteristics. 
The overarching hypothesis throughout this thesis is that patients with SLE have subclinical 
atherosclerosis and that the presence of increased endothelial activation indirectly assessed 
by the measurement of nitrated proteins, the presence of increased inflammation due to 
greater disease activity as well as specific auto-antibodies, particularly those directed 
against the HDL complex may be associated with increased likelihood of plaque/ IMT 
thickening. If this hypothesis is confirmed, it would make a strong argument for the screening 
of all patients with SLE to allow for early recognition of those who may have increased 
cardiovascular risk and would thus benefit from closer monitoring and early treatment in 
order to prevent mortality and morbidity. 
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3: MATERIALS AND METHODS 
3.1: Patient selection  
Throughout my research project, I have assessed three distinct, but overlapping, groups of 
patients with SLE: a longitudinal cohort comprised of 397 samples taken from 49 patients 
(longitudinal group); a cross-sectional cohort of 499 samples taken from 499 individual 
patients within two years of SLE diagnosis (early disease group) and a cross-sectional 
cohort of 100 patients with SLE with no history or symptoms suggesting CVD selected to 
undergo vascular US (vascular US group). Figure 10 represents the three cohorts 
considered and the number of patients overlapping between them. 
For my serological studies, I selected 100 healthy controls and 17 patients with rheumatoid 
arthritis (RA).  All the patients with SLE fulfilled the revised ACR classification criteria. 
Comprehensive demographic and clinical characterization was obtained for all the patients 
with SLE, including auto-antibody profile, disease activity profile and treatment, namely 
steroid dose at the time of sample collection as well as immunussupressant regimen when 
applied (mycophenolate mophetil, azathioprine, cyclophosphamide, cyclosporine and B-cell 
depletion) and whether the patient was taking hydroxychloroquine. 
I was able to access vascular US data from a non-SLE cohort in Cyprus, who had been 
scanned using the same protocol that I used.  Though these scans were not done by me and 
I had no involvement in acquisition of the data, I have used them as a control cohort for 
comparison with the vascular US data that I obtained in patients with SLE. For this reason I 
have described this non-SLE cohort below. 
I will now offer a more detailed description of each of these cohorts and their selection 
criteria.  
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  Figure 10: Venn diagram depicting the three overlapping cohorts assessed. The longitudinal 
cohort included 49 patients of which 47 were present on the early disease cohort and 18 on the 
vascular ultrasound group. The early disease group was comprised of 499 patients, 90 of which 
were also included on the vascular ultrasound cohort. Eighteen patients belong to all 3 groups. 
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Longitudinal group 
Longitudinal serum samples (n= 397) were selected retrospectively from a cohort of 49 
patients with SLE. On average, each patient had 8 samples (SD 2.16; min 3; max 14) 
covering a mean follow-up of 89 months (SD 46; min 14; max 180). Patients who had 
suffered flares of disease activity in different organ systems during the follow-up time 
considered were preferentially selected and examples of flares in all the main organs and 
systems were included. 
For all samples where data were available (94% of samples), I obtained anti-dsDNA and 
complement C3 levels and disease activity from the date of the sample and from the 
previous three assessments. Anti-dsDNA and C3 were measured in the routine clinical 
laboratory at UCLH using enzyme-linked immunosorbent assay (ELISA) (Shield Diagnostics, 
Dundee, UK) and laser nephelometry respectively. Data on ethnicity, gender, drug therapy 
and anti-Sm, anti-RNP, anti-Ro and anti-La (all tested by ELISA) status of the patients were 
obtained from the clinical records of the patients. 
For the longitudinal group, measurements of NN, NA, anti-NCS and anti-ApoA1 IgG levels 
using the assays described below were performed. 
Early disease group 
Since the University College Hospital (UCH) Lupus clinic began (in 1978) sera from all the 
patients followed up over the years has been routinely collected and stored at -800C for the 
purposes of research, following informed consent according to ethical approval (described 
below). From this vast cohort of stored sera samples, 499 samples obtained from 499 
patients within two years of diagnosis were selected.  The earliest sample was obtained in 
1978 and the last in 2011.  All patients had been under continuous follow-up between one 
and 34 years (mean 12.1 years). 47 of these patients were also in the longitudinal group but 
different samples from later time-points in the disease course were used. 
Data on age at diagnosis, ethnicity, death, CVD-related events and auto-antibody profile 
were also obtained in >90% of samples. Data on SLICC damage scores were only available 
for 236 patients who had been previously included in a retrospective study assessing the 10 
year-follow up data (Chambers, Allen et al. 2009).  
In the early disease group, only anti-ApoA1 IgG levels were measured using the ELISA 
protocol described below. 
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Vascular ultrasound group 
100 patients with SLE and with no history of CVD-related events or symptoms suggestive of 
underlying CVD, including angina, intermittent claudication and TIA were selected. Of these, 
90 were also in the early disease group and 18 were in the longitudinal group. Vascular 
ultrasound scans of both carotid and femoral territories (common carotid, common femoral 
and their bifurcations) were carried out as described in section 3.4: “Vascular ultrasound of 
carotid and femoral arteries.” Data on disease activity, ethnicity, auto-antibody profile and 
treatment were obtained from the patient’s clinical records.  
Sera belonging to the patients included in this group were tested for NN, nitrated ApoA1, 
total ApoA1, anti-ApoA1antibodies (IgG and IgM) and anti-CCP antibodies (IgG and IgM). 
The anti-CCP IgG and IgM levels were measured by Dr Geraldine Cambridge using an 
ELISA protocol previously published (Cambridge, Stohl et al. 2006). 
 Healthy controls – serological tests 
I tested samples from 100 healthy control subjects, which were originally obtained as part of 
the Health Survey for England (HSE) 2006 and were used with the permission of the Health 
and Social Care Information Centre and NatCen Social Research (Copyright © 2008, all 
rights reserved). Anonymised data on age, gender and ethnicity of the subjects as well as 
confirmation of the absence of long term illness or history of CVD were also provided by the 
same organization. 
 Disease controls – serological tests 
I selected 17 patients with RA and a small cohort of patients with myositis (n= 12) and 
Sjogren’s syndrome (n= 13). These samples were obtained from patients under regular 
follow-up at the General Rheumatology Outpatient Clinic at UCLH and had previously given 
informed consent regarding sera storage and authorization for broad use in research carried 
out by the Centre for Rheumatology.  
. Non-SLE controls – vascular US 
In order to have a control non-SLE cohort who had undergone assessment using a similar 
vascular US protocol to that which I have performed, the patients I selected were matched 
with patients from the Cyprus Epidemiological Study (Griffin, Nicolaides et al. 2009) . In this 
study, volunteers aged 40 years or older were recruited from three randomly selected towns 
in Cyprus. These individuals were selected regardless of the presence of known CVD or risk 
factors for CVD namely smoking, altered lipid profile or diabetes. Due to the age range of the 
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SLE patients, I could not find appropriate matched controls for patients less than 40 years of 
age. However, for 66 of the patients with SLE I had scanned, 2 age and sex matched non-
SLE controls from the Cyprus study were selected. Unfortunately, it was not possible to 
match patients according to their ethnicity as the Cyprus population is mostly Caucasian 
origin. The scanning method I used was the same as that used to assess the Cyprus cohort, 
as well as the image analysis software. Furthermore, I was trained and had one-on-one 
supervision with Dr Maura Griffin who performed all the vascular US scans for the Cyprus 
study. Intra and inter-observer variability were determined to demonstrate reproducibility of 
the method. Thus, it is possible to compare our findings to those of the Cyprus group. The 
limitations of this method will be further explored in the Discussion section. 
Ethical approval for all parts of the study was granted by the joint University College 
London/University College London Hospitals (UCL/UCLH) Research Ethics Committee 
(Reference 06/Q0505/79) and subjects gave informed consent for use of their stored serum 
samples. The 100 patients who underwent vascular ultrasound scanning gave separate 
informed consent for that procedure. The patients belonging to the Cyprus Epidemiological 
Study also gave separate informed consent before undergoing vascular US. 
All the patients included fulfilled the revised ACR classification criteria for SLE (Hochberg 
1997). The patients with SLE are/were under the care of the Lupus Clinic at UCLH and have 
been under continuous follow-up for between one and 34 years.  
 
3.2: Definition of disease activity and laboratorial profile 
Several serological variables were measured at the UCH associated clinical laboratory. ANA 
was measured by immunofluorescence with a Hep-2 substrate and a titre of ≥1:80 was 
considered positive. Rheumatoid factor was measured by both latex testing and RA particle 
agglutination (RAPA) assay techniques (positive titre ≥1:80). The ENA profile, including 
antibodies to Ro, La, Sm and RNP, were measured by ELISA. Anti-dsDNA was determined 
by ELISA (Shield Diagnostics, Dundee, UK) and immunofluorescence with Crithidia luciliae 
as the substrate. Anti-dsDNA positivity was considered if the Crithidia test was positive or if 
the ELISA result was at least twice the upper limit of normal (normal <50 U/l) on two 
occasions. Complement component C3 was measured by laser nephelometry (normal 0.9g-
1.8/L). 
The classic BILAG was used to determine disease activity clinically (Hay, Bacon et al. 1993). 
Activity on the date of the sample (current activity) for each organ system was defined as 
high if the BILAG score was A or B and low if it was C, D or E. Disease activity was also 
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defined based on the numerical overall BILAG score: a score of less than 5 was considered 
to correspond to low disease activity while of score of 5 or above as high. 
In order to reflect sustained disease activity, in the longitudinal group, the most recent four 
assessments were considered. Persistently low activity was defined as all systems BILAG C, 
D or E and persistently moderate-high disease activity was considered if there was either a 
score of at least one A or more than one B in any BILAG system on at least 2/4 occasions. 
Fewer than 10% of the samples did not fit into either of these categories and were therefore 
excluded from this analysis. 
In the early disease group, data on damage at 5 and 10 years post diagnosis (and up to 20 
years in some cases) had been obtained on 236 patients. These data were used as a clinical 
outcome measure in the assessment of this cohort. Damage was measured by the Systemic 
Lupus International Collaborative Clinics Damage Index (SLICC-DI).  
For the patients included on the vascular US group, an extensive laboratory characterization 
was obtained from the UCH associated laboratory, including ESR, CRP, serum 
immunoglobulins (IgG, IgA and IgM), serum creatinine (creat), serum urea (urea), urine 
protein:creatinine ration (Up:C), albumin (alb), vitamin D (vitD), t-cholesterol, HDL, LDL, total 
cholesterol/HDL ratio (tC:HDL) and homocysteine. In this group, an exact match between 
date of scan (DOS) and date of assessment was not possible for all the variables. When not 
available at the DOS, the closest test taken within a year of the DOS was considered (>90% 
patients). When no tests had been taken within a year of the DOS I considered that data for 
that variable were unavailable.  
Finally, for this group, besides getting the overall BILAG score at the DOS, full data on 
disease activity based on the BILAG score were obtained. For 80% of patients, these 
records covered all the follow up time at UCH since the diagnosis of SLE. For the remaining 
20%, the mean disease period for which there was no record of BILAG score was ~8 years. 
Nonetheless, I included their data in the analysis but it must be stressed that data are not 
complete for the whole duration of the disease but for the duration of disease from the 
beginning of BILAG score recording. Based on these records, I considered different 
categories which attempt to portray disease activity over time for each patient: 
1) Number of visits with ≥2 B flares and ≥1 A flare;  
2) Mean monthly global BILAG score  
3) Cumulative global BILAG score during the first year of follow up (sum of the global 
BILAG scores registered at every hospital visit during the first year after diagnosis);  
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4) Mean global BILAG score (sum of global BILAG scores divided by the number of 
visits).  
These are not classical measures of disease activity, but they represent an effort to illustrate 
the way disease developed over time as patients with more active disease had not only 
higher global BILAG scores but also more frequent visits to hospital corresponding to 
periods of disease flare. 
Data on sustained disease activity (i.e. persistently active or inactive) as described for the 
longitudinal group were also recorded.  
 
3.3: Serological tests 
The specific serologic tests carried out by myself where used differently on the different 
cohorts assessed, i.e. not all these assays were used in all the cohorts assessed. Table 4 
summons which assays were performed in each individual cohort. 
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 Longitunidal cohort 
(n= 49) 
Early SLE cohort 
(n= 499) 
Vascular US cohort 
(n= 100) 
Nitration: 
NN 
NA 
NapoA1 
 
 
 
- 
 
- 
- 
- 
 
 
- 
- 
Anti-NCS  - - 
Total apoA1 - -  
Anti-apoA1 
IgG 
IgM 
 
 
- 
 
 
- 
 
 
 
Anti-HDL IgG - -  
Anti-CCP 
IgG 
IgM 
 
- 
- 
 
- 
- 
 
 
 
 
Table 4: Different serological assays performed by the candidate for each individual 
patient cohort considered throughout this thesis. 
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With the exception of the measurement of anti-CCP IgG and IgM antibodies which was 
kindly undertaken by Dr Geraldine Cambridge as previously described, all the following 
ELISA protocols were developed, optimized and carried out by me. I tested the 499 samples 
of the early disease group for anti-ApoA1 IgG with the help of a BSc student, Maria Davari. 
A few reagents and materials were common to the different ELISA protocols described 
below.  
Some procedures were also shared by these ELISA protocols and include the covering of 
the plate with cling film during before each incubation period, except when the HRP 
substrate was added in which case the plate was covered with tin foil due to its light 
sensitivity. 
For all the assays, net optical density (OD) was determined by subtracting the reading of the 
control side from the test side for each sample, to eliminate the contribution of non-specific 
background binding. 
The alkaline phosphatase substrate (ALP) (KPL 50-80-00) was made up fresh for every 
assay by diluting one tablet of pNPP (nitrophenyl-phosphate) in a solution made up by 
adding 1mL of diethanolamine (DEA) buffer to 4mL of distilled water. 
The OD values were converted into absorbance units (AU) by comparison to the standard 
curve obtained from the serial dilution of a positive control (PC) loaded onto every plate. The 
standard curve always included PC dilutions above and below the dilution selected to test 
the patients’ sera. It was defined that the OD for the PC dilution corresponding to the dilution 
used for the sera samples was 100 AU. From the curve thus obtained, an equation was 
obtained and used to calculate the AU values for the individual serum samples tested. For 
each ELISA protocol, an example of the serial curve will be shown, including a curve 
equation and a R2 value to demonstrate quality of adjustment between the curve and the 
trend line equation. This method was selected because, with the exception of the total 
apoA1 ELISA, the PC used was a pooled sera sample and a correspondence between OD 
and a known concentration could not be established. 
When using the ALP substrate, 4 readings were taken at 15min intervals (15, 30, 45 and 
60min). For all the assays using this substrate, the 60min reading was selected as it yielded 
the higher net OD. 
All the protocols described were found to be reproducible with intra and inter-plate coefficient 
of variation of <10%. 
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3.3.1: Indirect ELISA for detection of nitrated nucleosomes 
96-well Nunc-streptavidin plate (Thermo Scientific 236004) was divided in half: the test side 
was coated with biotinylated polyclonal goat anti-nitrotyrosine antibody (Abcam 27646) 
diluted 1:1000 in PBS (Gibco by Life Technologies 18912-014) and the control side coated 
with PBS (75L per well). After one hour incubation at 37°C, the plate was washed 3 times 
with PBS-0.1% Tween (Sigma 274348). Blocking was done by adding 200L per well of 
0.5% ovalbumin (Sigma A2512) in PBS-0.1% Tween for one hour at 37°C. During this 
period, serum samples were thawed and diluted at 1:30 in PBS. A pooled sera sample was 
used as positive control (PC). After washing the plate 3 times with PBS-0.1% Tween, a 4-
point dilution of the PC starting at 1:15 was loaded in duplicate on the first row of both the 
test and control half of the plate. Patients’ serum samples (100L/well) were added to both 
sides of the plate. After incubating for 1h at 37°C, the plates were emptied and washed 4 
times with PBS-0.1% Tween. The primary antibody (rabbit anti-histone H3 antibody; sc-
10809, Santa Cruz Biotechnology) was then diluted at 1:2000 in 0.5% ovalbumin in PBS-
0.1% Tween and added to the plate (50L per well). After 1h incubation at RT, the plate was 
washed 3 times with PBS-0.1%Tween. The secondary antibody (goat anti-rabbit IgG HRP 
conjugate; Sigma 0545) was diluted at 1:2000 in 0.5% ovalbumin in PBS-0.1% Tween and 
50L was added to each well. After incubating for one hour at RT and washing, HRP 
substrate (KPL 52-00-03) was added (100L per well). Following a 10min incubation at RT, 
the reaction was stopped with TMB stop solution (KPL 50-85-06) and OD read at 450nm. 
3.3.2: Indirect ELISA for detection of nitrated albumin 
The ELISA protocol used to determine the NA levels was very similar to the one previously 
described for NN. The relevant differences are as follows: 
- the blocking agent was used was 0.5% agarose in PBS  
- the primary antibody used was a rabbit polyclonal anti-human albumin antibody (Abcam 
2406) 
3.3.3: Direct ELISA for detection of anti-nucleosome antibodies 
A 96-well Nunc-Maxisorb plate (Sigma M9410) was divided in 2 halves: the test side was 
coated with 50L per well of nucleosome antigen diluted 1:500 in 20mM Tris/HCL buffer (pH 
8.0) containing 0.15M of NaCl; while the control side was coated with the Tris buffer alone. 
The plates were incubated at 37°C for 2h and then emptied and washed 3 times with PBS-
0.1% Tween. Blocking was done by adding 200 µL per well of 1% BSA-PBS-0.1% Tween 
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and allowing for 1h incubation at 37°C. During this period, the sera samples were thawed 
and diluted 1:50 in 1% bovine serum albumin (BSA) (Sigma A7030)-PBS-0.1% Tween. A 
pooled sera sample was used as a PC and a 4-point dilution starting at 1:25 was done in 
duplicate. After washing the plate, the sera samples (50L/well) were loaded in duplicate 
into test and control side. The plate was left to incubate for 30min at 37°C and then washed 
4 times with PBS-0.1% Tween. Afterwards, 50L of rabbit polyclonal anti-human IgG HRP 
conjugate (sc-2778, Santa Cruz Biotechnology) diluted at 1:1000 in 1% BSA-PBST was 
added to each well. After incubating for 30min at 37°C, the plate was washed and HRP 
substrate was added (100L per well). After 10min incubation at RT, the reaction was 
stopped with TMB stop solution and OD read at 450nm.  
Figure 11 shows the typical standard curves for the NN (A), NA (B) and anti-NCS (C) ELISA 
protocols. 
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Figure 11: Typical standard curves for the NN (A), NA (B) and anti-NCS (C) ELISA protocols. A pooled 
sera sample was used as a PC for these assays. Absorbance units (AU) were determined based the 
curve equation obtained for each standard (R2> 0.95). 
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3.3.4: Direct ELISA for detection of anti-ApoA1 antibodies 
3.3.4.1: Anti-ApoA1 IgG antibodies 
A Nunc-Maxisorb 96 well ELISA plate was divided in half and the test side was coated with 
50 µL of 10µL/mL of ApoA1 (Sigma A0722) in 70% ethanol, whilst the control half of plate 
was coated with 50 µL per well of 70% ethanol. The plate was incubated for 90min at 37°C 
and then emptied and washed 3 times with PBS. After tapping and removing all remaining 
washing buffer, the plate was blocked with 100 µL per well of 1% BSA diluted in PBS and 
allowed to incubate for 1h at 37°C. During this time, the sera samples were thawed and 
diluted 1:50 in 1% BSA-PBS. After emptying and washing the plate 3 times with PBS, the 
sera samples were loaded unto the plate. All samples were tested in duplicate on both the 
control and test half. On the first row of each side of the plate, a 7-point dilution of the 
positive control was performed starting at 1:25 dilution on the first 2 wells and followed by 
serial dilutions down to 1:1600. The positive control used was pooled sera sample from 5 
patients with SLE. After loading, the plate was incubated for 1 hour at 37°C and then 
emptied and washed 4 times with PBS-0.1% Tween. 50 µL per well of goat anti-human IgG-
alkaline phosphatase conjugate ( Sigma 3150) diluted 1:1000 in 1% BSA-PBS was added 
and allowed to incubate at RT for 1h. Finally, 50 µL of ALP substrate (KPL 50-80-00) was 
added to each well and absorbance read at 405nm at 15, 30, 45 and 60min.  
3.3.4.2: Anti-ApoA1 IgM antibodies 
A Nunc-Maxisorb 96-well ELISA plate was divided in half: the test side was coated with 50 
µL per well of 10µL/mL of ApoA1 in 70% ethanol and the control half with 50 µL 70% 
ethanol. The plate was incubated for 90min at 37°C and then emptied and washed 3 times 
with PBS. After drying, the plate was blocked with 100 µL per well of 1% BSA diluted in PBS 
and kept overnight at 4°C. The plate was again washed 3 times with PBS and allowed to 
dry. In the meantime, the sera samples were thawed, diluted 1:50 in 1% BSA and loaded 
unto the plate and tested in duplicate on both the control and test half. A pooled sera sample 
from 4 patients with SLE was used as the positive control and a 7-point dilution was loaded 
into first row of each side of the plate, as described above. After loading, the plate was 
incubated for 1 hour at 37°C and then emptied and washed 4 times with PBS-0.1% Tween. 
50 µL per well of goat anti-human IgM-HRP conjugate (Sigma A 6907) diluted 1:5000 in 1% 
BSA-PBS was added and allowed to incubate at RT for 1h. After washing 3 times with PBS-
0.1% Tween, 50 µL of HRP substrate was added to each well and allowed to incubate for 
5min, when the reaction was stopped with TMB stop solution and OD read at 450nm.  
3.3.5: Direct ELISA for the detection of anti-HDL antibodies 
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Human HDL (Sigma L1567) was diluted in distilled water to a concentration of 2mg/mL and 
stored as 1mL aliquots at -80°C. Smaller aliquots for everyday use were kept at -20°C. A 
Nunc-Polysorb 96-well ELISA plate (Sigma M0661) was divided into 2 halves: the test side 
was coated with 50µL per well of 20 g/mL HDL in 70% EtOH while the control side was 
coated with 50uL per well of 70% EtOH. After incubating for 1h at 37°C, the plates were 
washed 2 times with PBS and allowed to dry. Blocking was done by adding 100L per well 
of 1% BSA-PBS and leaving ON at 4°C. The plates were then washed twice with PBS and 
sera samples were loaded into the plate diluted 1:100 in 1% BSA-PBS (100L/well). All 
samples were tested in duplicate. On the first row of either side of the plate, a 7-point dilution 
of the PC starting at 1:50 dilution was loaded. The PC was a pooled sera sample from 5 
patients with SLE. The loaded plate was allowed to incubate for 1h at 37°C and then washed 
3 times with PBS. The secondary antibody (anti-human IgG alkaline phosphatase - Sigma 
A3150) was diluted 1:1000 in 1% BSA-PBS and 50L added to each well. Following 30min 
incubation at 37°C, the plate was washed 3 times with PBS and each well was loaded with 
50 L of ALP substrate. The plate was kept at 37°C and OD read at 405nm at 15, 30, 45 and 
60min.  
 
Figure 12 depicts the typical standard curves for the anti-ApoA1 IgG (A), IgM (B) and anti-
HDL IgG (C) antibodies.   
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Figure 12: Typical standard curves for the anti-ApoA 1 IgG  (A), anti-ApoA1 IgM (B) and anti-HDL IgG  
(C) ELISA protocols. A pooled sera sample was used as a PC for these assays. Absorbance units (AU) 
were determined based the curve equation obtained for each standard (R2> 0.95). 
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3.3.6: Indirect ELISA for the detection of nitrated ApoA1 
A 96-well Polysorb plate was divided in two and the test side was coated with 75µL of goat 
anti-nitrotyrosine antibody (Abcam 27646) diluted 1:2000 in PBS while the control side was 
coated with PBS alone. After incubating for 1h at 37°C, the plates were washed 3 times with 
PBS and blocked with 150L of 1%BSA-PBS per well. Following ON incubation at 4C, the 
plates were washed 3 times with PBS and 50µL of each serum sample were added in 
duplicate to both test and control side (1:100 dilution in 1% BSA-PBS). A 7-point dilution of 
the PC was loaded on the first row on either side of the plate as previously described, 
starting at 1:50 dilution. The PC used was a pooled sera sample from 6 patients with SLE. 
The plates were allowed to incubate for 1h at 37°C, washed 3 times with PBS-0.1% Tween 
and 50µL of the primary antibody (mouse anti-human ApoA1 antibody - MAB011-A/13) 
diluted at 1:5000 in 1% BSA-PBS were loaded into each well. Following a 30min incubation 
at 37°C and 3 washes with PBS-0.1% Tween, 50 µL per well of rabbit anti-mouse IgG-HRP 
conjugate (Dako P0161) diluted 1:2000 in 1% BSA-PBS were loaded and the plate left to 
incubate for 30min at 37°C. During this incubation period, enough HRP substrate for the 
following step was kept at RT. The plates were then washed 3 times with PBS-0.1% Tween 
and 50µL per well of HRP substrate was added and allowed to incubate for 5min at RT when 
the reaction was stopped with 50µL per well of TMB stop solution. OD was read at 450nm. 
3.3.7: Indirect ELISA for the detection of total ApoA1 
A 96-well Polysorb plate was divided into test and control sides: the test side was coated 
with 50µL per well of mouse anti-human ApoA1 (MAB011-A/13) diluted 1µg/mL in PBS while 
the control side was coated with PBS alone. Following a 1h incubation at 37°C, the plate 
was washed twice with PBS, blocked with 150µL per well of 1% BSA-PBS and left ON at 
4°C. After washing 2 times with PBS, the sera samples were loaded in duplicate on the plate 
(50µL of 1:1000 dilution per sample). The PC loaded on the first row on either side was a 7-
point dilution of ApoA1 (Sigma A0722) starting at 1.5µg/mL. The loaded plate was incubated 
for 1h at 37°C and then washed 3 times with PBS-0.1% Tween. To each well, 50µL of 
primary antibody (goat anti-human ApoA1 - Ab 7613) diluted 1:5000 in 1%BSA-PBS 0.1% 
Tween were added and the plate left to incubate for at 37°C for 30min. Following 3 washes 
with PBS-0.1% Tween, 50µL per well of the secondary antibody (rabbit anti-goat IgG-HRP 
conjugate - Dako P0160) diluted 1:5000 in 1%BSA in PBS-0.1% Tween were loaded. After a 
30min incubation at 37°C, the plates were washed 3 times with PBS-0.1% Tween and 50µL 
per well of the HRP substrate added and allowed to incubate for 5min at RT until colour 
change had occurred. At this point, 50µL of TMB stop solution was added to each well and 
OD read at 450nm.  
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Figure 13 illustrates the typical standard curves for the NApoA1 (A) and TApoA1 (B) ELISA 
protocols. The TApoA1 ELISA was the only one for which each point of the standard curve 
corresponds to a known ApoA1 concentration because pure commercial ApoA1 was the 
positive control for this assay. Therefore, for this assay only, instead of AU, concentrations in 
ng/mL are shown. In the Results section, mg/dL was the chosen unit to express TApoA1 
concentration as it is the routinely used in clinical practice.  
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Figure 13: Standard curves for the NApoA1 (A) and TApoA1 (B) ELISA protocols. A pooled sera sample 
was used as a PC for the NApoA1 assay and absorbance units (AU) determined as previously described. 
In the TApoA1 ELISA, the standard curve was obtained using serial dilutions of human ApoA1. 
Consequently, each point of this curve corresponds to a known ApoA1 concentration (ng/mL)(R2> 0.95). 
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3.4: Vascular ultrasound of carotid and femoral arteries 
3.4.1: Vascular US hardware and software specifications 
The ultrasound equipment use was the Philips IU22. The probes used were the L9-3 MHz 
for the 2D imaging and the VL 13-5 MHz for the 3D assessment. 
IMT measurements were performed using QLAB Advanced Quantification Software® 
version 7.1 (Philips Ultrasound, Bothell, USA). The same software was used to do the 3D 
US assessment and select 2D images for further image analysis. 
For plaque area and texture assessment, Plaque texture analysis software – image analysis 
program for ultrasonic arterial wall changes and atherosclerotic plaques - version 4.5 (LifeQ 
Ltd Copyright 2013) was used. The same software was also used for the 3D plaque texture 
and volume analysis as described further in the Methods section. 
3.4.2: Vascular US protocol 
Patients lay on their back on an examination couch. The neck and groin were exposed and 
clothes protected with tissue paper. The examination was sequential and began by 
assessing the left carotid artery, followed by the right carotid artery, right common femoral 
artery and finally the left common femoral artery.  
IMT measures were only considered on the carotid arteries (CCA and carotid bulb) and were 
always done in the posterior arterial wall. Measurement of the IMT on the CFA was done 
purely to determine inter-observer variability. 
Whenever plaque was present, colour and Power Doppler images were obtained to ensure 
that the outline of the plaque was accurately determined. This was particularly important in 
echolucent plaques. Regardless of their location, all plaques were considered and thickness 
was measured using manual callipers.   
Unless prevented by anatomical constraints, 3D US imaging was performed when carotid 
plaques were found. Plaques in the femoral arteries were not included in the 3D imaging 
protocol. Dr Maura Griffin did all the 3D US assessments after the 4 sites had been imaged.  
At the end of this assessment, while the patient was still lying down, blood pressure (BP) 
was measured in the left upper arm using an automated BP reader (Omron M6 HEM-700-E). 
Three measurements were taken and the first discarded. The average systolic and diastolic 
BP value was calculated using the second and third readings. The mean BP value was 
calculated for each patient using the following formula: 
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Mean BP= Diastolic BP + 1/3(systolic BP – diastolic BP) 
 
The US protocol I used to scan all patients is as follows: 
1) Carotid US imaging 
An overall assessment of the whole length of the carotid artery from the proximal extremity 
of the CCA to the carotid bifurcation into ICA and ECA was obtained by sweeping the neck 
in 2D mode with the probe placed transversely. This was followed by retracting back from 
the carotid bifurcation to the proximal CCA in colour mode. This technique allows for a gross 
assessment of whether any changes (i.e. plaque) are present. The probe was then placed in 
the mid-section of the CCA and a longitudinal view was obtained. Once the artery was 
aligned (i.e. probe at a 90 degree angle thus showing clear differentiation between tissue 
interfaces), the image was zoomed in and a still picture was captured to allow for IMT 
measurement. After measuring the IMT, the image was un-frozen and a short video clip of 
the CCA was obtained for arterial wall motion analysis. The probe was then turned and a 
transverse view of the CCA was obtained. After aligning the vessel (i.e. showing IMT on the 
top and bottom of the artery), a measurement of the IMT was obtained. As in the longitudinal 
view, a video-clip of the CCA in transverse view was recorded.  
After completing the assessment of the CCA, I moved up to the bulb. When possible, a 
longitudinal view of the carotid bifurcation was obtained, showing a small segment of distal 
CCA, the carotid bulb and both the ICA and ECA (Figure 14). To confirm the relative position 
of the ICA and ECA, an image of the first ECA branch, the superior thyroid artery, was 
always obtained even when it was not possible to get all the vessels on the same plane. 
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Figure 14: Longitudinal US view of the carotid bifurcation:  the distal portion of the CCA 
gradually balloons to form the carotid bulb (signalled by the red line). Subsequently, the 
two branches formed after the first division of the CCA emerge:  ICA, the ECA and its first 
branch, the superior thyroid artery. 
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When this was not possible due to anatomical variations, a longitudinal view of the internal 
carotid artery was obtained, including a portion of the CCA, carotid bulb and proximal 
segment of the ICA. Once the vessels were aligned, a still image was recorded and the IMT 
in the bulb origin was obtained. Bulb origin was defined as the area when the CCA starts to 
balloon out. To ensure that no plaque was present, colour and Power Doppler images of the 
carotid bifurcation were obtained showing the absence of filling defects. The US probe was 
then re-positioned: a transverse view of the bulb origin taken just before the carotid 
bifurcation was obtained and the IMT was again measured. If plaque was present, the IMT 
measurement in the bulb was disregarded and the plaque thickness was considered instead. 
2) Femoral US 
The probe was placed transversely in the groin area. After identifying the CFA, the artery 
was followed in transverse until the bifurcation became apparent. The probe was then turned 
and a longitudinal view was obtained which included the distal portion of the CFA and the 
division into deep and superficial CFA. When the position of the branches of the CFA 
prevented capturing a view of the bifurcation, an image of the CFA continuing into deep 
femoral artery was accepted. As described before, colour and Power Doppler images were 
also obtained. Finally, a transverse view of the CFA was obtained. No video-clips of the 
arterial motion were taken. 
3.4.2.1: IMT measurement and characterization 
The measurement of the IMT in the CCA was performed by using the automated software 
(QLAB). A longitudinal image of the CCA was obtained and transferred to QLAB. A section 
of 2cm was then selected when possible (>95% patients) and IMT measurement was 
accepted when accuracy was at least 97%. Measurement of the IMT of the CCA in the 
transverse view was noted by using manual callipers. This method was also applied to the 
measurement of both longitudinal and transverse views of the bulb. 
With the exception of the patients selected for inter-observer variability assessment, IMT 
measurement on the CFAs was not obtained as there is no evidence for its clinical 
relevance.  
3.4.2.2: 2D plaque analysis – plaque area and texture 
For 2D plaque analysis, all plaques were considered regardless of their anatomical location 
and size. 
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Plaque type was established according to the visual scale after the images were reviewed by  
Dr Maura Griffin and I.  
For the assessment of plaque texture, I used the Plaque texture analysis software – image 
analysis program for ultrasonic arterial wall changes and atherosclerotic plaques - version 
4.5 (LifeQ Ltd Copyright 2013) as previously described. This software gives semi-automated 
measurements of plaque area (mm2) and GSM based on longitudinal images of each 
plaque. Before being analysed, each plaque imaged underwent normalization as previously 
described to ensure that all the images had homogenous settings.  
3.4.2.3: 3D plaque analysis – plaque volume and texture 
3D plaque analysis has only been done in carotid plaques. I identified 46 carotid plaques but 
had to exclude three from this part of the analysis as there were limitations to collecting 3D 
US plaque images. These include anatomical constraints (high carotid bifurcations with 
interposition of jaw) and presence of heavy calcification within the plaque. 
The images for the volume analysis are collected by capturing a longitudinal view of the 
plaque using the 3D probe described above. The image analysis software (QLAB) then 
allows adjusting the image settings to a set standard and to “slice” the plaque, thus obtaining 
multiple transverse view cuts along the length of the plaque. The thickness of the slices is a 
key element in determining plaque volume and therefore needs to be recorded. The set slice 
thickness I used most commonly was 2mm but in smaller plaques, I decided to use 1 and 
1.5mm slices so that each plaque had a minimum of 6 slices. Only the transverse slices 
where plaque was visualized were considered. After image normalization, area and GSM for 
each individual plaque slice or transverse view were determined.  
Plaque volume was determined by using the following formula: 
Volume= (area1 (mm2) x slice thickness1 (mm)) + … + (area x slice thickness) 
The use of 3D vascular US also permits to obtain a GSM value calculated from the different 
transversal slices obtained according to the method described above. As the slices go 
through the plaque, differences in plaque texture may become more apparent than when 
assessing the GSM based on a 2D image.  
Volume-based GSM (GSMvol) was calculated by using the following formula: 
GSMvol= (GSM 1 x area 1) + … +  (GSM  x area ) 
area 1 + … + area  
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Thus, for every plaque, volume-based texture was obtained based on the GSM of each 
individual slice and its corresponding area.   
 
3.4.3: Intra and inter-observer variability 
In order to demonstrate the reproducibility of my results, inter and intra-observer variability 
was assessed.  Inter-observed variability was determined by the sequential assessment of 
25 patients scanned by both Dr Griffin and myself following the method described above. To 
ensure that no bias occurred, Dr Griffin repeated the measurements in reversed order after I 
had finished the scanning protocol. Intra-observer variability was determined in 10 patients 
who I scanned twice, once as described above and then in reversed order.  
The same process was applied to the plaque area, plaque texture and plaque volume 
analysis to verify reproducibility of the image analysis methods. 
Intra and inter observer variability was found to be <10% in both methods. 
 
3.5: Statistical methods 
In the longitudinal study, NN, NA and anti-NCS levels were assessed together as they were 
considered to be potentially correlated. The outcome variable for each individual analysis 
was NN, NA and anti-NCS level. An examination of the distribution of these variables 
indicated that it was highly positively skewed in its distribution.  This was partly due to a 
large number of 0 values. Sometimes with positively skewed data it is possible to transform it 
to a normal distribution via the use a transformation. However, the data in this case was too 
skewed for this to be possible. Therefore, an alternative approach was required. Instead of 
using statistical methods based on assuming a normal distribution, it was assumed that the 
outcome followed a ‘negative binomial’ distribution. This is a distribution suitable for such 
skewed distributions. A further feature of the data is that there were multiple samples from 
each patient. Standard statistical methods assume that each individual observation is 
independent of each other. This is unlikely to be the case when there are repeated samples, 
as samples from the same subject are likely to have more similar outcomes than samples 
from different patients. To allow for this structure of the data, multilevel statistical methods 
were used for the analysis. Two-level models were used with individual measurements 
clustered within patients. As a result of both the structure of the data and the distribution of 
the outcome, all analysis was performed using multilevel negative binomial regression. The 
analysis was performed in two stages. Firstly the separate effect of each factor upon the 
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outcome was examined separately in a series of univariable analyses.  For explanatory 
variables measured on a continuous variable the shape of the relationship between each 
factor and the outcome was examined to see if a ‘linear’ relationship was appropriate, or 
whether a more curved relationship was more appropriate. One explanatory variable, 
dsDNA, was found to have a much skewed distribution, and so was analysed on the log 
scale. Subsequently the joint effect of the factors was examined in a multivariable analysis. 
This had the advantage that the effect of each factor upon the outcome is adjusted for the 
effects of the other variables, and so gives a better idea of the underlying factors associated 
with the outcome. To restrict the amount of variables in this second stage of the analysis, 
only factors showing at least some evidence of an association with the outcome in the 
univariable analysis (p<0.2) were considered for this part of the analysis. 
Before considering variables for the multivariable analysis, the collinearity between variables 
was examined. Collinearity is a statistical problem which occurs when you have highly 
correlated explanatory variables. This can cause problems with the fit of the regression 
models. Variance inflation factors (VIFs) were used to help assess this. 
In the multivariable analysis, a backwards selection procedure was employed to retain only 
the statistically significant variables. This involves removing non-significant variables, one at 
a time, until all remaining variables are statistically significant. 
Initially the separate effect of factor upon NN, NA and anti-NCS levels was examined in a 
series of univariable analyses. Due to the statistical methods used, the results are reported 
in terms of ratios. This gives the ratio of each variable values in one situation relative to 
another. For variables measured on a categorical scale, this represents the ratio of NN, NA 
and anti-NCS values in each group relative to the values in a baseline group. For variables 
measured on a continuous scale, these represent the relative change in the outcome level 
for a one-unit increase in that variable (ratios for differing sizes increases are reported where 
one-unit was either a very small or very large amount). In all instances a ratio of greater than 
1 would suggest an increased NN, NA or anti-NCS level, whilst a ratio of less than 1 would 
suggest a lower level. 
A similar methodological approach was used to analyse the results from the longitudinal 
assessment of anti-ApoA1. All the statistical analysis done for the longitudinal group, 
including the multivariable analysis was done using the statistical software Stata® 
(StataCorp LP, Texas, USA) by a statistician, Dr Paul Bassett.  
The univariable statistical analysis for the cross sectional assessment in the vascular 
ultrasound and early disease cohorts as well as the individual variable assessment on the 
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longitudinal cohort was done by me using Prism® (GraphPad Software, La Jolla, California, 
USA). Given the variables, namely anti-ApoA1 levels did not follow a normal distribution, 
non-parametric tests were performed: the Mann-Whitney test was used when comparing two 
variables and the Kruskall-Wallis test when comparing more than two variables. Statistical 
significance was considered when p value was less than 0.05. In the longitudinal group, in 
order to overcome clustering considering that repeated measures for each patient were 
used, the mean overall value was used for each individual patient. Kaplan-Meier analysis to 
assess the impact of anti-apoA1 positivity on mortality in the early SLE cohort was done by 
my supervisor Anisur Rahman and later reproduced by me under his guidance. I supervised 
a BSc student Maria Davari during her project which focused on anti-apoA1 measurement 
during early SLE and part of this univariate analysis was done by her under my supervision. 
Finally, when assessing the vascular US group, univariable analysis was done by me using 
both Prism® (GraphPad Software, La Jolla, California, USA) and SPSS 22® (IBM Corp, 
New York, USA). For variables with a normal distribution, parametric tests were used; 
otherwise, non-parametric tests were selected. To investigate correlations between 
variables, Spearman’s correlation was used when distribution was not found to be normal 
and Pearson’s correlation coefficient when distribution was normal, using 95% CI on both 
instances. r2 values equal or greater than 0.2 were considered provided that the p-value was 
less than 0.05.  
When assessing multiple comparisons, for instance, when comparing the IMT thickness 
measured at the right and left CCA for each individual patient, the Bonferroni correction was 
apply so that clustering could be minimized. This method was used to correct all the p values 
for multiple comparisons as follow-up test to ANOVA. 
A non-SLE cohort was selected based on population studies as previously described. All the 
statistical analysis comparing this group with the SLE cohort was done by Professor Andrew 
Nicolaides using SPSS 22® (IBM Corp, New York, USA) and later reproduced by me under 
Dr Griffin’s supervision. 
Multivariable analysis was not performed in the vascular US cohort as, after discussing with 
the statistician, I realized that in order to achieve significant statistical power at least ten 
patients for each variable considered would be required. Given that I had a limited number of 
patients I opted for doing an exploratory analysis using univariate statistical methods. This 
means that although my analysis is underpowered by the size of the sample considered 
compared with the number of variables included; I was able to explore the potencial 
correlations/ associations between them.   
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A final note concerns the usefulness of age adjusted statistical analysis, particularly when 
considering the vascular ultrasound group. Age adjustment is a statistical process applied to 
rates of disease, death or other health outcomes (i.e. individual variables) which allows for a 
fairer comparison between groups with different age distributions, as it renders them more 
comparable. The age-adjusted rates are those which would be have existed if the study 
population had a similar age distribution of a “standard”population previously defined. 
I consider by performing age-adjustment and power calculations would have improved the 
statistical analysis of my thesis. Unfortunately, I was not able to perform these two important 
statistical tests in a useful timeframe as I do not have possess the necessary software or 
statistical skills which would have allowed me to do it on my own, nor was I able to procure a 
statistician who could help me to do this and I acknowledge this as a flaw in my statistical 
methods. 
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4: RESULTS 
4.1: Overall population characterization 
The longitudinal cohort of patients with lupus included 40 women and 9 men with a mean 
age at the time of the first sample of 36 years (SD 13.0). The ethnic distribution mirrored that 
of our clinic: 47% Caucasian (n= 23), 36% Afro-Caribbean origin (n= 18) and 16% (n= 8) had 
other ethnic backgrounds, namely Asian. The 37 healthy controls selected had a mean age 
of 31.6 years (SD 6.0), two thirds were female and 73% were Caucasian. 
The early disease cohort included 499 subjects from which sera samples were taken within 
the first year following diagnosis. The mean age was 30 years (SD 12.27, range 1-77) and 
91.5% were female. Regarding ethnicity, 2/3 of patients were Caucasian (n= 316), 20% were 
of Afro-Caribbean origin (n= 106) and 11% were South Asian (n= 59). A minority of patients 
were of East Asian descent (n= 24) or other ethnic origin (n= 13).  
Regarding the disease control group, the mean age of the 17 patients with RA was 52 years 
(SD 15.8; range 22-87) and 71% (n= 12) were female, 76% (n= 13) were Caucasian, 18% 
(n= 3) Afro-Caribbean and 6% South Asian (n= 1). Serologically, 11 had seropositive RA (2 
were anti-CCP positive and RF negative; 1 was anti-CCP negative but RF positive and 8 
were positive both for anti-CCP and RF) and 6 were seronegative. Although data on disease 
activity score (DAS-28) were not available, patients were considered clinically to have active 
arthritis at the time of sample collection. No data on the treatment regimen at the time of 
sample were available. The small cohort of patients with myositis (n= 12) and Sjogren’s 
syndrome (n= 13) who were tested for NN levels included, respectively, 2 males and 10 
females (mean age: 48 years - SD 10.2; range 31-76) and 13 women (mean age: 54 - SD 
16.7; range 32-81), all of which were Caucasian. 
 
4.2: Protein nitration 
In order to assess nitration levels, three protein targets were selected: nucleosomes, 
albumin and apolipoprotein A1. NN, NA (and anti-NCS) levels were tested in sera samples 
selected from the longitudinal cohort of patients with SLE.  
NN, nitrated apoA1 and total apoA1 were tested in the cross-sectional group of patients who 
undergone vascular US (as described in section 3.1: Patient selection – Chapter 3: “Material 
and Methods”). I will only describe in detail the results obtained for the latter two assays. The 
findings for NN in the vascular US cohort were similar to those found for the longitudinal 
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group, but given the smaller sample size and cross-sectional nature of this cohort, the data 
are poorer and no further relevant findings were noted. The results regarding the correlations 
between these two variables and imaging data will be discussed in Chapter 4.3: Vascular 
US. 
 
4.2.1: Nitrated nucleosomes and nitrated albumin in the longitudinal cohort 
The presence of NN was found in at least one occasion in 63% of the patients. Patients with 
SLE had significantly (p= 0.0007) higher NN levels compared with healthy controls and 
patients with other auto-immune diseases, namely RA, myositis and Sjogren’s syndrome 
(p<0.0001) as shown on Graph 1. 
18 patients never had detectable serum NN during the follow-up period considered, following 
a non-Gaussian distribution. In the 31 patients who had detectable NN, the levels varied 
widely over time (mean 32 AU; median 0.0; SD 62.2; IQR 0.0-30.5). Table 5 shows a 
comparison between characteristics of NN positive and NN negative patients. As shown in 
table 5, all the patients who were NN negative were anti-Sm negative (18/18) whereas 35% 
of the NN-positive patients were anti-Sm positive (11/31). 
In the vascular US group, over a third of the patients (n= 37) were NN positive in their single 
samples.  The results for NN values in the US group are not considered any further in this 
thesis. All the results on NN and NA described in the following sections refer to the 
longitudinal cohort.  
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Graph 1: Comparison between nitrated nucleosome (NN) levels in patients with SLE, healthy 
controls (HC), rheumatoid arthritis (RA), auto-immune myositis and Sjogren’s syndrome (SS). 
Each point represents one patient for all columns. The column depicting patients with SLE 
includes the median NN level for each individual patient included in the longitudinal cohort to 
eliminate over-representation due to repeated samples per patient. 
(*** p< 0.001) 
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Variables 
NN-negative 
(n patients= 18) 
(n samples= 145) 
NN-positive 
(n patients=31) 
(n samples= 252) 
Mean Age at first sample(SD) 38 (13.1) 35 (12.8) 
% Female (n) 77.8 (14) 83.9 (26) 
Ethnicity 
       % AC (n) 
       % C (n) 
       % Other (n) 
 
27.8 (5) 
61.1 (11) 
11.1 (2) 
 
41.9 (13) 
38.7 (12) 
19.3 (6) 
Mean anti-dsDNA  IU/ml (SD) 217.2 (428.3) 381.3 (1038.0) 
Mean C3 g/l (SD) 1.0 (0.2) 0.9 (0.3) 
Mean Global BILAG score (SD) 5.8 (4.8) 7.8 (6.9) 
% anti-Sm positive (n) 0 (0) 35.5 (11)* 
% anti-RNP positive (n) 27.8 (5) 32.3 (10) 
% anti-Ro-positive (n) 38.9 (7) 41.9 (13)* 
% anti-La positive (n) 16.7 (3) 9.7 (3) 
% on hydroxychloroquine (n) 42.1 (61) 44.7 (113)* 
% on immunosuppressants (n) 25.5 (37) 63.2 (160)* 
% on ≥ 5mg/day prednisolone 
(n) 
67.5 (98) 78.3 (198) 
(* p< 0.05 on univariable analysis) 
Normal range for anti-dsDNA = 0 -50 IU/ml; for C3 0.9 – 1.8 g/L 
 
. 
  Table 5: Overall comparison between nitrated nucleosome (NN) positive and NN negative patients. 
Variables found to reach statistical significance in the univariable analysis are highlighted in bold. 
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NN-positive patients appeared to have more active disease; with higher anti-dsDNA levels 
(381.3 vs. 217.2 IU/mL) and higher global BILAG score (7.8 vs. 5.8). Moreover, NN-positive 
patients were also more likely to be taking immunosuppressive drugs (63.2% vs. 25.5%) but 
this was also not statistically significant.   
As shown in Table 6, the overall findings regarding the NA levels were similar to those found 
for the NN. 20 patients had detectable NA levels and 47.6% of the samples tested were 
positive for NA. NA levels did not follow a normal distribution. The majority of patients who 
were NA positive were female (16/20), the mean age was 34 (SD 11.4; 17-56) and the ethnic 
distribution was identical. In NA-positive patients, the levels varied over time (mean 28.8 AU; 
median 0.0 AU; SD 44.5; IQR 0.0-49.1). 
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Variable Category / term Ratio for NN 
(95% CI) 
p-
value 
for NN 
Ratio for NA 
(95% CI) 
p-value 
for NA 
Gender * 
Female (n= 336) 
Male (n= 61) 
1 
2.01 (1.06, 
3.81) 
0.03 
1 
5.00 
(2.50,9.98) 
<0.001 
Disease duration 
† 
Ratio given per 5-
year increase 
0.43 (0.23, 
0.79) 
0.005 
0.32 
(0.20,0.51) 
<0.001 
Age (at 
diagnosis) † 
Ratio given per 10-
year increase 
0.10 (0.02, 
0.46) 
<0.001 
0.04 
(0.01,0.16) 
0.002 
Ethnicity* Caucasian (n= 182 
) 
Afro-Caribbean 
(n=146 ) 
Other (n = 69) 
1 
0.75 (0.47, 
1.22) 
0.33 (0.17, 
0.63) 
0.003 
1 
2.07(1.26,3.40
) 
3.75 
(1.86,7.56) 
<0.001 
Overall ENA** 
        
 
 
Anti-Ro** 
      
 Anti-La** 
        
Anti-Sm** 
        
Anti-RNP** 
No (n= 165) 
Yes (n= 232) 
1 
3.43 (2.19, 
5.37) 
<0.001 
1 
3.19 
(1.93,5.27) 
<0.001 
No(n= 226) 
Yes(n= 171) 
1 
1.70 (1.12, 
2.59) 
0.01 
1 
1.81 (1.14, 
2.89) 
0.01 
No(n= 345) 
Yes(n= 52) 
1 
0.79 (0.41, 
1.50) 
0.47 
1 
0.46 (0.2, 
1.06) 
0.07 
No(n= 298) 
Yes(n= 99) 
1 
5.63 (3.66, 
8.67) 
<0.001 
1 
6.25 (3.84, 
10.2) 
<0.001 
No(n= 288) 
Yes(n= 109) 
1 
1.08 (0.69, 
1.70) 
0.74 
1 
1.72 
(1.06,2.79) 
0.03 
Anti-dsDNA level 
< 50IU/ml (n= 177) 
≥ 50IU/ml (n= 170) 
1 
0.76 (0.26, 
1.13) 
0.17 
1 
1.32 
(0.66,2.65) 
0.43 
C3 level 
< 0.9g/l (n= 139) 
≥0.9g/l (n= 208) 
1 
0.83 (0.57, 
1.20) 
0.32 
1 
1.26(0.86,1.87
) 
0.24 
Disease activity: 
(individual organ 
systems) 
General§ 
 
Mucocutaneous  
 
Neuropsychiatric  
 
Musculoskeletal  
 
Cardiorespiratory  
 
Vasculitis 
 
Renal System 
 
 
A, B (n= 31) 
C, D, E (n= 344) 
 
 
1 
0.96 (0.60, 
1.54) 
 
 
0.87 
 
 
 
1 
1.19 
(0.71,2.00) 
 
 
0.52 
 
A, B (n= 41) 
C, D, E (n= 334) 
1 
0.99 (0.63, 
1.56) 
0.95 
1 
1.32 
(0.76,2.29) 
0.33 
A, B (n= 18) 
C, D, E (n= 357) 
1 
0.56 (0.13, 
2.38) 
0.44 
1 
1.04 
(0.50,2.19) 
0.91 
A, B (n= 47) 
C, D, E (n= 328) 
1 
1.20 (0.47, 
3.04) 
0.71 
1 
0.68 
(0.43,1.05) 
0.08 
A, B (n= 13) 
C, D, E (n= 362) 
1 
0.43 (0.24, 
0.006 
1 
1.40 
0.72 
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Haematological 
 
0.78) (0.22,8.70) 
A, B (n= 12) 
C, D, E (n= 363) 
1 
0.33 (0.17, 
0.63) 
0.001 
1 
0.39(0.19,0.82
) 
0.01 
A, B (n= 41) 
C, D, E (n= 329) 
1 
1.09 (0.40, 
2.97) 
0.86 
1 
4.28 
(2.13,8.58) 
<0.001 
A, B (n= 95) 
C, D, E (n= 280) 
1 
1.21 (0.84, 
1.74) 
0.30 
1 
1.44 
(0.95,2.17) 
0.08 
Sustained 
disease activity 
Persistently Low 
(n= 166) 
Persistently Mod 
/High (n= 209) 
1 
 
 
0.91 (0.66, 
1.25) 
0.57 
1 
 
 
0.66 
(0.47,0.92) 
0.01 
      
Hydroxychloroqu
ine 
No (n= 223) 
Yes (n= 174) 
1 
3.52 (2.40, 
5.17) 
<0.001 
1 
3.21 
(2.08,4.95) 
<0.001 
Immunosuppress
ion 
No (n= 200) 
Yes (n= 197) 
1 
1.66 (1.17, 
2.34) 
0.004 
1 
1.33 
(0.89,1.98) 
0.16 
Prednisolone 
<7.5mg/day (n= 
101) 
>7.5mg/day (n= 
296) 
1 
0.81 (0.59, 
1.13) 
0.22 
1 
1.00 
(0.69,1.44) 
0.99 
Albumin 
Ratio given per 5g/l 
increase 
1.38 
(1.20,1.59) 
<0.001 
1.42 
(1.22,1.65) 
<0.001 
 
*For gender, n values refer to the numbers of samples taken from female and male subjects, 
rather than numbers of females and males in the cohort of patients. A similar stipulation applies 
to ethnicity where n values refer to the number of samples taken from patients of each ethnic 
group. 
 
† For the complex associations with disease duration and age, we carried out analysis of both 
linear and squared terms. The figures in the table refer to linear terms. The ratios for squared 
terms for NN are 0.66 (95% CI 0.51, 0.85) for disease duration and 1.56 (95% CI 1.20, 2.03) for 
age. The ratios for squared terms for NA are 0.59 (95% CI 0.46, 0.75) for disease duration and 
1.72 (95% CI 1.32, 2.24) for age. 
 
** For ENA, anti-Ro, anti-La and anti-Sm we did not have results from the date of every sample 
but it is assumed that the status of these antibodies generally remain stable 
 
§ “Disease activity in general system” refers to the BILAG score (A, B, C, D or E) in the General 
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Category of the BILAG index on the day when each sample was taken. The same principle 
applies to all the other organ systems listed in the table, which are the 8 different categories 
recorded in BILAG. 
 
 
  
Table 6: Univariable analysis of factors associated with serum nitrated nucleosomes (NN) and nitrated 
albumin (NA) levels in patients with SLE. Statistically significant p-values are highlighted in bold. 
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NN and NA levels where higher in men compared to women. For both outcomes a complex, 
non-linear relation with disease duration and age at diagnosis was found. NN and NA levels 
appear to be lowest in the youngest and oldest patients with a peak level at age 30 years. 
Similarly NN and NA levels are lowest for patients with the shortest and longest durations of 
disease with a peak level at around 8 years duration. 
Although no statistically significant relation between both NN and NA and disease activity 
was found either serologically (high anti-dsDNA and/or low C3) or clinically (overall BILAG 
score), when considering the individual organ systems, the presence of vasculitis (i.e. score 
of A or B) was associated with significantly higher NA and NN levels. NN, but not NA, levels 
were significantly higher in cardiorespiratory flares. NN levels also appeared to correlate with 
neuropsychiatric disease as patients who scored C, D or E in this system appeared to have 
lower NN compared to those with an A or B score. However, this difference did not reach 
statistical significance due to wide confidence intervals. No similar trend was observed when 
considering NA levels. There were no further associations between individual systems 
scores and either NN or NA levels. 
Upon overall comparison, NN and NA levels appear to correlate closely, however, the 
univariable analysis showed a few differences. The multivariable analysis exposed these 
differences further and as shown in Tables 7 and 8, NN and NA correlate differently with the 
variables considered. 
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Variable (NN) Category / term Ratio (95% CI) p-value 
Age (at diagnosis) * 
Linear term 
Squared term 
0.02 (0.003, 0.11) 
2.12 (1.64, 2.76) 
<0.001 
Anti-Sm No 
Yes 
1 
6.31 (3.39, 11.7) 
 
<0.001 
Vasculitis A, B 
C, D, E 
1 
0.40 (0.24, 0.69) 
 
<0.001 
Hydroxychloroquine No 
Yes 
1 
1.96 (1.09, 3.53) 
 
0.02 
Immunosuppression No 
Yes 
1 
2.96 (1.97, 4.46) 
 
<0.001 
*Ratio given for 10-year increase 
 
 
 
Variable (NA) Category / term Ratio (95% CI) p-value 
Disease duration  Ratio given per 5-year 
increase 
2.24 (1.55, 3.26) <0.001 
Age (at diagnosis) * Linear term 
Squared term 
0.01 (0.00, 0.04) 
2.58 (1.86, 3.56) 
<0.001 
Ethnicity Caucasian 
Afro-Caribbean 
Other 
1 
2.99 (1.35,6.65) 
14.9 (5.82, 38.0) 
 
<0.001 
Anti-La No 
Yes 
1 
0.16 (0.06, 0.49) 
 
<0.001 
Anti-Sm No 
Yes 
1 
28.2 (14.4, 55.3) 
 
<0.001 
Renal involvement A, B 
C, D, E 
1 
3.78 (2.07,6.90) 
 
<0.001 
Immunosuppression No 
Yes 
1 
1.45 (1.02, 2.05) 
 
0.04 
Albumin Ratio per 5g/l increase 1.12 (1.01,1.24) 0.03 
* Ratio given for a 10-year increase 
 
 
Table 7: Multivariable analysis of factors associated with serum nitrated nucleosome (NN) levels 
in patients with SLE. 
Table 8: Multivariable analysis of factors associated with serum nitrated albumin (NA) levels in 
patients with SLE. 
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Age at diagnosis, disease duration, anti-Sm positivity and treatment with 
immunosuppressives have a similar association with NN and NA. Anti-Sm positivity in 
particular has a remarkably strong independent association with higher NN and NA levels 
(p<0.001). 
However, whilst NN appear to correlate independently with vasculitis and treatment with HQ, 
NA is associated with anti-La negativity, albumin and absence/low active renal disease. 
 
4.2.2: Anti-nucleosome antibodies 
The cut-off for positivity was defined as the 97.5th percentile of the healthy controls (0.17 
AU). 85% samples were positive for anti-NCS and levels varied over time (mean 55.6 AU; 
median 10.6 AU; SD 94.5; IQR 0.0-77.4). The positive findings of the univariable analysis 
are shown in Table 9. 
No associations were found between anti-NCS levels and sex, age and ethnicity. The ENA 
overall status and positivity for the different ENA subtypes were not associated with 
differences in anti-NCS levels. 
Serologically, active disease defined by high anti-dsDNA and low C3 levels was associated 
with significantly higher anti-NCS levels (p< 0.0001 and p= 0.038 respectively) as shown on 
Figure 15-A and B.  
Clinically defined disease activity characterized by BILAG showed that higher disease 
activity at the time of the sample was associated with higher anti-NCS levels (p= 0.024). 
Similarly, persistently moderate-highly active disease was also associated with higher anti-
NCS levels as depicted on Figure 15-C and D.  
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Variable (anti-NCS) 
Number of 
samples (n) 
Mean anti-
NCS level 
(SD) 
p-value (high vs. 
low) 
(CI 95%) 
Sustained disease activity 
Persistently 
moderate/high 
Persistently low 
 
209 
166 
 
59.1 (99.4) 
49.1 (84.0) 
 
0.0242 
(1.12 – 2.59) 
Global BILAG score 
<5 
≥5 
 
166 
209 
 
49.1 (84.0) 
59.1 (99.4) 
 
0.0242 
(1.07 – 2.43) 
Anti-dsDNA 
High (>50 IU/mL) 
Normal (≤50 IU/mL) 
 
177 
170 
 
78.5 (112.5) 
37.5 (75.2) 
 
<0.0001 
(1.33 – 2.04) 
Complement (C3) 
Normal (≥0.9g/L) 
Low (<0.9g/L) 
 
209 
138 
 
50.1 (90.4) 
68.9 (105.6) 
 
<0.0001 
(0.79 – 0.9) 
Hydroxychloroquine use 
Yes 
No 
 
174 
223 
 
43.5 (76.9) 
65.2 (105.4) 
 
0.0375 
(1.17 – 2.34) 
Prednisolone daily dose 
<5mg/day 
≥5mg/day 
 
209 
188 
 
40.2 (76.9) 
72.8 (108.4) 
 
<0.0001 
(2.4 – 5.17) 
 
 
 
 
  
Table 9: Univariable analysis of factors associated with serum anti-nucleosome antibody levels in 
patients with SLE. 
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Figure 15: Anti-nucleosome antibody levels and measures of disease activity: comparison of 
anti-nucleosomes antibody levels and complement (C3) (A), anti-dsDNA (B), global BILAG score at 
the time of sample (C) and sustained disease activity (D)          
(*p< 0.05; ***p< 0.001) 
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Treatment also appeared to influence anti-NCS levels. Patients who were taking HQ at the 
time the sample was taken had significantly lower anti-NCS levels than those who were not 
(p< 0.0001). Similarly, patients who were on low dose prednisolone (<5mg daily) at the time 
of sample had significantly lower levels of anti-NCS compared to those on a higher steroid 
dose (p< 0.0001) as shown on Figure 16. The use of immunosuppressants was not 
associated with differences in anti-NCS levels. 
Multivariable analysis was also performed using a backwards selection procedure to retain 
only the statistically significant variables. The positive correlations elicited by the final 
regression model are summarised in Table 10. 
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Figure 16: Anti-nucleosome antibody levels and treatment: comparison of anti-nucleosomes 
antibody levels in patients on low (pred< 5mg/ daily) vs. high dose prednisolone (pred ≥5mg daily) 
(A) and with or without treatment with hydroxychloroquine (HQ) (B). 
(*** p< 0.001) 
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Variable (anti-NCS) Ratio (95% CI) P- value 
Sex (male vs. female) 2.38 vs. 1 
(1.72 – 4.69) 
<0.001 
Disease duration (**) 0.87 
(0.78 - 0.98) 
0.02 
Age at diagnosis (***) 0.59 
(0.49 – 0.72) 
<0.001 
RNP (neg vs. pos) 1 vs. 0.47 
(0.32 – 0.7) 
<0.001 
Anti-dsDNA (†) 1.79 
(1.4 – 2.28) 
<0.001 
Complement – C3 (*) 0.29 
(0.15 – 0.56) 
<0.001 
(†) variable analysed on the log scale (base 10) 
(*) ratios given for a 0.1 unit increase in C3 level 
(**) ratios given for a 5 year increase in disease duration 
(***) ratios given for a 10 year increase in age 
 
 
 
 
Table 10: Factors found to significantly influence serum anti-nucleosomes antibodies (anti-NCS) 
levels in patients with SLE in a multivariable analysis. 
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Males were found to have anti-NCS levels almost 3 times higher than females. Both greater 
disease duration and older age at diagnosis were found to be associated with lower anti-
NCS levels. A 5-year increase in disease duration was associated with a 13% reduction in 
anti-NCS levels, whilst a 10-year increase in the age at diagnosis was associated with a 
40% reduction in anti-NCS. 
Although the overall ENA status did not influence anti-NCS, anti-RNP positivity was 
associated with a 50% reduction in anti-NCS levels. 
Similar to the univariable analysis, multivariable analysis confirmed a correlation between 
serologically active disease (defined by high anti-dsDNA and low C3 levels) and significantly 
higher anti-NCS levels. However, the multivariable analysis showed only a non-significant 
trend between higher clinically defined disease activity and higher anti-NCS levels. No 
association between the type of treatment and anti-NCS was found. 
Finally, no association between NN and anti-NCS was shown and the two variables appear 
to vary independently of each other. 
 
4.2.3: Nitrated apolipoprotein A1 
The levels of nitrated ApoA1 measured in the sera of the patients included in the vascular 
US did not follow a normal distribution, hence all statistical analysis was performed using 
non-parametric tests. Patients with SLE had significantly higher levels of nitrated ApoA 1 
compared with HC (median 32.1 vs 20.1; IQR 12.3 - 11.5 vs. 11.2 - 36.12). The positivity 
cut-off was defined as the 97.5th percentile of the HC (371.4) and 12 patients with SLE had 
nitrated ApoA1 levels above this threshold. No statistically significant associations between 
nitrated ApoA1 and disease activity were found. However, a non-significant trend was 
observed with clinically defined active disease as shown on Figure 17-A. Neither 
complement (C3) nor anti-dsDNA levels correlated with nitrated ApoA1 (Figure 17-B and C 
respectively).  
No significant associations between nitrated ApoA1 and demographics, treatment and 
autoantibody profile (including anti-HDL and anti-ApoA1 IgG) were noted. NN and nitrated 
ApoA1 levels appeared to correlate as shown on Graph 2. Both variables were raised in 
patients with SLE compared with HC as illustrated on Figure 18. 
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Figure 17: Nitrated ApoA1 levels and disease activity: nitrated apolipoprotein A1 levels in low 
(overall BILAG< 5) vs. moderate-high (overall BILAG ≥5) disease activity (A); low vs. normal 
complement (B) and normal vs. high anti-dsDNA antibodies (C) (NS: non-significant). 
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  Figure 18: Comparison of nitrated nucleosomes (A) and nitrated apolipoprotein A1 (B) levels 
between patients with SLE and HC. 
(* p< 0.05; ** p< 0.01) 
Graph 2: Correlation between nitrated nucleosomes and nitrated apolipoprotein A1 levels. The 
line depicts the linear regression and its equation (n= 100, r2 0.37, p 0.06). 
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In order to fully assess the impact of nitration of ApoA1, I determined the concentration of 
total ApoA1 on the same sera samples. Neither nitrated Apo A1 nor TApoA1 followed a 
normal distribution and therefore, all statistical analysis was done using non-parametric 
tests. The median and IQR for patients with SLE and HC was 31.1 vs. 54.3 and 17.8 – 363.7 
vs. 36.9 – 286.5 respectively. As depicted on Graph 3, patients with SLE had significantly 
lower TApoA1 levels compared with HC.  
Moreover, the correlation between TApoA1 and nitrated ApoA1 is not the same in patients 
with SLE and HC. As shown on Figure 19, in patients with SLE higher TApoA1 levels appear 
to correlate with lower nitrated ApoA1 titres whereas in HC, the correlation between these 
two variables is constant regardless of TApoA1 concentration. 
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Figure 19: Comparison of the correlation between total and nitrated apolipoprotein A1 in 
patients with SLE and HC. The line depicts the linear regression curve and its equation (SLE n= 
100, r2 0.19, p= 0.1.; HC n= 100, r2 0.12, p= 0.17)  
Graph 3: Comparison of total apolipoprotein A1 levels between patients with SLE and HC. 
(*** p< 0.001) 
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Considering that apoA1 may potentially be an antigenic target given the presence of anti-
HDL and, in particular anti-ApoA1 antibodies, I assessed the correlation between these 
variables.  
When plotting TApoA1 against anti-ApoA1 and anti-HDL IgG levels I obtained the graphs 
depicted in Figure 20. While anti-ApoA1 IgG levels did not seem to influence TApoA1 
(Figure 19 – A), high levels of anti-HDL IgG were associated with a slight trend towards a 
decreased in TApoA1 (Figure 19 – B). This seems to suggest that anti-HDL but not anti-
ApoA1 antibodies may lead to a decrease in serum TApoA1. 
To further investigate this hypothesis, I defined four comparison groups: low and high anti-
ApoA1 IgG levels (≤ 25th percentile and ≥75th percentile, i.e. ≤31.1 and ≥181.0 respectively); 
low and high anti-HDL IgG levels (≤ 25th percentile and ≥75th percentile, i.e. ≤0.0 and ≥24.86 
respectively). I then applied a non-parametric T-test (Mann-Whitney) to compare each paired 
group, i.e. low vs. high anti-ApoA1 IgG and low vs. high anti-HDL IgG. My findings are 
summarized in Graph 4 and show that while there was no difference in TApoA1 levels 
between low vs. high anti-ApoA1 IgG antibodies, the presence of high anti-HDL IgG levels 
was associated with significantly lower TApoA1 levels (p= 0.006), thus supporting the 
hypothesis raised. 
No further statistically significant associations were found between TApoA1, demographics, 
other autoantibodies, disease activity, treatment and lipid profile, including HDL levels. 
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Figure 20: Comparison of the correlation between total apolipoprotein A1 and either anti-
ApoA1 IgG (A) or anti-HDL IgG antibodies (B). The line depicts the linear regression curve and its 
equation (A n= 100, r2 0.02, p= 0.4; B n= 100, r2 0.09, p= 0.1).  
Graph 4: Comparison of total apolipoprotein A1 concentrations in patients with low (≤25th 
percentile) vs. high (≥75th percentile) levels of anti-ApoA1 and anti-HDL IgG antibodies. 
(** p< 0.01) 
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4.2.4: Discussion 
Nitric oxide metabolism has important implications in regulating endothelial function, with 
both protective and pathological properties and has been proposed as a potential 
mechanism for the generation of autoantibodies as a result of post-translational modification 
of self-antigens (Ahsan, Ali et al. 2003, Anderton 2004, Ohmori and Kanayama 2005). 
Additionally, the presence of enhanced nitrosative stress may lead to increased apoptosis, 
thus contributing to the accumulation of cellular debris which may then lead to auto-reactive 
processes and ultimately to the generation of autoantibodies (Estevez and Jordan 2002, 
Kim, Kim et al. 2002, Kim, Kwon et al. 2002, Duan and Chen 2007). 
Several papers report on the presence of associations between NO synthase 
polymorphisms and SLE (Oates, Levesque et al. 2003, Serrano, Paez et al. 2004), the role 
of NO modified DNA and serum proteins in the pathogenesis of SLE and APS (Dixit and Ali 
2004, Khan and Ali 2006, Ames, Batuca et al. 2010).  
I chose serum nucleosomes as a potential target for nitration and developed a novel capture 
ELISA to measure the levels of NN. I found that mean NN levels are significantly higher in 
patients with SLE than in healthy controls, but there is a subset of patients with SLE who 
never test positive for NN. These persistently NN-negative patients comprise about one-third 
of the total population and have lower disease activity and anti-dsDNA antibody levels and 
less use of immunosuppressants than the other two-thirds. NN-negative patients are all anti-
Sm antibody negative. 
A strong association between anti-Sm and nitration was confirmed by the multivariable 
analysis of factors associated with NN and NA levels. To the best of my knowledge, the 
association between nitrosative stress and anti-Sm positivity has not been described before 
in SLE or any other disease state. The Sm antigen is a complex of ribonucleoproteins found 
in the spliceosome (McClain, Ramsland et al. 2002) and anti-Sm antibodies are highly 
specific to SLE. Anti-Sm have been found in lupus nephritis renal biopsies (Mannik, Merrill et 
al. 2003) and some retrospective studies reported associations between anti-Sm positivity 
and psychosis (Tikly, Burgin et al. 1996) or nephritis (Alba, Bento et al. 2003). A large 
Chinese study compared 469 anti-Sm antibody positive and 1115 anti-Sm antibody negative 
patients with SLE (Ni, Yao et al. 2009). The anti-Sm positive patients had higher disease 
activity, higher anti-dsDNA antibody and lower C3 levels than anti-Sm negative patients. 
Vasculitis occurred more often in anti-Sm positive than in anti-Sm negative patients (13.7% 
vs. 7.4%, p<0.05). Our recently published results show strong associations between NN 
levels, anti-Sm and vasculitis (Croca, Bassett et al. 2014).  
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Increased nitration may promote development of anti-Sm antibodies. Experiments on mice 
transgenic for the rearranged heavy chain variable region genes of a monoclonal anti-Sm 
antibody (Clarke 2008) showed that immature dendritic cells (DC) carrying surface Sm 
antigen interacted directly with B cells leading to the production of anti-Sm antibody. These 
DC obtained Sm antigen from apoptotic cell debris, which also contain nucleosomes 
complexed to High Mobility Group Box 1 (HMGB1) protein (Urbonaviciute, Furnrohr et al. 
2008). HMGB1 can activate DC (Yang, Postnikov et al. 2012) and also promotes phagocyte 
NO production by phagocytes. Thus nucleosome/HMGB1 complexes could stimulate the 
DC-B cell interaction leading to anti-Sm antibody production as well as driving NO 
production. It is not known whether nitration of HMGB1 itself alters its pro-inflammatory 
properties, but a recent study has shown that altering the redox state of HMGB1 through the 
oxidation of free thiol cysteine residues to form disulfide bonds makes it more pro-
inflammatory (Urbonaviciute, Furnrohr et al. 2008). If nitration of nucleosome/HMGB1 
complexes likewise promotes their pro-inflammatory properties this would create a potential 
positive feedback loop, and this is a mechanism that warrants further exploration.  
NA and NN levels were also associated with the use of immunosuppressants. This 
association is unlikely to arise simply from the fact that immunosuppressants are used more 
commonly in highly active disease, because persistent clinical disease activity, anti-dsDNA 
antibody and C3 levels were not associated with either NA or NN levels. The drugs 
themselves could promote nitration, but I know of no evidence supporting this. Cyclosporin 
can promote tyrosine nitration in endothelial cells (Redondo-Horcajo, Romero et al. 2010), 
but only two samples in this study were from patients taking cyclosporin and both were 
negative for NN. No differences between MMF and azathioprine were noted. 
Vasculitis is a relatively uncommon manifestation of SLE (Ni, Yao et al. 2009). In 
multivariable analysis I found a statistically significant association of high NN (but not NA) 
with vasculitis based on results from 9 different patients over an 11- year period. Review of 
the medical records showed that all these patients had cutaneous vasculitis at the time of 
their flares. It is possible that raised NN levels in patients without visible vasculitis may be a 
marker of subclinical vascular activation. It will therefore be interesting to see whether NN 
levels are associated with objective measures of atherosclerosis such as carotid ultrasound 
(Roman, Shanker et al. 2003). Peluffo et al and Aslan et al revised the evidence supporting 
the role of protein tyrosine nitration in CVD pathology and describe how post translational 
protein modifications may lead to gain and/or loss of function and contribute to disturb 
vascular homeostasis and consequently increase the risk of CVD (Peluffo and Radi 2007, 
Aslan and Dogan 2011). This potential association is underlined by the fact that 
peroxynitrite, a powerful nitrating and oxidising agent, is generated in atherosclerotic 
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plaques.  If such an association exists then NN levels may be relevant to assessment of 
CVD risk in patients with SLE. 
In summary, by developing a novel assay to measure serum NN levels I have demonstrated 
that these levels are raised in patients with SLE compared to healthy controls. NN-positivity 
is strongly linked to anti-Sm antibody positivity and may be a marker for neuropsychiatric 
flares and vasculitis in patients with SLE. Further studies in larger numbers of patients with 
these manifestations are required. Our group has now tested samples obtained from the 
SLICC sera bank from patients with SLE who had had various neurological manifestations, 
some potentially correlated with SLE (neuro-SLE) and others thought to be unrelated to 
lupus. All the samples were age and sex-matched for patients with SLE who had never had 
neurological manifestations. Preliminary data shows that samples from some patients whose 
neurological symptoms were originally not thought to be due to SLE (i.e. headaches) have 
high titres of NN, thus raising the hypothesis that they could in fact be associated with 
increased nitrosative stress and disease activity (data not published). 
As discussed in the introduction, the presence of apoptotic cellular debris may play a role in 
the development of the auto-antibodies which are one of the key features of SLE and the 
presence of apoptotic nucleosomes has been related to the presence of anti-NCS antibodies 
which have been described in SLE (Stemmer, Richalet-Secordel et al. 1996, Min, Kim et al. 
2002) (Kalaaji, Fenton et al. 2007). Several studies suggest that they may be useful to 
establish diagnosis, particularly in patients who are anti-dsDNA negative (Bizzaro, Villalta et 
al. 2012). Data have been published suggesting a potential association with target-organ 
involvement, namely with the presence of lupus nephritis (Mortensen, Fenton et al. 2008, 
Manson, Ma et al. 2009, Mortensen and Rekvig 2009), and disease activity (Ravirajan, 
Rowse et al. 2001, Simon, Cabiedes et al. 2004). It has also been suggested that anti-NCS 
antibody level  may be a useful biomarker to predict the occurrence of disease flares 
(Cozzani, Drosera et al. 2014).  
The majority of the patients with SLE whose sera I tested were anti-NCS positive (85%), 
which is in keeping with the figures reported in the literature (Min, Kim et al. 2002, Simon, 
Cabiedes et al. 2004, Isenberg, Manson et al. 2007, Cozzani, Drosera et al. 2014). The 
presence of active disease, defined either clinically (based on the BILAG score) or 
serologically (anti-dsDNA and C3 levels) was found to correlate with disease activity, 
echoing data already published. The association between higher anti-NCS and higher anti-
dsDNA levels was particularly robust as it was found to be significant in univariate and 
multivariate analysis emphasizing the strong link between these two autoantibodies 
(Saisoong, Eiam-Ong et al. 2006). 
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An association between lower anti-NCS levels and treatment with HQ and low corticosteroid 
dose (prednisolone <5mg daily) was found in univariate but not in multivariate analysis. 
There are no published data reporting on similar assessment of anti-NCS levels and 
treatment. 
Nitration of serum proteins is a post-translational modification and it may be hypothesized 
that this could be a potential mechanism contributing to the development of auto-antibodies 
(Ahsan, Ali et al. 2003, Anderton 2004, Ohmori and Kanayama 2005). Thus, I investigated 
whether the presence of NN correlated in any way with the levels of anti-NCS but found that 
this was not the case, as both variables vary independently.  
Finally, I selected ApoA1 as a potential target for nitration given its pivotal role in HDL 
function and consequently, its cardiovascular protective role. Zheng et al reported on ApoA1 
as a selective target for MPO-catalysed oxidative modification in human atheroma, 
suggesting that this could potentially be a mechanism for HDL dysfunction (Zheng, Nukuna 
et al. 2004). Later studies performed by Shao et al showed that although ApoA1 was in fact 
a target for nitration and chlorination, only the later led to significantly impaired cholesterol 
efflux, thus minimizing the role of this post-translational modification in ApoA1 function 
(Shao, Bergt et al. 2005). Bakillah using both an ELISA and Western Blot method reported 
that subjects with low serum HDL had significantly higher serum nitrated ApoA1 levels 
compared with those whose HDL level was normal. Moreover, the degree of nitrated ApoA1 
containing HDL was negatively correlated with levels of circulating ApoA1 (Bakillah 2009). 
Recently, Aslan et al revised several studies which assessed the in vivo and in vitro effects 
of ApoA1 nitration and concluded that ApoA1 is a clear target for tyrosine nitration and that 
there is sufficient evidence to support that nitrated ApoA1 could potentially be used as a 
CVD biomarker (Aslan and Dogan 2011). 
I found that patients with SLE had significantly lower levels of TApoA1 and higher levels of 
nitrated ApoA1 compared with HC. A non-significant trend between moderate-high disease 
activity and higher nitrated ApoA1 levels was observed but no statistically significant 
associations with anti-dsDNA and C3 were noted. However, when I compared the linear 
regression model between TApoA1 and nitrated apoA1 between patients with SLE and HC, I 
found that although there was no correlation in the HC cohort, there was a trend for patients 
with SLE who had higher TApoA1 levels to have lower nitrated ApoA1. Parastatidis et al 
reported their findings from an in vivo study using ApoA1-deficient mice describing how in 
the presence of lower ApoA1 levels, nitrosative stress appeared to be enhanced (increased 
protein nitration), supporting a potentially antioxidant effect which would support a specific 
protective role of ApoA1 (Parastatidis, Thomson et al. 2007). My findings also appear to 
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support this hypothesis, but further studies are required to firmly establish this mechanism in 
humans. Vasquez et al assessed HDL-dependent cholesterol efflux and endothelial function 
in obese women (BMI ≥30) and found that there was a positive correlation between these 
two variables. Moreover, women with increased BMI also had higher nitrated ApoA1 levels 
and this was associated with reduced cholesterol efflux, suggesting that this post-
translational modification may reduce ApoA1 ability to accept cholesterol from ABCA1 
transporters of peripheral macrophages. Hence, raising the hypothesis that increased 
nitrated ApoA1 levels may be a biomarker of increased nitrosative stress in the obese state, 
even in the absence of diabetes or dyslipidaemia (Vazquez, Sethi et al. 2012)  
Tyrosine residues are the preferred site for nitration (Ischiropoulos 1998, Radi 2004, Abello, 
Kerstjens et al. 2009) and I found that NN and nitrated ApoA1 levels were closely correlated 
as I had previously found for NN and NA, thus supporting the notion that nitration is a 
systemic process and therefore it affects several protein targets in a similar way. 
To assess whether the presence of nitrated ApoA1 was associated with increased anti-
ApoA1 and/or anti-HDL antibodies, I used a linear regression model and found that there 
was no correlation between nitrated ApoA1 and anti-ApoA1. However, although a similar no-
correlation pattern was observed for anti-HDL antibodies, there appeared to be a trend for 
lower TApoA1 concentration for the samples which had the highest anti-HDL levels. This 
raised the hypothesis that high anti-HDL levels could be associated with decreased TApoA1 
and this was confirmed when comparing the lowest and highest quartile of anti-HDL as a 
statistically significant difference was found. 
In summary, ApoA1 plays a central role in HDL function and has important cardiovascular 
protective functions. Reduced levels of ApoA1 are associated with increased CVD and the 
presence of increased nitrosative stress and nitrated Apo1 may be associated with impaired 
function and consequently, increased CV risk. Patients with SLE have lower TApoA1 and 
higher nitrated ApoA1 than HC, regardless of disease activity, treatment or classical 
autoantibody profile (ENA, anti-dsDNA, C3). However, the presence of anti-HDL IgG in high 
titres appear to be associated with lower TApoA1 levels. A similar pattern was observed for 
anti-ApoA1 IgG but it did not reach statistical significance. This supports the hypothesis that 
the presence of anti-HDL antibodies may be associated with increased ApoA1 clearance, 
possibly due to the formation of immune complexes, which would then support the notion 
that these antibodies may contribute to the increased CVD risk found in SLE. The presence 
of high levels of nitrated ApoA1 may also be a mechanism of HDL dysfunction and it would 
be relevant to assess the correlation and potentially causal association between these two 
variables. 
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4.3: Anti-apolipoprotein A1 and anti-HDL antibodies 
4.3.1: Anti-apoA1 IgG antibodies 
Anti-apoA1 IgG antibodies were tested in the longitudinal cohort and two separate cross-
sectional cohorts (early disease and vascular US groups as described on section 3.1: 
Patient selection). 
4.3.1.1: Longitudinal variation of anti-ApoA1 IgG levels 
Considering the 397 samples included in the longitudinal cohort previously described, 50% 
(198/397)  were positive for anti-ApoA1 IgG, defined as the 97.5th percentile of the 100 
healthy controls (46.7 AU).  
Anti-ApoA1 IgG levels were significantly higher (p= 0.0001) in patients with SLE (median 
48.5; IQR 5.9-10.7) compared with healthy controls (median 8.0; IQR 5.9-10.7) and patients 
with RA (median 0.0; IQR 0.0-4.3) as shown on Graph 5. 
The results of the univariable analysis between demographic and serological variables and 
anti-ApoA1 IgG are shown in Table 11. 
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Graph 5: Comparison of anti-ApoA1 levels between healthy controls (HC), patients with 
rheumatoid arthritis (RA) and SLE (each dot represents individual patients).  
(*** p<0.001) 
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Variable Category Ratio (95% CI) P-value 
Gender* Female (n=336) 1 
0.30 
 Male (n=61) 1.20 (0.85, 1.69) 
Disease duration  Ratio given per five year increase 1.00 (0.90, 1.11) 0.99 
Age at diagnosis Ratio given per ten year increase 1.02 (0.88, 1.18) 0.81 
Ethnicity* Caucasian (n=182) 1 
0.46  Afro-Caribbean (n=146) 1.19 (0.90, 1.57) 
 Other (n=69) 1.07 (0.75, 1.53) 
Overall ENA status** No (n=165) 1 
0.13 
 Yes (n=232) 0.82 (0.63, 1.06) 
Anti-Ro** No (n=226) 1 
0.41 
 Yes (n-171) 0.90 (0.69, 1.17) 
Anti-La** No (n=345) 1 
0.002 
 Yes (n=52) 0.54 (0.36, 0.80) 
Anti-Sm** No (n=298) 1 
0.004 
 Yes (n=99) 0.64 (0.47, 0.87) 
Anti-RNP** No (n=288) 1 
0.46 
 Yes (n=109) 1.11 (0.84, 1.47) 
Anti-dsDNA level < 50IU/ml (n=177) 1 
0.29 
 ≥ 50IU/ml  (n=170) 1.13 (0.90, 1.43) 
C3 level < 0.9g/l (n=139) 1 
0.09 
 ≥0.9g/l (n=208) 0.82 (0.66, 1.03) 
Disease activity in 
general system § 
A, B (n=31) 1 
0.32 
 C, D, E(n=344) 0.84 (0.60, 1.18) 
Disease activity in 
mucocutaneous 
A, B (n=41) 1 0.48 
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system § 
 C, D, E (n=334) 0.89 (0.65, 1.22) 
Disease activity in 
neuropsychiatric 
system § 
A, B (n=18) 1 
0.77 
 C, D, E (n=357) 0.93 (0.57, 1.52) 
Disease activity in 
musculoskeletal 
system § 
A, B (n=47) 1 
0.14 
 C, D, E (n=328) 0.80 (0.60, 1.08) 
Disease activity in 
cardiorespiratory 
system § 
A, B (n=13) 1 
0.06 
 C, D, E (n=362) 0.66 (0.42, 1.02) 
Disease activity in 
vascular system § 
A, B (n=12) 1 
0.40 
 C, D, E (n=363) 0.80 (0.47, 1.34) 
Disease activity in 
renal system § 
A, B (n=41) 1 
0.06 
 C, D, E n=329) 0.75 (0.55, 1.01) 
Disease activity in 
haematological system 
§ 
A, B (n=95) 1 
<0.001 
 C, D, E (n=280) 0.63 (0.50, 0.79) 
Sustained disease 
activity 
Persistently low (n=166) 1 
0.01 
 Persistently moderate/ high 1.30 (1.06, 1.59) 
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(n=209) 
Hydroxychloroquine No (n=223) 1 
0.003 
 Yes (n=174) 0.70 (0.55, 0.88) 
Immunosuppression No (n=200) 1 
0.35 
 Yes (n=197) 0.90 (0.73, 1.12) 
Oral prednisolone ≤ 7.5mg/day  (n=101) 1 
0.002 
 > 7.5mg/day (n=296) 1.39 (1.13, 1.71) 
*For gender, n values refer to the numbers of samples taken from female and male subjects, 
rather than numbers of females and males in the cohort of patients. A similar stipulation 
applies to ethnicity where n values refer to the number of samples taken from patients of 
each ethnic group. 
** For ENA, anti-Ro, anti-La and anti-Sm we did not have results from the date of every 
sample but it is assumed that positivity and negativity for these antigens generally remain 
stable 
§ “Disease activity in general system” refers to the BILAG score (A, B, C, D or E) in the 
General Category of the BILAG index on the day when each sample was taken. The same 
principle applies to all the other organ systems listed in the table, which are the 8 different 
categories recorded in BILAG. 
 
Table 11: Univariable analysis of factors associated with anti-ApoA1 IgG levels. The statistical 
significant associations are highlighted in bold. 
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No associations between anti-ApoA1 levels and either sex or ethnicity were found. Although 
anti-ApoA1 IgG levels were significantly lower in patients who were anti-La and anti-Sm 
positive, no statistically significant relationship was found with other serological markers, 
namely with C3 and anti-dsDNA which are the classical serological markers of disease 
activity. 
Nonetheless, when considering clinically defined disease activity based on the BILAG score, 
I found that patients who had persistently moderate or high disease activity had anti-ApoA1 
IgG levels 30% greater than those with persistently low activity (Graph 6).  
Moreover, patients with haematological flares (i.e. BILAG score A or B in this system) had 
significantly higher anti-ApoA1 IgG levels than those with a score of C, D or E (p< 0.001). A 
similar finding was observed for patients with renal or cardiorespiratory scores of A or B 
compared with those who scored C, D or E but on both instances, statistical significance was 
not reached (p= 0.06). A summary of these findings is depicted in Figure 20. 
The notion that anti-ApoA1 IgG levels appear to vary following a similar trend to that of 
disease activity, as defined by the BILAG, is further illustrated when individual patients are 
considered. Figure 22 depicts the variation of anti-ApoA1 IgG levels and global BILAG score 
in 8 patients. For the majority of them, these two variables appear to mirror each other (A-F) 
but for others, this variation is not as parallel (G-H). 
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Graph 6: Comparison of anti-ApoA1 IgG levels and sustained disease activity: patients with 
persistently moderate/ high disease activity have significantly higher anti-ApoA1 levels compared 
with those with persistently low activity.  
(** p<0.01) 
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Figure 21: Comparison of anti-ApoA1 IgG levels between BILAG scores of A/ B or C/ D/ E in the 
haematological (A), cardiorespiratory (B1) and renal (B2) systems.  
(** p< 0.01) 
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Figure 22: Longitudinal variation in anti-ApoA1 IgG levels and global BILAG score: longitudinal 
variation of anti-apoA1 levels and disease activity for eight different patients with SLE is represented. 
Anti-ApoA1 IgG levels parallel global disease activity in many (A-F) but not all (G-H) patients. 
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When looking at the influence of treatment on Anti-ApoA1 levels, I considered whether or not 
the patients were taking either HQ or IS, as well as the prednisolone dose they were taking 
at the time the sample was obtained. 
Interestingly, I found that in the samples from patients who were taking HQ had anti-ApoA1 
IgG levels 30% lower than samples from those who were not (p= 0.003). Similarly, patients 
who were on low dose steroids (≤7.5mg prednisolone daily) at the time the sample was 
taken had almost 40% lower anti-ApoA1 levels than those taking higher doses (p= 0.002). 
Figure 17 (A1 and A2) shows these two findings.  
No association between was found between anti-ApoA1 levels and treatment with IS at the 
time that the sample was taken. 
To investigate the association between treatment and anti-ApoA1 levels further, I compared 
the overall BILAG scores between patients taking HQ and low dose steroids with those not 
on HQ and moderate-high prednisolone dose (Figure 23 – A1 and A 2 respectively).  
I found that samples from patients on a lower prednisolone dose also had significantly lower 
disease activity (p= 0.017) which could potentially be a confounding factor. However, no 
difference in disease activity was found between patients taking HQ compared to those who 
were not, suggesting the effect of HQ could be independent of disease activity (Figure 23 - 
B1 and B2). 
To investigate the independent effect of each of the variables found to be significantly 
associated with anti-ApoA1 IgG levels, multivariable analysis was carried out. These findings 
are summarized in Table 11.  
No collinearity was observed between variables and the only variables which remained 
independently associated with higher anti-ApoA1 IgG levels were negativity for anti-La and 
anti-Sm, haematological disease activity and higher prednisolone dose. 
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Figure 23: Anti-apoA1 antibody levels and treatment: comparison of anti-ApoA1 levels between 
patients treated with or without  HQ (A1) and  low vs. high prednisolone dose (A2) as well as 
comparison between the global BILAG score in each of the 4 groups considered (B1 and B2).  
(*p<0.05) 
157 
 
 
 
 
 
 
Variable Category Ratio (95% CI) P-value 
Anti-La 
No 1 
0.006 
Yes 0.58 (0.39, 0.86) 
Anti-Sm 
No 1 
0.001 
Yes 0.58 (0.43, 0.80) 
Haematological 
system 
A, B 1 
0.66 (0.53, 0.83) 
<0.001 
C, D, E 
Prednisolone dose 
≤ 7.5mg/day 1 
0.008 
> 7.5mg/day 1.34 (1.08, 1.66) 
 
Table 12: Multivariable analysis of factors associated with anti-ApoA1 IgG antibodies levels in a 
longitudinal cohort of patients with SLE. 
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4.3.1.2: Cross-sectional assessment of anti-ApoA1 IgG levels 
Anti-apoA1 IgG levels were tested in two separate cross sectional cohorts: the early SLE 
group and the vascular US group. 
 Early SLE cohort 
Considering the patients’ immunological profile, 26 were ENA positive: 21 were anti-Ro 
positive, 6 La-positive, 15 anti-RNP positive and 11 anti-Sm positive. Furthermore, during 
the follow-up period, 59% (n= 29) had at least one positive anti-dsDNA measurement, 65% 
(n=32) had low C3 on at least one occasion and over 90% (n= 46) had a flare defined 
clinically by the classic BILAG score. All the eight systems of the classic BILAG were active 
at some point in the study. 
Based on the positivity cut-off previously described (46.7 AU), over 27% (n= 134) of the 499 
patients included in this cohort were found to be positive for anti-ApoA1 IgG in the first 
sample obtained within two years of SLE diagnosis (median 21.2; IQR 9.4-52.5). There was 
no correlation between the order of acquisition of samples and anti-apoA1 IgG level 
(Spearman correlation coefficient -0.115) suggesting that the storage time does not affect 
anti-apoA1 IgG levels. As reported above regarding the longitudinal group, no significant 
associations between anti-apoA1 IgG levels and age, gender or ethnicity were found. The 
mean anti-apoA1 IgG levels were significantly higher in patients with SLE (median 21.4 AU; 
IQR 11.2-52.9) compared with healthy controls (8.0 AU; IQR 5.9-10.7) (p<0.05).  
Considering serological variables, I found that during the course of their follow-up, over 2/3 
(n= 326) of patients were found to be anti-dsDNA positive while anti-cardiolipin antibodies 
were found to be present in 24.0% (n= 124). One quarter of the patients were found to be 
rheumatoid factor positive and over half were ENA positive (14.9% anti-Sm, 27.8% anti-
RNP, 37.5% anti-Ro and 13.9% anti-La).  
Significantly higher anti-ApoA1 IgG levels at the time of SLE diagnosis were found in 
patients who were or became anti-dsDNA positive (60.6 AU vs. 34.1 AU; p=0.0025). A 
similar finding was observed for those who developed anti-cardiolipin positivity compared to 
those who did not (80.1 AU vs. 41.6 AU; p=0.0062). Both these findings are depicted in 
Figure 24. No further associations between anti-ApoA1 IgG levels and other autoantibodies 
were found. 
When considering SLE-associated damage defined according to the SLICC Damage index, I 
found that positivity for anti-apoA1 IgG did not predict onset of damage during follow-up. As 
shown on Table 13, no statistically significant differences in damage scores at 5, 10, 15 and 
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20 years were observed between the different quartiles of anti-apoA1 IgG levels early in the 
course of SLE.  
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Figure 24: Early anti-apoA1, anti-dsDNA and anti-cardiolipin antibody levels: differences in anti-
ApoA1 IgG levels measured in early disease sera samples between patients found to be anti-dsDNA 
positive or negative (A) or anti-cardiolipin positive or negative (B). 
(*p<0.05; ** p<0.01) 
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Damage 
score 
Lowest 
quartile 
Second 
quartile 
Third 
quartile 
Highest 
quartile 
P value 
At 1 year 
(n=236) 
0.14 0.13 0.10 0.08 >0.05 
At 5 years 
(n=236) 
0.63 0.43 0.45 0.42 >0.05 
At 10 years 
(n=209) 
1.06 0.60 0.96 0.65 >0.05 
At 15 years 
(n=131) 
1.23 0.81 1.33 0.97 >0.05 
At 20 years 
(n=69) 
1.33 1.06 1.88 1.00 >0.05 
 
Table 13: Mean damage scores according to the SLICC Damage Index over a 20 year follow up 
stratified according to quartiles of anti-ApoA1 IgG levels in early disease sera samples. 
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During the course of follow-up, 40 patients (8.0%) suffered a CVD event (ischaemic heart 
disease confirmed either by raised cardiac enzymes and/ or ECG changes suggestive of MI 
and/ or by angiography in NSTEMI; or ischaemic stroke confirmed by imaging). Overall, the 
prevalence of CVD events was similar between anti-ApoA1 positive and negative patients 
(6.7% vs 8.5%; p>0.05).  
In order to further explore  potential differences in CVD-related mortality and/or morbidity, 
the 499 patients were divided into quartiles based on their anti-apoA1 IgG levels. I found that 
patients in the upper quartile were just as likely to have a CVD event compared with the 
lower quartile (prevalence 6.5% vs. 10.6%; p>0.05). A Kaplan-Meier Survival curve showing 
the proportion of patients CVD-free in the anti-apoA1 positive and negative groups at all-time 
points up to 34 years follow-up showed no statistically significant difference between the two 
groups (p= 0.89 by log-rank test) as shown on Graph 7. 
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Graph 7: CVD-free survival analysis: A Kaplan-Meier Survival curve shows no statistically significant 
differences in the proportion of patients CVD-free in the anti-apoA1 positive and negative at all-time 
points up to 34 years follow-up. 
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Considering the overall mortality, 66 of the 499 subjects died during the course of follow up 
and over 70% of these died before the age of 60 (n= 48). When looking at the anti-ApoA1 
IgG levels of these patients, those who tested positive in their early sample appeared to be 
more likely to have died than those who tested negative (17.1% vs. 12.4% mortality 
respectively), but this difference did not reach statistical significance (p=0.11).  
I then looked at the different anti-ApoA1 quartiles and found that there were 39 deaths in the 
upper quartile compared to 27 in the lower quartile (p=0.07).  
This pattern was more striking when looking at early mortality, i.e. deaths occurring below 
the age of 60. In this instance, I stratified patients based on their serum anti-ApoA1 IgG 
levels into upper (>21.2 AU) and lower halves (≤21.2 AU) than quartiles to include all the 
patients and found that there significantly more deaths in the upper compared with the lower 
half (31 vs. 17; p=0.023). However, as shown on Graph 8, a Kaplan-Meyer survival curve 
showing the percentage survival of patients in the anti-apoA1 positive and negative groups 
at all-time points up to 34 years follow-up showed no statistically significant differences 
between groups. 
Furthermore, there was no evidence to support the idea that early deaths in patients with 
higher anti-apoA1 IgG were due to CVD. Table 14 shows the causes of death for patients 
who died before or after 60 years of age and in summary no differences between these two 
groups were found. 
Of the six patients who died from CVD under the age of 60, only one was anti-apoA1 IgG 
positive at the time of diagnosis. 
  
165 
 
 
 
 
 
 
 
Cause of death 
Death< 60 years  (n= 
48) 
% 
Deaths ≥60 years (n= 
18) 
% 
CVD-related 
events 
6 13 3 17 
Infection 15 31 3 17 
Cancer 8 17 8 44 
Renal 4 8 1 6 
Other 15 31 3 17 
 
 
Table 14: Causes of death in patients before and after the age of sixty years showing no significant 
differences between the two groups. 
Graph 8: Survival analysis: a Kaplan-Meyer survival curve showing the percentage survival of patients 
in the anti-apoA1 positive and negative groups at all-time points up to 34 years follow-up showed no 
statistically significant differences between groups. 
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Vascular US cohort 
The findings of the vascular US group were similar to those reported for the longitudinal and 
early SLE cohorts and will be explored with further detail on section 4.3 Vascular Ultrasound. 
Briefly, the median anti-apoA1 level at the time of the scan was 66.7 AU (IQR 31.1-181.0) 
and two thirds of the patients (n= 66) were found to have levels greater than the positivity 
cut-off previously defined (46.7AU). Age at scan and C3 levels were found to have a 
significant negative correlation with anti-ApoA1 IgG levels (r2 -0.23 and -0.25; p 0.03 and 
0.012 respectively). As previously described for the early disease cohort, an association 
between early anti-ApoA1 IgG levels and anti-dsDNA was observed (r2 0.3; p= 0.0006). No 
further statistically significant associations with auto-antibody profile were found. 
A significant positive correlation between early anti-ApoA1 levels and mean CCA IMT was 
found (r2 0.24; p=0.021) but no further associations between anti-ApoA1 IgG levels and 
either total plaque area (TpA) or total plaque thickness (TpT) were observed. Similarly, anti-
ApoA1 levels did not appear to influence plaque texture assessed by the GSM value. 
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4.3.2: Anti-ApoA1 IgM antibodies 
A cross-sectional assessment of anti-apoA1 IgM levels was done using sera belonging to 
the patients included in the vascular US cohort (n= 100). 
Patients with SLE had significantly higher levels than HC (median 17.2 vs 7.8; IQR 3.9-107.5 
vs 4.7-13.0) as shown on Graph 9. The positivity cut-off was defined as the 97.5th percentile 
of the 100 HC tested (167.2 AU) and under one third of the patients (n= 22) was found to be 
positive. 
The relevant findings regarding the factors influencing the anti-ApoA1 IgM levels are 
summarized in Table 15. 
No associations between general demographic variables and anti-ApoA1 IgM levels were 
found. Although a significant correlation with total serum IgM levels and anti-ApoA1 IgM was 
noted, no further correlations with general laboratorial findings were established, namely with 
lipid profile. 
With regards to the auto-antibody profile, patients who were anti-RNP positive had 
significantly lower anti-ApoA1 IgM levels (p= 0.01) but no further significant associations 
emerged. 
A positive correlation between anti-ApoA1 IgM levels and GSM was found but no statistically 
significant associations with other US-related variables were observed. 
Disease activity appeared to correlate with anti-ApoA1 IgM levels, specifically the global 
BILAG score during the first year after diagnosis. A non-significant trend was found between 
sustained disease activity and anti-ApoA1 IgM levels: patients with higher levels of anti-
ApoA1 IgM appear to be more likely to have persistently low activity while the inverse was 
found for patients who were persistently active. No significant associations with other clinical 
and serological markers of disease activity were observed.  
Patients who had undergone treatment with B-cell depletion, i.e. rituximab +/- 
cyclophosphamide according to the Rheumatology department protocol at UCLH (n= 31), 
had significantly lower anti-ApoA1 IgM levels. However, they were also found to have 
significantly lower total serum IgM levels (r2 -0.40; p< 0.0001) which could potentially be a 
confounding factor. In addition, patients who were treated with B-cell depletion had 
significantly more active disease, with a higher global BILAG score at the time of scan 
(p=0.04) and higher mean global BILAG score during follow-up (p< 0.0001). Moreover, these 
patients had a greater number of visits with ≥1 A flare and/or ≥2 B flares in at least one 
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organ system (p= 0.0007 and 0.003 respectively) and their mean and cumulative global 
BILAG score during the first year of follow up (p= 0.0004 and 0.0002 respectively) was also 
higher. Figure 25 illustrates these findings. 
Finally, 16 patients were positive for both anti-apoA1 IgG and IgM. Over 70% of the anti-
ApoA1 IgM positive patients were also anti-apoA1 IgG positive (16/22), while only less than 
a quarter of patients found to be anti-ApoA1 IgG positive were also anti-apoA1 IgM positive. 
Combined positivity between early anti-ApoA1 levels and either anti-apoA1 IgG or IgM was 
found in a minority of patients (12/66 and 7/22 respectively. However, as previously stated, 
when considering the power of correlation, these findings did not reach statistical 
significance (Spearman’s correlation; CI 95%). 
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Variable r2 
(95% CI) 
p-value 
RNP positivity -0.26 
(0.1 – 0.47) 
0.01 
Disease activity 
Mean global BILAG score during the 1st year after SLE 
diagnosis 
Cumulative global BILAG during the 1st year after SLE 
diagnosis 
Mean global BILAG score/ year 
 
-0.21 (0.1 – 1.2) 
 
-0.22 (0.2 – 1.0) 
 
-0.23 (0.5 – 1.2) 
 
0.01 
 
0.04 
 
0.03 
Serum IgM (g/L) 0.44 <0.0001 
B-cell depletion -0.35 0.003 
 
 
Graph 9: Comparison between anti-ApoA1 IgM levels between patients with SLE and 
healthy controls (HC). 
(** p< 0.01) 
 
Table 15: Factors significantly correlated with anti-ApoA1 IgM (Spearman’s correlation; CI 95%). 
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Figure 25: Anti-apoA1 IgM levels and B-cell depletion: comparison between anti-ApoA1 IgM levels 
between patients treated with B-cell depletion and those who did not receive this treatment (A) and 
comparison of disease activity between these two groups at the time of the scan (B), during follow 
up (C) and over the first year of follow up (D). 
(** p< 0.001; ** p< 0.01) 
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4.3.3: Anti-HDL IgG antibodies 
Anti-HDL IgG antibodies were tested cross-sectionally in the vascular US group. 
Patients with SLE had significantly higher anti-HDL levels than HC (median 7.7 vs 1.9; IQR 
0.0-24.9 vs 0.0-8.4) as shown on Graph 10. The upper limit of normal was defined as the 
97.5th percentile based on the HC measurements as 22.5 AU and 27 patients were found to 
be positive. 
Although a significant correlation between anti-HDL levels and age at scan was found (r2 
0.22; p=0.04 CI 95%), no associations with ethnicity and auto-antibody profile, including anti-
ENA were noted. Although the majority of patients found to be anti-HDL positive were also 
anti-ApoA1 IgG positive (18/27), the reverse was not observed as less than a third of anti-
ApoA1 positive patients were also anti-HDL positive (18/66). Moreover, over one third of 
anti-HDL positive patients were also found to be anti-apoA1 IgG positive on their early 
disease sample (10/27). However, only a minority of patients had combined positivity for 
both anti-HDL and anti-ApoA1 IgG (3/27). 
A statistically significant negative correlation between anti-HDL and total ApoA1 levels was 
observed (r2 -0.21; p=0.03; CI 95%). This finding was further illustrated when comparing total 
ApoA1 levels between the upper quartile (anti-HDL >24.9 AU) and the lower quartile (anti-
HDL≤ 0.0 AU) of anti-HDL as shown on Figure 26-A.  
 However, no significant associations between anti-HDL and lipid profile, namely with HDL 
levels was noted even when comparing the upper and lower quartiles of anti-HDL antibodies 
(Figure 26-B). 
Similarly, disease activity defined either clinically through the BILAG score or serological by 
anti-dsDNA and C3 was not found to correlate significantly with anti-HDL.  
No associations between anti-HDL and nitrated protein levels, nitrated ApoA1 or NN, were 
found. 
Anti-HDL levels also correlated with vascular US findings, in particular with TpA and TpT and 
these findings will be further explored in section 4.3 Vascular Ultrasound. 
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Graph 10: Comparison of anti-HDL IgG levels between patients with SLE and HC (** p< 0.01). 
Figure 26: Comparison of total serum apolipoprotein A1 (A) and HDL levels (B) between the 
upper and lower quartiles of anti-HDL IgG (* p< 0.05; NS: non-significant).  
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4.3.4: Discussion 
Comparable to what has been previously reported (Dinu, Merrill et al. 1998, Delgado Alves, 
Ames et al. 2002, Alves and Ames 2003, Delgado Alves, Kumar et al. 2003, Batuca, Ames 
et al. 2007, Batuca, Ames et al. 2009, O'Neill, Giles et al. 2010); I found that anti-ApoA1 
levels were significantly higher in SLE compared to healthy controls in all the groups studied. 
Interestingly, 27% of 499 patients were positive for anti-apoA1 IgG very early in the disease 
course. Arbuckle et al showed that many autoantibodies are present in patients with SLE 
even in stored samples taken before diagnosis of SLE (Arbuckle, McClain et al. 2003), but 
results of anti-apoA1 levels measured in early disease samples have not been published to 
date. The association between autoantibody levels and disease activity is not a new concept 
and other papers have also shown associations between serological markers and activity in 
particular systems; anti-nucleosome antibodies and renal lupus (Manson, Ma et al. 2009), 
interleukin-6 and haematological lupus (Ripley, Goncalves et al. 2005) and nitrated 
nucleosomes and vasculitis (Croca, Bassett et al. 2014). Nonetheless, none of these 
biomarkers has substituted C3 and anti-dsDNA as the gold standard for assessing lupus 
activity. 
O’Neill et al showed that anti-apoA1 IgG levels were higher in patients with persistently 
active disease compared with those with quiescent disease and that they rose at times of 
disease flare (O'Neill, Giles et al. 2010). This study was limited by its cross-sectional nature 
as did not study serial samples taken over long periods, thus preventing the use of 
multivariable analysis and elimination of potential confounding factors. I tested multiple 
samples taken from 49 patients longitudinally and univariate analysis suggested an 
association of anti-apoA1 levels with disease activity defined both clinically through the 
BILAG score and serologically through C3 and anti-dsDNA levels. Patients who had a 
haematology score of either A or B at the time of the sample had significantly higher levels of 
anti-ApoA1 than those with scores of C, D or E. Similarly, patients with an overall BILAG 
score greater than 5 at the time of the sample had greater anti-ApoA1 levels than those with 
a lower score. HQ appeared to have a similar effect, as samples taken at a time when the 
patients were taking HQ had significantly lower anti-ApoA1 levels. However, when using 
multivariate analysis, then only variables whose associations with anti-ApoA1 levels 
remained statistically significant were the presence of active haematological disease (BILAG 
score A/B), higher corticosteroid dose (prednisolone >7.5mg daily) and negativity for anti-La 
and anti-Sm.  
The differences between the univariate and multivariate analysis regarding the associations 
between steroid dose, HQ and disease activity can be explained by the presence of 
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confounding factors, such as disease activity, given that the treatment regimen, namely the 
steroid dose is chiefly determined by the clinical scenario. However, the power of 
multivariate analysis also lies in the number of samples available and how many variables 
are considered and it can be argued that it may disregard potentially important associations, 
particularly if two variables are closely related. In fact, when I compared the disease activity 
between patients on ≤7.5mg prednisolone daily and those on higher doses, I found that the 
former also had lower disease activity. Therefore, it appears that the association between 
anti-ApoA1 and steroid dose may be due to the disease activity at the time of the sample 
rather than to the steroid dose per se. However, the same was not true for HQ. When I 
compared the disease activity between samples taken when the patients were on HQ vs. 
those when the patients weren’t on HQ, I found no differences. This may signify that the 
correlation between HQ and lower anti-ApoA1 levels is not due to disease activity, but may 
in fact depend on the effect of HQ.  
Although the association between anti-ApoA1 antibodies and treatment with HQ was not 
supported by the multivariate analysis, the beneficial role of HQ on the lipid profile has been 
suggested in RA. Wallace et al (Wallace, Metzger et al. 1990) reported a 15-20% decrease 
in TG, t-cholesterol and LDL in patients with RA who were taking HQ, suggesting that it 
could potentially reverse the deleterious effects of steroids. Munro et al ((Munro, Morrison et 
al. 1997) reported further benefits of HQ use in HDL, showing that after 6 months of 
treatment, total HDL and the HDL/ t-cholesterol ratio were significantly increased, with 
median HDL levels raising by 15%. To place these results in context, it has been shown that 
a 10% fall in serum t-cholesterol leads to a 10% decrease in death from MI and of 21% of 
non-fatal ACS (Law, Wald et al. 1994). Other measures to reduce cholesterol have variable 
effects in the lipid profile: lipid lowering diet can lead to a 2-13% reduction in total cholesterol 
(Ramsay, Yeo et al. 1991), while statins usually elicit a 20-30% reduction in total cholesterol 
and 15% raise in HDL (Shepherd, Cobbe et al. 1995). More recently, a study by Morris et al 
(Morris 2011) shows that the use of HQ is independently associated with lower LDL, t-
cholesterol, LDL/HDL and t-cholesterol/ HDL ration in a cohort of 706 patients with RA. A 
non-significant trend towards with HDL and lower TG levels in patients taking HQ was also 
noted. 
Although it is considered to be a disease modifying drug (DMARD) in RA, HQ has a 
relatively weak anti-inflammatory effect and is therefore unlikely that its impact on the lipid 
profile is due to a better control of systemic inflammation. In vivo studies showed that 
chloroquine, which is structurally similar to HQ, inhibits cholesterol synthesis in rat 
hepatocytes (Beynen, van der Molen et al. 1981). It has been suggested that this effect may 
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be due to the fact that HQ lowers the lysosomal pH which could in turn inhibit the proteolysis 
of internalized cholesterol esters (Beynen, van der Molen et al. 1981). Even if the use of HQ 
is not associated with reduced anti-ApoA1 levels all the available evidence supports its use 
in SLE not only to treat symptoms directly related with the disease but also to potentially 
provide some degree of cardiovascular protection. 
The atheroprotective role of ApoA1 has been extensively reported (Hahn 2010, O'Neill, Giles 
et al. 2010, Teixeira, Cutler et al. 2012). The occurrence of dysfunctional HDL in 
inflammatory diseases such as SLE has also been suggested as a potentially important 
factor in the increased CVD risk observed in these patients (Hahn, Grossman et al. 2007). 
Several studies suggest that one of the mechanisms through which HDL function is impaired 
may be the presence of anti-ApoA1 (Batuca, Ames et al. 2007, Batuca, Ames et al. 2009, 
O'Neill, Giles et al. 2010, Vuilleumier, Bratt et al. 2010). Previous studies confirmed the 
presence of IgG anti-apoA1 antibodies in patients with SLE, indicated an association with 
higher disease activity and suggested a possible link with the development of 
atherosclerosis (Shoenfeld, Szyper-Kravitz et al. 2007, Batuca, Ames et al. 2009, O'Neill, 
Giles et al. 2010, Radwan, El-Lebedy et al. 2013). However, to establish unequivocally a 
causal effect, long-term follow up is required, including vascular scanning data and multiple 
serial samples from patients with fluctuating disease activity. No previous study has fulfilled 
all these requirements but in my thesis I have tried to do so by studying three distinct but 
overlapping patient groups: longitudinal, early SLE and vascular US.  
I found no association between anti-apoA1 IgG positivity early in disease and development 
of CVD later. The numbers of patients with CVD were relatively small (42/518), but I also 
found no association between anti-apoA1 and the presence of carotid or femoral plaque or 
increased CCA IMT in the 100 patients scanned. Moreover, the presence of anti-ApoA1 
antibodies did not appear to influence plaque texture assessed by GSM. Thus no convincing 
link between anti-apoA1 and atherosclerosis or CVD in patients with SLE has emerged. This 
agrees with the findings reported by Radwan et al in Egyptian patients with SLE (Radwan, 
El-Lebedy et al. 2013) but contrasts with those of Vuilleumier et al , who found that, in 133 
Swiss patients with RA followed for a median of 9 years, baseline IgG anti-apoA1 positivity 
was strongly associated with risk of developing a major cardiovascular event (Hazard Ratio 
4.7, 95% CI 1.9-11.2) even after adjusting for standard CVD risk factors in multivariable 
analysis (Vuilleumier, Reber et al. 2004). However, this RA cohort was older (mean age 65 
years) contained more males (30%) and had a higher rate of CVD events compared to our 
group or other SLE groups reported in the literature (Shoenfeld, Szyper-Kravitz et al. 2007, 
Batuca, Ames et al. 2009, O'Neill, Giles et al. 2010, Radwan, El-Lebedy et al. 2013). It may 
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well be that longer-term studies will be needed in SLE than in RA to identify predictive 
effects of factors such as autoantibodies on CVD risk. Notably, in a large inception cohort 
study, 1249 patients with SLE were followed for a median of 8 years and only older age and 
male gender were identified as CVD risk factors in multivariable analysis (Urowitz, Ibanez et 
al. 2007, Urowitz, Gladman et al. 2010). 
Although no associations between anti-ApoA1 and CVD emerged, I found a statistically 
significant association between anti-apoA1 positivity early in disease and increased risk of 
dying before the age of 60. The reason for this association is unexplained. Development of 
damage (due to disease activity or therapy) is a powerful risk factor for mortality (Rahman, 
Gladman et al. 2001) in SLE but I found no association between anti-apoA1 IgG levels and 
SLICC-DI score over a 10-year follow-up period on over 200 patients. However, many of the 
patients who died before the age of 60 were not represented amongst these 200, their early 
death precluding long-term follow-up. 
Regarding anti-ApoA1 IgM antibodies, I decide to measure their levels in the vascular US 
cohort due to the potential protective role attributed to IgM antibodies not only in auto-
immunity, but also in atherosclerosis. Manson et al summarized in a comprehensive review 
the protective role played by natural IgM in several processes traditionally implied in the 
development of autoimmunity (Manson, Mauri et al. 2005). The potentially protective role of 
IgM may be attributed to its low affinity, predominantly intravascular distribution and lack of 
interaction with Fc-receptors in phagocytic cells (Virella 1993). 
Ajeganova et al tested the sera of 215 patients with RA and found that those with higher 
anti-phosphorylcholine IgM antibodies at baseline were more likely to remain in remission 
regardless of the treatment chosen (rituximab versus anti-TNF agent). The authors suggest 
that the presence of low levels of this specific type of IgM antibodies may identify an 
immunological profile which predicts inferior therapy response (Ajeganova, Fiskesund et al. 
2011). Stoehr et al also described how the production of self-reactive IgM induced by TLR9-
expressing peritoneal B1 cells in lupus-prone mice led to reduced Th17 cell development 
and consequently abrogated severe autoimmunity (Stoehr, Schoen et al. 2011). The 
protective role of IgM-producing serosal B1-cells appears to also extend to atherosclerosis 
as reported by Kyaw et al who review their potentially atheroprotective role (Kyaw, Tipping et 
al. 2012).  
Considering the immunological basis for atherosclerosis, several studies have reported on 
the potentially atheroprotective role for IgM. Chronic kidney disease has a strong correlation 
with CVD and CVD-related risk factors such as diabetes and several studies have been 
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developed to assess the role of IgM antibodies. Virella et al measured IgG and IgM 
antibodies directed against oxidized LDL in a cohort of patients with type I diabetes (n=36), a 
group notoriously recognized as having increased CVD risk. They found a predominance of 
IgG antibodies in diabetic patients compared with HC and this difference was enhanced 
when considering patients who had diabetic nephropathy. However the data reported were 
not enough to support the protective role of IgM antibodies (Virella, Carter et al. 2008). 
Similarly, Carrero et al reported that  low level of natural IgM directed against the exposed 
phosphorylcholine in inflammatory phospholipids is an independent predictor of death 
among patients who are under haemodialysis (Carrero, Hua et al. 2009). Yilmaz et al report 
how HIV-positive patients have significantly lower IgM and higher IgG antibodies directed 
against oxidized LDL and argued that this may be a contributing factor to the excess CVD 
risk found among these patients (Yilmaz, Jennbacken et al. 2014). 
Interestingly, Karvonen et al described a negative correlation between IgM antibodies 
directed against oxidized LDL and carotid IMT (Karvonen, Paivansalo et al. 2003). The 
opposite though was reported by Fredrikson et al who found a more rapid IMT progression 
of carotid disease in the presence of IgM directed against apolipoprotein B-100 (Fredrikson, 
Hedblad et al. 2007). Animal studies conducted by Cesena et al showed that in 
hypercholesterolemic apoE deficient mice, treatment with polyclonal IgM reduced aortic 
atherosclerosis (Cesena, Dimayuga et al. 2012). Lewis et al also described their findings on 
the influence of natural IgM antibodies on atherosclerosis. They selected serum from IgM 
deficient mice and found that compared with normal controls these had larger aortic 
atherosclerotic plaque, more complex crystal formation and increased smooth muscle cell 
content. Moreover, this effect appeared to be at least partly independent of C1q (Lewis, 
Malik et al. 2009). 
I found a weak positive correlation between anti-ApoA1 IgM levels and GSM, but no other 
associations with US findings was observed. Higher GSM is associated with increased 
connective tissue deposition in the plaque and as discussed in the introduction this may 
signify greater plaque stability. However, the mechanism through which anti-ApoA1 IgM 
antibodies could lead to these changes has not been previously discussed in the literature. I 
did not find any statistically significant associations between anti-ApoA1 IgM levels and 
disease activity or autoantibody profile. Patients who were treated with rituximab did have 
lower anti-ApoA1 IgM levels but they also had lower total serum IgM levels and therefore I 
did not think this to be a relevant finding.   
To date, there are no papers reporting on the measurement of anti-Apoa1 IgM antibodies or 
their relation with either disease activity or markers of atherosclerosis.  
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4.4: Vascular Ultrasound 
4.4.1: Overview of vascular ultrasound results 
4.4.1.1: Cohort characterization 
103 patients were scanned using the protocol previously described. However, three of the 
patients scanned were later felt not to fulfil the revised 1982 ACR criteria for SLE  (Hochberg 
1997) and were therefore excluded from the analysis (n= 100). 
95% of the patients were women and the overall mean age was 45.2 years (SD 12.4; range 
20-66). The mean age at SLE diagnosis was 29.2 (SD 10.9; range 8-56) and on average 
patients had been under follow up in for 16 years (SD 10.0; range 2-46). 
56 patients were Caucasian, 25 were of Afro-Caribbean-origin, 11 were South Asian and 8 
patients had other ethnic backgrounds (Chinese or mixed race). 
Overall, patients had a broad spectrum of organ involvement, most commonly skin, joints 
and kidney. Biopsy proven lupus nephritis was present in 37 patients. A few patients had 
had vasculitis and/or serositis during the course of their disease while definite neurological 
involvement was exceedingly rare (n= 1). Less than one third of the patients (n= 26) had a 
formal diagnosis of hypertension and a very small minority had diabetes (n=2). Although only 
10 patients were smokers at the time of the scan, 17 had been smokers at some point in 
their life.  
Data on each individual patient’s general laboratory biochemistry assessment, including 
renal function tests, albumin levels, lipid profile and homocysteine were obtained from the 
UCH associated laboratory. Further data on auto-antibody profile were also collected. For 
each patient, BP measurements at the time of the scan were taken as previously described.  
Most of these patients had normal BP although sBP was raised in 34 patients; only 22 had 
sBP greater than 130mmHg.  
For the majority of patients, renal function was found to be normal, with serum creatinine 
levels above the upper limit of normal for only 11 patients. Nonetheless, urine 
protein:creatinine ratio was found to be raised in almost a quarter of patients (n= 24) 
although serum albumin levels were reduced in only 6 patients. 
Treatment with ACE-inhibitors was noted on 35% of patients either for BP control or due to 
kidney disease and proteinuria. 
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Despite normal mean values, t-cholesterol, LDL and triglyceride levels were found to be 
elevated in 43, 46 and 10 patients respectively. Only 8 patients had HDL levels below the 
lower limit of normal. Treatment with statins was documented in 13 patients. 
Regarding vitamin D measurement, over one third of patients (n= 36) were found to have 
either deficient or insufficient levels and a similar number were or had been on vitamin D 
supplements recently. 
Homocysteine was measured in half the patients and levels were found to be raised 
compared to what could be expected for the age and gender of the cohort. Treatment with 
folic acid supplements was only taken by patients being treated with methotrexate.  
When considering the auto-antibody profile, 70% of patients were found to be anti-dsDNA 
positive at some point in their disease course and over half (n= 54) had reduced C3 levels. 
At the time of scan, close to 40% of patients had either raised anti-dsDNA or reduced C3 
levels (n= 38 and 36 respectively). 
Close to two thirds of patients (n= 58) were found to be ENA positive and positivity for the 
different subtypes was as follows: anti-Ro 41%, anti-La 16%, anti-RNP 32% and Sm 17%.  
A minority of patients was positive for anti-phospholipid antibody profile (anti-cardiolipin n= 
13; anti-β2GP1 n= 9; lupus anticoagulant n= 12), anti-C1q (n=21), anti-CCP (n=4) or 
rheumatoid factor (n=7). 
Overall, patients were found to have normal serum immunoglobulin levels, although 20% (n= 
23) had raised serum IgG levels and almost all of those had high anti-dsDNA levels. 
With regards to SLE-related treatment, 65% were taking hydroxychloroquine at the time of 
scan and 45% were on immunosuppressants. Most commonly, patients were either on 
azathioprine (n= 17) or MMF (n= 18), while a smaller number was treated with methotrexate 
(n= 5) or other drugs (n= 5), including tacrolimus and mepacrine). 
The mean daily prednisolone dose was 4.6mg but over one third of patients (n= 37) were not 
taking any steroids at the time of the scan while a minority was taking >7.5mg (n= 14). 
Finally, 31 patients had undergone at least one cycle of B-cell depletion during the course of 
their follow up. 
A summary of these findings is presented in Table 16. 
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Variable Mean SD (range) Normal range 
BP (mmHg) 
Systolic 
Diastolic 
Mean 
 
126.3 
75.8 
92.6 
 
15.9 (94-168) 
10.4 (55-109) 
11 (70-124.7) 
 
120 
80 
100 
Renal function tests 
Urea (mmol/L) 
Creatinine (µmol/L) 
U protein:creatinine 
(mg/mmol) 
 
5.6 
73.6 
50.7 
 
2.9 (2-17.5) 
31.8 (40-227) 
84.0 (4-567) 
 
2.5-8 
<106 
<45 
Albumin (g/L) 43.1 4.9 (19-5) 30-50 
Lipid profile 
t-cholesterol (mmol/L) 
LDL (mmol/L) 
HDL (mmol/L) 
Triglycerides (mmol/L) 
t-cholesterol:HDL 
 
4.8 
2.62 
1.7 
1.1 
3.1 
 
1.1 (2.5-7.3) 
0.9 (0.8-4.8) 
0.5 (0.4-2.8) 
1.1 (2.5-7.3) 
0.9 (1.6-5.6) 
 
<5.2 
<2.0 
>1.0 
<2.2 
Homocystein (µmol/L) 14.9 5.6 (8-38) 6-15 
Inflammatory markers 
CRP (mg/dL) 
ESR (mm/h) 
 
2.8 
21.1 
 
2.7 (0.6-15.5) 
18.4 (2-86) 
 
<5 
<20 
Vitamin D (nmol/L) 60.2 33.3 (7-228) 25-137 
Anti-dsDNA (IU/L) 96.8 166.7 (1-712) <50 IU/L 
Complement (C3) (mg/dL) 1.0 0.2 (0.49-1.46) ≥0.9g/L 
Anti-C1q antibodies 
Positive 
Negative 
 
21 
55 
 
- 
- 
 
- 
- 
Anti-cardiolipin antibodies    
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Positive 
Negative 
13 
82 
- 
- 
- 
- 
Anti-β2 GP1 antibodies 
Positive 
Negative 
 
9 
20 
 
- 
- 
 
- 
- 
Lupus anticoagulant 
Positive 
Negative 
 
12 
78 
 
- 
- 
 
- 
- 
Anti-CCP antibodies 
Positive 
Negative 
 
4 
36 
 
- 
- 
 
- 
- 
Rheumatoid factor 
Positive 
Negative 
 
7 
65 
 
- 
- 
 
- 
- 
Serum immunoglobulins 
(g/L) 
IgG 
IgM 
IgA 
 
13.3 
1.1 
2.8 
 
5.2 (4.62-
32.32) 
1.0 (0.1-6.6) 
1.5 (0.1-9.12) 
 
7-16g/L 
0.4-2.3g/L 
0.7-4g/L 
Treatment 
Prednisolone (daily dose 
mg)  
 
4.6 
 
6.1 (0-50) 
 
- 
Immunosuppressants (Y/N) Y = 65 / N = 35 
Hydroxychloroquine (Y/N) Y = 45 / N = 55 
B-cell depletion (Y/N) Y = 31 / N = 69 
 
 
Table 16: General characterization of the vascular US cohort: blood pressure (BP), general 
biochemistry laboratory findings, auto-antibody profile and treatment of the 100 patients who 
underwent vascular US. 
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4.4.1.2: General vascular US findings – IMT and plaque presence 
 Plaque presence 
36 patients were found to have plaque and a total of 84 plaques were identified. 22 patients 
had plaque in one or two sites and 15 were found to have plaque in at least three of the four 
territories assessed. 14% of patients had plaque exclusively in the carotids and in 7% of 
patients plaque was only found in the femoral bifurcation. 5% of patients had plaque in all 
four territories assessed.  
Patients found to have plaque were significantly older (mean age 53.9; SD 8.76; range 27-
66) than those without plaque (mean age 40.0; SD 11.38; range 20-66) (p<0.0001) but no 
associations with gender or ethnicity were found.  
The overall mean plaque score classified using a visual scale was 3.1 (SD 0.91; range 1-5) 
but the majority of plaques had visual scores between 1 and 3. 
Full plaque characterization including area, volume and texture will be explored in the next 
section. 
 
 IMT measurements 
My findings regarding the IMT measurement taken in the CCA and bulb, as well as the mean 
CCA IMT and mean overall IMT are summarized in Table 17. 
When considering the IMT measured in the CCA, I found that none of the patients scanned 
had thickened IMT at this level, i.e. all patients had an IMT of less than 0.1cm on both CCAs. 
Notwithstanding this observation, IMT thickness was significantly greater in the bulb region 
compared to the CCA even in patients with no plaque anywhere in the carotid territory 
(Graph 11). 
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Measurement site IMT (cm) SD Range 
Right CCA 0.053 0.009 0.040-0.080 
Right Bulb 0.110 0.070 0.050-0.420 
Left CCA 0.056 0.050 0.040-0.100 
Left Bulb 0.120 0.075 0.050-0.350 
Mean CCA IMT 
Mean overall IMT 
0.054 
0.087 
0.008 
0.038 
0.040-0.088 
0.045-0.210 
 
 
 
 
 
 
  
Table 17: IMT measurements taken on the mid-section of  the CCA and carotid bulb. Mean CCA 
IMT and mean overall IMT are also included (CCA: common carotid; SD: standard deviation). 
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Graph 11: IMT in the CCA and carotid bulb: comparison of the IMT thickness between the CCA and 
bulb region in patients without plaque, showing that the IMT measured at the bulb is significantly 
greater than at the CCA even in the absence of plaque anywhere in the carotid territory. (*** p< 0.001) 
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Although none of the patients had plaque in the CCA i.e. they all had normal IMT 
measurements at this level, when I compared the IMT thickness in the CCA between 
patients without plaque and those with plaque at any site, I found that the latter had 
significantly thicker CCA IMT (p< 0.0001) (Figure 27-A). 
I then decided to investigate whether different plaque locations had any influence on this 
finding and compared the CCA IMT between patients with no plaque and with patients who 
had plaque exclusively either at the carotid bulb or the femoral bifurcation (Figure 27-B). I 
found that regardless of the location of plaque, patients with plaque had significantly thicker 
CCA IMT compared to patients without plaque (p<0.0001 and p<0.0033 respectively). 
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Figure 26: Comparison of the IMT thickness in the CCA between patients without plaque and 
patients with plaque on any site (A) and plaque exclusively on the bulb or on the femoral 
bifurcation (B). (* p<0.05; ** p< 0.01) 
187 
 
Considering the full patient characterization, several variables appeared to correlate 
significantly with the mean CCA IMT. Table 18 summarizes these findings. 
Both disease duration and age at scan appear to correlate with thicker CCA IMT, in 
particular the latter. The same is true for BP, with all three measurements having a 
significant association with the IMT, in particular the systolic BP.  
Another interesting observation was the positive correlation found between mean CCA IMT 
and the number of sites with plaque, total plaque area and total plaque thickness. This 
reiterates the previously described finding that patients with plaque anywhere had 
significantly thicker IMT than those without plaque (Graph 19-B). 
The lipid profile also had a significant influence over the mean CCA IMT with higher t-
cholesterol and LDL levels being associated with higher mean CCA IMT. No association 
between TG and HDL was found, namely, no inverse negative correlation or even trend was 
found between HDL levels and IMT. 
Finally, of the serological tests I developed, the only one for which a weak correlation with 
mean CCA IMT was found was the  anti-ApoA1 IgG level in early disease (but not IgG anti-
apoA1 at the time of the sample).  
No further statistically significant correlations were found to influence the mean CCA IMT. 
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Variables r2 (Spearman correlation; 
95% CI) 
p- value 
Age at scan (yrs) 0.55 (0.7 – 1.4) <0.0001 
Disease duration at scan 
(yrs) 
0.39 (1.2 – 2.0) 0.02 
BP (mmHg) 
Systolic 
Diastolic 
Mean 
 
0.4 (1.2 – 2.6) 
0.22 (0.8 – 1.7) 
0.32 (1.1 – 2.4) 
 
<0.0001 
0.03 
0.001 
Number sites with plaque 0.39 (0.8 – 1.6) <0.0001 
Total plaque area (mm2) 0.40 (1.7 – 3.1) <0.0001 
Total plaque thickness 
(cm) 
0.40 (1.4 – 2.7) <0.0001 
T-cholesterol (mmol/L) 0.36 (1.1 – 2.7) 0.0002 
LDL (mmol/L) 0.31 (1.4 – 2.3) 0.002 
Early anti-ApoA1 IgG (AU) 0.24 (1.0 – 2.1) 0.02 
 
  
Table 18: Factors significantly influencing the mean CCA IMT (Spearman’s correlation; CI 95%) 
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4.4.1.3: Plaque characterization 
 4.4.1.3.1: Plaque area and 2D texture analysis 
Considering the 36 patients who were found to have plaque on at least one site, the mean 
total plaque area was 78.67 mm2 (SD 69.75; range 6.89-317.93) and the mean total plaque 
thickness was 0.67 cm (SD 0.07; range 0.16-2.78). All the 84 plaques identified were 
included in this analysis. 
To investigate the variables which had a statistically significant influence on plaque area and 
thickness, Spearman’s correlation was applied. The positive findings of this analysis are 
summarized in Table 19. Overall both these outcomes were affected in a similar manner by 
similar variables, although subtle differences were noted. 
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Variables Total plaque 
area (mm2) 
(r2; 95% CI) 
p-value Total plaque thickness 
(mm) 
(r2; 95% CI) 
p-value 
Age at scan (yrs) 0.56 (2.1 – 3.9) <0.0001 0.58 (1.9 – 3.6) <0.0001 
Disease duration (yrs) 0.29 (1.2 – 2.7) 0.004 0.32 (1.3 – 2.5) 0.0001 
Systolic BP (mmHg) 0.27 (1.0 – 2.3) 0.007 0.29 (1.1 – 2.8) 0.004 
US findings 
N sites with plaque (n) 
US class 
Cumulative AUS 
Mean CCA IMT (cm) 
 
0.99 (2.0 – 3.2) 
0.93 (1.9 – 3.0) 
0.84 (1.5 – 4.1) 
0.39 (1.7 – 3.2) 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
 
0.99 (2.0 – 3.0) 
0.93 (2.2 – 4.1) 
0.85 (1.2 – 3.7) 
0.39 (1.3 – 3.5) 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Anti-La positivity -0.33 (0.7 – 1.3) 0.001 -0.33 (1.0 – 1.9) 0.001 
Disease activity (BILAG) 
Persistently moderate/high  
Persistently low 
N visits with A flare in at 
least one system (n) 
 
0.21 (0.5 – 1.0) 
-0.21 (0.6 – 0.9) 
0.23 (1.0 – 1.3) 
 
0.035 
0.035 
0.023 
 
0.18 (0.8 – 1.1) 
-0.18 (0.4 -0.9) 
0.21 (1.1 – 1.6) 
 
0.07 
0.07 
0.03 
Homocysteine (µmol/L) 0.31 (0.8 – 1.7) 0.04 0.31 (0.4 – 1.0) 0.05 
Triglycerides (mmol/L) 0.27 (1.2 – 2.0) 0.007 0.28 (1.2 – 2.7) 0.005 
t-cholesterol:HDL 0.25 (1.1 – 2.0) 0.013 0.23 (1.0 – 1.6) 0.02 
Anti-HDL IgG (AU) 0.21 (1.2 – 1.8) 0.03 0.21 (0.7 – 1.2) 0.039 
Anti-CCP IgM (AU) -0.26 (1.0 – 1.9) 0.02 -0.23 (1.0 – 1.6) 0.04 
 
 
  
Table 19: Factors significantly associated with total plaque area and thickness (Spearman’s 
correlation; CI 95%). 
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Similar to what I found for the mean CCA IMT, both age and disease duration at scan were 
found to correlate with larger and thicker plaques. While neither the dBP nor the mBP 
appear to correlate with either plaque area or thickness, the sBP was weakly correlated with 
both variables. 
A striking positive correlation between the number of sites with plaque, US class and 
cumulative AUS and both plaque area and thickness was observed and a similar, although 
weaker correlation was found with the mean CCA IMT. 
When considering the general biochemical laboratory profile, I found that homocysteine had 
the strongest positive correlation with both plaque area and thickness, although both TG and 
t-cholesterol:HDL ratio also showed a statistically significant association. With regards to 
auto-antibody profile, only anti-La positivity emerged as relevant, with a negative correlation 
found between this and plaque area and thickness. No other ENA subtypes had any 
significant correlation with these two variables. 
Interestingly, clinically defined disease activity was found to significantly correlate with 
plaque area but not thickness. Patients who had persistently moderate/ high disease activity 
tended to have greater plaque area than those with persistently low disease activity. 
Moreover, the number of visits in which an A flare in at least one of the organ systems 
considered was recorded was found to have a positive correlation with both plaque area and 
thickness. 
A non-significant positive trend between plaque presence and anti-HDL IgG is shown in 
Graph 12. Plaque size-related variables (area and thickness) were found to correlate 
positively with anti-HDL levels (Graph 13).  
No statistically significant associations with either anti-ApoA1 IgG or IgM, tApoA1 or nitrated 
ApoA1 were found (Figure 28). 
  
192 
 
 
 
 
 
 
 
  
Graph 13: Plaque area and anti-HDL antibody levels: there is a statistically significant correlation 
between total plaque area and anti-HDL IgG levels (p=0.033). The line represents the linear 
regression and its equation (r2 0.56). 
Graph 12: Comparison of anti-HDL IgG levels between patients with and without plaque. 
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Figure 28: Correlation between plaque area and anti-ApoA1 IgG (A) and IgM (B), total ApoA1 (C) 
and nitrated ApoA1 (D). The line represents the linear regression and its equation. Statistical 
significance was not found for any of these variables (A r2 0.1; B r2 0.16; C r2 0.32; D r2 0.09). 
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Finally, with regards to plaque texture analysis, I found that based on the qualitative scale (0-
5), the average value was 3, which represent plaques that are mainly echolucent although 
there is also a significant connective tissue component. The majority of the plaques were 
heterogeneous and discrete white areas were identified in two thirds. The predominance of 
echolucent but heterogeneous plaques was further emphasized when a quantitative scale, 
the GSM was applied. The GSM of the plaques identified in the vascular US cohort did not 
follow a normal distribution as shown on Figure 29. The median GSM value was 48.9 (IQR 
34.3-59.0). Considering that the GSM represents a spectrum of echogenicity where the 
lower the values (from 0) represent maximum echolucence, i.e. greater lipid content, while 
the higher values describe greater echogenicity (high calcium/ fibrotic tissue content), my 
findings support the concept that the majority of plaques are predominantly echolucent as 
suggested by the qualitative visual scale previously described. 
The factors found to influence GSM significantly are summarized on Table 20. 
A positive association between renal function and GSM was found with serum creatinine and 
to a lesser extent serum urea found to significantly correlate with GSM. No correlation 
between GSM and urine protein: creatinine ratio was found. 
Sustained disease activity was also found to influence GSM. Patients who had persistently 
moderate/ high disease activity were found to have higher GSM values. An inverse 
correlation was observed for patients who had persistently low disease activity. 
Although serological markers of disease activity (anti-dsDNA and C3) were not found to 
influence GSM, the presence of anti-CCP antibodies appeared to correlate negatively with 
GSM while the presence of anti-ApoA1 IgM had a positive correlation with this outcome. 
However, when looking at the total serum IgM level, this was also found to correlate with 
GSM in a similar manner and therefore, this could be a potentially confounding factor. The 
total serum IgA levels were found to correlate inversely with GSM.  
Finally, a non-statistically significant positive trend between total plaque area and GSM was 
found (p= 0.06) but not with total plaque thickness (p= 0.388). 
Neither total ApoA1, nitrated ApoA1, age at scan, disease duration or lipid profile were found 
to significantly influence GSM. 
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Variables GSM 
(r2; 95% CI) 
p-value 
Sustained disease 
activity 
moderate/high  
low 
 
0.52 (1.3 – 2.1) 
-0.52 (1.5 – 2.3) 
 
0.001 
0.001 
Renal function 
Urea (mmol/L) 
Creatinine (µmol/L) 
 
0.33 (0.9 – 1.4) 
0.46 ((1.1 – 2.0) 
 
0.05 
0.005 
Anti-C1q positivity 0.44 (1.2 – 2.9) 0.02 
Serum IgM (mg/dL) 0.35 (1.0 – 2.7) 0.04 
Serum IgA (mg/dL) -0.39 (0.8 – 1.6) 0.02 
Anti-apoA1 IgM (AU) 0.35 (0.7 – 1.1) 0.04 
Anti-CCP positivity -0.46 (1.6 – 3.0) <0.0001 
Anti-ApoA1 IgM (AU) 0.35 (1.1 – 1.9) 0.04 
Table 20: Factors found to be significantly correlated with GSM (Spearman’s correlation; CI 95%). 
Figure 29: Histogram and table of frequencies showing the GSM distribution in the vascular US 
cohort. 
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4.4.1.3.2: Plaque volume and 3D texture analysis 
As previously established, at present, only carotid plaques can be adequately assessed by 
3D US. Therefore, of the 84 plaques identified in 36 patients, only 40 plaques were included 
in this section. An additional two carotid plaques were identified, but due to heavy 
calcification or anatomical constraints, image analysis was not feasible and they were 
excluded.  
The mean volume of the carotid plaques considered was 37.79mm3 (SD 35.7; range 2.52-
119.64). Table 21 shows the variables found to significantly influence plaque volume on 
univariable analysis. 
Similar to what was previously described regarding plaque area, both age and disease 
duration on the scan were found to correlate with plaque volume. The same applies to the 
influence of BP, with sBP as the only significant correlation. 
As previously noted for total plaque area and thickness, the general vascular US findings 
(number of sites with plaque, US class and cumulative AUS score) were shown to influence 
plaque volume significantly and a strong correlation between plaque area, thickness and 
volume was also found. 
With regards to serological findings, anti-HDL IgG was found to have a positive correlation 
with plaque volume while both anti-La and anti-ApoA1 IgM positivity were noted to have a 
negative correlation. 
No other statistically significant associations were found, with renal function, lipid profile or 
disease activity. 
  
197 
 
 
Variables Total plaque volume 
(mm3) 
(r2; 95% CI) 
p-value 
Age at scan (yrs) 0.56 (1.3 – 2.4) <0.0001 
Disease duration (yrs) 0.23 (1.0 – 1.8) 0.02 
Systolic BP (mmHg) 0.23 (1.3 – 2.1) 0.02 
US findings 
N sites with plaque 
US class 
Cumulative AUS 
Mean CCA IMT (cm) 
Total plaque area (mm2) 
Total plaque thickness 
(cm) 
 
0.83 (2.4 – 3.6) 
0.80 (2.5 – 4.0) 
0.71 (2.5 – 3.2) 
0.44 (1.7 – 3.1) 
0.85 (0.6 – 1.9) 
0.84 (1.2 – 2.1) 
 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
<0.0001 
Anti-La positivity -0.27 (1.2 – 2.1) 0.006 
Anti-dsDNA (IU/L) -0.21 (1.0 – 1.9) 0.04 
Anti-CCP IgM (AU) -0.30 (1.3 – 2.5) 0.004 
Anti-HDL IgG (AU) 0.24 (1.5 – 2.1) 0.02 
 
Table 21: Factors found to significantly correlate with total plaque volume (Spearman’s 
correlation; CI 95%). 
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Considering plaque texture analysis using volume assessment (GSMvol), I found very few 
variables whose influence was statistically significant and this could, at least partly be due to 
the relatively small number of cases assessed. A summary of these findings is shown in 
Table 22. 
A significant positive correlation was found between volume-based GSM (GSMvol) and 2D 
US-based GSM as Graph 14 depicts. Similar to what was found for GSM, disease activity 
also appeared to significantly influence GSMvol although the strength of this correlation was 
weaker than that previously noted.  
Positivity for anti-β2GP1 antibodies and lupus anticoagulant was found to have a significant 
negative correlation with GSMvol. As described for GSM, an inverse correlation with anti-
CCP positivity was also found. 
A non-significant negative trend between the levels of HDL and GSMvol was found but the 
levels of anti-HDL or anti-ApoA1 antibodies did not influence this outcome. 
No other serological variables were found to influence GSMvol significantly, such as renal 
function, serum immunoglobulin levels, lipid or remaining auto-antibody profile. 
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Variables GSMvol 
(r2; 95% CI) 
p-value 
Mean GSM 0.38 (1.2 – 2.5) 0.04 
Sustained disease activity 
moderate/high  
low 
 
0.38 (1.1 – 1.9) 
-0.38 (0.9 – 1.4) 
 
0.049 
0.049 
Anti-β2GP1 positivity -0.44 (1.2 – 2.0) <0.0001 
Lupus anticoagulant positivity -0.39 (1.0 – 2.1) 0.02 
Anti-CCP positivity -0.30 (0.8 – 1.7) <0.0001 
 
 
 
 
 
 
Table 22: Factors found to correlate significantly with GSMvol (Spearman’s correlation; CI 95%). 
 
Graph 14: Correlation between 2D US-based GSM (GSM) and volume-based GSM (GSMvol). The 
line depicts the linear regression and its equation (n=40, r2 0.69, p= 0.02). 
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4.4.1.4: Comparison of vascular US findings between a SLE and a non-SLE cohort 
In order to compare the vascular US findings from the cohort of patients with SLE  with a non 
SLE cohort, the patients were age and sex matched with non-SLE patients selected from the 
Cyprus epidemiological study as previously described. For each of the patients with SLE, 
two matched controls were found (n= 132). Due to the fact that the Cyprus cohort excluded 
individuals aged below 40-years of age, adequate matching was only possible for 66 of my 
patients with SLE. The data presented in this section will therefore only consider this sub-
section of the SLE cohort. 
Figure 30 depicts the age histograms for both populations showing a normal distribution 
while Table 23 summarizes the age and sex distribution as well as the general vascular US 
findings for the two groups. 
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  Figure 30: Histograms representing the age distribution for the SLE cohort (A) and the age and 
sex matched non-SLE controls selected from the Cyprus epidemiological study (B). 
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Variables 
SLE cohort 
– mean 
values 
(n= 66) 
SD (range) 
Non-SLE 
cohort – 
mean values 
(n= 132) 
SD (range) 
Sex 
(n Female : Male) 
63 : 3 - 126 : 6 - 
Age at scan 
(years) 
52.6 7.6 (40-66) 52.6 7.5 (40-66) 
N sites w/ plaque 1.2 1.4 (0-4) 0.82 1.2 (0-4) 
Cumulative AUS 11.3 7.8 (0-26) 9.1 6.6 (0-28) 
Mean CCA IMT 
(cm) 
0.057 0.008 (0.04-0.09) 0.064 0.01 (0.035-0.095) 
Total plaque 
thickness (cm) 
0.30 0.37 (0-1.41) 0.17 0.26 (0-1.14) 
Total plaque area 
(mm2) 
41.8 60.9 (0-317.9) 14.34 25.9 (0-128) 
Mean plaque GSM 48.6 21.6 (19-128) 14.6 10.8 (0.25-40.25) 
 
Table 23: Comparison between sex and age distribution and general vascular US findings 
between the SLE and non-SLE cohorts. 
 
203 
 
Age and sex matching between the two groups was successfully achieved. Although the 
cumulative AUS score was not significantly different in the two cohorts, the number of sites 
with plaque was significantly greater in patients with SLE compared with the non-SLE cohort 
(p= 0.0047). 
As shown in Figure 31-A, the mean CCA IMT was significantly greater in the non-SLE group. 
However, total plaque thickness and total plaque area were markedly increased in the SLE 
patients compared with the non-SLE group (Figure 31-B and C respectively). 
Significant differences were also noted regarding plaque texture: GSM was significantly 
greater in the SLE group compared with non-SLE controls as shown on Graph 15. 
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Figure 31: Comparison between the mean CCA IMT (A), total plaque thickness (B) and 
total plaque area (C) between the SLE and non-SLE cohorts. 
(* p< 0.05; *** P< 0.001) 
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Graph 15: Comparison between the mean GSM between the SLE and non-SLE cohorts. 
(** p< 0.01; *** P< 0.001) 
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When comparing individual characteristics between the two groups, the absolute number of 
individuals who were smokers at the time of the scan was similar in both cohorts (SLE group 
n= 11; Non-SLE group n= 13) and a similar proportion of individuals with diabetes was also 
observed (SLE group n= 2; Non-SLE group n= 4). However, a different picture was observed 
for blood pressure measurements as those belonging to the non-SLE group had significantly 
higher sBP and dBP than those noted for patients with SLE (p= 0.0015; p<0.0001 
respectively) as shown on Graph 16. 
The lipid profile was also found to be markedly different between the two groups: patients 
with SLE had significantly lower total cholesterol, triglycerides and LDL levels, but higher 
HDL levels compared with the non-SLE individuals as show in Figure 32-A, B, C and D 
respectively. 
Although it was still within the normal range for the majority of patients, serum creatinine was 
significantly higher in the SLE group (Figure 32-E). 
Finally, serum homocysteine levels were also markedly higher in patients with SLE 
compared with the non-SLE individuals (Figure 32-F). 
 
  
207 
 
 
 
 
 
 
 
Graph 16: Comparison between the systolic and diastolic blood pressure between the SLE 
and non-SLE cohorts. 
(** p< 0.01; *** P< 0.001) 
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Figure 32: Comparison between SLE and non-SLE groups regarding the total cholesterol (A), 
triglycerides (B), HDL (C), LDL (D), serum creatinine (E) and serum homocysteine (F). 
(* p< 0.05; ** p< 0.01; *** P< 0.001) 
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Taking into account the hypothesis that patients with SLE may have accelerated 
atherosclerosis, I explored the correlation between age at scan and both IMT thickness and 
plaque area using a linear regression model.  
As shown on Figure 33-A, no differences were found when plotting age at scan and mean 
CCA IMT for both groups. However, if total plaque thickness was considered, patients with 
SLE appear to have a steeper regression line which suggests that the progression of plaque 
thickness could be happening faster in patients with SLE (Figure 33-B). This is further 
emphasised if age is plotted against total plaque area as shown on Figure 34, suggesting 
that there is potentially a different plaque growth pattern in patients with SLE compared with 
non-SLE controls. 
Looking at this hypothesis on a different angle, I compared the correlation between mean 
CCA IMT and either total plaque thickness or total plaque area and found a similar pattern 
supporting the notion that plaque progression may be occurring differently in the two groups 
(Figure 35).  
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Figure 33: Comparison between SLE and non-SLE groups using a linear regression model 
depicting age at scan plotted against mean CCA IMT (A) and total plaque thickness (B). 
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Figure 34: Comparison between SLE and non-SLE groups using a linear regression model 
depicting age at scan plotted against total plaque area. 
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Figure 35: Comparison between SLE and non-SLE groups using a linear regression model 
depicting mean CCA IMT plotted against total plaque thickness (A) and total plaque area (B). 
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4.4.1.5: Discussion 
SLE has been established as one of the strongest, independent risk factors for CVD (D'Cruz, 
Khamashta et al. 2007, Pennell and Keenan 2011). However, atherosclerosis is a gradual 
process and formation of plaque starts well before there is any clinical evidence, i.e. there is 
a period of subclinical atherosclerotic or CVD (Stary, Chandler et al. 1995). As the majority 
of patients with SLE score low in the traditional risk scores (Bessant, Hingorani et al. 2004, 
O'Neill, Pego-Reigosa et al. 2009), they usually don’t receive any targeted treatment such as 
statins until they either develop symptoms suggestive of CVD (namely angina, TIA or 
intermittent claudication) or have a major CVD-related event (stroke, MI). Therefore, any 
strategies that are put in place will be, at best, to achieve secondary prevention. 
In the SLE cohort, 36 out of 100 patients with SLE with no evidence of CVD already had 
plaque. The 36% prevalence is in keeping to what has been previously reported by other 
groups (Manzi, Selzer et al. 1999, Svenungsson, Jensen-Urstad et al. 2001, Doria, 
Shoenfeld et al. 2003, Roman, Shanker et al. 2003, Selzer, Sutton-Tyrrell et al. 2004, Wolak, 
Todosoui et al. 2004) and is significantly higher than what has been reported in healthy 
individuals (Svenungsson, Jensen-Urstad et al. 2001, Roman, Shanker et al. 2003, 
Thompson, Sutton-Tyrrell et al. 2008).  
The fact that I have included the femorals in the US assessment has increased the 
sensitivity of the method as in 7% of patients, plaque was found exclusively on this location. 
Although usually in research, only carotids are assessed, given that atherosclerosis is a 
generalised process, including the femorals increases the chances of identifying plaque. 
Moreover, the involvement of multiple territories increases the likelihood of coronary 
involvement. This is supported by my finding that patients who had femoral plaques only, the 
IMT thickness in the CCA was significantly different from patients with no femoral plaques 
(Graph 13). This result supports the notion that atherosclerosis involves the arterial bed 
globally and that the presence of plaque, regardless of its location, signals the generalised 
presence of on-going endothelial dysfunction/ damage. This is further supported by the fact 
that patients who had plaque in the bulb region, despite not having IMT greater than 0.1cm, 
had significantly thicker IMT than those without plaque.  
Carotid atherosclerosis is usually the most widely used variable when studying CVD and its 
correlation with risk of event or different biomarkers. However, there are different studies 
focusing on peripheral atherosclerosis, namely on the femoral territory which highlight the 
relevance of considering this vascular bed when establishing a risk profile. Brevetti et al 
showed how patients with peripheral artery disease had greater atherosclerotic burden and 
more echolucent plaques compared with those who only had coronary artery disease and 
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suggested that the presence of femoral plaques, particularly those with reduced GSM may 
have increased CVD risk, namely of cerebrovascular disease (Brevetti, Sirico et al. 2008). 
These findings were supported by the work of Schiano et al who assessed the risk of MI and 
stroke in patients with femoral atherosclerosis and found that the presence of echolucent 
femoral plaques is associated with increased prevalence of CVD-related events (Schiano, 
Sirico et al. 2012). The median GSM of the femoral plaques identified in the vascular US 
cohort was 52. This is relatively low value, which is in keeping with the increased CVD risk 
found among patients with SLE, further emphasizing the need for a comprehensive vascular 
assessment in order to optimize risk stratification. 
The significant differences found between the IMT thicknesses in the bulb vs. CCA, even in 
the absence of plaque in either of these sites, have been previously reported and are 
thought to be due to the normal physiological difference in blood flow between the two sites 
(Roman, Saba et al. 1992). While in the CCA, the blood flow is laminar, minimizing shear 
stress forces, in the bulb the blood flow becomes turbulent, therefore stimulating the 
proliferation of smooth muscle cells. 
As summarized in Table 3 of the Introduction, the majority of studies focused on assessing 
the impact of plaque in defining the risk for CVD-events have shown that the presence of 
plaque, particularly those with greater area and eliciting a significant luminal stenosis (>50%) 
is associated with increased risk of ACS, regardless of the CCA IMT value (Salonen and 
Salonen 1991, Held, Hjemdahl et al. 2001, Hunt, Evans et al. 2001, van der Meer, Bots et al. 
2004, Johnsen, Mathiesen et al. 2007). The patients included in the vascular US cohort who 
were found to have plaque seldom had a luminal stenosis greater than 50% (3/84), but 
although the plaques did not encroach into the lumen, the total plaque area was significant, 
suggesting that the plaque growth may occur predominantly along the arterial wall as will be 
discussed further down.  
As previously described, besides the size (area and/or volume), the composition of the 
plaque has substantial influence in the risk of CVD-related events. The fact that the mean 
overall qualitative plaque score in the cohort I assessed is 3, shows that in these patients, 
the plaques found are predominantly cholesterol rich and could potentially be associated 
with a greater risk of rupture. Despite being useful, the characterization of plaque using a 
qualitative scale is inevitably subjective and has limited power in distinguishing plaques 
which have similar echographic appearance. Thus, the use of a quantitative measurement 
such as the GSM is not only more accurate but also more sensitive in portraying subtle 
differences in plaque texture (El-Barghouty, Levine et al. 1996, Aly and Bishop 2000, Prahl, 
Holdfeldt et al. 2010). The GSM ranges from 0 to 250 and the score has a positive 
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correlation with plaque echogenicity (i.e. echogenic plaques have a high GSM, echolucent 
plaques have low GSM). The majority of the plaques identified in this SLE cohort have a low 
GSM, which means that patients have predominately echolucent or lipid rich plaques 
(Goncalves, Lindholm et al. 2004, Sztajzel, Momjian et al. 2005).  
The division of plaques into echolucent versus echogenic as a synonym for collagen-rich 
versus lipid rich has been increasingly disputed, as new concepts on plaque echogenicity 
and its correlation with the nature of the echogenic tissue it contains, emerge. Moving from 
the original view that the presence of echogenic material within the plaque was due either to 
the presence of calcium and/ or fibrous tissue, Goncalves et al established that the 
echogenicity of carotid plaque was mainly determined by their elastin and calcium content 
and only to a lesser extent by collagen or lipids (Goncalves, Lindholm et al. 2004). Other 
groups have focused on the issue of determining why plaques appear to be echolucent 
rather than echogenic in US assessment and found that it may also be due to the presence 
of neovascularization. Several studies of contrast US using microbubbles have shown that 
the presence of increased intra-plaque vascularization is associated with decreased 
echogenicity and low GSM, suggesting that the presence of neovascularization may be a 
relevant feature when determining plaque texture. It is argued that the presence of increased 
intra-plaque vascularization may lead to increased plaque haemorrhage and consequently 
increased risk of plaque rupture and thrombosis (Coli, Magnoni et al. 2008, Owen, Shalhoub 
et al. 2010, Staub, Partovi et al. 2011, Zhou, Xing et al. 2013). In non-contrast US, these 
micro-blood vessels appear as intensely white, non-calcified regions within the plaque 
described as “discrete white areas” and when present may correlate with neovascularization 
(Shah, Falk et al. 1995, Griffin, Kyriacou et al. 2010). 
Another factor to take into account when assessing plaque echogenicity is whether its 
texture is homogenous or heterogeneous. Heterogeneous plaques typically present with 
echolucent and echogenic areas and are best described as a type 3 plaque; using the 
qualitative scale this score defines a plaque constituted by echolucent and echogenic 
material in similar proportions (AbuRahma, Wulu et al. 2002). Petersen et al assessed the 
value of considering plaque heterogeneity as a predictor of death in hospitalised 
cardiological patients. They reported that of the 541 patients assessed, 361 had carotid 
plaques and during follow-up, 83 died (all-cause deaths). Using a multi-variable analysis 
model, they showed that plaque heterogeneity was an independent predictor of death and 
that patients with heterogeneous plaques had a Kaplan-Meier survival estimate of 73% 
compared with 90% for patients without plaque and 79% for patients with homogenous 
plaque (p= 0.0001) (Petersen, Pecanha et al. 2006). Several hypotheses are raised by these 
findings. The presence of echolucent areas in an echogenic plaque may correspond to areas 
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of intra-plaque haemorrhage with increased risk of rupture and or thrombosis and therefore 
be associated with acute CVD events. Another explanation is that the presence of different 
components within the same plaque leads to opposing shear stress forces when the plaque 
is subjected to the stress of high velocity blood flow. This could increase the risk of rupture 
through mechanical stresses with the same end result: plaque rupture/ thrombosis and CVD 
acute events. Further studies assessing plaque mobility and its correlations with GSM and 
CVD events are required to answer these questions. 
The relevance of considering plaque echogenicity stems from several studies which have 
highlighted the concept that in addition to the presence of plaque and its size, the texture or 
composition of plaque also correlates with the risk for CVD-related events. Many of these 
studies are undertaken in the context of cerebrovascular disease, correlating the findings of 
carotid US and recurrence of stroke. The general consensus is that the presence of 
echolucent plaques is associated with a significant increase of cerebral events compared 
with echogenic plaques (Mathiesen, Bonaa et al. 2001, Biasi, Froio et al. 2004, Johnsen, 
Mathiesen et al. 2007, Kakkos, Stevens et al. 2007, Kakkos, Sabetai et al. 2009, Singh, 
Atam et al. 2013, Ariyoshi, Okuya et al. 2015). Overall, these studies have been done in 
either the general population or in specific risk groups, namely among diabetic patients and 
usually have a greater proportion of male subjects. Therefore, it may be difficult to transpose 
these findings to the setting of SLE were the prototypical patients are relatively young 
women with few traditional CVD-risk factors. 
Some sub-group analysis however, focusing on specific subject groups may offer some 
insights. Reporting on the findings from the Tromsø study, Johnsen et al described how the 
presence of carotid plaque is a stronger predictor of MI in women compared with men 
(almost 3-fold increased risk). Moreover, it was found that the risk of MI among women 
increased with plaque echolucency, supporting the data previously discussed (Johnsen, 
Mathiesen et al. 2007). The vascular US cohort I tested included mainly women and for 
those who were found to have plaque, the median GSM was low, thus emphasizing how 
their risk for having a MI may be increased. 
Although there appears to be some consensus that low GSM plaques are associated with 
increased prevalence of cerebrovascular events and overall CVD events, Zureik et al 
described, in a large study, (n=561) how aortic arterial stiffness correlates with the presence 
of echogenic plaques (qualitative scale score 3-4), regardless of the BP status and carotid 
IMT thickness (Zureik, Temmar et al. 2002, Zureik, Bureau et al. 2003). It is argued that both 
plaque echogenicity and arterial stiffness share common pathophysiological processes 
leading to connective tissue extracellular matrix deposition (collagen, proteoglycans and 
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elastin) and therefore, the presence of increased arterial stiffness could be expected in the 
presence of fibrous-rich and not lipid-rich plaques (Stary 1989, Stary, Chandler et al. 1995). 
Although the presence of lipid-rich plaques has been associated with increased plaque 
instability and risk of rupture, several cross-sectional studies report a strong association 
between the presence of increased arterial stiffening and CVD-related events, namely 
stroke, MI and congestive heart failure (Hirai, Sasayama et al. 1989, Meaume, Benetos et al. 
2001, Meaume, Rudnichi et al. 2001, Mitchell, Tardif et al. 2001). The caveat is that there 
are no similar studies focusing  on an  SLE population and therefore the basis for 
extrapolating these findings to patients with Lupus is lacking. 
Tarnoki et al published interesting data assessing the impact of the genetic background on 
the prevalence of plaque and its characteristics and concluded that there was a strong 
influence of heritability on the ultrasound characteristics of carotid plaque, arguing that 
unshared environmental factors account only for a modest portion of the variance (Tarnoki, 
Baracchini et al. 2012). There have been several studies discussing potential genes which 
may be implicated in the pathogenesis of SLE although a clear etiological link is yet to be 
firmly established. Whether there are genetic characteristics shared between SLE and 
plaque presence and its composition has not been described but this could be a potential 
link between these two apparently distinct clinical entities. 
Plaque echogenicity may also be an important factor in the decision making process of 
whether or not to start lipid-lowering treatment in patients with SLE. Several groups have 
reported on the benefits of treatment with statins in regards to increasing plaque 
echogenicity even in non-hypercholesterolemic individuals, regardless of changes in plaque 
size or IMT thickness (Watanabe, Sugiyama et al. 2005, Kadoglou, Gerasimidis et al. 2008, 
Yamagishi, Kato et al. 2009). This raises the question of whether patients with SLE who are 
found to have plaque, particularly if it is echolucent, should be started on treatment with 
statins regardless of their lipid profile. To date, there is no specific guidance on this matter 
and the decision depends largely on the attending physician. 
Regarding the factors that may influence plaque echogenicity, a myriad of potential 
biomarkers has been reported. Data from the Tromsø study has suggested that low HDL 
levels are independently associated with plaque echolucency (Mathiesen, Bonaa et al. 
2001). Moreover, high HDL cholesterol levels appear to reduce plaque growth in subjects 
with pre-existing atherosclerosis, raising the hypothesis that HDL may in fact stabilize plaque 
and reduce lipid accumulation and intra-plaque inflammation (Johnsen, Mathiesen et al. 
2005). There was no mention of HDL function assessment in this study, as only serum HDL 
concentration was determined. The Tromsø study also assessed 2726 post-menopausal 
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women and correlated bone density with plaque echogenicity, reporting that lower bone 
mass was associated with an increased risk of echogenic and even calcified atherosclerotic 
plaques (Jorgensen, Joakimsen et al. 2004). Finally, the influence of albuminuria, a known 
factor found to be associated with atherosclerosis, on plaque initiation and growth was 
assessed. Multivariate analysis supported the notion that higher albumin-to-creatinine ratio 
was associated with greater plaque area and increased plaque progression, particularly 
among patients who did not present plaque in the baseline assessment, leading to the 
conclusion that albuminuria is an independent risk factor for plaque initiation and growth 
(Jorgensen, Jenssen et al. 2007). 
Increased BMI and other traditional lipid profile changes were also reported to correlate 
independently with increased plaque echolucency, namely, TG and IDL-cholesterol 
(Gronholdt, Nordestgaard et al. 1998). Diabetes was also found to be associated with 
increased plaque echolucency (Ostling, Hedblad et al. 2007) but in non-diabetic patients, 
high levels of glycated haemoglobin (HbA1c) levels were independently associated with 
increased plaque echogenicity (Jorgensen, Jenssen et al. 2004). No clear explanation for 
this fact is offered, but it is hypothesised that the presence of raised HbA1c may be 
associated with early atherosclerosis or that it may lead to accelerated atherosclerosis and 
consequently faster progression from echolucent to echogenic plaques. The Northern 
Manhattan Study reported on the influence of homocysteine in both tPA and plaque 
echogenicity and described that raised homocysteine levels were associated with increased 
tPA (Alsulaimani, Gardener et al. 2013). However, the influence of homocysteine in plaque 
texture was less clear as the top two quartiles of homocysteine were more likely to have 
either echolucent or echogenic plaque. The authors hypothesise that this U-shaped curve 
may signify that high homocystein levels are a factor in both vulnerable echolucent plaques 
and in later echogenic plaques that may signify a longstanding atherosclerotic process.  
Several groups have reported on the influence of inflammatory biomarkers and plaque 
echolucency, namely IL-6 (Yamagami, Kitagawa et al. 2004) and CRP (Gronholdt, Sillesen 
et al. 2001), but whether they are causal or merely accompany the atherosclerotic process is 
yet to be established.  
In my vascular US cohort, I found that BP was weakly correlated with either TpA and TpT 
and this is probably due to the very low prevalence of hypertension among the patients 
assessed. Of the traditional CVD risk factors, I found that increased TG and homocysteine 
levels were associated with bigger plaques. Neither t-cholesterol nor LDL were found to 
correlate with plaque size and this is again probably due to the very low presence of 
dyslipidaemia in the patients tested. Nonetheless, the more sensitive t-cholesterol:HDL was 
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noted to positively correlate with both TpA and TpT. The presence of clinically active disease 
was associated with increased plaque burden but serological markers of disease activity 
were not, nor were any other auto-antibodies with the exception of anti-HDL IgG antibodies 
which were positively correlated with TpA and TpT as previously discussed. 
The final point for discussion is the comparison between the vascular US findings between 
the SLE and the non-SLE cohorts. I would like to emphasise the limitations of this analysis. 
Firstly, there is the different demographic background: the SLE is a multi-ethnic, London-
based cohort while the non-SLE is a Caucasian, Cypriot population with a specific genetic, 
social and environmental background. Secondly, age-matching was only possible for 
patients who were 40-year old or older (n=66) which further diminishes the size of the SLE 
sub-group included in the analysis. Thirdly, patients from the non-SLE cohort were not 
screened for established or likely CVD.  Lastly, although the vascular US equipment, 
protocol and scanner (Dr Griffin) were the same for both cohorts, the assessment was not 
performed within the same timeframe nor was the physical circumstances similar as the non-
SLE cohort was scanned in Cyprus. Therefore, any hypothesis raised by the comparison 
between these two groups must be cautious and viewed critically. Nonetheless, I believe that 
the data are sufficiently novel and relevant to be described, presented and discussed as it 
highlights a few interesting points. 
There were no significant differences in CCA IMT between the two groups, and although the 
non-SLE cohort had slightly greater mean values, they were still well within the range of 
normal. However, patients with SLE had plaque in more territories than the non-SLE cohort 
and plaque area and thickness were significantly greater. Moreover, the plaques from 
patients with SLE had significantly higher mean GSM compared to non-SLE subjects. When 
comparing the characteristics from both groups, although by shared similar smoking and 
diabetes prevalence, non-SLE patients had an increased prevalence of high BP as well as 
higher t-cholesterol, LDL and TG levels and lower HDL. In contrast, patients with SLE had 
higher homocysteine levels. Higher serum creatinine level was also noted in the SLE cohort, 
but for the vast majority of patients it still fell within the normal range. However, a significant 
number of patients with SLE had increased urine protein-creatinine ratio and as previously 
discussed this may be associated with increased plaque initiation and growth. This suggests 
that although patients with SLE have fewer traditional CVD risk factors, they have increased 
atherosclerotic burden compared with non-SLE controls which is in keeping with all the 
literature regarding SLE-related mortality and morbidity.  
Given that SLE is a chronic inflammatory disease, it could be argued that patients with 
Lupus would have more echolucent plaques compared with non-SLE controls and in fact, I 
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found a significant correlation between increased disease activity and TpA suggesting that 
increased inflammation is a relevant factor for atherogenesis in the context of SLE.  
However, I found precisely the opposite: patients with SLE had significantly higher GSM 
compared with non-SLE controls. This could be due to several factors, none the least with 
the distinct demographic background of the two populations. Patients from the non-SLE 
cohort had a greater prevalence of a pro-atherogenic lipid profile and increased BP, which 
are two strong traditional CVD factors associated with increased plaque echolucency which 
could at least partially account for the lower GSM in this group. In addition, if we considered 
that the natural history of plaque is to become more echogenic over time (Stary 2000), it may 
be hypothesised that the reason why plaques are more echogenic in the SLE group is due to 
early plaque initiation. This seems to be plausible as shown on the regression model 
depicting age at scan plotted against TPT and TpA (Figure 25 and 26). Alternatively, it may 
be argued that the atherosclerotic process does not in fact start earlier in SLE, but may 
occur in an accelerated fashion which could also be supported by the later graphs. The fact 
that the growth pattern, i.e. the correlation between TpA and TpT and CCA IMT, is different 
in the SLE cohort compared with the non-SLE cohort supports the hypothesis that the 
atherosclerotic process is happening faster in SLE as there is very little IMT thickening even 
when plaque is present. This is supported by the fact that I found that patients with increased 
disease activity over time had increased GSM suggesting that in patients with active 
disease, the presence of accelerated atherosclerosis may be further enhanced. 
The use of 3D US in the vascular US cohort added very little to what was found in the 2D 
assessment and this is likely to be due to the smaller number of plaques assessed by this 
method (n= 40) as only carotid plaques were considered and anatomical constraints 
rendered the technique impossible to perform.
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5: FINAL DISCUSSION AND FUTURE WORK 
Atherosclerosis has long ceased to be viewed as a rather passive cholesterol accumulation 
on the vascular walls which occurs inexorably over time. It is now understood as a dynamic 
accumulation of oxidized cholesterol over time that is primarily driven by the immune system 
(Libby, Ridker et al. 2002). The acknowledgement of the central role played by the immune 
system in the pathogenesis of atherosclerosis and consequently of cardiovascular disease, 
has led to an increased interest in the way atherosclerosis develops in the context of chronic 
inflammatory conditions. The conclusion is that autoimmunity and immune system 
dysfunction are associated with increased morbidity and mortality due to CVD. It is 
hypothesized that this could be due to accelerated atherosclerosis (Skaggs, Hahn et al. 
2012). SLE in particular has become the paradigm of this concept, with several studies 
reporting a much increased risk of MI/ angina (Manzi, Meilahn et al. 1997), greater 
prevalence of carotid plaque in US assessment (Roman, Shanker et al. 2003), increased 
prevalence of coronary artery calcification on MRI assessment (Asanuma, Oeser et al. 2003) 
and overall increased CV risk independent of traditional risk factors (Esdaile, Abrahamowicz 
et al. 2001). Hence, SLE has been established as one of the strongest, independent risk 
factors for CVD (D'Cruz, Khamashta et al. 2007, Pennell and Keenan 2011). 
Although several mechanisms have been proposed, the full pathogenesis which is likely to 
be multifactorial is yet to be fully established. 
Nitric oxide metabolism has important implications in regulating endothelial function, with 
both protective and pathological properties. Given the associations between increased 
vascular activation and enhanced nitrosative stress, a plausible hypothesis would be that the 
chronic inflammation present in SLE, could lead to an increase NO release and 
consequently to increased concentration of nitrated proteins. The rationale which correlates 
these changes with increased atherosclerotic burden, would be that increased widespread 
vascular activation could lead to endothelial injury, one of the earliest phenomena in 
atherosclerosis. I chose to study three different targets for nitration: nucleosomes (NN), 
albumin (NA) and apoA1 (NapoA1). Although I did find an association between disease 
activity and NN, in particular with neuropsychiatric and vasculitic flares, no associations 
between levels of nitrated proteins with either IMT, presence of plaque, plaque size and 
echogenicity were evident. This finding suggests that the presence of serum protein nitration 
does not correlate with increased atherosclerotic burden in US assessment. However, this 
lack of correlation may be interpreted as a consequence of the protein targets I selected, or 
due to the fact that circulating nitrated proteins do not reach significantly high levels to elicit 
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significant changes and that the measurement of tissue nitrated proteins may be a more 
sensitive marker.  
Another aspect that may be considered is the lipoprotein metabolism, particularly in what 
concerns HDL, whose atheroprotective role has long been established. ApoA1 is the main 
component of HDL and its integrity is essential to adequate HDL function. Reduced levels of 
ApoA1 are associated with increased CVD and the presence of increased nitrosative stress 
and nitrated Apo1 may be associated with impaired function and consequently, increased 
CV risk (Hahn 2010, O'Neill, Giles et al. 2010, Teixeira, Cutler et al. 2012). Patients with SLE 
have lower TApoA1 and higher nitrated ApoA1 than HC, regardless of disease activity, 
treatment or classical autoantibody profile (ENA, anti-dsDNA, C3).  
A potential mechanism for the reduced TApoA1 levels in patients with SLE, is the presence 
of anti-ApoA1 antibodies reported in the serum of patients with SLE (Dinu, Merrill et al. 1998, 
Delgado Alves, Ames et al. 2002, Alves and Ames 2003, Delgado Alves, Kumar et al. 2003, 
Batuca, Ames et al. 2007, Batuca, Ames et al. 2009, O'Neill, Giles et al. 2010). I also found 
that anti-ApoA1 levels were significantly higher in SLE compared to healthy controls in all the 
groups studied. Almost one third of patients were positive for anti-apoA1 IgG very early in 
the disease course. However, I did not find any associations between anti-apoA1 IgG 
positivity early in disease and development of CVD later in life or increased atherosclerotic 
burden as assessed by vascular US. No significant associations between anti-ApoA1 and 
CVD-related variables were found. In contrast the presence of anti-HDL IgG in high titres did 
appear to be associated with lower TApoA1 levels. This association supports the hypothesis 
that the presence of anti-HDL antibodies might be associated with increased ApoA1 
clearance, possibly due to the formation of immune complexes, which would then support 
the notion that these antibodies may contribute to the increased CVD risk found in SLE. The 
presence of high levels of nitrated ApoA1 may also be a mechanism of HDL dysfunction and 
it would be relevant to assess the correlation and potentially causal association between 
these two variables. The occurrence of dysfunctional HDL in inflammatory diseases, such as 
SLE, has also been suggested as a potentially important factor in the increased CVD risk 
observed in these patients (Hahn, Grossman et al. 2007). The presence of nitrated ApoA1 
could be a potential mechanism for impaired HDL function. 
The challenge for the clinician is to identify patients with greater atherosclerotic burden at a 
very early stage, preferably before symptomatic CVD emerges. Although vascular US is a 
reliable and reproducible method, it is not readily available and the plaque texture 
characterization is not performed routinely by most imaging departments. Therefore, the 
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ideal situation would be to identify a panel of biomarkers which correlated with the presence 
of atherosclerotic disease.  
The use of vascular US, in particular of multiple vascular territories (central/ carotid and 
peripheral/ femorals) is a non-invasive, non-irradiating, reproducible method that allows for 
an accurate assessment of the true atherosclerotic burden of an otherwise asymptomatic 
patient. Moreover, the extent of atherosclerotic disease (i.e. presence of plaque in multiple 
sites) has prognostic value in predicting the risk of coronary events (Schiano, Sirico et al. 
2012). The global atherosclerotic load may be express as the total plaque area (TpA) and/ or 
total plaque thickness (TpT). 
In the SLE cohort I selected, 36 out of 100 patients with SLE with no evidence of CVD 
already had plaque which falls into the range of what has been previously reported (Manzi, 
Selzer et al. 1999, Svenungsson, Jensen-Urstad et al. 2001, Doria, Shoenfeld et al. 2003, 
Roman, Shanker et al. 2003, Selzer, Sutton-Tyrrell et al. 2004, Wolak, Todosoui et al. 2004). 
The much higher prevalence of  atherosclerosis among individuals who typically have a low 
score in the traditional risk stratification tools  (Bessant, Hingorani et al. 2004, O'Neill, Pego-
Reigosa et al. 2009) comparably with matched HC (Svenungsson, Jensen-Urstad et al. 
2001, Roman, Shanker et al. 2003, Thompson, Sutton-Tyrrell et al. 2008) may be 
potentiated by the difficulty in diagnosing subclinical CVD and establishing primary 
prevention strategies. 
I attempted to combine the vascular US findings obtained from a cohort of patients with SLE 
with variables measured routinely in clinical practice  (BP, CRP, renal function, ESR), some 
tests which can be performed in most hospitals (homocysteine, vitamin D) and with specific 
research biomarkers (anti-ApoA1, anti-HDL, nitrated proteins). I found that the BP was 
weakly correlated with both TpA and TpT and this is probably due to the very low prevalence 
of hypertension among the patients assessed. Among the other traditional CVD risk factors, I 
found that increased TG and homocysteine levels were associated with increased plaque 
size. Neither t-cholesterol nor LDL were found to correlate with plaque size and this is again 
probably due to the very low presence of dyslipidaemia in the patients tested. Nonetheless, 
the more sensitive t-cholesterol:HDL was noted to correlate positively with both TpA and 
TpT. The presence of clinically active disease was associated with increased plaque burden, 
but serological markers of disease activity were not, nor were any other auto-antibodies with 
the exception of anti-HDL IgG antibodies which were positively correlated with TpA and TpT. 
Finally, I found a significant correlation between increased disease activity and TpA 
suggesting that increased inflammation may be a relevant factor for atherogenesis in the 
context of SLE. Patients with increased disease activity over time also had increased GSM 
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suggesting that in patients with active disease, plaque progression may be developing 
differently as discussed below. 
It is worth comparing the vascular US findings between the SLE and the non-SLE cohorts. 
Despite the limitations previously noted, this analysis raises a few relevant points. The first is 
not new as it concerns the much greater atherosclerotic burden of patients with SLE 
compared with age and sex-matched controls, as expressed by the differences regarding 
TpA, TpT and number of vascular territories involved. The emphasis of these findings is 
further enhanced by the fact that patients with SLE had fewer traditional CVD risk factors 
compared with the non-SLE subjects, particularly in regards to the lipid and BP profile. 
The second point regards plaque echogenicity. I found that although the majority of plaques 
identified in the SLE cohort had a low GSM (mean GSM 48) and could therefore be 
considered to be predominately echolucent or lipid rich (Goncalves, Lindholm et al. 2004, 
Sztajzel, Momjian et al. 2005), non-SLE individuals had significantly lower GSM. The 
association between plaque echogenicity and risk of CVD-events has not been established 
unequivocally. Although the general consensus is that the presence of echolucent plaques is 
associated with increased cerebral events (Mathiesen, Bonaa et al. 2001, Biasi, Froio et al. 
2004, Johnsen, Mathiesen et al. 2007, Kakkos, Stevens et al. 2007, Kakkos, Sabetai et al. 
2009, Singh, Atam et al. 2013, Ariyoshi, Okuya et al. 2015), their presence has been shown 
to correlate with aortic stiffness (Zureik, Temmar et al. 2002, Zureik, Bureau et al. 2003) 
which in turn has been associated with CVD-related events, namely stroke, MI and 
congestive heart failure (Hirai, Sasayama et al. 1989, Meaume, Benetos et al. 2001, 
Meaume, Rudnichi et al. 2001, Mitchell, Tardif et al. 2001). Overall, these studies have been 
done in either the general population or in specific risk groups, namely among diabetic 
patients and usually have a greater proportion of male subjects. Therefore, it may be difficult 
to compare these findings to the setting of SLE were in the main the patients are relatively 
young women with few traditional CVD-risk factors.  
Several explanations for the differences found between the SLE and the non-SLE cohorts 
may be hypothesised ranging from the genetic differences of two ethnically different 
populations to the differences in lipid (pro-atherogenic in the non-SLE cohort) and BP profile 
(higher in the non-SLE group).  
An alternative explanation for why the plaques found in patients with SLE are more 
echogenic than those found on non-SLE individuals could be their “age”. If we accept that 
“older” plaques are more echogenic (Stary 2000), the reason why patients with SLE have 
plaques with increased GSM compared with non-SLE individuals may be that their plaque 
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formation starts earlier. Alternatively the atherosclerotic process may start at a similar age, 
but occurs in an accelerated fashion.  Both these hypotheses are supported by the 
regression models depicting age at scan plotted against TPT and TpA. The later hypothesis 
that the crucial difference is the rate of plaque progression is further supported by the fact 
that the plaque growth pattern (i.e. the correlation between TpA and TpT and CCA IMT) is 
different in the SLE cohort compared with the non-SLE cohort. This observation suggests 
that the atherosclerotic process is happening faster in SLE as there is very little IMT 
thickening even when plaque is present. This could be the reason why patients with 
sustained active disease have more echogenic plaques, as the presence of chronic 
inflammation could further enhance a process of accelerated atherosclerosis. 
 
In this final chapter of my thesis, I think it is appropriate to reflect on the work I have done so 
far, highlight the questions it raised and consider how they may persued in the future.  
One of the main achievements stemming from this thesis was the construction of a 
comprehensive database for 100 patients with SLE which includes full demographic and 
SLE-related characterization, notably disease course, main organs or systems involved, 
immunological profile, disease activity over time and type of treatment as well as CVD-
specific risk factors, namely lipid profile, smoking habits and BMI. This is a useful data set to 
build upon the work I have done and explore further the potential implications of other 
variables which can potentially influence the increased atherosclerotic burden of patients 
with SLE. 
Ideally, a follow-up project to re-assess these same patients in 2-3 years’ time will be 
developed. This would allow comparing plaque and IMT progression, not only in terms of 
qualitative measures such as IMT/ plaque thickness and area, but also plaque texture 
modifications over time.  
With regards to assessing other serological variables which might correlate with plaque 
characteristics, I would like to measure dysfunctional HDL levels in these patients and see 
whether any significant associations emerge. I would also like to investigate whether the 
presence of anti-ApoA1 IgG/ IgM and anti-HDL antibodies correlates with increased 
dysfunctional HDL.  
Moreover, I think it would be interesting to explore different targets which may correlate 
better with vascular damage and therefore be associated with subclinical atherosclerosis. A 
potential candidate would be endothelial microparticles, as it has been suggested that they 
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are increased in SLE and other systemic inflammatory conditions. For this project, plasma 
samples rather than sera would be necessary and I have already collected plasma samples 
for a majority of patients. 
Finally, at present, a motion analysis software is being developed in order to allow for a 
quantification of arterial expansion and eventually correlate it with other, more established 
methods such as pulse wave velocity. The goal is to find an US-based surrogate marker that 
allows for a non-invasive, reproducible method to assess arterial stiffness. I am also 
collaborating with the developers of this software with the goal to find a measurable variable 
that translates the movement of plaque observed with every cardiac cycle.  This is being 
accomplished by identifying the different motion vectors generated by the movement of 
plaque with systolic and diastolic variations. The hypothesis is that if, within a plaque, 
opposite motion vectors are identified (discordant plaque motion), it may signify that there 
are increased shear stress forces which may then be associated with increased risk of 
plaque rupture (i.e. unstable/ vulnerable plaque). The opposite could also  found to be true, 
i.e. plaques which have homogenous motion vectors may have a reduced risk of rupture and 
therefore be more stable (concordant plaque motion). Should this software prove to be 
reliable and yield a quantitative variable, associations with other biological variables as the 
ones I have explored in my thesis may be identified. Another goal would be to design a 
prospective study to assess whether the presence of distinctive plaque and arterial wall 
motion patterns influences prognosis, specifically whether it is associated with differences in 
the incidence of CVD-related events. I have already obtained the required imaging data, 
including arterial motion loops and plaque motion loops, and am working with Professor 
Nicolaides and Dr Griffin with a view to continue to develop this potentially new tool. 
Overall, my goal would be to try to establish a reliable and accurate risk profile of patients 
with SLE who are more likely to have subclinical atherosclerotic disease with the intention of 
obtaining a vascular US-based risk assessment thus allowing for more aggressive SLE 
treatment as well as for stricter management of other aspects such as lipid profile, 
hypertension and diabetes. Ultimately I would like to have contributed to a better 
assessment of the actual atherosclerotic burden of patients with SLE thereby allowing 
primary prevention strategies to be developed which will minimize the occurrence of CVD-
related events. 
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Systemic lupus erythematosus is a multisystem, autoimmune disease known to be one of the strongest risk factors for atherosclero-
sis. Patients with SLE have an excess cardiovascular risk compared with the general population, leading to increased cardiovascular
morbidity and mortality. Although the precise explanation for this is yet to be established, it seems to be associated with the
presence of an accelerated atherosclerotic process, arising from the combination of traditional and lupus-specific risk factors.
Moreover, cardiovascular-disease associated mortality in patients with SLE has not improved over time. One of the main reasons
for this is the poor performance of standard risk stratification tools on assessing the cardiovascular risk of patients with SLE.
Therefore, establishing alternative ways to identify patients at increased risk eﬃciently is essential. With recent developments
in several imaging techniques, the ultimate goal of cardiovascular assessment will shift from assessing symptomatic patients to
diagnosing early cardiovascular disease in asymptomatic patients which will hopefully help us to prevent its progression. This
review will focus on the current status of the imaging tools available to assess cardiac and vascular function in patients with SLE.
1. Introduction
Systemic lupus erythematosus (SLE) is a multisystem, au-
toimmune disease and is one of the strongest known risk
factors for atherosclerosis and coronary artery disease (CAD)
[1, 2]. The range of cardiovascular disease (CVD) in SLE is
broad and includes atherosclerosis, vascular inflammation,
Raynaud’s phenomenon, endothelial dysfunction, and a pro-
coagulant tendency associated with antiphospholipid anti-
bodies. The impact of SLE-associated CVD on both mor-
tality and morbidity is impressive: the incidence of CAD is
over 7 times greater in patients with SLE than in healthy
controls, even when matched for cardiovascular risk factors
[3]. Moreover, female patients with SLE between 35 and 44
years old have an incidence of myocardial infarction over 50
times greater than the observed in the Framingham dataset
[4]. These findings account for the bimodal mortality pattern
in SLE: an early peak (<1 year of diagnosis) associated with
renal involvement and infection and a later peak (8 years
after diagnosis) due to premature myocardial infarction [5].
In addition to an increased risk of CAD, patients with SLE
are at greater risk for stroke, with a prevalence that can reach
20% and with a high recurrence rate and greater mortality
than matched controls [6].
The reason why patients with SLE have a higher cardio-
vascular mortality and morbidity seems to be related to the
presence of an accelerated atherosclerotic process [7, 8],
which seems to be due to a complex interplay of traditional
and lupus-specific risk factors [3, 9–11]. On the one hand,
some of the factors contributing to an accelerated atheroscle-
rosis may be associated with the disease itself: the systemic
inflammation associated with poorly controlled SLE could
contribute to plaque destabilization. On the other hand,
patients with SLE have a high prevalence of traditional CVD
risk factors [3, 10] such as hypertension, altered lipid profile
[12], and impaired glucose tolerance, which to some extent
result from chronic corticosteroid therapy [13]. However,
not only has no unequivocal correlation been established
between corticosteroid use and atherosclerosis in SLE, but
some evidence seems to suggest an increased cardiovascular
risk among patients who are under treated with steroids,
thus implying that having poorer disease control is associated
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with a higher vascular risk than steroid therapy per se [7].
The generally accepted notion is that systemic inflammation
related to SLE contributes both to an accelerated atheroscle-
rosis and plaque destabilization which in turn is the ma-
jor cause of acute plaque disruption responsible for acute
cardiovascular events such as myocardial infarction.
The relevance of accurate cardiovascular assessment in
patients with SLE has been emphasized by recent studies that
show that mortality associated with CVD has not improved
over time, opposing the trend seen for other causes of mor-
tality such as lupus nephritis [14, 15]. Several reasons can be
hypothesised to explain this but one of the strongest is the
poor performance of standard risk stratification tools (based
on the Framingham risk equation) [16] in patients with
SLE, which prevents an accurate assessment of the actual
cardiovascular risk of the individual patient [9, 17]. It is,
therefore, essential to find alternative ways to assess and
identify patients with SLE at increased risk for CVD efficient-
ly. Several imaging techniques have been studied as potential
tools to assess these patients better, with particular emphasis
in noninvasive screening tools aimed at detecting subclinical
atherosclerosis.
This paper will focus on the current status of imaging
assessment of cardiac and vascular function among patients
with SLE. There are two possible roles for this type of assess-
ment. One is to identify CVD in patients with suspicious
symptoms or other good reasons to suspect CVD (e.g., heavy
smoking). The more challenging role is to diagnose CVD in
asymptomatic patients with few or no risk factors other than
SLE itself. It is important to remember that though SLE is
associated with an increased relative risk of developing CVD
compared to healthy controls, the absolute risk of developing
CVD in an individual patient remains small. For example, in
a recent multicentre study of 1249 patients recruited within
15 months of the diagnosis of SLE and followed for up to 8
years, only 74 patients developed CVD [18]. Thus, it would
be diﬃcult to justify invasive or repeated imaging to screen
for CVD in the majority of patients with SLE.
2. Assessing Cardiac Involvement
SLE-associated cardiac involvement can be divided into
4 groups: pericarditis/pericardial eﬀusion, valvular disease,
myocardial dysfunction, and coronary-artery disease (CAD).
For the purpose of this paper, we will focus only on the last
two groups.
2.1. SLE-AssociatedMyocardial Dysfunction. In SLE, myocar-
dial dysfunction may be due to several features such as CAD,
valvular disease, drug-related cardiotoxicity (e.g., cyclophos-
phamide and chloroquine), and lupus myocarditis. After the
introduction of corticosteroid therapy, the prevalence of
autopsy-identified SLE-related myocarditis decreased from
50%–75% [19] to 25%–30% [20]. However, clinically ev-
ident lupus myocarditis is identified in less than 10% of
patients, showing the high prevalence of subclinical dis-
ease [21]. In fact, clinical manifestations of SLE-associated
myocarditis are subtle and nonspecific. The fact that systolic
function is preserved until late stages of the disease accounts
for the low sensitivity of echocardiographic assessment [22].
Although still considered the gold standard for pericardial
and valvular evaluation [22, 23], its use in lupus myocarditis
diagnosis is limited. However, it can give some indication of
left ventricle diastolic dysfunction through the presence of
impaired myocardial relaxation, decreased compliance, and
increased filling pressure [22]. Another way to assess cardiac
function is through left ventricle angiography, both by the
conventional method and by using Technetium-99m myo-
cardial perfusion imaging (SPECT), which permits accurate
assessment of left ventricle volume and function [24, 25].
However, these methods have largely been replaced by MRI
imaging [26].
The definite diagnosis of lupus myocarditis is histologi-
cal, with typical features being interstitial oedema, focal ne-
crosis/fibrosis, and focal or diﬀuse inflammatory cellular in-
filtrates [27]. However, despite being the gold standard for
diagnosis, endomyocardial biopsy cannot be used routinely
or repeatedly, particularly in asymptomatic patients. Cardiac
magnetic resonance (CMR) is sensitive to many of the chan-
ges that characterize lupus myocarditis, particularly through
T2-weighted imaging (myocardial oedema) [28, 29] and
early (EGE) and late (LGE) gadolinium-enhanced CMR [28,
30]. The combination of EGE, LGE, and T2 imaging sequen-
ces has been reported to have 76% sensitivity and 95.5%
specificity for the detection of myocardial inflammation
[28]. In addition, CMR is superior to other techniques in
assessment of left ventricle size, function, and mass, provides
high spatial resolution, is noninvasive and has high repro-
ducibility and low intra and interobserver variability [26].
In a recent study, we carried out CMR and transthoracic
echocardiography in 22 patients with SLE (11 patients with
previous CVD and 11 age-sex matched controls) [30]. We
found that CMR was more sensitive than echocardiography
for the detection of myocardial changes, especially late
gadolinium enhancement (LGE) in areas of previous infarc-
tion [30]. In contrast to a previous report [31], we did not
find widespread small areas of LGE in the myocardial tissues
of these patients. Mavrogeni et al. [32] reported LGE in 18/20
patients with autoimmune rheumatic diseases (three with
SLE). Ten patients also had myocardial biopsies with a 50%
agreement between biopsy and CMR results.
CT imaging is not considered an adequate tool for eval-
uation of cardiac muscle due to radiation exposure, move-
ment artefacts and application of contrast media which pre-
vents use in patients with renal failure and severe heart failure
[33].
2.2. Coronary Artery Assessment. As stated before, SLE is
associated with a significantly increased risk of CAD. The
presence of CAD can be evaluated directly by coronary arte-
riography and indirectly by assessing left ventricle ejection
function and ventricular wall motion through radionuclide
ventriculography, echocardiography, SPECT, and CMR [22].
2D echocardiography is the most widely used method for
routine assessment of left ventricle ejection fraction in pa-
tients with known CAD. Other methods, such as tissue Dop-
pler imaging and 3D echocardiography have been proposed
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as superior alternatives; however, they still have not replaced
conventional echocardiography [22]. Turiel et al. [34] have
proposed a global index of left ventricle function (TEI index)
aimed at systolic and diastolic left ventricle function. How-
ever, its validity in SLE has yet to be shown. Stress echocar-
diography using either exercise or pharmacological stimulus
can be a useful method for diagnosis and risk stratification in
patients with suspected or known CAD [22].
Presently, several studies have shown the utility of MRI
imaging in assessment of CAD—though not in patients
with SLE [26, 28, 35]. Stress CMR (i.e., using dobutamine
or adenosine) is an accurate method to identify ischemia-
induced wall motion abnormalities, with a greater sensitivity
(86% versus 74%) and specificity (86% versus 70%) than
stress echocardiography [36]. In addition, perfusion defects
can be identified with gadolinium-enhanced CMRI as well as
positron emission tomography (PET) [37] and SPECT [25].
One additional benefit from PET imaging is the possibility of
identifying stable plaques as a high uptake of contrast seems
to be associated with a higher macrophage content which
would correlate with the presence of intraplaque active in-
flammation [38]. However, the use of radioisotopes for PET
limits its applicability.
Electron beam CT (EB-CT) can be used to quantify cor-
onary artery calcification as a measure of coronary athe-
rosclerosis. Asanuma et al. [7] compared EB-CT findings
in 65 patients with SLE and 68 age-/sex-/ethnicity-matched
controls. Mean calcification scores was significantly higher in
patients than controls. After adjustment for cardiac risk fac-
tors including age, sex, smoking, hypertension, triglyceride,
and homocysteine levels, patients with SLE were still 9.8
times more likely to have coronary calcification than con-
trols. The reason for this was unclear. In a subsequent paper
Kiani et al. [39] found coronary calcification in 43% of 200
women with SLE, but the only factors predicting this in
multiple logistic regression analysis were age and body mass
index. SLE disease activity was not associated with coronary
calcification. CT angiography can be used to detect plaques
in the coronary arteries. In a recent study [40], Ishimori et al.
carried out both adenosine stress CMR and CTA in 18 female
patients with SLE who had suﬀered chest pain within the
previous six months and in 10 healthy control women. Eight
patients with SLE, but no control subjects had abnormal
perfusion on stress CMR. This was severe in 7 cases even
though none of the patients had obstructive CAD detectable
by CTA and only two of the 18 subjects had any CTA ab-
normalities. The perfusion defects were not characteristic of
coronary artery disease [40]. Thus, it seems likely that stress
CMR was detecting microvascular ischemia in patients with
SLE though larger studies are required.
Invasive methods for assessing coronary circulation such
as intravascular ultrasound (IVUS) and IVUS with virtual
histology [41], optical coherence tomography [42], coronary
angioscopy [43], and invasive MRI [44] may prove their
usefulness in the future by allowing direct plaque imaging.
However, presently their predictive value and impact on risk
stratification is yet to be established.
3. Assessing Peripheral Vascular Involvement
Peripheral vascular involvement in SLE can be associated
with active vasculitis, endothelial dysfunction and athero-
sclerosis. For the purpose of this paper, we will focus on the
latter two.
3.1. Endothelial Dysfunction. The endothelium is the main
regulator of vascular wall homeostasis. It regulates vascular
tone and permeability, platelet and leukocyte adhesion and
aggregation, and finally, vascular thrombosis. The term
“endothelial dysfunction” describes a nonadaptive state of
phenotypic modulation characterized by a loss or deregu-
lation of the homeostatic mechanisms operative in healthy
endothelial cells [45]. Current evidence suggests that endo-
thelial dysfunction is an early event in atherogenesis and con-
tributes to all the stages of plaque development [46]. Al-
though there are currently no imaging methods that can ef-
fectively assess endothelial function, several functional meth-
ods have been developed to try and address this issue. The
hallmark of endothelial dysfunction is an impaired endo-
thelium-dependent vasodilatation [47]. Peripheral studies
include flow-mediated vasodilatation assessment [47–49],
forearm perfusion techniques, pulse wave analysis, and skin
laser Doppler flowmetry [45]. Other potential markers of
endothelial dysfunction correlate with circulating procoag-
ulant, prothrombotic, and proinflammatory mediators, but
with the exception of C-reactive protein, evidence for their
independent predictive value is still lacking [45]. Although
very few studies of this nature have been done in SLE [48, 49],
attenuated flow-mediated dilation has been a consistent find-
ing, suggesting the presence of impaired endothelial func-
tion in these patients even before overt cardiovascular disease
is apparent.
3.2. Peripheral Vascular Assessment. The presence of com-
mon carotid artery intimal-medial thickening and discrete,
nonobstructive carotid atherosclerosis has been shown to
be independently associated with subsequent cardiovascular
risk in several longitudinal studies [50, 51].
Ultrasound assessment of carotid atherosclerosis is an
accurate, noninvasive method that allows for assessment of
arterial wall thickness and degree of plaque. Manzi et al. [52]
studied the prevalence of carotid atherosclerosis as measured
by B-mode ultrasound in 175 women with SLE, finding that
40% had at least 1 focal plaque and that more than 20% had
a at least one large plaque (>50% of the vessel diameter) or
multiple plaques with at least one medium plaque (30%–
50% of the vessel diameter). Patients with higher cumu-
lative damage measured by the modified Systemic Lupus
International Collaborative Clinics (SLICC) damage score
were more likely to have plaque, even after excluding the
cardiovascular components of the SLICC index. A strong
association between duration of use and cumulative dose
of corticosteroids was also found. Other groups, working
independently have also found a prevalence of carotid plaque
in the order of 40% in patients with SLE [8]. A longitudinal
study from theManzi group [53] assessed plaque progression
in 217 female patients with SLE followed for 10 years using
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Table 1: Overview and comparison of diﬀerent imaging methods in atherosclerotic plaque assessment (IMT: intima-media thickness; CVD:
cardiovascular disease).
Imaging method
Plaque
characterization
Advantages Disadvantages
Published data from
patients with SLE
Carotid ultrasound
IMT and plaque in
carotid arteries
No radiation
rapid-convenient
correlates with risk of
future CVD
Interpretation is operator
dependent. High frequency of
plaque in Patients with SLE
(clinical implications unclear)
Yes [22, 23, 54, 55, 58]
Magnetic resonance
imaging (MRI)
Structure of
myocardium
quantification of lipid
content
No radiation
more sensitive than
echo for myocardial
change
Expensive
use of gadolinium limited in
patients with renal impairment
motion artefacts.
Lower spatial resolution in
vascular assessment.
Longer length of study time
Yes
[2, 13, 18, 30, 33–36]
Computed
tomography (CT)
Quantification of
calcium, fibrous and
lipid component
Noninvasive detection
of vulnerable plaques
Motion artefacts.
Contraindicated in renal
impairment
Low resolution
Yes [17, 41, 42]
Intravascular
ultrasound-based
methods
Plaque volume
Luminal and vessel
dimensions
calcium content
Good penetration
depth
complements
coronary angiography
Invasive
lower spatial resolution
No
Positron emission
tomography (PET)
Plaque macrophage
content
Not established for widespread
clinical use
Yes [26, 27]
Optical CT
Plaque
microstructure
(fibrous cap thickness
measurement)
High spatial
resolution
Invasive
limited depth of penetration
No
Invasive MR
Plaque morphology
and structure
Not established for widespread
clinical use
No
Coronary angioscopy
Direct plaque surface
visualization
Three-dimensional
view of plaque
Superficial assessment of plaque.
Risk of coronary occlusion
No
ultrasound. Progression of plaque occurred in 27% of pa-
tients and, overall, the mean increase in intima-media thick-
ness was 0.011mm/year. Plaque progression was greater in
patients with SLE when compared with matched controls,
suggesting that B-mode ultrasoundmay be a useful surrogate
end point in SLE clinical management [53]. Importantly, this
group went on to show, for the first time, that increase in
IMT or the presence of plaque predicted increased risk of car-
diovascular events [54]. They followed 224 women with
lupus but no previous cardiovascular events. Over a 10-year
followup period, 73 of them suﬀered either cardiac or ce-
rebrovascular events. In multivariable analysis, higher IMT
and presence of plaque at baseline predicted increased risk
of cardiovascular events. For IMT, the hazard ratio was 1.24
(95% CI 1.04 to 1.48) per mm increase and the hazard ratio
for presence of plaque was 5.97 (95% CI 1.52 to 23.38) [54].
Further enhancement of ultrasound assessment of carotid
plaques can be achieved using integrated backscatter analysis
of carotid-intima complex. This method has been shown to
correlate with the calcium and collagen content of vascular
wall, therefore noninvasively evaluating arterial sclerosis
[55]. However, its usefulness in SLE has not been established
[56].
High-resolution CT imaging has also been studied as an
alternative and more accurate method of assessing carotid
plaques. CT angiography has been shown to not only pro-
vide an accurate analysis of the degree of stenosis but also
to correlate with histological findings of atheromatous pla-
ques at the carotid bifurcation [57]. However, limitations as-
sociated with the use of contrast and radiation exposure are
of concern.
A potential role for MRI imaging has emerged; as its use
hasmuch less limitation than CTmethods [58], and there is a
good correlation between them. In addition to assessing inti-
mal and medial thickening, both methods yield information
concerning the pattern of plaque calcification. Whether this
correlates with the risk of embolic stroke is yet to be definitely
established.
Presently, cutting edge, multimodal imaging research us-
ing animal models is aimed at determining ways to accurately
assess plaque stability [59–61]. In animal models, factors like
atherosclerotic plaque neovascularisation, thickness of fi-
brous plaque, lipid-rich necrotic-core, and macrophage con-
tent have been related to an increased plaque disruption risk.
However, clinical implications in humans have not been es-
tablished.
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Table 1 summarises the diﬀerent methods of imaging de-
scribed in this paper with their advantages and disadvan-
tages.
4. Conclusion
In summary, patients with SLE have a high risk of developing
CVD. Despite their relevance, traditional reversible risk fac-
tors solely cannot account for the overall cardiovascular
risk increase, which also depends on disease and treatment
related issues. In this paper, we have described a number
of technological advances that have enhanced the ability of
clinicians to assess the myocardium, coronary arteries, and
peripheral vessels in patients with CVD. For most of them,
there is little or no information about use in patients with
SLE. Some of these imaging techniques, for example, PET
scanning and CT angiography, should clearly be reserved
for patients with SLE with known CVD or very high CVD
risk (based on traditional risk factors as well as the presence
of SLE). Others, such as echocardiography and carotid ul-
trasound are convenient and noninvasive and could be used
as screening tools in asymptomatic patients though it is still
unclear how best to manage patients who have abnormal-
ities on these tests. Perhaps the best way to use these imaging
methods in the future will be in combination with assess-
ment of traditional risk factors, disease activity measure-
ments, and blood tests relevant to CVD [62]. This holistic
assessment could then be used to identify patients who
would benefit frommore accurate but more invasive imaging
methods such as cardiac MRI.
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with systemic lupus erythematosus: a
retrospective longitudinal cohort study
Sara Croca1*, Paul Bassett2, Charis Pericleous1, Karim Fouad Alber1, David Latchman3, David Isenberg1,4, Ian Giles1,
Anisur Rahman1 and Yiannis Ioannou1,4Abstract
Introduction: Circulating nucleosomes released from apoptotic cells are important in the pathogenesis of systemic
lupus erythematosus (SLE). Both nucleosomes and anti-nucleosome antibodies are deposited in inflamed tissues in
patients with SLE. Active inflammation promotes nitration of tyrosine residues on serum proteins. Our hypothesis
was that levels of nitrated nucleosomes would be elevated in patients with SLE and could be associated with
disease activity. We therefore carried out a retrospective longitudinal study to investigate factors affecting levels of
nitrated nucleosomes (NN) in patients with SLE.
Methods: A novel serum ELISA was developed to measure serum NN and modified to measure serum nitrated
albumin (NA). Levels of both NN and NA were measured in 397 samples from 49 patients with SLE followed
through periods of disease flare and remission for a mean of 89 months. Anti-nucleosome antibody (anti-nuc) levels
were measured in the same samples. The effects of 24 different clinical, demographic and serological variables on
NN, NA and anti-nuc levels were assessed by univariable and multivariable analysis.
Results: Patients with SLE had higher mean NN than healthy controls or patients with other autoimmune
rheumatic diseases (P =0.01). Serum samples from 18 out of 49 (36.7%) of SLE patients were never positive for NN.
This group of 18 patients was characterized by lower anti-double stranded DNA antibodies (anti-dsDNA), disease
activity and use of immunosuppressants. In the remaining 63.3%, NN levels were variable. High NN was significantly
associated with anti-Sm antibodies, vasculitis, immunosuppressants, hydroxychloroquine and age at diagnosis. NN levels
were raised in neuropsychiatric flares. NN levels did not completely parallel NA results, thus providing additional
information over measuring nitration status alone. NN levels were not associated with anti-nuc levels.
Conclusions: NN are raised in a subset of patients with SLE, particularly those who are anti-Sm positive. Elevated NN
may be a marker of vascular activation and neuropsychiatric flares in these patients.Introduction
Nitration and nucleosomes are both relevant to the patho-
genesis of systemic lupus erythematosus (SLE). Nitration
may be linked to development of cardiovascular disease
(CVD). Patients with SLE have an increased risk of devel-
oping CVD [1] for reasons that are not fully understood
[2,3]. Nitric oxide (NO) produced by the vascular endo-
thelium is an important metabolite involved in processes* Correspondence: sara.croca.10@ucl.ac.uk
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reproduction in any medium, provided the orsuch as vasodilatation and inhibition of platelet aggrega-
tion [4]. When produced in excess, for example under
conditions of systemic inflammation, NO can cause chem-
ical alteration of lipids and proteins. In particular, tyrosine
residues within proteins can be nitrated irreversibly, form-
ing nitrotyrosine. In patients with SLE, the serum nitrite
level (an index for NO production) correlates with disease
activity and levels of anti-double stranded DNA (anti-
dsDNA) antibodies [4]. Patients with active lupus nephritis
have higher levels of nitrotyrosine than those without
renal disease [5,6]. In theory, any serum protein contain-
ing tyrosine residues may be nitrated. We are particularly
interested in nitration of histones within nucleosomes.td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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apoptotic debris is not cleared efficiently in patients
with SLE [7]. Both nucleosome and anti-nucleosome
antibody levels are elevated in these patients [8] and de-
position of nucleosome-anti-nucleosome complexes is
important in lupus nephritis [9]. Thus, our hypothesis is
that levels of nitrated nucleosomes (NN) in the serum
of patients with SLE could rise, particularly during flares
of disease activity. We developed a novel enzyme-linked
immunosorbent assay (ELISA) to test this hypothesis.
The principle of this novel ELISA is that serum proteins
containing nitrotyrosine residues are captured on the plate
using an anti-nitrotyrosine antibody and the subset of cap-
tured proteins that contain histones are then detected
using a polyclonal anti-histone antibody. The method de-
tects any analyte that contains both histones and nitrotyr-
osine. Since histones in serum occur primarily in the form
of nucleosomes we refer to this as a NN ELISA rather
than nitrated histone ELISA. Nucleosomes nitrated on
proteins other than histones would also be detected.
Hence, the ELISA detects the presence of nitrated tyrosine
residues upon a protein either complexed with histones or
upon core histones themselves.
We carried out measurements of NN levels in 397 sam-
ples taken from 49 patients at different time points, in-
cluding times of disease flare and remission. We carried
out univariable and multivariable analyses to determine
the demographic and clinical factors that are associated
with NN levels. We also measured levels of nitrated albu-
min (NA) as a surrogate marker of overall nitrative stress
(given that albumin is a ubiquitous protein in serum) and
the levels of anti-nucleosome antibodies (anti-nuc). Anti-
nuc levels were measured to test whether they correlate
with NN levels, which could be the case if nitration of nu-
cleosomes is important in making them more antigenic.
Methods
Patients and samples
Longitudinal serum samples (n = 397) were selected
retrospectively from a cohort of 49 patients with SLE
followed at University College London Hospital (UCLH)
with a mean of eight samples per patient (SD 2.16; min
3; max 14) and a mean follow-up of 89 months (SD 46;
min 14; max 180). All patients fulfilled the revised
American College of Rheumatology (ACR) classification
criteria for SLE [10]. We particularly selected patients
who had suffered flares of disease activity. Samples were
also obtained from 37 healthy control subjects and 38
autoimmune disease controls (13 with rheumatoid arth-
ritis, 12 with myositis and 13 with Sjogren’s syndrome).
For all SLE patient samples where data were available
(94% of samples), we obtained anti-dsDNA antibody and
complement C3 levels and disease activity from the date
of the sample and from the previous three assessments.Anti-dsDNA antibody and C3 levels were measured in the
routine clinical laboratory at UCLH using enzyme-linked
immunosorbent assay (ELISA) (Shield Diagnostics, Dundee,
UK) and laser nephelometry, respectively. Based on the
normal limits for our laboratory, anti-dsDNA level >50
IU/ml was defined as high and C3 level <0.9 g/l as low.
Disease activity was measured using the classic British
Isles Lupus Assessment Group (BILAG) index [11]. The
more recent BILAG 2004 index was not used as many of
the samples had been taken before 2004. Current activity
(on the date of the sample) for each system was defined as
high if the BILAG score was A or B and low if it was C, D
or E. Disease activity over the most recent four assessments
was characterized as persistently low activity (if BILAG C,
D or E was recorded in all systems on each occasion) or
persistently moderate-high activity (in the presence of A
or ≥1 B score in any BILAG system on at least two out of
four occasions). Over 90% of all samples fell into one of
those two categories and the rest were excluded from this
part of the analysis.
Data on ethnicity, gender, drug therapy and anti-Sm,
anti-RNP, anti-Ro and anti-La (all tested by ELISA) anti-
body status of the patients were obtained from the clinical
records of the patients.
Ethical approval was granted by the joint UCL/UCLH
Research Ethics Committee and subjects gave informed
consent for use of their stored serum samples.
Serum assays
Capture ELISA to detect nitrated nucleosomes
The whole assay was done at room temperature (RT) ex-
cept where specified and plates were washed three to four
times with PBS-0.1% Tween (PBST) between steps. We di-
vided 96-well streptavidin plates in half: the test side was
coated with biotinylated polyclonal goat anti-nitrotyrosine
antibody (Abcam 27646, VWR Lutterworth, UK) diluted
1:1,000 in PBS and the control side coated with PBS (75
μL per well). After one hour incubation, plates were
washed and blocked with 200 μL of 0.5% ovalbumin in
PBST (OVA-BST) for one hour. After washing, serum
samples were loaded in duplicate onto the plates (100
μL/well) at 1:30 dilution in PBS such that each sample was
loaded in two wells on the test side and two matching wells
on the control side. After one hour incubation at 37°C
and washing, 50 μL per well of rabbit anti-histone H3
antibody (sc-10809, Santa Cruz Biotechnology, Santa
Cruz, CA, USA) diluted at 1:2,000 in OVA-BST were
added and the plates were incubated for one hour. After
washing, 50 μL per well of goat anti-rabbit IgG horse rad-
ish peroxidase (HRP) conjugate (Dako P0448, Dako, Ely,
UK) diluted at 1:2,000 in 0.5% OVA-BST was added. After
incubating for one hour and washing, HRP substrate was
added (100 μL per well) and incubated for 10 minutes.
The reaction was stopped with 100 μL sulphuric acid and
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for each sample was calculated by subtracting the OD in
the control well from that in the matching test well to ex-
clude non-specific background binding.
In order to be able to compare OD values obtained from
different plates on different days, we prepared an in-house
standard positive control sample that was loaded in serial
dilutions (range 1:15 to 1:120) on every plate. This in-
house standard was prepared by pooling serum samples
from several patients who had been found to have high
serum NN levels in this assay. The mean net OD from du-
plicate test samples was converted to absorbance units
(AU) by comparison to the standard curve of OD for the
serial dilutions of the positive control sample on each
Plate. A total of 100 AU was defined as the OD given by a
1:30 dilution of the positive control sample. The OD for
this 1:30 dilution was reproducibly high, ranging between
1.03 and 1.37.
The NN assay was reproducible with an intra and
inter-plate coefficient of variation of <10%.
Capture ELISA to detect nitrated albumin
This ELISA protocol was identical to the NN capture
ELISA with the following exceptions. The blocking agent
was 0.5% agarose in PBS and the anti-histone H3 anti-
body used was replaced with a rabbit polyclonal anti-
human albumin antibody (Abcam 2406).
Direct ELISA to detect anti-nucleosome antibodies (IgG)
All steps were carried out at 37°C. The test side of the plate
was coated with 50 μL per well of nucleosome antigen
(Arotec ATN02-02, Binding Site Ltd, Birmingham, UK) di-
luted 1:500 in 20 mM Tris/HCL buffer (pH 8.0) containing
0.15 M of NaCl; the control side was coated with buffer
alone. Incubation for two hours, then blocking with 1% bo-
vine serum albumin in PBST (BSA-PBST) for one hour were
followed by sample loading in duplicate into test and control
wells at 1:50 dilution in BSA-PBST. As the positive control, a
pooled serum sample was serially diluted (range 1:15 to
1:120) and loaded in the same way. After a 30-minute incu-
bation, goat polyclonal anti-human IgG HRP conjugate
(A6029, Sigma, Dorset, UK) diluted at 1:1,000 in BSA-PBST
was added. After incubating for 30 minutes, HRP substrate
was added and subsequent steps were as for the NN ELISA.
Statistical methods
The three outcomes in the analyses were serum NN levels,
NA levels and anti-nuc levels. All outcomes were found to
have a highly positively skewed distribution, which could
not be transformed to a more normally distributed scale.
Thus, the outcomes were assumed to follow a negative bi-
nomial distribution. Due to the longitudinal nature of the
cohort, multiple samples for each patient were considered.
To allow for the non-independence of the data, multilevelstatistical methods were used for analysis. Two level models
were used with individual measurements clustered within
patients. The analyses, performed using multilevel negative
binomial regression, were performed in two stages. First,
the separate effect of each factor upon the outcome was
examined in a series of univariable analyses. Subsequently,
the joint effect of factors was examined in a multivariable
analysis. A backward selection procedure was employed to
retain only the statistically significant variables. Variance
inflation factors were used to assess collinearity between
variables and, as a result, some variables that were collin-
ear with other variables were excluded from the multivari-
able stage of the analysis.
Additional analyses grouped patients as either NN posi-
tive or negative depending on their nitrated nucleosome
values. Variables measured at the patient level were com-
pared between groups using either Fisher’s exact test for
the categorical variables or the unpaired t-test for continu-
ous variables.
Sample level variables were analyzed using multilevel re-
gression methods to allow for the repeat measurements
from each patient. Multilevel logistic regression was used to
compare binary variables between groups, while multilevel
linear regression was used for continuous variables. Con-
tinuous variables found to have a positively skewed distri-
bution were given a log transformation before the analysis.
Results
Characteristics of subjects
The mean age of the patients with SLE at the time of
the earliest sample assayed was 36 years (SD 13.0) and
81% were female. A total of 23 were Caucasian, 18
Afro-Caribbean and 8 other ethnicities. For the healthy
controls, the mean age was 31.6 years (SD 6.0) and 62%
were female. A total of 27 were Caucasian, 1 Afro-
Caribbean and 6 other ethnicities.
Of the 49 patients with SLE, 21 were anti-Ro positive, 6
anti-La positive, 15 anti-RNP positive and 11 anti-Sm
positive. During the follow-up period, 29 patients had at
least one elevated anti-dsDNA, 32 had at least one low C3
and 46 suffered at least one flare (BILAG A or B in at least
one system). Flares in all eight systems of the classic
BILAG index were represented in the cohort.
Serum NN levels are higher in patients with SLE than in
healthy controls or patients with other
autoimmune diseases
Figure 1 shows that mean levels of serum NN in patients
with SLE were significantly higher in patients with SLE than
in healthy controls or patients with other autoimmune dis-
eases - rheumatoid arthritis, myositis or Sjogren’s syndrome
(P = 0.01 by one-way ANOVA/Kruskal Wallis test). We do
not have formal disease activity measurements for the pa-
tients with these other diseases but in most cases, samples
Figure 1 NN levels in patients with SLE compared to healthy and autoimmune disease controls. This figure shows the results obtained in
the NN ELISA on testing serum samples from patients with SLE in comparison with healthy controls and patients with other autoimmune
rheumatic diseases (myositis, rheumatoid arthritis and Sjogren’s syndrome). NN levels were higher in the SLE group than the other groups
(P = 0.01 by one way ANOVA/Kruskal Wallis test). NN, nitrated nucleosomes; SLE, systemic lupus erythematosus.
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levels were very low in 31/38 of these patients, we do
not believe that active rheumatoid arthritis, myositis or
Sjogren’s syndrome is associated with raised NN levels.
Serum NN are present in 63% of patients with SLE and
the levels of NN in these patients vary over time
Of the 49 patients with SLE tested, 18 never had detect-
able serum NN, whereas the other 31 (63%) had serum
NN levels that varied significantly over time (mean 32 AU,
SD 62.2, range 0 to 270). The characteristics of the 18
NN-negative patients and the other 31 patients are com-
pared in Table 1. All patients who never had NN were
anti-Sm negative, whereas 35% of the others were anti-Sm
positive (P = 0.004). This clear dichotomy did not apply to
any of the other antibody specificities that were tested,
though the mean anti-dsDNA level in NN-positive pa-
tients was almost twice that seen in NN-negative patients.
A total of 63.2% of NN-positive samples, but only 25.2%
of NN-negative samples, came from patients who were
taking immunosuppressants (P = 0.001).
Figure 2 shows the variation of serum NN levels over
time in five patients with SLE (patients SLE 9, 15, 18,
41 and 42) compared to variations in anti-dsDNA level
(Figures 2A-E) and global BILAG score (Figures 2F-J).
None of these patients showed close relationships be-
tween anti-dsDNA and NN over time. In some cases,
such as SLE 9, 15 18 and 42, NN levels follow disease
activity more closely than anti-dsDNA. This is espe-
cially striking in cases SLE 15 and 42, where anti-
dsDNA is always low. However, there are other cases
where the NN level is persistently low and anti-dsDNA
follows activity more closely (patient SLE 41) and it is
important to remember that approximately a third of
patients never had raised NN levels.Clinical, demographic and serological variables associated
with serum NN and NA levels in patients with SLE
Our hypothesis was that the levels of NN in patients with
SLE would be affected both by the overall level of nitration
and by the level of serum nucleosomes present as a target
for nitration. If this were true, there should be detectable
differences between the variables influencing serum NN
levels and those influencing NA levels. These differences
clearly exist, as shown in Table 2, which includes results
from univariable analysis of 24 factors.
NN levels were twice as high in men as in women. NA
levels were five times as high in men as in women. The ef-
fects of ethnicity on NA are the opposite of the effects on
NN. Caucasians had the lowest NA levels but highest NN
levels of any ethnic group. For both NN and NA there was
a complex non-linear relationship with both disease dur-
ation and age at diagnosis. NN levels were lowest in very
young and very old subjects with a peak NN level at age
30 and at disease duration of eight years.
Anti-Sm positivity was strongly associated with both
elevated NN and elevated NA.
We did not detect any association with the commonly
used serological markers of active lupus (elevated anti-
dsDNA and low C3) or with persistent overall disease activ-
ity for either NN or NA. Considering the individual systems
of the body, we found that vasculitis flares (that is, A or B
score in the vasculitis domain of BILAG) were associated
with significantly raised serum NN and NA. NN but not
NA was raised in cardiorespiratory flares. Renal flares were
associated with a significant decrease in NA but not in NN.
There were no statistically significant differences between
flare (A/B) and non-flare (C/D/E) samples for other systems
but for neuropsychiatric flares the NN levels in C/D/E sam-
ples were approximately 50% of those in A/B samples. This
difference did not reach statistical significance due to wide
Table 1 Comparison of patients with SLE who never had serum NN with the rest of the group
NN-negative NN-positive P-value
(n patients = 18) (n patients = 31)
(n samples = 144) (n samples = 253)
Mean age at first sample (SD)(*) 37.7 (13.1) 34.9 (12.8) 0.47
% Female (n)(*) 77.8 (14) 83.9 (26) 0.71
Ethnicity(*) 0.41
% AC (n) 27.8 (5) 41.9 (13)
% C (n) 61.1 (11) 38.7 (12)
% Other (n) 11.1 (2) 19.3 (6)
Median anti-dsDNA IU/ml (IQR)(**) (†) 29 (13, 97) 82 (17, 171) 0.18
Mean C3 g/l (SD)(**) 1.0 (0.2) 0.9 (0.3) 0.10
Median Global BILAG score (IQR)(**) (†) 5 (2, 8) 5 (3, 10) 0.22
% anti-Sm positive (n)(*) 0.0 (0) 35.5 (11) 0.004
% anti-RNP positive (n)(*) 27.8 (5) 32.3 (10) 1.00
% anti-Ro-positive (n)(*) 38.9 (7) 45.2 (14) 0.77
% anti-La positive (n)(*) 16.7 (3) 9.7 (3) 0.66
% on hydroxychloroquine (n)(**) 42.1 (61) 44.7 (113) 0.66
% on immunosuppressants (n)(**) 25.7 (37) 63.2 (160) 0.001
% on ≥5 mg/day corticosteroids (n)(**) 68.1 (98) 78.3 (198) 0.31
(*)Analysis performed at the patient level.
(**)Analysis performed at the sample level.
(†)Statistical comparison performed on log scale.
Footnote - Global BILAG score is calculated from the formula A = 9, B = 3, C = 1, D = 0, E = 0 as described in previous papers [12]. Bold type indicates statistically
significant P-values (P <0.05). BILAG, British Isles Lupus Assessment Group; NN, nitrated nucleosomes; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.
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atric flares on NA levels.
Treatment with hydroxychloroquine was associated with
elevated NN and NA levels. Immunosuppressants (includ-
ing mycophenolate, azathioprine, methotrexate and cyclo-
phosphamide) were only associated with elevated NN,
whereas high dose corticosteroid treatment was associated
with neither NN nor NA.
Tables 3 and 4 show the results of multivariable analysis
of associations with NN and NA, respectively. Disease
duration, ethnicity, negative anti-La, albumin and low
renal disease activity are all associated with NA but not
NN, whereas hydroxychloroquine and high vasculitis dis-
ease activity are associated with NN but not NA. Age at
diagnosis, anti-Sm antibody positivity and treatment with
immunosuppressants all show similar associations with
both NN and NA levels. In particular, anti-Sm positivity
shows a very strong independent association with both
NN and NA (P <0.001 for both).
There is no association between serum levels of NN and
anti-nuc in multivariable analysis and different variables
are associated with these outcomes
Both univariable and multivariable analyses of the factors
associated with serum anti-nuc levels were performed.
Only the results of multivariable analysis are presentedhere (in Table 5), as use of anti-nuc as a biomarker in SLE
has been studied extensively by other authors [13-15] and
is not the subject of our paper.
Samples obtained from men had higher anti-nuc levels
than samples from women. Both increasing age at diagno-
sis and increasing disease duration were associated with
significant reductions in anti-nuc levels. Increasing anti-
nuc levels were associated with elevated anti-dsDNA as
noted by previous authors [14,15] and with low C3. In con-
trast to the results obtained with NN and NA, there was no
relationship between anti-nuc and anti-Sm status. There
were no associations between treatment with hydroxychlor-
oquine or immunosuppressants and levels of anti-nuc.
Most importantly from the point of view of the present
study, there was no significant association between NN
and anti-nuc levels on multivariable analysis suggesting
that nitration probably does not affect the immunogenicity
of nucleosomes.
Discussion
In this paper we describe a novel capture ELISA that mea-
sures serum levels of NN. Mean NN levels are significantly
higher in patients with SLE than in healthy controls or in
patients with other autoimmune rheumatic diseases but
there is a subset of patients with SLE who never test posi-
tive for NN. These persistently NN-negative patients
Figure 2 Variation of NN and anti-dsDNA levels and global BILAG scores over time. This figure shows the variation of serum NN levels over
time in five patients compared to anti-dsDNA levels (A-E) and global BILAG scores (F-J). anti-dsDNA, anti-double stranded DNA antibodies; BILAG,
British Isles Lupus Assessment Group; NN, nitrated nucleosomes.
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Table 2 Univariable analysis of factors associated with serum NN and NA levels in patients with SLE
Variable Category/term Ratio for NN
(95% CI)
P-value for NN Ratio for NA
(95% CI)
P-value
for NA
Gender * Female (n = 336) 1 1
Male (n = 61) 2.01 (1.06, 3.81) 0.03 5.00 (2.50,9.98) <0.001
Disease duration† Ratio given per 5-year increase 0.43 (0.23, 0.79) 0.005 0.32 (0.20,0.51) <0.001
Age (at diagnosis)† Ratio given per 10-year increase 0.10 (0.02, 0.46) <0.001 0.04 (0.01,0.16) 0.002
Ethnicity* Caucasian (n = 182 ) 1 1
Afro-Caribbean (n = 146 ) 0.75 (0.47, 1.22) 2.07 (1.26,3.40)
Other (n = 69) 0.33 (0.17, 0.63) 0.003 3.75 (1.86,7.56) <0.001
Any ENA** No (n = 165) 1 1
Yes (n = 232) 3.43 (2.19, 5.37) <0.001 3.19 (1.93,5.27) <0.001
Anti-Ro** No (n = 226) 1 1
Yes (n = 171) 1.70 (1.12, 2.59) 0.01 1.81 (1.14,2.89) 0.01
Anti-La** No (n = 345) 1 1
Yes (n = 52) 0.79 (0.41, 1.50) 0.47 0.46 (0.20,1.06) 0.07
Anti-Sm** No (n = 298) 1 1
Yes (n = 99) 5.63 (3.66, 8.67) <0.001 6.25 (3.84,10.2) <0.001
Anti-RNP** No (n = 288) 1 1
Yes (n = 109) 1.08 (0.69, 1.70) 0.74 1.72 (1.06,2.79) 0.03
Anti-dsDNA level <50 IU/ml (n = 177) 1 1
≥50 IU/ml (n = 170) 0.76 (0.26, 1.13) 0.17 1.32 (0.66,2.65) 0.43
C3 level <0.9 g/l (n = 139) 1 1
≥0.9 g/l (n = 208) 0.83 (0.57, 1.20) 0.32 1.26 (0.86,1.87) 0.24
Disease activity in general system§ A, B (n = 31) 1 1
C, D, E (n = 344) 0.96 (0.60, 1.54) 0.87 1.19 (0.71,2.00) 0.52
Disease activity in mucocutaneous system A, B (n = 41) 1 1
C, D, E (n = 334) 0.99 (0.63, 1.56) 0.95 1.32 (0.76,2.29) 0.33
Disease activity in neuropsychiatric system A, B (n = 18) 1 1
C, D, E (n = 357) 0.56 (0.13, 2.38) 0.44 1.04 (0.50,2.19) 0.91
Disease activity in musculoskeletal system A, B (n = 47) 1 1
C, D, E (n = 328) 1.20 (0.47, 3.04) 0.71 0.68 (0.43,1.05) 0.08
Disease activity in cardiorespiratory system A, B (n = 13) 1 1
C, D, E (n = 362) 0.43 (0.24, 0.78) 0.006 1.40 (0.22,8.70) 0.72
Disease activity in vascular system A, B (n = 12) 1 1
C, D, E (n = 363) 0.33 (0.17, 0.63) 0.001 0.39 (0.19,0.82) 0.01
Disease activity in renal system A, B (n = 41) 1 1
C, D, E (n = 329) 1.09 (0.40, 2.97) 0.86 4.28 (2.13,8.58) <0.001
Disease activity in hematological system A, B (n = 95) 1 1
C, D, E (n = 280) 1.21 (0.84, 1.74) 0.30 1.44 (0.95,2.17) 0.08
Overall disease activity over last four assessments Persistently low (n = 166) 1 1
Persistently mod/high (n = 209) 0.91 (0.66, 1.25) 0.57 0.66 (0.47,0.92) 0.01
Hydroxychloroquine No (n = 223) 1 1
Yes (n = 174) 3.52 (2.40, 5.17) <0.001 3.21 (2.08,4.95) <0.001
Immunosuppression No (n = 200) 1 1
Yes (n = 197) 1.66 (1.17, 2.34) 0.004 1.33 (0.89,1.98) 0.16
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Table 2 Univariable analysis of factors associated with serum NN and NA levels in patients with SLE (Continued)
Oral corticosteroids ≤7.5 mg/day (n = 101) 1 1
>7.5 mg/day (n = 296) 0.81 (0.59, 1.13) 0.22 1.00 (0.69,1.44) 0.99
Albumin Ratio given per 5 g/l increase 1.38 (1.20,1.59) <0.001 1.42 (1.22,1.65) <0.001
*For gender, n values refer to the numbers of samples taken from female and male subjects, rather than the numbers of females and males in the cohort of
patients. A similar stipulation applies to ethnicity where n values refer to the number of samples taken from patients of each ethnic group.
†For the complex associations with disease duration and age, we carried out analysis of both linear and squared terms. The figures in the table refer to linear
terms. The ratios for squared terms for NN are 0.66 (95% CI: 0.51, 0.85) for disease duration and 1.56 (95% CI: 1.20, 2.03) for age. The ratios for squared terms for
NA are 0.59 (95% CI: 0.46, 0.75) for disease duration and 1.72 (95% CI: 1.32, 2.24) for age.
**For ENA, anti-Ro, anti-La and anti-Sm we did not have results from the date of every sample but it is assumed that positivity and negativity for these antigens
generally remain stable.
§“Disease activity in general system” refers to the BILAG score (A, B, C, D or E) in the General Category of the BILAG index on the day when each sample was
taken. The same principle applies to the remaining organ systems listed in the table, which are the eight different categories recorded in BILAG. Bold type
indicates statistically significant P-values (P <0.05).
Table 4 Multivariable analysis of factors associated with
serum NA levels in patients with SLE
Variable Category/term Ratio
(95% CI)
P-value
Disease duration Ratio given per
five-year increase
2.24 (1.55, 3.26) <0.001
Age (at diagnosis) * Age 0.01 (0.00, 0.04) <0.001
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lower disease activity and anti-dsDNA antibody levels and
less use of immunosuppressants than the other two-thirds.
NN-negative patients are all anti-Sm antibody negative.
Currently, available serum biomarkers for monitoring
patients with SLE are antibodies (particularly anti-dsDNA)
or markers of immune activation, such as depleted com-
plement levels. Potential new serum biomarkers include
pro-inflammatory chemokines [16]. The ELISA described
in our current paper is novel in that, rather than an anti-
body or cytokine, it measures levels of an antigen, which
has been chemically modified in vivo. The critical import-
ance of nucleosomes in the pathogenesis of lupus nephritis
has been established by a number of authors. Berden and
colleagues showed that nucleosome/anti-nucleosome com-
plexes can cause nephritis in murine models of SLE [9,17].
The elegant electron microscopy studies of Rekvig’s
group demonstrated that deposited IgG co-localizes
with electron-dense chromatin structures in renal biop-
sies from human and murine lupus nephritis [18,19].
More recently, Kanapathipillai et al. showed a direct
stimulatory effect of nucleosomes alone (not requiring
complexed antibodies) on expression of chemokines byTable 3 Multivariable analysis of factors associated with
serum NN levels in patients with SLE
Variable Category/term Ratio (95% CI) P-value
Age (at diagnosis) * Age 0.02 (0.003, 0.11) <0.001
Age 2.12 (1.64, 2.76)
Anti-Sm No 1
Yes 6.31 (3.39, 11.7) <0.001
Disease activity
in vascular system
A, B 1
C, D, E 0.40 (0.24, 0.69) 0.001
Hydroxychloroquine No 1
Yes 1.96 (1.09, 3.53) 0.02
Immunosuppression No 1
Yes 2.96 (1.97, 4.46) <0.001
*Ratio given for 10-year increase. NN, nitrated nucleosomes; SLE, systemic
lupus erythematosus.mesangial cells from NZB/W F1 mice [20]. There is also
evidence that chemical modification of nucleosomes, spe-
cifically hyperacetylation, can alter their biological effects
in SLE. Dieker et al. demonstrated that samples from 26
of 35 patients with SLE bound more strongly to a triacety-
lated 22-amino acid peptide from histone H4 than to the
non-acetylated version of the same peptide [21]. Subcutane-
ous administration of the triacetylated, but not the non-
acetylated, peptide accelerated development of proteinuria
and increased mortality in MRL/lpr mice [21] and this effect
was not mediated via an increase in anti-nucleosome anti-
body levels. In the same paper, this group showed that
hyperacetylated nucleosomes stimulated expression of co-
stimulatory molecules and pro-inflammatory cytokines by
dendritic cells (DC) from MRL/lpr mice [21]. However, theyAge2 2.58 (1.86, 3.56)
Ethnicity Caucasian 1
Afro-Caribbean 2.99 (1.35,6.65)
Other 14.9 (5.82, 38.0) <0.001
Anti-La No 1
Yes 0.16 (0.06, 0.49) <0.001
Anti-Sm No 1
Yes 28.2 (14.4, 55.3) <0.001
Disease activity
in renal system
A, B 1
C, D, E 3.78 (2.07,6.90) <0.001
Immunosuppression No 1
Yes 1.45 (1.02, 2.05) 0.04
Albumin Ratio per 5 g/l increase 1.12 (1.01,1.24) 0.03
*Ratio given for a 10-year increase. NA, nitrated albumin; SLE, systemic
lupus erythematosus.
Table 5 Multivariable analysis of factors associated with serum anti-nuc levels in patients with SLE
Variable Category/term Ratio (95% CI) P-value
Gender Female 1
Male 2.83 (1.72, 4.69) <0.001
Disease duration Ratio given per 5-year increase 0.87 (0.78, 0.98) 0.02
Age (at diagnosis) Ratio given per 10-year increase 0.59 (0.49, 0.72) <0.001
RNP No 1
Yes 0.47 (0.32, 0.70) <0.001
dsDNA Ratio given per 10-fold increase (1 unit on log scale) 1.79 (1.40, 2.28) <0.001
C3 Ratio given per 0.1 g/l increase 0.29 (0.15, 0.56) <0.001
NN level Ratio given per 10-fold increase (1 unit on log scale) 0.88 (0.72,1.07) 0.20
Anti-nuc, Anti-nucleosome antibody; dsDNA, double stranded DNA; RNP, ribonucleoprotein; SLE, systemic lupus erythematosus.
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the serum of humans or mice. Our current paper is the first
to look specifically at nitration of nucleosomes and the first
to measure serum levels of modified nucleosomes in pa-
tients with SLE. We found that elevated NN level is itself a
specific marker for SLE and is also strongly associated with
another SLE-specific biomarker in anti-Sm. Though these
are promising findings, limitations of our work include the
absence of strong association with overall disease activity
and expression of results in terms of binding of our in-
house control serum sample. If NN is to be a useful bio-
marker in patients with SLE, a more generally applicable
standard must be found. In a recently published paper,
Pratesi et al. [22] showed that sera from patients with
rheumatoid arthritis, but not from healthy controls or
patients with other autoimmune rheumatic diseases, con-
tained antibodies to deiminated histone H4. They postu-
lated that the deiminated H4 autoantigens could derive
from neutrophil extracellular traps in these patients. A
modification of our NN assay, using anti-citrulline rather
than anti-nitrotyrosine as the capture antibody, could po-
tentially be used to detect deiminated histones in the
serum of patients with rheumatoid arthritis.
There was a strong association between anti-Sm positiv-
ity and nitration in the multivariable analysis of factors as-
sociated with NN and NA levels. To our knowledge this
association between nitrative stress and anti-Sm positivity
has not been described before. The Sm antigen is a com-
plex of ribonucleoproteins in the spliceosome [23]. Anti-
Sm antibodies were first recognized in 1966 [24], and are
highly specific to patients with SLE. Anti-Sm antibodies
have been found in lupus nephritis renal biopsies [25].
Some retrospective studies reported associations between
anti-Sm positivity and psychosis [26] or nephritis [27],
while others found no association between anti-Sm anti-
bodies and any clinical outcome [28]. A large Chinese
study compared 469 anti-Sm antibody positive and 1,115
anti-Sm antibody negative patients with SLE [29]. The
anti-Sm positive patients had higher disease activity,higher anti-dsDNA antibody and lower C3 levels than
anti-Sm negative patients. Vasculitis occurred more often
in anti-Sm positive than in anti-Sm negative patients
(13.7% vs 7.4%, P <0.05). Our current results show strong
associations among NN levels, anti-Sm and vasculitis.
Increased nitration may promote development of anti-
Sm antibodies. Experiments on mice transgenic for the
rearranged heavy chain variable region genes of a mono-
clonal anti-Sm antibody [30] showed that immature DC
carrying surface Sm antigen interacted directly with B cells
leading to the production of anti-Sm antibody. These DC
obtained Sm antigen partly from apoptotic cell debris,
which also contains nucleosomes complexed to the High
Mobility Group Box 1 (HMGB1) protein [31]. HMGB1
can activate DC [32] and also promotes NO production by
phagocytes. Thus nucleosome/HMGB1 complexes could
stimulate the DC-B cell interaction that leads to anti-Sm
antibody production as well as driving NO production. It
is not known whether nitration of HMGB1 itself alters its
pro-inflammatory properties. However, a recent study [33]
has shown that altering the redox state of HMGB1 through
the oxidation of free thiol cysteines to form disulfide bonds
makes it more pro-inflammatory. If nitration of nucleo-
some/HMGB1 complexes likewise promotes their pro-
inflammatory properties this would create a potential
positive feedback loop, and this is a mechanism that
warrants further exploration. It may also be interesting
to look at nitration of the Sm antigen.
NA and NN levels were associated with use of immuno-
suppressants. This association is unlikely to arise simply
from the fact that immunosuppressants are used more
commonly in highly active disease, because persistent clin-
ical disease activity, anti-dsDNA antibody and C3 levels
were not associated with either NA or NN levels. In future
studies it may also be interesting to look at correlations
with erythrocyte sedimentation rate and/or C-reactive
protein but we do not have data on those variables for this
study. We collected data on anti-dsDNA and C3 because
those biomarkers are more closely associated with flares in
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we know of no evidence supporting this. Cyclosporin can
promote tyrosine nitration in endothelial cells [34], but
only two samples in this study were from patients taking
cyclosporin and both were negative for NN.
A large inception cohort study has shown that 40% of
1,206 patients with SLE suffered from neuropsychiatric
symptoms, which were associated with reduced quality of
life but that in the majority of cases these were not due to
active inflammation and did not require immunosuppres-
sion [35]. It is important, however, to identify the subpopu-
lation of patients in whom these symptoms are due to
active cerebral SLE. With appropriate treatment, the symp-
toms are significantly more likely to resolve in those
patients compared to patients in whom the symptoms are
not due to active SLE [35]. Current imaging techniques
and blood tests do not accurately distinguish patients
with active neuropsychiatric SLE from those who have
neuropsychiatric symptoms not caused by SLE. Our re-
sults suggesting that elevated NN levels could poten-
tially be a marker for neuropsychiatric flares are based
on results from 11 different patients taken over a 12-
year period. Over 70% of the neuropsychiatric manifes-
tations in these patients were headaches and seizures. It
is important to extend these results by testing larger
numbers of samples from patients with a wider range of
neuropsychiatric manifestations.
Vasculitis is a relatively uncommon manifestation of
SLE [29]. In multivariable analysis we found a statisti-
cally significant association of high NN (but not NA)
with vasculitis based on results from nine different
patients over an 11-year period. Review of the medical
records showed that all these patients had cutaneous
vasculitis at the time of their flares. It is possible that
raised NN levels in patients without visible vasculitis
may be a marker of subclinical vascular activation. It
will, therefore, be interesting to see whether NN levels
are associated with objective measures of atherosclerosis,
such as carotid ultrasound [2]. This potential association
is underlined by the fact that peroxynitrite, a powerful
nitrating and oxidizing agent, is generated in athero-
sclerotic plaques. If such an association exists, then NN
levels may be relevant to assessment of CVD risk in pa-
tients with SLE.
Conclusion
By developing a novel assay to measure serum NN levels
we have demonstrated that these levels are raised in pa-
tients with SLE compared to healthy controls and patients
with other autoimmune rheumatic diseases. NN-positivity
is strongly linked to anti-Sm antibody positivity and may
be a marker for neuropsychiatric flares and vasculitis in
patients with SLE. Further studies in larger numbers of pa-
tients with these manifestations are required.Abbreviations
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with systemic lupus erythematosus are associated
with disease activity and corticosteroid therapy:
an observational study
Sara Croca1, Paul Bassett2, Sharon Chambers1, Maria Davari1, Karim Fouad Alber1, Oliver Leach1, Yiannis Ioannou1,3,
Ian Giles1, David Isenberg1,3 and Anisur Rahman1*Abstract
Introduction: IgG anti-apolipoprotein A-1 (IgG anti-apoA-1) antibodies are present in patients with systemic lupus
erythematosus (SLE) and may link inflammatory disease activity and the increased risk of developing atherosclerosis
and cardiovascular disease (CVD) in these patients. We carried out a rigorous analysis of the associations between
IgG anti-apoA-1 levels and disease activity, drug therapy, serology, damage, mortality and CVD events in a large
British SLE cohort.
Methods: Serum IgG anti-apoA-1 levels were measured in 100 healthy controls to define a cut-off for positivity. In
499 patients with SLE we obtained the earliest stored serum sample from their disease course and measured IgG
anti-apoA-1 level. We then examined associations between IgG anti-apoA-1 positivity in early disease and the
development of damage, CVD or death over a mean follow-up period of 12.1 years in these patients. In a separate
study, we measured IgG anti-apoA-1 levels in 397 samples taken longitudinally from 49 patients with SLE over a
mean period of 89 months of fluctuating disease activity and carried out multi-variable analysis to examine the
demographic, serological, disease activity and treatment factors associated with IgG anti-apoA-1 level over time.
Results: In the longitudinal study, IgG anti-apoA-1 levels were significantly higher in patients with persistently
active disease, those on high dose corticosteroid and those not taking hydroxychloroquine. Of the 499 subjects
who had early disease IgG anti-apoA-1 levels measured, 135 (27%) were positive. However, we found no convincing
associations between early IgG anti-apoA-1 positivity and development of damage, mortality or CVD.
Conclusions: IgG anti-apoA-1 developed early in a quarter of our patients with SLE, but this had no major impact on
subsequent clinical outcomes. However, levels of IgG anti-apoA-1 vary over time and are associated with disease
activity, treatment with high dose corticosteroid and not taking hydroxychloroquine.Introduction
Antibodies to apolipoprotein A-1 (anti-apoA-1) have
been reported in the serum of patients with systemic
lupus erythematosus (SLE) [1-4]. Several groups found
independently that levels were elevated in patients with
active SLE compared with inactive SLE [1-4], although
none carried out multivariable analysis to exclude the* Correspondence: anisur.rahman@ucl.ac.uk
1Centre for Rheumatology Research, University College London, 5 University
Street, London WC1E 6JF, UK
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unless otherwise stated.effect of confounding factors. Apolipoprotein A-1 is the
main constituent of high-density lipoprotein, which plays a
major role in preventing atherosclerosis [5,6]. It has been
suggested that anti-apoA-1 could interfere with this pro-
tective effect and thus promote atherosclerosis [2,4]. IgG
anti-apoA-1 have also been associated with markers of in-
creased plaque vulnerability such as intra-plaque macro-
phage, neutrophil and matrix metalloproteinase content
[7] and are associated with increased levels of the surrogate
plaque vulnerability markers interleukin-6, tumour necro-
sis factor alpha and matrix metalloproteinase-9 in patientshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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levels are found in patients with acute coronary syndromes
[9], are a risk factor for major cardiovascular events in the
12 months after myocardial infarction [10] and are associ-
ated with significantly increased risk of major cardiovascu-
lar events in patients with rheumatoid arthritis (RA) [11].
Anti-apoA-1 antibodies have thus attracted particular
interest as a possible mediator between inflammation and
the recognised increased risk of developing cardiovascular
disease (CVD) in patients with SLE.
In a large multinational study of 9,547 patients with SLE
there were 1,255 deaths, of which 313 were due to CVD
[12]. Patients with SLE have fivefold to 10-fold greater risk
of developing CVD than age-matched controls [13], rising
to 50-fold in women between the ages of 35 and 44 [14].
Subclinical vascular disease is more common in patients
with SLE than in age-matched and sex-matched controls
[15,16]. Patients with SLE who suffer CVD events do so at
a relatively young age – a mean of 49 years for women
[13]. Standard methods based on the Framingham equa-
tions underestimate CVD risk in patients with SLE
[17,18]. Alternative stratification tools to identify athero-
sclerosis – for example, vascular ultrasound – may be use-
ful [19,20]. If IgG anti-apoA-1 have a true predictive value
for CVD this could also be helpful. Previously, we did not
find high IgG anti-apoA-1 levels in 24 patients with SLE
who suffered CVD events [2]. Radwan and colleagues
found no relationship between IgG anti-apoA-1 and ca-
rotid intima-media thickness in 80 Egyptian patients with
SLE but, unlike most other SLE groups studied, none of
their patients had carotid plaques [4].
Previous studies of IgG anti-apoA-1in patients with
SLE were limited by having small numbers of patients,
lack of multivariable analysis and short-term follow-up
after the samples were taken. Here, we address these is-
sues to answer the following questions: which demo-
graphic, serological, clinical and treatment factors are
significantly associated with changing IgG anti-apoA-1
levels over time in patients with SLE? What is the preva-
lence of positivity for IgG anti-apoA-1 early in the dis-
ease course of SLE? Does positivity for IgG anti-apoA-1
early in the disease course predict subsequent damage,
cardiovascular disease and/or mortality?
Methods
Ethical approval for all parts of the study was granted by
the joint University College London/University College
London Hospitals Research Ethics Committee (Reference
06/Q0505/79) and subjects gave informed consent for use
of their stored serum samples.
Healthy control subjects
We tested samples from 100 healthy control subjects ori-
ginally obtained as part of the Health Survey for England2006 [21]. The samples were provided to us by the Health
and Social Care Information Centre together with
anonymised data on age, and the gender and ethnicity
of the subjects and absence of long-term illness or pre-
vious CVD were confirmed. Their median age was
43 years (range 20 to 69), 49% were female and the eth-
nic distribution was 83% Caucasian, 8% Afro-Caribbean
and 9% South Asian.Patients with systemic lupus erythematosus
The University College London Hospitals SLE clinic has
been running since 1979 and we have followed over 600
patients with SLE since then, all fulfilling the revised
American College of Rheumatology classification criteria
[22]. From this population of patients we selected two
different groups who were studied to answer different
questions.Early disease group
For 499 patients we were able to obtain serum samples
taken within 1 year of diagnosis and stored at −80°C.
The earliest of these samples was obtained in 1978 and
the most recent in 2011. We tested all of these samples
for IgG anti-apoA-1 antibodies – using the enzyme-
linked immunosorbent assay (ELISA) described below –
to find out what proportion of patients with SLE have
IgG anti-apoA-1 early in the disease course. These 499
patients with SLE had been under continuous follow-up
for between 1 and 34 years (mean 12.1 years). We inves-
tigated whether positivity for IgG anti-apoA-1 within the
first year of the disease was associated with the following
outcomes: death from any cause; death before the age of
60; CVD – defined as either myocardial infarction with
typical enzyme and/or ECG changes, ischaemic stroke
confirmed by imaging or non-infarct coronary disease
confirmed by angiography; and damage as measured by
the Systemic Lupus International Collaborative Clinics
Damage Index (SLICC-DI) [23].
Data on death and CVD were available for all 499 pa-
tients from review of their clinical records. Data on
SLICC-DI scores were only available for 236 patients.
These patients had been studied between 2006 and 2008
in a project designed specifically to collect comprehen-
sive data on damage scores from patients who had been
followed in the clinic for at least 10 years by then (that
is, had been diagnosed between 1979 and 1996) [24].
Only 236 such patients were available and thus only
SLICC-DI data from those patients are included in the
current report.
For the early disease samples we did not have data on
other autoantibodies, or on the disease activity or dam-
age scores at the time of the sample.
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Longitudinal serum samples (n = 397) were selected retro-
spectively from a group of 49 patients with SLE with a
mean of eight samples per patient (standard deviation
(SD) 2.16; minimum 3; maximum 14) that had been ob-
tained during a mean period of 89 months (SD 46; mini-
mum 14; maximum 180) in the course of their disease.
The patients were selected on the basis that they had vary-
ing levels of disease activity over time, including examples
of flares in all of the main organs and systems of the body.
By coincidence, 47 patients in this group were also mem-
bers of the early disease group, but the longitudinal serum
samples used in this part of the project were different
from the early disease samples used in the other part of
the project.
For all samples where data were available (94%), we ob-
tained anti-dsDNA and complement C3 levels and disease
activity from the date of the sample and from the previous
three assessments. Anti-dsDNA and C3 were measured in
the routine clinical laboratory at University College London
Hospitals using the ELISA (Shield Diagnostics, Dundee,
UK) and laser nephelometry respectively. Based on the nor-
mal limits for our laboratory, anti-dsDNA level >50 IU/ml
was defined as high and C3 level <0.9 g/l as low.
Disease activity was measured using the classic British
Isles Lupus Assessment Group (BILAG) index [25]. The
more recent BILAG 2004 index was not used because
many of the samples had been taken before 2004. Dis-
ease activity over the most recent four assessments was
characterised as persistently low activity (all systems
BILAG C, D or E) or persistently moderate–high activity
(A or ≥1 B in any BILAG system on at least 2/4 occa-
sions). Over 90% of all samples fell into one of those two
categories and the rest were excluded from this part of
the analysis. Global BILAG score was calculated using
the formula A = 12, B = 5, C = 1, D = E = 0 as described
previously [26].
Data on ethnicity, gender, drug therapy and the anti-
Sm, anti-RNP, anti-Ro and anti-La (all tested by ELISA)
status of the patients were obtained from the clinical re-
cords of the patients. We did not have data on SLICC-
DI score at the time of each sample.
Direct ELISA to detect IgG anti-ApoA-1 antibodies
IgG anti-ApoA-1 antibodies were detected by a modifi-
cation of the direct ELISA protocol described previously
[2,27]. All steps were carried out at 37°C except where
specified. A Nunc-Maxisorb 96-well ELISA (Fisher Scientific,
Loughborough, UK) plate was divided in half. One side (the
test side) was coated with 10 μg/ml apolipoprotein A-1
(A0722; Sigma St Louis, Missouri, USA) in 70% ethanol. The
other side (the control side) was coated with 70% ethanol.
After incubation for 90 minutes, the plates were washed
and blocked with 1% bovine serum albumin diluted inphosphate-buffered saline for 1 hour. Serum samples at 1:50
dilution in 1% bovine serum albumin–phosphate-buffered
saline were tested in duplicate such that each sample was
added to two test wells and two control wells. On each
plate, a seven-point dilution of the positive control (a
pool of six serum samples from patients known to have
high serum IgG anti-apoA-1) was performed starting at
1:25 dilution. Following incubation for 1 hour, goat anti-
human IgG–alkaline phosphatase conjugate (A3150;
Sigma) diluted 1:1,000 in 1% bovine serum albumin–phos-
phate-buffered saline was added at room temperature for
1 hour followed by alkaline phosphatase substrate. Ab-
sorbance at 405 nm was recorded after 60 minutes. The
net optical density (OD) reading for each sample was cal-
culated by subtracting the OD in the control well from
that in the matching test well to exclude nonspecific back-
ground binding. The mean net OD from the duplicate
samples was converted to absorbance units (AU) by com-
parison with the standard curve of OD for the serial dilu-
tions of the positive control sample on each plate. A value
of 100 AU was defined as the OD given by a 1:50 dilution
of the positive control sample. This assay was reproducible
with intraplate and interplate coefficients of variation <10%.
Statistical analysis
In the longitudinal group, assessment of anti-ApoA-1
levels showed a highly positive skewed distribution, which
could not be transformed to a normally distributed scale.
The outcomes were thus assumed to follow a negative bi-
nomial distribution. Owing to the longitudinal nature of
this group, multiple samples for each patient were consid-
ered. To allow for the non-independence of the data,
multilevel statistical methods were used for analysis. Two-
level models were used with individual measurements
clustered within patients. The analyses, performed using
multilevel negative binomial regression, were performed
in two stages. Firstly the separate effect of each factor
upon the outcome was examined in a series of univariable
analyses. Subsequently the joint effect of factors was ex-
amined in a multivariable analysis. A backward selection
procedure was employed to retain only the statistically sig-
nificant variables. Variance inflation factors were used to
assess collinearity between variables, and as a result some
variables that were collinear with other variables were ex-
cluded from the multivariable stage of the analysis.
In the early disease group, associations between anti-
ApoA-1 levels and clinical outcomes were analysed using
the statistical analysis software Prism. Univariable analysis
was performed using the Mann–Whitney U test, as the
sample did not follow a normal distribution. Statistical sig-
nificance was considered when P <0.05. Survival curves
for cardiovascular disease events and mortality were pro-
duced using the Kaplan–Meier method. For the analysis
of mortality, patients who were not known to have died
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of the study period or at the time of loss to follow-up if
that applied (for example, patients who moved away from
London). For the analysis of CVD events, patients who
had no such events were censored at the time of death,
loss to follow-up or the end of the study period. The sur-
vival curves were compared using the log-rank test.Results
Longitudinal group: elevated IgG anti-apoA-1 level was
associated with high disease activity, high-dose steroids
and not being treated with hydroxychloroquine
The mean age of the 49 patients in the longitudinal group
was 36 years (SD 13.0) and 81% were female. Twenty-
three patients were Caucasian, 18 were Afro-Caribbean
and eight were other ethnicities. Twenty-one patients
were anti-Ro-positive, six were anti-La-positive, 15 were
anti-RNP-positive and 11 were anti-Sm-positive. During
the follow-up period, 29 patients had at least one elevated
anti-dsDNA level, 32 had at least one low C3 level and 46
suffered at least one flare (BILAG A or B in at least one
system). Flares in all eight systems of the classic BILAG
index were represented in the cohort.
Figure 1 shows that the IgG anti-apoA-1 level was
higher in the 397 samples from patients with SLE (median
48.5, interquartile range (IQR) 16.0 to 87.5) than in the
100 healthy controls (median 8.0, IQR 5.9 to 10.7) (P =
0.0001). A positivity cutoff value was defined as the 97.5th
percentile of 100 healthy controls (46.7 AU). Fifty per cent
of the samples from patients with SLE were found to be
IgG anti-ApoA-1-positive.
Table 1 presents the results of univariable analysis to as-
sess association of 24 clinical, demographic and serological
variables with serum IgG anti-apoA-1 level.Figure 1 Comparison of IgG anti-apoA-1 levels in serum
samples from patients with SLE and healthy controls. anti-apoA-
1, antibodies to apolipoprotein A-1; AU, absorbance units; HC,
healthy controls; IgG, immunoglobulin G; SLE, systemic
lupus erythematosus.IgG anti-apoA-1 levels were significantly lower in pa-
tients with positive anti-La and anti-Sm but there was
no relationship with C3 or anti-dsDNA.
Patients with persistent moderate/high disease activity
had 30% higher IgG anti-apoA-1 levels than those with
persistently low activity. Those with haematological
BILAG scores of A or B on the day of the sample had
higher IgG anti-apoA-1 levels than those with scores of C,
D or E (P <0.001). A similar trend was observed for pa-
tients with renal or cardiorespiratory A or B scores al-
though statistical significance was not reached (P = 0.06
for both).
Patients treated with hydroxychloroquine had IgG anti-
apoA-1 levels 30% lower than those who were not taking
hydroxychloroquine, whereas those on higher dose pred-
nisolone (>7.5 mg/day) had levels 39% higher than those
taking lower doses.
Table 2 presents the results of multivariable analysis. No
collinearity was observed between variables. Only negativ-
ity for anti-La and anti-Sm, haematological disease activity
and taking higher dose prednisolone remained as inde-
pendently associated variables.
As shown in Figure 2, IgG anti-apoA-1 levels varied
over time and paralleled disease activity (measured by
global BILAG score) closely in many (Figure 2A,B,C,D,E,
F), but not all patients (Figure 2G,H).
IgG anti-apoA-1 positivity was seen in 27% of early disease
samples and was not associated with mortality or CVD
The mean age of the 499 subjects at the time when the
early disease sample was taken was 30 years (SD 12.27,
range 1 to 77) and 91.5% were female. Ethnic distribution
was Caucasian 61%, African/Caribbean 20.5%, South
Asian 11.4%, East Asian 4.6%, and other 2.5%.
Median IgG anti-apoA-1 levels were significantly higher
in patients with SLE (median 21.4 AU, IQR 11.2 to 52.9)
than in healthy controls (median 8.0 AU, IQR 5.9 to 10.7)
(P <0.05) and 27% of patients tested positive in the first
sample obtained after diagnosis of SLE. There was no
correlation between the order of acquisition of samples
and IgG anti-apoA-1 level (Spearman correlation coeffi-
cient −0.115), suggesting that storage time does not
affect IgG anti-apoA-1 level.
As seen in the longitudinal group, there were no sig-
nificant associations between IgG anti-apoA-1 level and
age, gender or ethnicity.
During follow-up, 40 patients (8.0%) suffered a CVD
event; that is, coronary heart disease confirmed by en-
zyme or electrocardiography changes of myocardial in-
farction or by angiography for nonmyocardial infarction
CAD or ischaemic stroke confirmed by imaging. The
prevalence of CVD events did not differ between anti-
apoA-1-positive and anti-apoA-1-negative patients (6.7%
vs. 8.5%, P >0.05). A Kaplan–Meier survival curve showing
Table 1 Univariable analysis of factors associated with serum IgG anti-apoA-1 levels in the longitudinal group
Variable Category Ratio (95% CI) P value
Gendera Female (n = 336) 1
Male (n = 61) 1.20 (0.85, 1.69) 0.30
Disease duration Ratio given per 5-year increase 1.00 (0.90, 1.11) 0.99
Age (at diagnosis) Ratio given per 10-year increase 1.02 (0.88, 1.18) 0.81
Ethnicitya Caucasian (n = 182) 1
Afro-Caribbean (n = 146) 1.19 (0.90, 1.57)
Other (n = 69) 1.07 (0.75, 1.53) 0.46
Any ENAb No (n = 165) 1
Yes (n = 232) 0.82 (0.63, 1.06) 0.13
Anti-Rob No (n = 226) 1
Yes (n-171) 0.90 (0.69, 1.17) 0.41
Anti-Lab No (n = 345) 1
Yes (n = 52) 0.54 (0.36, 0.80) 0.002
Anti-Smb No (n = 298) 1
Yes (n = 99) 0.64 (0.47, 0.87) 0.004
Anti-RNPb No (n = 288) 1
Yes (n = 109) 1.11 (0.84, 1.47) 0.46
Anti-dsDNA level <50 IU/ml (n = 177) 1
≥50 IU/ml (n = 170) 1.13 (0.90, 1.43) 0.29
C3 level <0.9 g/l (n = 139) 1
≥0.9 g/l (n = 208) 0.82 (0.66, 1.03) 0.09
Disease activity in general systemc A, B (n = 31) 1
C, D, E (n = 344) 0.84 (0.60, 1.18) 0.32
Disease activity in mucocutaneous systemc A, B (n = 41) 1
C, D, E (n = 334) 0.89 (0.65, 1.22) 0.48
Disease activity in neuropsychiatric systemc A, B (n = 18) 1
C, D, E (n = 357) 0.93 (0.57, 1.52) 0.77
Disease activity in musculoskeletal system c A, B (n = 47) 1
C, D, E (n = 328) 0.80 (0.60, 1.08) 0.14
Disease activity in cardiorespiratory systemc A, B (n = 13) 1
C, D, E (n = 362) 0.66 (0.42, 1.02) 0.06
Disease activity in vascular systemc A, B (n = 12) 1
C, D, E (n = 363) 0.80 (0.47, 1.34) 0.40
Disease activity in renal systemc A, B (n = 41) 1
C, D, E (n = 329) 0.75 (0.55, 1.01) 0.06
Disease activity in haematological systemc A, B (n = 95) 1
C, D, E (n = 280) 0.63 (0.50, 0.79) <0.001
Overall disease activity over last four assessments Persistently low (n = 166) 1
Persistently moderate/high (n = 209) 1.30 (1.06, 1.59) 0.01
Hydroxychloroquined No (n = 223) 1
Yes (n = 174) 0.70 (0.55, 0.88) 0.003
Immunosuppressiond No (n = 200) 1
Yes (n = 197) 0.90 (0.73, 1.12) 0.35
Oral prednisoloned ≤7.5 mg/day (n = 101) 1
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(Continued)
>7.5 mg/day (n = 296) 1.39 (1.13, 1.71) 0.002
Bold data indicate values of P <0.05. anti-apoA-1, antibodies to apolipoprotein A-1; BILAG, British Isles Lupus Assessment Group; CI, confidence interval; IgG, immunoglobulin
G. ENA; antibodies to extractable nuclear antigens. aFor gender, n values refer to the numbers of samples taken from female and male subjects, rather than numbers of
females and males in the cohort of patients. A similar stipulation applies to ethnicity, where n values refer to the number of samples taken from patients of each ethnic
group. bFor ENA, anti-Ro, anti-La and anti-Sm, we did not have results from the date of every sample but it is assumed that positivity and negativity for these antigens
generally remain stable. c ‘Disease activity in general system’ refers to the BILAG score (A, B, C, D or E) in the General Category of the BILAG index on the day when each
sample was taken. The same principle applies to all of the other organ systems listed in the table, which are the eight different categories recorded in the BILAG. dRefers
to drugs being taken on the date of the sample.
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anti-apoA-1-negative groups free of CVD at all time points
up to 34 years of follow-up showed no significant differ-
ence between groups (Figure 3; P = 0.89 by log-rank test).
Similarly, positivity for IgG anti-apoA-1 did not pre-
dict onset of damage during follow-up. Table 3 presents
damage scores at 5, 10, 15 and 20 years after stratifica-
tion into quartiles based on the early disease sample IgG
anti-apoA-1 level with no significant differences in dam-
age score between the quartiles at any time point.
During follow-up, 63.0% and 24.0% of patients were at
some time positive for anti-dsDNA and anti-cardiolipin anti-
bodies respectively. One-quarter of the patients were found
to be rheumatoid factor-positive and over one-half were
positive for antibodies to extractable nuclear antigens (14.9%
anti-Sm, 27.8% anti-RNP, 37.5% anti-Ro and 13.9% anti-La).
Patients who developed anti-dsDNA positivity had
higher IgG anti-apoA-1 in their early disease samples than
those who did not (median 22.5 AU vs. 17.1 AU, P =
0.0012) and a similar relationship was found for those
who developed anti-cardiolipin antibodies (IgG anti-
apoA-1 25.5 AU vs. 21.0 AU, P = 0.025). There were no re-
lationships with other autoantibodies.
Regarding mortality, 13% of patients died (n = 66), 48
of them before the age of 60. A Kaplan–Meier survival
curve showing the percentage survival of subjects in the
anti-apoA-1-positive and anti-apoA-1-negative groups at
all time points up to 34 years of follow-up showed no
significant difference between groups (Figure 4; P = 0.22
by log-rank test).
There was no indication that deaths in patients youn-
ger than 60 or in patients with raised IgG anti-apoA-1Table 2 Multivariable analysis of factors associated with IgG
Variable Category
Anti-La No
Yes
Anti-Sm No
Yes
Activity in the haematological system A, B
C, D, E
Steroids ≤7.5 mg/day
>7.5 mg/day
anti-apoA-1, antibodies to apolipoprotein A-1; CI, confidence interval; IgG, immunogwere due disproportionately to CVD. In the over 60s,
the causes of death were 17% CVD, 44% cancer, 17% in-
fection, 6% renal and 17% other. In the under 60s, the
causes were 13% CVD, 17% cancer, 31% infection, 8%
renal and 31% other. Of the six patients who died from
CVD under the age of 60, only one had positive IgG
anti-apoA-1 at the time of diagnosis.
Discussion
Previous studies confirmed the presence of IgG anti-
apoA-1 antibodies in patients with SLE, indicated an as-
sociation with higher disease activity and suggested a
possible link with the development of CVD [1-4]. In this
paper we have confirmed the association with disease ac-
tivity by carrying out multivariable analysis of factors af-
fecting IgG anti-apoA-1 levels in longitudinal samples
from a group of 49 patients whose disease activity varied
over time. We investigated the prevalence of elevated
IgG anti-apoA-1 in early disease and its predictive value
for CVD and mortality by studying 499 patients followed
for a mean of 12.1 years after the date of the sample.
We showed that 27% of 499 patients were positive for
IgG anti-apoA-1 very early in the disease course. Arbuckle
and colleagues showed that many autoantibodies are
present in patients with SLE even in stored samples taken
before diagnosis of SLE [28]. However, anti-apoA-1 levels
in early disease samples have not been studied before.
We found no association between IgG anti-apoA-1 posi-
tivity early in disease and increased risk of dying as survival
curve analysis showed no difference between the anti-
apoA-1-positive and anti-apoA-1-negative groups. Devel-
opment of damage (due to disease activity or therapy) is aanti-apoA-1 level in the longitudinal cohort
Ratio (95% CI) P value
1
0.58 (0.39, 0.86) 0.006
1
0.58 (0.43, 0.80) 0.001
1
0.66 (0.53, 0.83) <0.001
1
1.34 (1.08, 1.66) 0.008
lobulin G.
Figure 2 Longitudinal variation in IgG anti-apoA-1 levels and global BILAG score in eight patients with SLE over time. Time points on
the x axis are successive follow-up visits. IgG anti-apoA-1 parallels global disease activity in many (A) to (F) but not all (G), (H) patients. anti-apoA-
1, antibodies to apolipoprotein A-1; AU, absorbance units; BILAG, British Isles Lupus Assessment Group; IgG, immunoglobulin G.
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no association between IgG anti-apoA-1 level and SLICC-
DI score over a 10-year follow-up period in over 200 pa-
tients (Table 3).
We found no association between IgG anti-apoA-1
positivity early in disease and development of CVD later.
The numbers of patients with CVD were relatively small
(40/499). We have thus found no convincing link be-
tween IgG anti-apoA-1 and CVD in patients with SLE in
this study. This finding agrees with those of Radwan andcolleagues [4] in Egyptian patients with SLE but con-
trasts with those of Vuilleumier and colleagues, who
found that, in 133 Swiss patients with RA followed for a
median of 9 years [11], baseline IgG anti-apoA-1 positivity
was strongly associated with risk of developing a major
cardiovascular event (hazard ratio 4.7, 95% confidence
interval 1.9 to 11.2), even after adjusting for standard
CVD risk factors in multivariable analysis. However, this
RA cohort was older (mean age 65 years), contained more
males (30%) and had higher rate of CVD events compared
Figure 3 Kaplan–Meier survival curve comparing percentage
CVD-free survival in patients who were anti-apoA-1-positive
(n = 135) and anti-apoA-1-negative (n = 364) in their early disease
sample. Time (x axis) measured in years. The number of subjects at risk
at each time point was as follows: 499 at time 0, 275 at 10 years, 94 at
20 years and 27 at 30 years. anti-apoA-1, antibodies to apolipoprotein
A-1; CVD, cardiovascular disease.
Figure 4 Kaplan–Meier survival curve comparing percentage
survival in patients who were anti-apoA-1-positive (n = 135) and
anti-apoA-1-negative (n =364) in their early disease sample. Time
(x axis) measured in years. The number of subjects at risk at each time
point was as follows: 499 at time 0, 290 at 10 years, 103 at 20 years and
31 at 30 years. anti-apoA-1, antibodies to apolipoprotein A-1.
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ture [1,4]. Longer-term studies may well be needed in SLE
than in RA to identify predictive effects of factors such as
autoantibodies on CVD risk. Notably, in a large inception
cohort study, 1,249 patients with SLE were followed for a
median of 8 years and only older age and male gender
were identified as CVD risk factors in multivariable ana-
lysis [30].
Our study had a number of limitations. We did not
study different isotypes of IgG anti-apoA-1 antibodies.
In future, it may be worthwhile to investigate whether
specific isotypes are more strongly associated with over-
all or organ-specific disease activity. We defined CVD by
review of the notes and did not have detailed informa-
tion on CVD events (such as troponin rise and degree of
arterial stenosis). Other studies, such as those of Vuilleu-
mier and colleagues defined CVD using harder end-
points [9,11]. The number of patients in the longitudinal
group was relatively small at 49. The surprising finding
that elevated IgG anti-apoA-1 levels were associated
with negativity for anti-Sm and anti-La thus needs to be
confirmed in a larger cohort. If this is confirmed, it mayTable 3 Mean damage scores over 20 years stratified by quar
sample
Lowest quartile
Damage score at 1 year (n = 236) 0.14
Damage score at 5 years (n = 236) 0.63
Damage score at 10 years (n = 209) 1.06
Damage score at 15 years (n = 131) 1.23
Damage score at 20 years (n = 69) 1.33
anti-apoA-1, antibodies to apolipoprotein A-1; IgG, immunoglobulin G.be useful to investigate whether associations of IgG
anti-apoA-1 and different forms of disease activity are
different in anti-Sm-positive or anti-La-positive versus
anti-Sm-negative or anti-La-negative patients.
Previously we showed that IgG anti-apoA-1 levels were
higher in patients with persistently active disease than qui-
escent disease and rose at times of disease flare [2]. How-
ever, we did not study serial samples taken over long
periods and were unable to carry out multivariable ana-
lysis. By studying samples taken from 49 patients longi-
tudinally, we have confirmed the association of IgG
anti-apoA-1 level with disease activity, particularly
haematological activity. The association with haemato-
logical activity, however, may arise partly from the fact
that there were more patients with BILAG A or B
scores in the haematology system than in any other sys-
tem. In previous papers we have also demonstrated as-
sociations between serological markers and activity in
particular systems: anti-nucleosome antibodies and
renal lupus [31], interleukin-6 and haematological lupus
[32], and nitrated nucleosomes and vasculitis [33].
Hydroxychloroquine was associated with lower IgG
anti-apoA-1, and high-dose corticosteroids with highertile of serum IgG anti-apoA-1 level in the early disease
Second quartile Third quartile Highest quartile
0.13 0.10 0.08
0.43 0.45 0.42
0.60 0.96 0.65
0.81 1.33 0.97
1.06 1.88 1.00
Croca et al. Arthritis Research & Therapy  (2015) 17:26 Page 9 of 10anti-apoA-1. In many patients, IgG anti-apoA-1 levels
varied in parallel with disease activity over time. These
results, however, do not prove a causal relationship be-
tween presence of IgG anti-apoA-1 antibodies and de-
velopment of inflammation or disease activity in SLE.
The possibility of a causal relationship would be an in-
teresting question for future work.
Conclusion
In summary, this comprehensive analysis shows that IgG
anti-apoA-1 antibodies are found commonly in patients
with SLE and develop early in the disease course. Levels
are associated with high disease activity and treatment
with corticosteroids, but we have shown no convincing
link with CVD. It remains possible that such a link will be
shown in longer-term studies or by studying more sensi-
tive measures of atherosclerosis such as plaque echogeni-
city, thickness, area or volume using vascular ultrasound
scanning [34,35].
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